BRCA1	BRCA1	B620	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
secreted	secrete	S263	VBN	I-VP	O
and	and	A530	CC	O	O
exhibits	exhibit	E213	VBZ	B-VP	O
properties	property	P616	NNS	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
granin	granin	G650	NN	I-NP	O
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
are	be	A600	VBP	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
most	most	M230	JJS	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
inherited	inherit	I563	VBN	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
function	function	F523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
remained	remain	R530	VBN	I-VP	O
elusive	elusive	E421	JJ	B-ADJP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
now	now	N000	RB	B-ADVP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
BRCA1	BRCA1	B620	NN	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
190	190	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kD	kD	K300	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
with	with	W300	IN	B-PP	O
sequence	sequence	S252	NN	B-NP	O
homology	homology	H542	NN	I-NP	O
and	and	A530	CC	O	O
biochemical	biochemical	B252	JJ	B-NP	O
analogy	analogy	A542	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
granin	granin	G650	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

Interestingly	Interestingly	I536	RB	B-ADVP	O
,	,	0000	,	O	O
BRCA2	BRCA2	B620	NN	B-NP	O
also	also	A420	RB	B-ADVP	O
includes	include	I524	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
motif	motif	M310	NN	I-NP	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
granin	granin	G650	NN	I-NP	O
consensus	consensus	C525	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
C	C	C000	NN	I-NP	O
terminus	terminus	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	CC	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
granins	granin	G652	NNS	I-NP	O
localize	localize	L242	VBP	B-VP	O
to	to	T000	TO	B-PP	O
secretory	secretory	S263	JJ	B-NP	O
vesicles	vesicle	V242	NNS	I-NP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
secreted	secrete	S263	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
regulated	regulate	R243	VBN	I-NP	O
pathway	pathway	P300	NN	I-NP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
post	post	P230	AFX	B-ADVP	O
-	-	0000	HYPH	B-NP	O
translationally	translationally	T652	RB	B-VP	O
glycosylated	glycosylate	G424	VBN	I-VP	O
and	and	A530	CC	O	O
are	be	A600	VBP	B-VP	O
responsive	responsive	R215	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
hormones	hormone	H652	NNS	B-NP	O
.	.	0000	.	O	O

As	As	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
regulated	regulate	R243	VBN	I-NP	O
secretory	secretory	S263	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
function	function	F523	VB	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
not	not	N300	RB	O	O
previously	previously	P612	RB	B-VP	O
described	describe	D261	VBN	I-VP	O
for	for	F600	IN	B-PP	O
tumour	tumour	T560	NN	B-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
products	product	P632	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Ovarian	Ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
risk	risk	R200	NN	I-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
carriers	carrier	C620	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
modified	modify	M313	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
HRAS1	HRAS1	H620	NN	I-NP	O
variable	variable	V614	JJ	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
tandem	tandem	T535	JJ	B-NP	O
repeat	repeat	R130	NN	I-NP	O
(	(	0000	(	O	O
VNTR	VNTR	V536	NN	B-NP	O
)	)	0000	)	O	O
locus	locus	L200	NN	B-NP	O
.	.	0000	.	O	O

Women	Woman	W500	NNS	B-NP	O
who	who	W000	WP	B-NP	O
carry	carry	C600	VBP	B-VP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
17q21	17q21	Q000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
have	have	H100	VBP	B-VP	O
an	an	A500	DT	B-NP	O
80	80	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
40	40	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
70	70	0000	CD	B-NP	O
(	(	0000	(	O	O
ref	ref	R100	NN	B-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
variable	variable	V614	JJ	I-NP	O
penetrance	penetrance	P536	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
other	other	O360	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
and	and	A530	CC	I-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
genetic	genetic	G532	JJ	B-NP	O
factors	factor	F236	NNS	I-NP	O
play	play	P400	VBP	B-VP	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
tumourigenesis	tumourigenesis	T562	NN	B-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
HRAS1	HRAS1	H620	NN	I-NP	O
variable	variable	V614	JJ	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
tandem	tandem	T535	JJ	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
(	(	0000	(	O	O
VNTR	VNTR	V536	NN	B-NP	O
)	)	0000	)	O	O
polymorphism	polymorphism	P456	NN	B-NP	O
,	,	0000	,	O	O
located	located	L230	JJ	B-NP	O
1	1	0000	CD	I-NP	O
kilobase	kilobase	K412	NN	I-NP	O
(	(	0000	(	O	O
kb	kb	K100	NN	B-NP	O
)	)	0000	)	O	O
downstream	downstream	D523	RB	B-ADVP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HRAS1	HRAS1	H620	NN	I-NP	O
proto	proto	P630	AFX	O	O
-	-	0000	HYPH	O	O
oncogene	oncogene	O525	NN	B-NP	O
(	(	0000	(	O	O
chromosome	chromosome	C652	NN	B-NP	O
11p15	11p15	P000	CD	I-NP	O
.	.	0000	.	I-NP	O
5	5	0000	CD	I-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
one	one	O500	CD	B-NP	O
possible	possible	P214	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
modifier	modifier	M316	NN	I-NP	O
of	of	O100	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
penetrance	penetrance	P536	NN	I-NP	O
.	.	0000	.	O	O

Individuals	Individual	I531	NNS	B-NP	O
who	who	W000	WP	B-NP	O
have	have	H100	VBP	B-VP	O
rare	rare	R600	JJ	B-NP	O
alleles	allele	A420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
VNTR	VNTR	V536	NN	I-NP	O
have	have	H100	VBP	B-VP	O
an	an	A500	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
certain	certain	C635	JJ	B-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
cancers	cancer	C526	NNS	B-NP	B-Disease
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
4	4	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
whether	whether	W360	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
rare	rare	R600	JJ	B-NP	O
HRAS1	HRAS1	H620	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
increases	increase	I526	VBZ	B-VP	O
susceptibility	susceptibility	S213	NN	B-NP	O
to	to	T000	TO	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
typed	type	T130	VBN	I-VP	O
a	a	A000	DT	B-NP	O
panel	panel	P540	NN	I-NP	O
of	of	O100	IN	B-PP	O
307	307	0000	CD	B-NP	O
female	female	F540	JJ	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
at	at	A300	IN	B-PP	O
this	this	T200	DT	B-NP	O
locus	locus	L200	NN	I-NP	O
using	use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
PCR	PCR	P260	NN	I-NP	O
-	-	0000	HYPH	O	O
based	base	B230	VBN	B-NP	O
technique	technique	T252	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
for	for	F600	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

11	11	0000	CD	B-NP	O
times	time	T520	NNS	I-NP	O
greater	great	G636	JJR	I-NP	O
for	for	F600	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
carriers	carrier	C620	NNS	I-NP	O
harbouring	harbour	H616	VBG	B-VP	O
one	one	O500	CD	B-NP	O
or	or	O600	CC	I-NP	O
two	two	T000	CD	I-NP	O
rare	rare	R600	JJ	I-NP	O
HRAS1	HRAS1	H620	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
,	,	0000	,	O	O
compared	compare	C516	VBN	B-PP	O
to	to	T000	TO	B-PP	O
carriers	carrier	C620	NNS	B-NP	O
with	with	W300	IN	B-PP	O
only	only	O540	RB	B-NP	O
common	common	C500	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
015	015	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
magnitude	magnitude	M253	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
relative	relative	R431	JJ	I-NP	O
risk	risk	R200	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
HRAS1	HRAS1	H620	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
altered	alter	A436	VBN	I-VP	O
by	by	B000	IN	B-PP	O
adjusting	adjust	A323	VBG	B-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
known	know	K500	VBN	I-NP	O
risk	risk	R200	NN	I-NP	O
factors	factor	F236	NNS	I-NP	O
for	for	F600	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
(	(	0000	(	O	O
5	5	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Susceptibility	Susceptibility	S213	NN	B-NP	O
to	to	T000	TO	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
appear	appear	A160	VB	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
affected	affect	A123	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
rare	rare	R600	JJ	B-NP	O
HRAS1	HRAS1	H620	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
to	to	T000	TO	B-VP	O
show	show	S000	VB	I-VP	O
the	the	T000	DT	B-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
modifying	modifying	M315	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
penetrance	penetrance	P536	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease

A	A	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
homeodomain	homeodomain	H535	NN	I-NP	O
-	-	0000	HYPH	O	O
encoding	encode	E523	VBG	B-VP	O
gene	gene	G500	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
CpG	CpG	C120	NN	I-NP	O
island	island	I245	NN	I-NP	O
interrupted	interrupt	I536	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
unstable	unstable	U523	JJ	B-ADJP	O
(	(	0000	(	O	O
CTG	CTG	C320	NN	B-NP	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
repeat	repeat	R130	NN	I-NP	O
.	.	0000	.	O	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
(	(	0000	(	O	O
CTG	CTG	C320	NN	O	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
expansion	expansion	E215	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
untranslated	untranslated	U536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
-	-	0000	HYPH	O	O
encoding	encode	E523	VBG	B-VP	O
gene	gene	G500	NN	B-NP	O
,	,	0000	,	O	O
DMPK	DMPK	D512	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
maps	map	M120	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
19q13	19q13	Q000	CD	I-NP	O
.	.	0000	.	O	O

3	3	0000	LS	B-LST	O
.	.	0000	.	O	O

Characterisation	Characterisation	C623	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
patient	patient	P353	NN	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
thus	thus	T200	RB	I-VP	O
far	far	F600	RB	I-VP	O
generated	generate	G563	VBN	I-VP	O
conflicting	conflict	C514	VBG	B-VP	O
data	datum	D300	NNS	B-NP	O
on	on	O500	IN	B-PP	O
alterations	alteration	A436	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
steady	steady	S300	JJ	I-NP	O
state	state	S300	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
DMPK	DMPK	D512	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
final	final	F540	JJ	I-NP	O
DMPK	DMPK	D512	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
expansion	expansion	E215	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
19	19	0000	CD	I-NP	O
is	be	I200	VBZ	B-VP	O
gene	gene	G500	NN	B-NP	O
rich	rich	R200	JJ	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
possible	possible	P214	JJ	B-ADJP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
repeat	repeat	R130	NN	I-NP	O
expansion	expansion	E215	NN	I-NP	O
may	may	M000	MD	B-VP	O
lead	lead	L300	VB	I-VP	O
to	to	T000	TO	B-PP	O
dysfunction	dysfunction	D215	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
transcription	transcription	T652	NN	B-NP	O
units	unit	U532	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
vicinity	vicinity	V253	NN	I-NP	O
,	,	0000	,	O	O
perhaps	perhaps	P612	RB	B-ADVP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
consequence	consequence	C525	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromatin	chromatin	C653	NN	B-NP	O
disruption	disruption	D261	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
searched	search	S623	VBN	I-VP	O
for	for	F600	IN	B-PP	O
genes	gene	G520	NNS	B-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
CpG	CpG	C120	NN	I-NP	O
island	island	I245	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
DMPK	DMPK	D512	NN	B-NP	O
.	.	0000	.	O	O

Sequencing	Sequencing	S252	NN	B-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
shows	show	S200	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
island	island	I245	NN	I-NP	O
extends	extend	E235	VBZ	B-VP	O
over	over	O160	IN	B-NP	O
3	3	0000	CD	I-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
interrupted	interrupt	I536	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
(	(	0000	(	O	O
CTG	CTG	C320	NN	O	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
repeat	repeat	R130	NN	I-NP	O
.	.	0000	.	O	O

Comparison	Comparison	C516	NN	B-NP	O
of	of	O100	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
sequences	sequence	S252	NNS	I-NP	O
downstream	downstream	D523	JJ	B-ADJP	O
(	(	0000	(	O	O
centromeric	centromeric	C536	JJ	B-ADJP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	O	O
and	and	A530	CC	O	O
mouse	mouse	M200	NN	B-NP	O
identified	identify	I353	VBD	B-VP	O
regions	region	R252	NNS	B-NP	O
of	of	O100	IN	B-PP	O
significant	significant	S251	JJ	B-NP	O
homology	homology	H542	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
correspond	correspond	C621	VBP	B-VP	O
to	to	T000	TO	B-PP	O
exons	exon	E252	NNS	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
predicted	predict	P632	VBN	B-VP	O
to	to	T000	TO	B-VP	O
encode	encode	E523	VB	I-VP	O
a	a	A000	DT	B-NP	O
homeodomain	homeodomain	H535	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

RT	RT	R300	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
PCR	PCR	P260	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
shows	show	S200	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
called	call	C430	VBN	I-VP	O
DM	DM	D500	NN	B-NP	B-Disease
locus	locus	L200	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
associated	associate	A230	VBN	B-NP	O
homeodomain	homeodomain	H535	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
DMAHP	DMAHP	D510	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
skeletal	skeletal	S243	JJ	B-NP	O
muscle	muscle	M240	NN	I-NP	O
,	,	0000	,	I-NP	O
heart	heart	H630	NN	I-NP	O
and	and	A530	CC	I-NP	O
brain	brain	B650	NN	I-NP	O
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
retinoblastoma	retinoblastoma	R351	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
the	the	T000	DT	B-NP	O
27	27	0000	CD	I-NP	O
exons	exon	E252	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
promoter	promoter	P653	NN	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
or	or	O600	CC	I-NP	I-Disease
sporadic	sporadic	S163	JJ	I-NP	I-Disease
bilateral	bilateral	B436	JJ	I-NP	I-Disease
retinoblastoma	retinoblastoma	R351	NN	I-NP	I-Disease
by	by	B000	IN	B-PP	O
using	use	U252	VBG	B-VP	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

For	For	F600	IN	B-PP	O
improvement	improvement	I516	NN	B-NP	O
over	over	O160	IN	B-PP	O
previous	previous	P612	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
set	set	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
primers	primer	P656	NNS	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
designed	design	D253	VBN	I-VP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
allow	allow	A400	VBP	B-VP	O
for	for	F600	IN	B-PP	O
amplification	amplification	A514	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	coding	C352	NN	I-NP	O
and	and	A530	CC	I-NP	O
splicing	splicing	S142	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
only	only	O540	RB	B-ADVP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
positioning	positioning	P235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
(	(	0000	(	O	O
PCR	PCR	P260	NN	B-NP	O
)	)	0000	)	O	O
primers	primer	P656	NNS	B-NP	O
was	be	W200	VBD	B-VP	O
such	such	S200	JJ	B-ADJP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
resulting	result	R243	VBG	I-NP	O
PCR	PCR	P260	NN	I-NP	O
products	product	P632	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
of	of	O100	IN	B-PP	O
different	different	D165	JJ	B-NP	O
sizes	size	S200	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
enabled	enable	E514	VBD	B-VP	O
us	us	U200	PRP	B-NP	O
to	to	T000	TO	B-VP	O
analyze	analyze	A542	VB	I-VP	O
two	two	T000	CD	B-NP	O
different	different	D165	JJ	I-NP	O
exons	exon	E252	NNS	I-NP	O
simultaneously	simultaneously	S543	RB	B-ADVP	O
and	and	A530	CC	O	O
still	still	S340	RB	B-ADJP	O
distinguish	distinguish	D235	JJ	I-ADJP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
banding	banding	B535	NN	I-NP	O
profiles	profile	P614	NNS	I-NP	O
for	for	F600	IN	B-PP	O
both	both	B300	DT	B-NP	O
(	(	0000	(	O	O
biplex	biplex	B142	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
using	use	U252	VBG	B-VP	O
this	this	T200	DT	B-NP	O
approach	approach	A162	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
were	be	W600	VBD	B-VP	O
able	able	A140	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
mutation	mutation	M350	NN	B-NP	O
in	in	I500	IN	B-PP	O
22	22	0000	CD	B-NP	O
new	new	N000	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
overall	overall	O164	JJ	I-NP	O
efficiency	efficiency	E125	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
procedure	procedure	P623	NN	I-NP	O
when	when	W500	WRB	B-ADVP	O
we	we	W000	PRP	B-NP	O
used	use	U230	VBD	B-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
pass	pass	P200	NN	I-NP	O
regimen	regimen	R250	NN	I-NP	O
was	be	W200	VBD	B-VP	O
only	only	O540	RB	B-NP	O
48	48	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
small	small	S540	JJ	B-NP	O
insertions	insertion	I526	NNS	I-NP	O
and	and	A530	CC	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
and	and	A530	CC	O	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
roughly	roughly	R240	RB	B-NP	O
equal	equal	E240	JJ	I-NP	O
proportions	proportion	P616	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Type	Type	T100	NN	B-NP	B-Disease
II	II	I000	CD	I-NP	I-Disease
human	human	H500	JJ	I-NP	I-Disease
complement	complement	C514	NN	I-NP	I-Disease
C2	C2	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Allele	Allele	A400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
specific	specific	S121	JJ	I-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
substitutions	substitution	S123	NNS	I-NP	O
(	(	0000	(	O	O
Ser189	Ser189	S600	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
Phe	Phe	P000	NN	B-NP	O
;	;	0000	:	O	O
Gly444	Gly444	G400	NN	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
Arg	Arg	A620	NN	I-NP	O
)	)	0000	)	O	O
cause	cause	C200	VBP	B-VP	O
impaired	impaired	I516	JJ	B-NP	O
C2	C2	C000	NN	I-NP	O
secretion	secretion	S263	NN	I-NP	O
.	.	0000	.	O	O

Type	Type	T100	NN	B-NP	B-Disease
II	II	I000	CD	I-NP	I-Disease
complement	complement	C514	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	I-Disease
C2	C2	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
selective	selective	S423	JJ	I-NP	O
block	block	B420	NN	I-NP	O
in	in	I500	IN	B-PP	O
C2	C2	C000	NN	B-NP	O
secretion	secretion	S263	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Type	Type	T100	NN	I-NP	O
II	II	I000	CD	I-NP	O
C2	C2	C000	NN	I-NP	O
null	null	N400	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
(	(	0000	(	O	O
C2Q0	C2Q0	C200	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
two	two	T000	CD	B-NP	O
major	major	M260	JJ	I-NP	O
histocompatibility	histocompatibility	H232	NN	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
(	(	0000	(	O	O
MHC	MHC	M200	NN	B-NP	O
)	)	0000	)	O	O
that	that	T300	WDT	B-NP	O
differ	differ	D160	VBP	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
MHC	MHC	M200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
more	more	M600	RBR	I-NP	O
common	common	C500	JJ	I-NP	O
Type	Type	T100	NN	I-NP	B-Disease
I	I	I000	CD	I-NP	I-Disease
C2	C2	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
Type	Type	T100	NN	B-NP	B-Disease
II	II	I000	CD	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
Type	Type	T100	NN	I-NP	O
II	II	I000	CD	I-NP	O
C2Q0	C2Q0	C200	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
isolated	isolate	I243	VBN	I-VP	O
and	and	A530	CC	O	O
transfected	transfecte	T652	VBN	B-VP	O
separately	separately	S163	RB	B-ADVP	O
into	into	I530	IN	B-PP	O
L	L	L000	NN	B-NP	O
-	-	0000	HYPH	B-VP	O
cells	cell	C420	NNS	B-NP	O
.	.	0000	.	O	O

Subsequent	Subsequent	S125	JJ	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
biology	biology	B420	NN	I-NP	O
,	,	0000	,	O	O
biosynthetic	biosynthetic	B253	JJ	B-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
immunofluorescence	immunofluorescence	I514	NN	B-NP	O
studies	study	S320	NNS	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
C2	C2	C000	NN	B-NP	O
secretion	secretion	S263	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
impaired	impaired	I516	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
Type	Type	T100	NN	B-NP	B-Disease
II	II	I000	CD	I-NP	I-Disease
C2	C2	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
because	because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
different	different	D165	JJ	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
at	at	A300	IN	B-PP	O
highly	highly	H240	RB	B-NP	O
conserved	conserve	C526	VBN	I-NP	O
residues	residue	R232	NNS	I-NP	O
in	in	I500	IN	B-PP	O
each	each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
C2Q0	C2Q0	C200	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
is	be	I200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
5	5	0000	CD	I-NP	O
(	(	0000	(	O	O
nucleotide	nucleotide	N243	NN	B-NP	O
C566	C566	C000	NN	I-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
T	T	T000	NN	B-NP	O
;	;	0000	:	O	O
Ser189	Ser189	S600	NN	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
Phe	Phe	P000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
C2Q0	C2Q0	C200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
linked	link	L523	VBN	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
MHC	MHC	M200	NN	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
A11	A11	A000	NN	I-NP	O
,	,	0000	,	O	O
B35	B35	B000	NN	B-NP	O
,	,	0000	,	O	O
DRw1	DRw1	D600	NN	B-NP	O
,	,	0000	,	O	O
BFS	BFS	B120	NN	B-NP	O
,	,	0000	,	O	O
C4A0B1	C4A0B1	C100	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
is	be	I200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
11	11	0000	CD	I-NP	O
(	(	0000	(	O	O
G1930	G1930	G000	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
;	;	0000	:	O	O
Gly444	Gly444	G400	NN	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
Arg	Arg	A620	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
C2Q0	C2Q0	C200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
linked	link	L523	VBN	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
MHC	MHC	M200	NN	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
A2	A2	A000	NN	I-NP	O
,	,	0000	,	O	O
B5	B5	B000	NN	B-NP	O
,	,	0000	,	O	O
DRw4	DRw4	D600	NN	B-NP	O
,	,	0000	,	O	O
BFS	BFS	B120	NN	B-NP	O
,	,	0000	,	O	O
C4A3B1	C4A3B1	C100	NN	B-NP	O
.	.	0000	.	O	O

Each	Each	E200	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
C2	C2	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
retained	retain	R353	VBN	I-VP	O
early	early	E640	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
secretory	secretory	S263	JJ	I-NP	O
pathway	pathway	P300	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
mutants	mutant	M353	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
models	model	M342	NNS	B-NP	O
for	for	F600	IN	B-PP	O
elucidating	elucidate	E423	VBG	B-VP	O
the	the	T000	DT	B-NP	O
C2	C2	C000	NN	I-NP	O
secretory	secretory	S263	NN	I-NP	O
pathway	pathway	P300	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Defective	Defective	D123	JJ	B-NP	O
dimerization	dimerization	D562	NN	I-NP	O
of	of	O100	IN	B-PP	O
von	von	V500	NN	B-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
factor	factor	F236	NN	I-NP	O
subunits	subunit	S153	NNS	I-NP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
Cys	Cys	C200	NN	I-NP	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	B-NP	O
Arg	Arg	A620	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
type	type	T100	NN	B-NP	B-Disease
IID	IID	I300	NN	I-NP	I-Disease
von	von	V500	NN	I-NP	I-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
T	T	T000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
C	C	C000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
nt	nt	N300	NN	B-NP	O
8567	8567	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
von	von	V500	NN	I-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
factor	factor	F236	NN	I-NP	O
(	(	0000	(	O	O
vWF	vWF	V100	NN	B-NP	O
)	)	0000	)	O	O
transcript	transcript	T652	NN	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
type	type	T100	NN	B-NP	B-Disease
IID	IID	I300	NN	I-NP	I-Disease
von	von	V500	NN	I-NP	I-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
no	no	N000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
apparent	apparent	A165	JJ	I-NP	O
abnormality	abnormality	A156	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
both	both	B300	DT	B-NP	O
alleles	allele	A420	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
parents	parent	P653	NNS	I-NP	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
sister	sister	S236	NN	I-NP	O
;	;	0000	:	O	O
thus	thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
originated	originate	O625	VBD	B-VP	O
de	de	D000	FW	B-NP	O
novo	novo	N100	FW	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
proposita	proposita	P612	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
also	also	A420	RB	B-ADVP	O
had	have	H300	VBD	B-VP	O
asymptomatic	asymptomatic	A251	JJ	B-NP	O
parents	parent	P653	NNS	I-NP	O
who	who	W000	WP	B-NP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
not	not	N300	RB	O	O
available	available	A141	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
study	study	S300	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
structural	structural	S362	JJ	I-NP	O
consequences	consequence	C525	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
identified	identify	I353	VBN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
CyS2010	CyS2010	C200	NN	I-NP	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	B-NP	O
Arg	Arg	A620	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
evaluated	evaluate	E143	VBN	I-VP	O
by	by	B000	IN	B-PP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
vWF	vWF	V100	NN	I-NP	O
carboxyl	carboxyl	C612	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
residues	residue	R232	NNS	B-NP	O
1366	1366	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
2050	2050	0000	CD	I-NP	O
.	.	0000	.	O	O

Insect	Insect	I523	NN	B-NP	O
cells	cell	C420	NNS	I-NP	O
infected	infect	I512	VBN	B-VP	O
with	with	W300	IN	B-PP	O
recombinant	recombinant	R251	JJ	B-NP	O
baculovirus	baculovirus	B241	NN	I-NP	O
expressing	express	E216	VBG	B-VP	O
normal	normal	N654	JJ	B-NP	O
vWF	vWF	V100	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
secreted	secrete	S263	VBD	B-VP	O
a	a	A000	DT	B-NP	O
disulfide	disulfide	D241	NN	I-NP	O
linked	link	L523	VBD	B-VP	O
dimeric	dimeric	D562	JJ	B-NP	O
molecule	molecule	M424	NN	I-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
apparent	apparent	A165	JJ	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
mass	mass	M200	NN	I-NP	O
of	of	O100	IN	B-PP	O
150	150	0000	CD	B-NP	O
kDa	kDa	K300	NN	I-NP	O
before	before	B160	IN	B-PP	O
reduction	reduction	R323	NN	B-NP	O
,	,	0000	,	O	O
yielding	yield	Y435	VBG	B-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
band	band	B530	NN	I-NP	O
of	of	O100	IN	B-PP	O
80	80	0000	CD	B-NP	O
kDa	kDa	K300	NN	I-NP	O
after	after	A136	IN	B-PP	O
disulfide	disulfide	D241	NN	B-NP	O
bond	bond	B530	NN	I-NP	O
reduction	reduction	R323	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
cells	cell	C420	NNS	B-NP	O
expressing	express	E216	VBG	B-VP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
fragment	fragment	F625	NN	I-NP	O
secreted	secrete	S263	VBD	B-VP	O
a	a	A000	DT	B-NP	O
monomeric	monomeric	M562	JJ	I-NP	O
molecule	molecule	M424	NN	I-NP	O
of	of	O100	IN	B-PP	O
apparent	apparent	A165	JJ	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
mass	mass	M200	NN	I-NP	O
of	of	O100	IN	B-PP	O
80	80	0000	CD	B-NP	O
kDa	kDa	K300	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
remained	remain	R530	VBD	B-VP	O
unchanged	unchanged	U525	JJ	B-ADJP	O
after	after	A136	IN	B-PP	O
reduction	reduction	R323	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
CyS2010	CyS2010	C200	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
essential	essential	E253	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
dimerization	dimerization	D562	NN	I-NP	O
of	of	O100	IN	B-PP	O
vWF	vWF	V100	NN	B-NP	O
subunits	subunit	S153	NNS	I-NP	O
through	through	T620	IN	B-PP	O
disulfide	disulfide	D241	NN	B-NP	O
bonding	bonding	B535	NN	I-NP	O
of	of	O100	IN	B-PP	O
carboxyl	carboxyl	C612	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
domains	domain	D520	NNS	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
corresponding	corresponding	C621	JJ	I-NP	O
codon	codon	C350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
defective	defective	D123	JJ	B-NP	O
multimer	multimer	M435	NN	I-NP	O
formation	formation	F653	NN	I-NP	O
in	in	I500	IN	B-PP	O
type	type	T100	NN	B-NP	B-Disease
IID	IID	I300	NN	I-NP	I-Disease
von	von	V500	NN	I-NP	I-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Wiskott	Wiskott	W230	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
effector	effector	E123	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
GTPase	GTPase	G312	NN	I-NP	O
CDC42Hs	CDC42H	C320	NNS	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
implicated	implicate	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
actin	actin	A235	NN	B-NP	O
polymerization	polymerization	P456	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Rho	Rho	R000	NN	I-NP	O
family	family	F540	NN	I-NP	O
of	of	O100	IN	B-PP	O
GTPases	GTPas	G312	NNS	B-NP	O
control	control	C536	VBP	B-VP	O
diverse	diverse	D162	JJ	B-NP	O
biological	biological	B424	JJ	I-NP	O
processes	process	P620	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
cell	cell	C400	NN	B-NP	O
morphology	morphology	M614	NN	I-NP	O
and	and	A530	CC	O	O
mitogenesis	mitogenesis	M325	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
identified	identify	I353	VBN	I-VP	O
WASP	WASP	W210	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
defective	defective	D123	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
Wiskott	Wiskott	W230	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
WAS	WAS	W200	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
effector	effector	E123	NN	I-NP	O
for	for	F600	IN	B-PP	O
CDC42Hs	CDC42H	C320	NNS	B-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
not	not	N300	RB	O	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
Rho	Rho	R000	NN	I-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
,	,	0000	,	O	O
Rac	Rac	R200	NN	B-NP	O
and	and	A530	CC	I-NP	O
Rho	Rho	R000	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
interaction	interaction	I536	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
dependent	dependent	D153	JJ	B-ADJP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
G	G	G000	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
-	-	0000	HYPH	O	O
binding	bind	B535	VBG	B-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

Cellular	Cellular	C460	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
epitope	epitope	E131	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
tagged	tag	T230	VBN	I-NP	O
WASP	WASP	W210	NN	I-NP	O
produces	produce	P632	VBZ	B-VP	O
clusters	cluster	C423	NNS	B-NP	O
of	of	O100	IN	B-PP	O
WASP	WASP	W210	NN	B-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
highly	highly	H240	RB	I-VP	O
enriched	enrich	E562	VBN	I-VP	O
in	in	I500	IN	B-PP	O
polymerized	polymerized	P456	JJ	B-NP	O
actin	actin	A235	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
clustering	clustering	C423	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
observed	observe	O126	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
terminally	terminally	T654	RB	B-NP	O
deleted	delete	D430	VBN	I-NP	O
WASP	WASP	W210	NN	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
inhibited	inhibit	I513	VBN	I-VP	O
by	by	B000	IN	B-PP	O
coexpression	coexpression	C216	NN	B-NP	O
with	with	W300	IN	B-PP	O
dominant	dominant	D530	JJ	B-NP	O
negative	negative	N231	JJ	I-NP	O
CDC42Hs	CDC42H	C320	NNS	I-NP	O
-	-	0000	HYPH	B-NP	O
N17	N17	N000	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
not	not	N300	RB	O	O
with	with	W300	IN	B-PP	O
dominant	dominant	D530	JJ	B-NP	O
negative	negative	N231	JJ	I-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Rac	Rac	R200	NN	B-NP	O
or	or	O600	CC	I-NP	O
Rho	Rho	R000	NN	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
WASP	WASP	W210	NN	B-NP	O
provides	provide	P613	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
link	link	L520	NN	I-NP	O
between	between	B350	IN	B-PP	O
CDC42Hs	CDC42H	C320	NNS	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
actin	actin	A235	NN	I-NP	O
cytoskeleton	cytoskeleton	C324	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
suggests	suggest	S232	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
for	for	F600	IN	B-PP	O
many	many	M500	JJ	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cellular	cellular	C460	JJ	I-NP	O
abnormalities	abnormality	A156	NNS	I-NP	O
in	in	I500	IN	B-PP	O
WAS	WAS	W200	NNP	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
WASP	WASP	W210	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
contains	contain	C535	VBZ	B-VP	O
two	two	T000	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
domains	domain	D520	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
homologous	homologous	H542	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
other	other	O360	JJ	B-NP	O
proteins	protein	P635	NNS	I-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
action	action	A235	NN	B-NP	O
organization	organization	O625	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-PP	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
frequent	frequent	F625	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
idiopathic	idiopathic	I313	JJ	B-NP	O
Addison	Addison	A325	NN	I-NP	B-Disease
'	'	0000	POS	B-NP	I-Disease
s	s	S000	NNS	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
young	young	Y520	JJ	B-NP	O
adult	adult	A343	JJ	I-NP	O
male	male	M400	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
Linked	Link	L523	VBN	B-VP	I-Disease
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	I-Disease
(	(	0000	(	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
demyelination	demyelination	D545	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
central	central	C536	JJ	I-NP	I-Disease
nervous	nervous	N612	JJ	I-NP	I-Disease
system	system	S235	NN	I-NP	I-Disease
,	,	0000	,	O	O
adrenal	adrenal	A365	JJ	B-NP	B-Disease
insufficiency	insufficiency	I521	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
accumulation	accumulation	A254	NN	B-NP	O
of	of	O100	IN	B-PP	O
very	very	V600	RB	B-NP	O
long	long	L520	JJ	I-NP	O
chain	chain	C500	NN	I-NP	O
fatty	fatty	F300	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
in	in	I500	IN	B-PP	O
tissue	tissue	T200	NN	B-NP	O
and	and	A530	CC	I-NP	O
body	body	B300	NN	I-NP	O
fluids	fluid	F432	NNS	I-NP	O
.	.	0000	.	O	O

ALD	ALD	A430	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	I-PP	O
mutation	mutation	M350	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
located	locate	L230	VBN	B-VP	O
in	in	I500	IN	B-PP	O
Xq28	Xq28	X200	NN	B-NP	O
that	that	T300	WDT	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
peroxisomal	peroxisomal	P625	JJ	I-NP	O
transporter	transporter	T652	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
unknown	unknown	U525	JJ	B-NP	O
function	function	F523	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
of	of	O100	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
cerebral	cerebral	C616	JJ	I-NP	O
form	form	F650	NN	I-NP	O
(	(	0000	(	O	O
45	45	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
that	that	T300	WDT	B-NP	O
develops	develop	D141	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
boys	boy	B200	NNS	B-NP	O
between	between	B350	IN	B-PP	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
12	12	0000	CD	I-NP	O
yr	yr	Y600	NN	I-NP	O
.	.	0000	.	O	O

Adrenomyeloneuropathy	Adrenomyeloneuropathy	A365	NN	B-NP	B-Disease
(	(	0000	(	O	O
AMN	AMN	A500	NN	B-NP	B-Disease
)	)	0000	)	O	O
involves	involve	I514	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
spinal	spinal	S154	JJ	I-NP	O
cord	cord	C630	NN	I-NP	O
and	and	A530	CC	O	O
peripheral	peripheral	P616	JJ	B-NP	O
nerves	nerve	N612	NNS	I-NP	O
in	in	I500	IN	B-PP	O
young	young	Y520	JJ	B-NP	O
adults	adult	A343	NNS	I-NP	O
(	(	0000	(	O	O
35	35	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Adrenal	Adrenal	A365	JJ	B-NP	B-Disease
insufficiency	insufficiency	I521	NN	I-NP	I-Disease
(	(	0000	(	O	O
Addisons	Addison	A325	NNS	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
frequently	frequently	F625	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
AMN	AMN	A500	NN	B-NP	B-Disease
or	or	O600	CC	O	O
cerebral	cerebral	C616	JJ	B-NP	B-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
and	and	A530	CC	O	O
may	may	M000	MD	B-VP	O
remain	remain	R500	VB	I-VP	O
the	the	T000	DT	B-NP	O
only	only	O540	RB	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
(	(	0000	(	O	O
8	8	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
cases	case	C200	NNS	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
prevalence	prevalence	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
among	among	A520	IN	B-PP	O
adults	adult	A343	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Addisons	Addison	A325	NNS	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
remains	remain	R520	VBZ	B-VP	O
unknown	unknown	U525	JJ	B-ADJP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
evaluate	evaluate	E143	VB	I-VP	O
this	this	T200	DT	B-NP	O
prevalence	prevalence	P614	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
performed	perform	P616	VBD	B-VP	O
biochemical	biochemical	B252	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
very	very	V600	RB	B-NP	O
long	long	L520	JJ	I-NP	O
chain	chain	C500	NN	I-NP	O
fatty	fatty	F300	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
in	in	I500	IN	B-PP	O
14	14	0000	CD	B-NP	O
male	male	M400	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
(	(	0000	(	O	O
age	age	A200	NN	B-NP	O
ranging	range	R525	VBG	B-VP	O
from	from	F650	IN	B-PP	O
12	12	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
45	45	0000	CD	I-NP	O
yr	yr	Y600	NN	I-NP	O
at	at	A300	IN	B-PP	O
diagnosis	diagnosis	D252	NN	B-NP	O
)	)	0000	)	O	O
previously	previously	P612	RB	B-VP	O
diagnosed	diagnose	D252	VBN	I-VP	O
as	as	A200	IN	B-PP	O
having	have	H152	VBG	B-VP	O
primary	primary	P656	JJ	B-NP	O
idiopathic	idiopathic	I313	JJ	I-NP	O
adrenocortical	adrenocortical	A365	JJ	I-NP	B-Disease
insufficiency	insufficiency	I521	NN	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
5	5	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
14	14	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
(	(	0000	(	O	O
35	35	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
elevated	elevate	E413	VBN	B-NP	O
plasma	plasma	P425	NN	I-NP	O
concentrations	concentration	C525	NNS	I-NP	O
of	of	O100	IN	B-PP	O
very	very	V600	RB	B-NP	O
long	long	L520	JJ	I-NP	O
chain	chain	C500	NN	I-NP	O
fatty	fatty	F300	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
.	.	0000	.	O	O

None	None	N500	NN	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
adrenocortical	adrenocortical	A365	JJ	B-NP	O
antibodies	antibody	A531	NNS	I-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
electrophysiological	electrophysiological	E423	JJ	B-NP	O
tests	test	T232	NNS	I-NP	O
and	and	A530	CC	O	O
magnetic	magnetic	M253	JJ	B-NP	O
resonance	resonance	R252	NN	I-NP	O
imaging	image	I525	VBG	B-VP	O
it	it	I300	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
determined	determine	D365	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
two	two	T000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
cerebral	cerebral	C616	JJ	B-NP	B-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
had	have	H300	VBD	B-VP	O
adrenomyeloneuropathy	adrenomyeloneuropathy	A365	NN	B-NP	B-Disease
with	with	W300	IN	B-PP	O
cerebral	cerebral	C616	JJ	B-NP	O
involvement	involvement	I514	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
had	have	H300	VBD	B-VP	O
preclinical	preclinical	P624	JJ	B-NP	O
AMN	AMN	A500	NN	I-NP	B-Disease
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
support	support	S163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
ALD	ALD	A430	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
frequent	frequent	F625	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
idiopathic	idiopathic	I313	JJ	B-NP	O
Addisons	Addison	A325	NNS	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
children	child	C436	NNS	B-NP	O
and	and	A530	CC	I-NP	O
adults	adult	A343	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Tumor	Tumor	T560	NN	B-NP	B-Disease
suppression	suppression	S162	NN	I-NP	O
and	and	A530	CC	O	O
apoptosis	apoptosis	A132	NN	B-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
prostate	prostate	P623	NN	I-NP	B-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
mediated	mediate	M300	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
locus	locus	L200	NN	I-NP	O
within	within	W350	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
10pter	10pter	P360	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
q11	q11	Q000	NN	I-NP	O
.	.	0000	.	O	O

Prostate	Prostate	P623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
leading	lead	L352	VBG	I-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
male	male	M400	JJ	B-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
deaths	death	D320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
United	United	U530	NNP	I-NP	O
States	State	S320	NNPS	I-NP	O
.	.	0000	.	O	O

Yet	Yet	Y300	RB	B-ADVP	O
,	,	0000	,	O	O
despite	despite	D213	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
international	international	I536	JJ	I-NP	O
effort	effort	E163	NN	I-NP	O
,	,	0000	,	O	O
little	little	L340	JJ	B-NP	O
is	be	I200	VBZ	B-VP	O
known	know	K500	VBN	I-VP	O
about	about	A130	IN	B-PP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
underlie	underlie	U536	VBP	B-VP	O
this	this	T200	DT	B-NP	O
devastating	devastate	D123	VBG	I-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

Prostate	Prostate	P623	NN	B-NP	O
secretory	secretory	S263	JJ	I-NP	O
epithelial	epithelial	E134	JJ	I-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	O	O
androgen	androgen	A536	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
prostate	prostate	P623	NN	I-NP	B-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
undergo	undergo	U536	VBP	B-VP	O
apoptosis	apoptosis	A132	NN	B-NP	O
in	in	I500	IN	B-PP	O
response	response	R215	NN	B-NP	O
to	to	T000	TO	B-PP	O
androgen	androgen	A536	NN	B-NP	O
deprivation	deprivation	D161	NN	I-NP	O
and	and	A530	CC	O	O
,	,	0000	,	O	O
furthermore	furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
most	most	M230	JJS	B-NP	O
prostate	prostate	P623	NN	I-NP	B-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
become	become	B250	VBP	B-VP	O
androgen	androgen	A536	NN	B-NP	O
independent	independent	I531	JJ	B-ADJP	O
and	and	A530	CC	I-ADJP	O
refractory	refractory	R162	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
further	further	F636	JJ	B-NP	O
therapeutic	therapeutic	T613	JJ	I-NP	O
manipulations	manipulation	M514	NNS	I-NP	O
during	during	D652	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
progression	progression	P626	NN	I-NP	O
.	.	0000	.	O	O

Definition	Definition	D153	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
events	event	E153	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
trigger	trigger	T626	VBP	B-VP	O
apoptosis	apoptosis	A132	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
prostate	prostate	P623	NN	I-NP	O
could	could	C430	MD	B-VP	O
provide	provide	P613	VB	I-VP	O
important	important	I516	JJ	B-NP	O
insights	insight	I523	NNS	I-NP	O
into	into	I530	IN	B-PP	O
critical	critical	C632	JJ	B-NP	O
pathways	pathway	P320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
development	development	D141	NN	I-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
elucidate	elucidate	E423	VB	B-VP	O
the	the	T000	DT	B-NP	O
perturbations	perturbation	P636	NNS	I-NP	O
of	of	O100	IN	B-PP	O
those	those	T200	DT	B-NP	O
key	key	K000	JJ	I-NP	O
pathways	pathway	P320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
neoplastic	neoplastic	N142	JJ	B-NP	O
transformation	transformation	T652	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
functional	functional	F523	JJ	I-NP	O
definition	definition	D153	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
locus	locus	L200	NN	I-NP	O
within	within	W350	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
10pter	10pter	P360	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
q11	q11	Q000	NN	I-NP	O
that	that	T300	WDT	B-NP	O
mediates	mediate	M320	VBZ	B-VP	O
both	both	B300	CC	O	O
in	in	I500	FW	B-NP	O
vivo	vivo	V100	FW	I-NP	O
tumor	tumor	T560	NN	I-NP	O
suppression	suppression	S162	NN	I-NP	O
and	and	A530	CC	O	O
in	in	I500	FW	B-NP	O
vitro	vitro	V360	FW	I-NP	O
apoptosis	apoptosis	A132	NN	I-NP	O
of	of	O100	IN	B-PP	O
prostatic	prostatic	P623	JJ	B-NP	B-Disease
adenocarcinoma	adenocarcinoma	A352	NN	I-NP	I-Disease
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
defined	define	D153	VBN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
10	10	0000	CD	I-NP	O
was	be	W200	VBD	B-VP	O
transferred	transfer	T652	VBN	I-VP	O
via	via	V000	IN	B-PP	O
microcell	microcell	M262	NN	B-NP	O
fusion	fusion	F250	NN	I-NP	O
into	into	I530	IN	B-PP	O
a	a	A000	DT	B-NP	O
prostate	prostate	P623	NN	I-NP	B-Disease
adenocarcinoma	adenocarcinoma	A352	NN	I-NP	I-Disease
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
.	.	0000	.	O	O

Microcell	Microcell	M262	NN	B-NP	O
hybrids	hybrid	H163	NNS	I-NP	O
containing	contain	C535	VBG	B-VP	O
only	only	O540	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
10pter	10pter	P360	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
q11	q11	Q000	NN	I-NP	O
were	be	W600	VBD	B-VP	O
suppressed	suppress	S162	VBN	I-VP	O
for	for	F600	IN	B-PP	O
tumorigenicity	tumorigenicity	T562	NN	B-NP	O
following	follow	F452	VBG	B-PP	O
injection	injection	I523	NN	B-NP	O
of	of	O100	IN	B-PP	O
microcell	microcell	M262	NN	B-NP	O
hybrids	hybrid	H163	NNS	I-NP	O
into	into	I530	IN	B-PP	O
nude	nude	N300	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
complemented	complement	C514	VBN	I-NP	O
hybrids	hybrid	H163	NNS	I-NP	O
undergo	undergo	U536	VBP	B-VP	O
programmed	program	P626	VBN	I-VP	O
cell	cell	C400	NN	B-NP	O
death	death	D300	NN	I-NP	O
in	in	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
via	via	V000	IN	B-PP	O
a	a	A000	DT	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
that	that	T300	WDT	B-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
require	require	R260	VB	I-VP	O
nuclear	nuclear	N246	JJ	B-NP	O
localization	localization	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
p53	p53	P000	NN	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
functionally	functionally	F523	RB	B-ADVP	O
define	define	D150	VBP	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
designated	designate	D253	VBN	B-VP	O
PAC1	PAC1	P200	NN	B-NP	O
,	,	0000	,	O	O
for	for	F600	IN	B-PP	O
prostate	prostate	P623	NN	B-NP	O
adenocarcinoma	adenocarcinoma	A352	NN	I-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	O	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
tumor	tumor	T560	NN	B-NP	O
suppression	suppression	S162	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
prostate	prostate	P623	NN	I-NP	B-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
and	and	A530	CC	O	O
furthermore	furthermore	F636	RB	B-VP	O
strongly	strongly	S365	RB	I-VP	O
suggest	suggest	S230	VBP	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
death	death	D300	NN	I-NP	O
pathway	pathway	P300	NN	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
functionally	functionally	F523	RB	I-VP	O
restored	restore	R236	VBN	I-VP	O
in	in	I500	IN	B-PP	O
prostatic	prostatic	P623	JJ	B-NP	B-Disease
adenocarcinoma	adenocarcinoma	A352	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Low	Low	L000	JJ	B-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA2	BRCA2	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
and	and	A530	CC	O	O
other	other	O360	JJ	B-NP	O
cancers	cancer	C526	NNS	I-NP	B-Disease
.	.	0000	.	O	O

Inherited	Inherit	I563	VBN	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
familial	familial	F540	JJ	B-NP	O
tumour	tumour	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
predispose	predispose	P632	VBP	B-VP	O
individuals	individual	I531	NNS	B-NP	O
to	to	T000	TO	B-PP	O
particular	particular	P632	JJ	B-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
to	to	T000	TO	B-PP	O
an	an	A500	DT	B-NP	O
involvement	involvement	I514	NN	I-NP	O
in	in	I500	IN	B-PP	O
inherited	inherit	I563	VBN	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
to	to	T000	TO	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
tumour	tumour	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
targets	target	T623	NNS	B-NP	O
for	for	F600	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
type	type	T100	NN	I-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
familial	familial	F540	JJ	I-NP	O
forms	form	F652	NNS	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
exception	exception	E213	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
contributes	contribute	C536	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
fraction	fraction	F623	NN	I-NP	O
of	of	O100	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
but	but	B300	CC	O	O
undergoes	undergo	U536	VBZ	B-VP	O
mutation	mutation	M350	NN	B-NP	O
at	at	A300	IN	B-PP	O
very	very	V600	RB	B-NP	O
low	low	L000	JJ	I-NP	O
rates	rate	R320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
finding	finding	F535	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
other	other	O360	JJ	B-NP	O
genes	gene	G520	NNS	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
the	the	T000	DT	B-NP	O
principal	principal	P652	JJ	I-NP	O
targets	target	T623	NNS	I-NP	O
for	for	F600	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
,	,	0000	,	O	O
recently	recently	R253	RB	B-ADVP	O
identified	identify	I353	VBD	B-VP	O
familial	familial	F540	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
BRCA2	BRCA2	B620	NN	B-NP	O
(	(	0000	(	O	O
refs	ref	R120	NNS	B-NP	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
8	8	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
accounts	account	A253	VBZ	B-VP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
roughly	roughly	R240	RB	B-ADJP	O
equal	equal	E240	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
.	.	0000	.	O	O

Like	Like	L200	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
,	,	0000	,	O	O
BRCA2	BRCA2	B620	NN	B-NP	O
behaves	behave	B120	VBZ	B-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
dominantly	dominantly	D534	RB	I-NP	O
inherited	inherit	I563	VBN	I-NP	O
tumour	tumour	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Individuals	Individual	I531	NNS	B-NP	O
who	who	W000	WP	B-NP	O
inherit	inherit	I563	VBP	B-VP	O
one	one	O500	CD	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
are	be	A600	VBP	B-VP	O
at	at	A300	IN	B-PP	O
increased	increase	I526	VBN	B-NP	O
risk	risk	R200	NN	I-NP	O
for	for	F600	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
tumours	tumour	T562	NNS	I-NP	B-Disease
they	they	T000	PRP	B-NP	O
develop	develop	D141	VBP	B-VP	O
lose	lose	L200	VB	I-VP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
by	by	B000	IN	B-PP	O
heterozygous	heterozygous	H362	JJ	B-NP	O
deletion	deletion	D435	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
coding	coding	C352	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
huge	huge	H200	JJ	B-ADJP	O
,	,	0000	,	O	O
composed	compose	C512	VBN	B-VP	O
of	of	O100	IN	B-PP	O
26	26	0000	CD	B-NP	O
exons	exon	E252	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
span	span	S150	VBP	B-VP	O
10	10	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
443	443	0000	CD	I-NP	O
bp	bp	B100	NN	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
investigate	investigate	I512	VBP	B-VP	O
the	the	T000	DT	B-NP	O
rate	rate	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA2	BRCA2	B620	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
set	set	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
cell	cell	C400	NN	B-NP	O
lines	line	L520	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
represent	represent	R162	VBP	B-VP	O
twelve	twelve	T410	CD	B-NP	O
other	other	O360	JJ	I-NP	O
tumour	tumour	T560	NN	I-NP	B-Disease
types	type	T120	NNS	I-NP	O
.	.	0000	.	O	O

Surprisingly	Surprisingly	S616	RB	B-ADVP	O
,	,	0000	,	O	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
BRCA2	BRCA2	B620	NN	B-NP	O
are	be	A600	VBP	B-VP	O
infrequent	infrequent	I516	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
cancers	cancer	C526	NNS	B-NP	B-Disease
including	include	I524	VBG	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
probable	probable	P614	JJ	I-NP	O
germline	germline	G654	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
pancreatic	pancreatic	P526	JJ	I-NP	B-Disease
tumour	tumour	T560	NN	I-NP	I-Disease
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
for	for	F600	IN	B-PP	O
BRCA2	BRCA2	B620	NN	B-NP	O
in	in	I500	IN	B-PP	O
susceptibility	susceptibility	S213	NN	B-NP	O
to	to	T000	TO	B-PP	O
pancreatic	pancreatic	P526	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Founding	Found	F535	VBG	B-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
southern	southern	S365	JJ	B-NP	O
Sweden	Sweden	S350	NNP	I-NP	O
.	.	0000	.	O	O

Nine	Nine	N500	CD	B-NP	O
different	different	D165	JJ	I-NP	O
germ	germ	G650	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
susceptibility	susceptibility	S213	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
15	15	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
47	47	0000	CD	B-NP	O
kindreds	kindred	K536	NNS	I-NP	O
from	from	F650	IN	B-PP	O
southern	southern	S365	JJ	B-NP	O
Sweden	Sweden	S350	NNP	I-NP	O
,	,	0000	,	O	O
by	by	B000	IN	B-PP	O
use	use	U200	NN	B-NP	O
of	of	O100	IN	B-PP	O
SSCP	SSCP	S210	NN	B-NP	O
and	and	A530	CC	I-NP	O
heteroduplex	heteroduplex	H363	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
exons	exon	E252	NNS	I-NP	O
and	and	A530	CC	O	O
flanking	flank	F452	VBG	B-VP	O
intron	intron	I536	NN	B-NP	O
region	region	R250	NN	I-NP	O
and	and	A530	CC	B-PP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
truncation	truncation	T652	NN	I-NP	O
test	test	T230	NN	I-NP	O
for	for	F600	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
11	11	0000	CD	I-NP	O
,	,	0000	,	O	O
followed	follow	F430	VBN	B-VP	O
by	by	B000	IN	B-PP	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
but	but	B300	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
predicted	predict	P632	VBN	I-VP	O
to	to	T000	TO	I-VP	O
give	give	G100	VB	I-VP	O
rise	rise	R200	NN	B-NP	O
to	to	T000	TO	B-PP	O
premature	premature	P653	JJ	B-NP	O
translation	translation	T652	NN	I-NP	O
termination	termination	T653	NN	I-NP	O
and	and	A530	CC	O	O
include	include	I524	VBP	B-VP	O
seven	seven	S150	CD	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
insertions	insertion	I526	NNS	I-NP	O
or	or	O600	CC	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
acceptor	acceptor	A213	NN	I-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
Cys61Gly	Cys61Gly	C240	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
zinc	zinc	Z520	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
binding	bind	B535	VBG	B-NP	O
motif	motif	M310	NN	I-NP	O
.	.	0000	.	O	O

Four	Four	F600	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
Swedish	Swedish	S320	JJ	I-NP	O
founding	founding	F535	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
the	the	T000	DT	B-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
2595	2595	0000	CD	I-NP	O
deletion	deletion	D435	NN	I-NP	O
A	A	A000	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
C	C	C000	NN	I-NP	O
1806	1806	0000	CD	I-NP	O
T	T	T000	NN	I-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
3166	3166	0000	CD	I-NP	O
insertion	insertion	I526	NN	I-NP	O
TGAGA	TGAGA	T200	NN	I-NP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
1201	1201	0000	CD	I-NP	O
deletion	deletion	D435	NN	I-NP	O
11	11	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
intragenic	intragenic	I536	JJ	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
D17S855	D17S855	D200	NN	I-NP	O
supports	support	S163	VBZ	B-VP	O
common	common	C500	JJ	B-NP	O
origins	origin	O625	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Eleven	Eleven	E415	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
15	15	0000	CD	I-NP	O
kindreds	kindred	K536	NNS	I-NP	O
manifesting	manifest	M512	VBG	B-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
breast	breast	B623	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
several	several	S164	JJ	B-NP	O
of	of	O100	IN	B-PP	O
them	them	T500	PRP	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
predominant	predominant	P635	JJ	I-NP	O
ovarian	ovarian	O165	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
set	set	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
32	32	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
no	no	N000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
alterations	alteration	A436	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
included	include	I524	VBN	I-VP	O
1	1	0000	CD	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
kindred	kindred	K536	NN	I-NP	O
manifesting	manifest	M512	VBG	B-VP	O
clear	clear	C460	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
region	region	R250	NN	I-NP	O
and	and	A530	CC	I-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
in	in	I500	IN	B-PP	O
associated	associate	A230	VBN	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
.	.	0000	.	O	O

Other	Other	O360	JJ	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
types	type	T120	NNS	I-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
/	/	0000	SYM	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
included	include	I524	VBD	B-VP	O
prostatic	prostatic	P623	JJ	B-ADJP	B-Disease
,	,	0000	,	O	I-Disease
pancreas	pancreas	P526	NN	B-NP	I-Disease
,	,	0000	,	O	I-Disease
skin	skin	S250	NN	B-NP	I-Disease
,	,	0000	,	O	I-Disease
and	and	A530	CC	O	I-Disease
lung	lung	L520	NN	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
malignant	malignant	M425	JJ	I-NP	B-Disease
melanoma	melanoma	M450	NN	I-NP	I-Disease
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
oligodendroglioma	oligodendroglioma	O423	NN	I-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
carcinosarcoma	carcinosarcoma	C625	NN	I-NP	B-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
,	,	0000	,	O	O
12	12	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
16	16	0000	CD	B-NP	O
kindreds	kindred	K536	NNS	I-NP	O
manifesting	manifest	M512	VBG	B-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
or	or	O600	CC	O	O
linkage	linkage	L520	NN	B-NP	O
contained	contain	C535	VBD	B-VP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
only	only	O540	RB	B-NP	O
6	6	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
31	31	0000	CD	I-NP	O
families	family	F542	NNS	I-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
<	<	0000	SYM	B-NP	O
.	.	0000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
confirms	confirm	C516	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
involvement	involvement	I514	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
in	in	I500	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
predisposition	predisposition	P632	NN	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
subset	subset	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
often	often	O135	RB	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Rapid	Rapid	R130	JJ	B-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
regionally	regionally	R254	RB	B-NP	O
clustered	cluster	C423	VBN	I-NP	O
germ	germ	G650	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
by	by	B000	IN	B-PP	O
multiplex	multiplex	M431	JJ	B-NP	O
heteroduplex	heteroduplex	H363	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

UKCCCR	UKCCCR	U260	NNP	B-NP	O
Familial	Familial	F540	NNP	I-NP	O
Ovarian	Ovarian	O165	NNP	I-NP	B-Disease
Cancer	Cancer	C526	NNP	I-NP	I-Disease
Study	Study	S300	NNP	I-NP	O
Group	Group	G610	NNP	I-NP	O
.	.	0000	.	O	O

Germ	Germ	G650	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
are	be	A600	VBP	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
substantial	substantial	S123	JJ	I-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
early	early	E640	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	O	I-Disease
/	/	0000	SYM	B-NP	I-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Since	Since	S520	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
isolation	isolation	I243	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
last	last	L230	JJ	B-NP	O
year	year	Y600	NN	I-NP	O
,	,	0000	,	O	O
>	>	0000	SYM	B-NP	O
65	65	0000	CD	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
scattered	scatter	S236	VBN	B-VP	O
throughout	throughout	T623	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
detected	detect	D323	VBN	I-VP	O
,	,	0000	,	O	O
making	make	M252	VBG	B-VP	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
time	time	T500	NN	I-NP	O
consuming	consuming	C525	NN	I-NP	O
and	and	A530	CC	O	O
technically	technically	T252	RB	B-ADJP	O
challenging	challenging	C452	JJ	I-ADJP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
developed	develop	D141	VBN	I-VP	O
a	a	A000	DT	B-NP	O
multiplex	multiplex	M431	JJ	I-NP	O
heteroduplex	heteroduplex	H363	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
designed	design	D253	VBN	I-VP	O
to	to	T000	TO	I-VP	O
analyze	analyze	A542	VB	I-VP	O
one	one	O500	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
quarter	quarter	Q636	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
sequence	sequence	S252	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
step	step	S310	NN	I-NP	O
screening	screening	S265	NN	I-NP	O
procedure	procedure	P623	NN	I-NP	O
and	and	A530	CC	O	O
that	that	T300	WDT	B-NP	O
will	will	W400	MD	B-VP	O
detect	detect	D323	VB	I-VP	O
approximately	approximately	A162	RB	B-NP	O
50	50	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
so	so	S000	RB	B-VP	O
far	far	F600	RB	I-VP	O
reported	report	R163	VBN	I-VP	O
in	in	I500	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
/	/	0000	SYM	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
used	use	U230	VBN	I-VP	O
this	this	T200	DT	B-NP	O
technique	technique	T252	NN	I-NP	O
to	to	T000	TO	B-VP	O
analyze	analyze	A542	VB	I-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
in	in	I500	IN	B-PP	O
162	162	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
/	/	0000	SYM	B-NP	I-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	O	O
identified	identify	I353	VBD	B-VP	O
12	12	0000	CD	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
35	35	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
undescribed	undescribed	U532	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
tetramerisation	tetramerisation	T365	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
TP53	TP53	T100	NN	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
Li	Li	L000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Fraumeni	Fraumeni	F650	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
details	detail	D342	NNS	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
classic	classic	C420	JJ	B-NP	O
Li	Li	L000	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Fraumeni	Fraumeni	F650	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
344	344	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
tumour	tumour	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
TP53	TP53	T100	NN	I-NP	O
.	.	0000	.	O	O

Codon	Codon	C350	NN	B-NP	O
344	344	0000	CD	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
key	key	K000	JJ	I-NP	O
residue	residue	R230	NN	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
tetramerisation	tetramerisation	T365	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
proline	proline	P645	NN	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
leucine	leucine	L250	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
predicted	predict	P632	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
profound	profound	P615	JJ	B-NP	O
implications	implication	I514	NNS	I-NP	O
for	for	F600	IN	B-PP	O
tetramerisation	tetramerisation	T365	NN	B-NP	O
and	and	A530	CC	O	O
potentially	potentially	P353	RB	B-ADVP	O
DNA	DNA	D500	NN	B-NP	O
binding	binding	B535	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
report	report	R163	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
this	this	T200	DT	B-NP	O
residue	residue	R230	NN	I-NP	O
in	in	I500	IN	B-PP	O
either	either	E360	CC	B-NP	O
sporadic	sporadic	S163	JJ	I-NP	B-Disease
tumours	tumour	T562	NNS	I-NP	I-Disease
or	or	O600	CC	B-PP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
germline	germline	G654	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
report	report	R163	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
germline	germline	G654	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
tetramerisation	tetramerisation	T365	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
appear	appear	A160	VB	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
remarkable	remarkable	R562	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
spectrum	spectrum	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
tumours	tumour	T562	NNS	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
leiomyosarcoma	leiomyosarcoma	L526	NN	I-NP	B-Disease
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
established	establish	E231	VBN	I-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
tumour	tumour	T560	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
and	and	A530	CC	O	O
cytogenetic	cytogenetic	C325	JJ	B-NP	O
and	and	A530	CC	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
studies	study	S320	NNS	I-NP	O
carried	carry	C630	VBN	B-VP	O
out	out	O300	RP	B-PRT	O
,	,	0000	,	O	O
providing	provide	P613	VBG	B-VP	O
an	an	A500	DT	B-NP	O
extensive	extensive	E235	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
spectrum	spectrum	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
RB1	RB1	R100	NN	B-NP	O
germ	germ	G650	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
retinoblastoma	retinoblastoma	R351	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
searched	search	S623	VBN	I-VP	O
for	for	F600	IN	B-PP	O
germ	germ	G650	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
RB1	RB1	R100	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
119	119	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
retinoblastoma	retinoblastoma	R351	NN	I-NP	I-Disease
.	.	0000	.	O	O

Previous	Previous	P612	JJ	B-NP	O
investigations	investigation	I512	NNS	I-NP	O
by	by	B000	IN	B-PP	O
Southern	Southern	S365	JJ	B-NP	O
blot	blot	B430	NN	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
and	and	A530	CC	O	O
PCR	PCR	P260	NN	B-NP	O
fragment	fragment	F625	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
length	length	L523	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
had	have	H300	VBD	B-VP	O
revealed	reveal	R143	VBN	I-VP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
48	48	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
71	71	0000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
applying	apply	A145	VBG	B-VP	O
heteroduplex	heteroduplex	H363	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
nonisotopic	nonisotopic	N523	JJ	B-NP	O
SSCP	SSCP	S210	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
detected	detect	D323	VBD	B-VP	O
germ	germ	G650	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
premature	premature	P653	JJ	B-NP	O
termination	termination	T653	NN	I-NP	O
codons	codon	C352	NNS	I-NP	O
or	or	O600	CC	O	O
disruption	disruption	D261	NN	B-NP	O
of	of	O100	IN	B-PP	O
splice	splice	S142	NN	B-NP	O
signals	signal	S254	NNS	I-NP	O
in	in	I500	IN	B-PP	O
51	51	0000	CD	B-NP	O
(	(	0000	(	O	O
72	72	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
71	71	0000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Four	Four	F600	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
also	also	A420	RB	B-ADVP	O
showed	show	S300	VBD	B-VP	O
rare	rare	R600	JJ	B-NP	O
sequence	sequence	S252	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
preferentially	preferentially	P616	RB	I-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
single	single	S524	JJ	B-NP	O
base	base	B200	NN	I-NP	O
substitutions	substitution	S123	NNS	I-NP	O
.	.	0000	.	O	O

Recurrent	Recurrent	R265	JJ	B-NP	O
transitions	transition	T652	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
at	at	A300	IN	B-PP	O
most	most	M230	JJS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
14	14	0000	CD	I-NP	O
codons	codon	C352	NNS	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
25	25	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
27	27	0000	CD	I-NP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
contains	contain	C535	VBZ	B-VP	O
two	two	T000	CD	B-NP	O
CGA	CGA	C200	NN	I-NP	O
codons	codon	C352	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
mutations	mutation	M352	NNS	B-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
terminal	terminal	T654	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
may	may	M000	MD	B-VP	O
not	not	N300	RB	I-VP	O
be	be	B000	VB	I-VP	O
oncogenic	oncogenic	O525	JJ	B-ADJP	O
.	.	0000	.	O	O

When	When	W500	WRB	B-ADVP	O
these	these	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
combined	combine	C515	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
of	of	O100	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
previous	previous	P612	JJ	I-NP	O
investigations	investigation	I512	NNS	I-NP	O
,	,	0000	,	O	O
mutations	mutation	M352	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
99	99	0000	CD	B-NP	O
(	(	0000	(	O	O
83	83	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
119	119	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
spectrum	spectrum	S123	NN	I-NP	O
comprises	comprise	C516	VBZ	B-VP	O
15	15	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
large	large	L620	JJ	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
,	,	0000	,	O	O
26	26	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
small	small	S540	JJ	I-NP	O
length	length	L523	NN	I-NP	O
alterations	alteration	A436	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
42	42	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
base	base	B200	NN	I-NP	O
substitutions	substitution	S123	NNS	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
correlation	correlation	C643	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
location	location	L235	NN	I-NP	O
of	of	O100	IN	B-PP	O
frameshift	frameshift	F652	NN	B-NP	O
or	or	O600	CC	O	O
nonsense	nonsense	N525	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
phenotypic	phenotypic	P531	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
age	age	A200	NN	B-NP	O
at	at	A300	IN	B-PP	O
diagnosis	diagnosis	D252	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
tumor	tumor	T560	NN	B-NP	B-Disease
foci	focus	F200	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
manifestation	manifestation	M512	NN	B-NP	O
of	of	O100	IN	B-PP	O
nonocular	nonocular	N524	JJ	B-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Phenotypic	Phenotypic	P531	JJ	B-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
30	30	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
40	40	0000	CD	I-NP	O
CAG	CAG	C200	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Huntington	Huntington	H535	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
HD	HD	H300	NN	B-NP	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
reveals	reveal	R142	VBZ	B-VP	O
HD	HD	H300	NN	B-NP	B-Disease
cases	case	C200	NNS	I-NP	O
with	with	W300	IN	B-PP	O
36	36	0000	CD	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
and	and	A530	CC	O	O
apparently	apparently	A165	RB	B-ADVP	O
normal	normal	N654	JJ	B-NP	O
elderly	elderly	E436	JJ	I-NP	O
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
36	36	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
39	39	0000	CD	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
.	.	0000	.	O	O

Abnormal	Abnormal	A156	JJ	B-NP	O
CAG	CAG	C200	NN	I-NP	O
expansions	expansion	E215	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
IT	IT	I300	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
15	15	0000	CD	I-NP	O
gene	gene	G500	NN	I-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
Huntington	Huntington	H535	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
HD	HD	H300	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
diagnostic	diagnostic	D252	JJ	I-NP	O
setting	setting	S352	NN	I-NP	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
necessary	necessary	N260	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
define	define	D150	VB	I-VP	O
the	the	T000	DT	B-NP	O
limits	limit	L532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CAG	CAG	C200	NN	I-NP	O
size	size	S200	NN	I-NP	O
ranges	range	R520	NNS	I-NP	O
on	on	O500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
and	and	A530	CC	I-NP	O
HD	HD	H300	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	O
associated	associate	A230	VBN	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
.	.	0000	.	O	O

Most	Most	M230	JJS	B-NP	O
large	large	L620	JJ	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
defined	define	D153	VBD	B-VP	O
the	the	T000	DT	B-NP	O
limits	limit	L532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
and	and	A530	CC	I-NP	O
pathological	pathological	P342	JJ	I-NP	O
size	size	S200	NN	I-NP	O
ranges	range	R520	VBZ	B-VP	O
employed	employ	E514	VBN	I-VP	O
PCR	PCR	P260	NN	B-NP	O
assays	assay	A200	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
included	include	I524	VBD	B-VP	O
the	the	T000	DT	B-NP	O
CAG	CAG	C200	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
CCG	CCG	C200	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
tract	tract	T623	NN	I-NP	O
that	that	T300	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
thought	think	T230	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
invariant	invariant	I516	JJ	B-ADJP	O
.	.	0000	.	O	O

Many	Many	M500	JJ	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
experiments	experiment	E216	NNS	I-NP	O
found	find	F530	VBD	B-VP	O
an	an	A500	DT	B-NP	O
overlap	overlap	O164	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
and	and	A530	CC	I-NP	O
disease	disease	D200	NN	I-NP	O
size	size	S200	NN	I-NP	O
ranges	range	R520	NNS	I-NP	O
.	.	0000	.	O	O

Subsequent	Subsequent	S125	JJ	B-NP	O
findings	finding	F535	NNS	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
CCG	CCG	C200	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
vary	vary	V600	VBP	B-VP	O
by	by	B000	IN	B-PP	O
8	8	0000	CD	B-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
lengths	length	L523	NNS	I-NP	O
suggested	suggest	S230	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
limits	limit	L532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
and	and	A530	CC	I-NP	O
disease	disease	D200	NN	I-NP	O
size	size	S200	NN	I-NP	O
ranges	range	R520	NNS	I-NP	O
should	should	S430	MD	B-VP	O
be	be	B000	VB	I-VP	O
reevaluated	reevaluate	R143	VBN	I-VP	O
with	with	W300	IN	B-PP	O
assays	assay	A200	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
exclude	exclude	E243	VBP	B-VP	O
the	the	T000	DT	B-NP	O
CCG	CCG	C200	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
.	.	0000	.	O	O

Since	Since	S520	IN	B-SBAR	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
between	between	B350	IN	B-NP	O
30	30	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
40	40	0000	CD	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
rare	rare	R600	JJ	B-ADJP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
consortium	consortium	C526	NN	I-NP	O
was	be	W200	VBD	B-VP	O
assembled	assemble	A251	VBN	I-VP	O
to	to	T000	TO	I-VP	O
collect	collect	C423	VB	I-VP	O
such	such	S200	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
178	178	0000	CD	I-NP	O
samples	sample	S514	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
reanalyzed	reanalyze	R542	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Cambridge	Cambridge	C516	NNP	B-NP	O
by	by	B000	IN	B-PP	O
using	use	U252	VBG	B-VP	O
assays	assay	A200	NNS	B-NP	O
specific	specific	S121	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
CAG	CAG	C200	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
optimized	optimize	O135	VBN	I-VP	O
methods	method	M320	NNS	B-NP	O
for	for	F600	IN	B-PP	O
reliable	reliable	R414	JJ	B-NP	O
sizing	sizing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
CAG	CAG	C200	NN	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
and	and	A530	CC	O	O
show	show	S000	NN	B-NP	O
cases	case	C200	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
the	the	T000	DT	B-NP	O
dangers	danger	D526	NNS	I-NP	O
of	of	O100	IN	B-PP	O
using	use	U252	VBG	B-VP	O
PCR	PCR	P260	NN	B-NP	O
assays	assay	A200	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
include	include	I524	VBP	B-VP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
CAG	CAG	C200	NN	I-NP	O
and	and	A530	CC	I-NP	O
CCG	CCG	C200	NN	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
.	.	0000	.	O	O

Seven	Seven	S150	CD	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
36	36	0000	CD	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
confirms	confirm	C516	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
.	.	0000	.	O	O

Individuals	Individual	I531	NNS	B-NP	O
without	without	W300	IN	B-PP	O
apparent	apparent	A165	JJ	B-NP	O
symptoms	symptom	S513	NNS	I-NP	O
or	or	O600	CC	I-NP	O
signs	sign	S252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
HD	HD	H300	NN	B-NP	B-Disease
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
at	at	A300	IN	B-PP	O
36	36	0000	CD	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
(	(	0000	(	O	O
aged	age	A230	VBN	B-NP	O
74	74	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
78	78	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
79	79	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
87	87	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
37	37	0000	CD	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
(	(	0000	(	O	O
aged	age	A230	VBN	B-VP	O
69	69	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
38	38	0000	CD	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
(	(	0000	(	O	O
aged	age	A230	VBN	B-VP	O
69	69	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
90	90	0000	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
39	39	0000	CD	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
(	(	0000	(	O	O
aged	age	A230	VBN	B-NP	O
67	67	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
90	90	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
95	95	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
detailed	detailed	D343	JJ	I-NP	O
case	case	C200	NN	I-NP	O
histories	history	H236	NNS	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
exceptional	exceptional	E213	JJ	I-NP	O
case	case	C200	NN	I-NP	O
from	from	F650	IN	B-PP	O
this	this	T200	DT	B-NP	O
series	series	S620	NN	I-NP	O
will	will	W400	MD	B-VP	O
be	be	B000	VB	I-VP	O
presented	present	P625	VBN	I-VP	O
a	a	A000	DT	B-NP	O
95	95	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
man	man	M500	NN	I-NP	O
with	with	W300	IN	B-PP	O
39	39	0000	CD	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
who	who	W000	WP	B-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
have	have	H100	VB	I-VP	O
classical	classical	C424	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
HD	HD	H300	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
apparently	apparently	A165	RB	I-NP	O
healthy	healthy	H430	JJ	I-NP	O
survival	survival	S614	NN	I-NP	O
into	into	I530	IN	B-PP	O
old	old	O430	JJ	B-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
some	some	S500	DT	B-NP	O
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
36	36	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
39	39	0000	CD	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
may	may	M000	MD	B-VP	O
not	not	N300	RB	I-VP	O
always	always	A420	RB	I-VP	O
be	be	B000	VB	I-VP	O
fully	fully	F400	RB	B-ADJP	O
penetrant	penetrant	P536	JJ	I-ADJP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
and	and	A530	CC	I-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
among	among	A520	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Jewish	Jewish	J200	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Canavan	Canavan	C515	NN	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Canavan	Canavan	C515	NN	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
inherited	inherit	I563	VBN	I-VP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
recessive	recessive	R210	JJ	I-NP	O
trait	trait	T630	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
aspartoacylase	aspartoacylase	A216	NN	B-NP	I-Disease
(	(	0000	(	O	O
ASPA	ASPA	A210	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Canavan	Canavan	C515	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
from	from	F650	IN	B-PP	O
an	an	A500	DT	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
background	background	B265	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
ASPA	ASPA	A210	NN	B-NP	O
that	that	T300	WDT	B-NP	O
lead	lead	L300	VBP	B-VP	O
to	to	T000	TO	B-PP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
enzymatic	enzymatic	E525	JJ	B-NP	O
activity	activity	A231	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
E285A	E285A	E000	NN	B-NP	O
and	and	A530	CC	I-NP	O
Y231X	Y231X	Y200	NN	I-NP	O
are	be	A600	VBP	B-VP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
predominant	predominant	P635	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
account	account	A253	VBP	B-VP	O
for	for	F600	IN	B-PP	O
97	97	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
current	current	C653	JJ	I-NP	O
study	study	S300	NN	I-NP	O
was	be	W200	VBD	B-VP	O
aimed	aim	A530	VBN	I-VP	O
at	at	A300	IN	B-PP	O
finding	find	F535	VBG	B-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
Canavan	Canavan	C515	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
25	25	0000	CD	B-NP	O
independent	independent	I531	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
of	of	O100	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
background	background	B265	NN	I-NP	O
.	.	0000	.	O	O

Eight	Eight	E230	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
and	and	A530	CC	I-NP	O
three	three	T600	CD	I-NP	O
previously	previously	P612	RB	I-NP	O
characterized	characterize	C623	VBN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
accounted	account	A253	VBD	B-VP	O
for	for	F600	IN	B-PP	O
80	80	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
40	40	0000	CD	B-NP	O
/	/	0000	SYM	I-NP	O
50	50	0000	CD	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
A305E	A305E	A000	NN	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
accounted	account	A253	VBD	B-VP	O
for	for	F600	IN	B-PP	O
48	48	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
24	24	0000	CD	B-NP	O
/	/	0000	SYM	I-NP	O
50	50	0000	CD	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
of	of	O100	IN	B-PP	O
western	western	W236	JJ	B-NP	O
European	European	E615	JJ	I-NP	O
descent	descent	D253	NN	I-NP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
predominant	predominant	P635	JJ	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
each	each	E200	DT	O	O
accounted	account	A253	VBD	B-VP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
eight	eight	E230	CD	I-NP	O
novel	novel	N140	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
identified	identify	I353	VBN	B-VP	O
included	include	I524	VBD	B-VP	O
1	1	0000	CD	B-NP	O
-	-	0000	HYPH	B-NP	O
and	and	A530	CC	I-NP	O
4	4	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
(	(	0000	(	O	O
32	32	0000	CD	B-NP	O
deltaT	deltaT	D430	NN	I-NP	O
and	and	A530	CC	O	O
876	876	0000	CD	B-NP	O
deltaAGAA	deltaAGAA	D432	NN	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
I16T	I16T	I300	NN	B-NP	O
,	,	0000	,	O	O
G27R	G27R	G600	NN	B-NP	O
,	,	0000	,	O	O
D114E	D114E	D000	NN	B-NP	O
,	,	0000	,	O	O
G123E	G123E	G000	NN	B-NP	O
,	,	0000	,	O	O
C152Y	C152Y	C000	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
R168C	R168C	R200	NN	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
32	32	0000	CD	I-NP	O
deltaT	deltaT	D430	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
only	only	O540	JJ	I-NP	O
known	known	K500	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
of	of	O100	IN	B-PP	O
African	African	A162	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
American	American	A562	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
with	with	W300	IN	B-PP	O
Canavan	Canavan	C515	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
heterozygosity	heterozygosity	H362	NN	I-NP	O
for	for	F600	IN	B-PP	O
876	876	0000	CD	B-NP	O
deltaAGAA	deltaAGAA	D432	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
independent	independent	I531	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
from	from	F650	IN	B-PP	O
England	England	E524	NNP	B-NP	O
.	.	0000	.	O	O

Six	Six	S200	CD	B-NP	O
single	single	S524	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
changes	change	C520	NNS	I-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
from	from	F650	IN	B-PP	O
Turkey	Turkey	T620	NNP	B-NP	O
(	(	0000	(	O	O
D114E	D114E	D000	NN	B-NP	O
,	,	0000	,	O	O
R168C	R168C	R200	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
The	The	T000	DT	B-NP	O
Netherlands	Netherlands	N364	NNP	I-NP	O
(	(	0000	(	O	O
I16T	I16T	I300	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
Germany	Germany	G650	NNP	B-NP	O
(	(	0000	(	O	O
G27R	G27R	G600	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
Ireland	Ireland	I645	NN	B-NP	O
(	(	0000	(	O	O
C152Y	C152Y	C000	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Canada	Canada	C530	NNP	B-NP	O
(	(	0000	(	O	O
G123E	G123E	G000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
PCR	PCR	P260	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
based	base	B230	VBN	B-NP	O
protocol	protocol	P632	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
described	describe	D261	VBN	I-VP	O
that	that	T300	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
introduce	introduce	I536	VB	I-VP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	FW	B-NP	O
vitro	vitro	V360	FW	I-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
clones	clone	C452	NNS	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
all	all	A400	DT	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
led	lead	L300	VBD	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
ASPA	ASPA	A210	NN	B-NP	I-Disease
and	and	A530	CC	O	O
should	should	S430	MD	B-VP	O
therefore	therefore	T616	RB	I-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
Canavan	Canavan	C515	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
and	and	A530	CC	O	O
chromosomal	chromosomal	C652	JJ	B-NP	O
localization	localization	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
Atm	Atm	A350	NNP	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
homolog	homolog	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Atm	Atm	A350	NNP	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
homolog	homolog	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
defective	defective	D123	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
(	(	0000	(	O	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
T	T	T000	NN	B-NP	I-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
coding	cod	C352	VBG	I-NP	O
sequence	sequence	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Atm	Atm	A350	NNP	I-NP	O
transcript	transcript	T652	NN	I-NP	O
was	be	W200	VBD	B-VP	O
cloned	clone	C453	VBN	I-VP	O
and	and	A530	CC	O	O
found	find	F530	VBN	B-VP	O
to	to	T000	TO	I-VP	O
contain	contain	C535	VB	I-VP	O
an	an	A500	DT	B-NP	O
open	open	O150	JJ	I-NP	O
reading	reading	R352	NN	I-NP	O
frame	frame	F650	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
a	a	A000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
3066	3066	0000	CD	B-NP	O
amino	amino	A500	NN	I-NP	O
acids	acid	A232	NNS	I-NP	O
with	with	W300	IN	B-PP	O
84	84	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
overall	overall	O164	JJ	I-NP	O
identity	identity	I353	NN	I-NP	O
and	and	A530	CC	O	O
91	91	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
similarity	similarity	S546	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
ATM	ATM	A350	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

Variable	Variable	V614	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
Atm	Atm	A350	NN	B-NP	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
different	different	D165	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
.	.	0000	.	O	O

Fluorescence	Fluorescence	F462	NN	B-NP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
and	and	A530	CC	I-NP	O
linkage	linkage	L520	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
located	located	L230	JJ	B-VP	O
the	the	T000	DT	B-NP	O
Atm	Atm	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
on	on	O500	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
9	9	0000	CD	I-NP	O
,	,	0000	,	O	O
band	band	B530	NN	B-NP	O
9C	9C	C000	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
region	region	R250	NN	I-NP	O
homologous	homologous	H542	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
region	region	R250	NN	I-NP	O
on	on	O500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
11q22	11q22	Q000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
q23	q23	Q000	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
homolog	homolog	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
WASP	WASP	W210	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
highly	highly	H240	RB	I-VP	O
conserved	conserve	C526	VBN	I-VP	O
and	and	A530	CC	O	O
maps	map	M120	NNS	B-NP	O
near	near	N600	IN	B-PP	O
the	the	T000	DT	B-NP	O
scurfy	scurfy	S261	NN	I-NP	O
(	(	0000	(	O	O
sf	sf	S100	NN	B-NP	O
)	)	0000	)	O	O
mutation	mutation	M350	NN	B-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
WASP	WASP	W210	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
homolog	homolog	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
mutated	mutate	M300	VBN	B-VP	O
in	in	I500	IN	B-PP	O
Wiskott	Wiskott	W230	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
isolated	isolate	I243	VBN	I-VP	O
and	and	A530	CC	I-VP	O
sequenced	sequence	S252	VBN	I-VP	O
.	.	0000	.	O	O
the	the	T000	DT	B-NP	O
predicted	predict	P632	VBN	I-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
86	86	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
identical	identical	I353	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
WASP	WASP	W210	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
feature	feature	F360	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
GGA	GGA	G200	NN	I-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
that	that	T300	WDT	B-NP	O
codes	cod	C320	VBZ	B-VP	O
for	for	F600	IN	B-PP	O
polyglycine	polyglycine	P424	NN	B-NP	O
and	and	A530	CC	O	O
varies	vary	V620	VBZ	B-VP	O
from	from	F650	IN	B-PP	O
15	15	0000	CD	B-NP	O
to	to	T000	TO	I-NP	O
17	17	0000	CD	I-NP	O
triplets	triplet	T614	NNS	I-NP	O
in	in	I500	IN	B-PP	O
different	different	D165	JJ	B-NP	O
Mus	Mus	M200	NN	I-NP	O
musculus	musculus	M242	NN	I-NP	O
strains	strain	S365	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
structure	structure	S362	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
WASP	WASP	W210	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
expressed	express	E216	VBN	I-VP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
approximately	approximately	A162	RB	I-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	O	O

4	4	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
kb	kb	K100	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
in	in	I500	IN	B-PP	O
thymus	thymus	T520	NN	B-NP	O
and	and	A530	CC	I-NP	O
spleen	spleen	S145	NN	I-NP	O
.	.	0000	.	O	O

Chromosomal	Chromosomal	C652	JJ	B-NP	O
mapping	mapping	M152	NN	I-NP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
interspecific	interspecific	I536	JJ	I-NP	O
M	M	M000	NN	I-NP	O
.	.	0000	.	O	O

Musculus	Musculus	M242	NN	B-NP	O
/	/	0000	SYM	I-NP	O
M	M	M000	NN	I-NP	O
.	.	0000	SYM	I-NP	O
spretus	spretus	S163	NN	I-NP	O
backcross	backcross	B262	RB	B-ADVP	O
placed	place	P423	VBD	B-VP	O
the	the	T000	DT	B-NP	O
Wasp	Wasp	W210	NNP	I-NP	O
locus	locus	L200	NN	I-NP	O
near	near	N600	IN	B-PP	O
the	the	T000	DT	B-NP	O
centromere	centromere	C536	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
,	,	0000	,	O	O
inseparable	inseparable	I521	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
Gata1	Gata1	G300	NN	B-NP	O
,	,	0000	,	O	O
Tcfe3	Tcfe3	T210	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
scurfy	scurfy	S261	NN	B-NP	O
(	(	0000	(	O	O
sf	sf	S100	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
localization	localization	L242	NN	I-NP	O
makes	make	M200	VBZ	B-VP	O
Wasp	Wasp	W210	NNP	B-NP	O
a	a	A000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
for	for	F600	IN	B-PP	O
involvement	involvement	I514	NN	B-NP	O
in	in	I500	IN	B-PP	O
scurfy	scurfy	S261	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
T	T	T000	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
-	-	0000	HYPH	O	O
mediated	mediate	M300	VBN	B-VP	O
fatal	fatal	F340	JJ	B-NP	B-Disease
lymphoreticular	lymphoreticular	L516	JJ	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
has	have	H200	VBZ	B-VP	O
previously	previously	P612	RB	I-VP	O
been	be	B500	VBN	I-VP	O
proposed	propose	P612	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
homolog	homolog	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
Wiskott	Wiskott	W230	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Northern	Northern	N636	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
sf	sf	S100	NN	B-NP	O
tissue	tissue	T200	NN	I-NP	O
samples	sample	S514	NNS	I-NP	O
indicated	indicate	I532	VBD	B-VP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
WASP	WASP	W210	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
in	in	I500	IN	B-PP	O
liver	liver	L160	NN	B-NP	O
and	and	A530	CC	I-NP	O
skin	skin	S250	NN	I-NP	O
,	,	0000	,	O	O
presumably	presumably	P625	RB	B-ADVP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
consequence	consequence	C525	NN	I-NP	O
of	of	O100	IN	B-PP	O
lymphocytic	lymphocytic	L512	JJ	B-NP	O
infiltration	infiltration	I514	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
non	non	N500	JJ	B-NP	O
abnormalities	abnormality	A156	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
amount	amount	A530	NN	I-NP	O
or	or	O600	CC	I-NP	O
size	size	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
mRNA	mRNA	M650	NN	B-NP	O
present	present	P625	JJ	B-ADJP	O
.	.	0000	.	O	O

Colchicine	Colchicine	C425	NN	B-NP	O
in	in	I500	IN	B-PP	O
breast	breast	B623	NN	B-NP	O
milk	milk	M420	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
Mediterranean	Mediterranean	M365	JJ	I-NP	I-Disease
fever	fever	F160	NN	I-NP	I-Disease
.	.	0000	.	O	O

OBJECTIVE	OBJECTIVE	O123	NN	B-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
clarify	clarify	C461	VB	I-VP	O
whether	whether	W360	IN	B-SBAR	O
colchicine	colchicine	C425	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
excreted	excrete	E263	VBN	I-VP	O
in	in	I500	IN	B-PP	O
breast	breast	B623	NN	B-NP	O
milk	milk	M420	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
to	to	T000	TO	B-VP	O
compare	compare	C516	VB	I-VP	O
its	its	I320	PRP$	B-NP	O
concentrations	concentration	C525	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
serum	serum	S650	NN	I-NP	O
and	and	A530	CC	I-NP	O
breast	breast	B623	NN	I-NP	O
milk	milk	M420	NN	I-NP	O
of	of	O100	IN	B-PP	O
lactating	lactate	L235	VBG	B-NP	O
women	woman	W500	NNS	I-NP	O
who	who	W000	WP	B-NP	O
have	have	H100	VBP	B-VP	O
familial	familial	F540	JJ	B-NP	B-Disease
Mediterranean	Mediterranean	M365	JJ	I-NP	I-Disease
fever	fever	F160	NN	I-NP	I-Disease
(	(	0000	(	O	O
FMF	FMF	F510	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

METHODS	METHODS	M320	NNS	B-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
radioimmunoassay	radioimmunoassay	R352	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
determined	determine	D365	VBD	B-VP	O
colchicine	colchicine	C425	NN	B-NP	O
concentrations	concentration	C525	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
serum	serum	S650	NN	I-NP	O
and	and	A530	CC	I-NP	O
breast	breast	B623	NN	I-NP	O
milk	milk	M420	NN	I-NP	O
of	of	O100	IN	B-PP	O
4	4	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
at	at	A300	IN	B-PP	O
various	various	V620	JJ	B-NP	O
time	time	T500	NN	I-NP	O
points	point	P532	NNS	I-NP	O
,	,	0000	,	O	O
following	follow	F452	VBG	B-PP	O
oral	oral	O640	JJ	B-NP	O
administration	administration	A352	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
drug	drug	D620	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
study	study	S300	NN	I-NP	O
evaluated	evaluate	E143	VBD	B-VP	O
4	4	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
FMF	FMF	F510	NN	B-NP	B-Disease
who	who	W000	WP	B-NP	O
had	have	H300	VBD	B-VP	O
been	be	B500	VBN	I-VP	O
taking	take	T252	VBG	I-VP	O
colchicine	colchicine	C425	NN	B-NP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
long	long	L520	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
term	term	T650	NN	I-NP	O
basis	basis	B200	NN	I-NP	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
.	.	0000	.	O	O

Colchicine	Colchicine	C425	NN	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
excreted	excrete	E263	VBN	I-VP	O
in	in	I500	IN	B-PP	O
breast	breast	B623	NN	B-NP	O
milk	milk	M420	NN	I-NP	O
.	.	0000	.	O	O

Its	Its	I320	PRP$	B-NP	O
levels	level	L142	NNS	I-NP	O
ranged	range	R523	VBD	B-VP	O
between	between	B350	IN	B-PP	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

9	9	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
8	8	0000	CD	I-NP	O
.	.	0000	.	O	O

6	6	0000	CD	B-NP	O
ng	ng	N200	NN	I-NP	O
/	/	0000	SYM	I-NP	O
ml	ml	M400	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
were	be	W600	VBD	B-VP	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
those	those	T200	DT	B-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
serum	serum	S650	NN	I-NP	O
(	(	0000	(	O	O
parallel	parallel	P640	JJ	B-NP	O
concentration	concentration	C525	NN	I-NP	O
time	time	T500	NN	I-NP	O
curves	curve	C612	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
appeared	appear	A163	VBD	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
considerable	considerable	C523	JJ	I-NP	O
variation	variation	V635	NN	I-NP	O
in	in	I500	IN	B-PP	O
colchicine	colchicine	C425	NN	B-NP	O
milk	milk	M420	NN	I-NP	O
concentration	concentration	C525	NN	I-NP	O
among	among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
might	might	M230	MD	B-VP	O
be	be	B000	VB	I-VP	O
related	related	R430	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
individual	individual	I531	JJ	B-NP	O
breast	breast	B623	NN	I-NP	O
milk	milk	M420	NN	I-NP	O
composition	composition	C512	NN	I-NP	O
and	and	A530	CC	O	O
,	,	0000	,	O	O
possibly	possibly	P214	RB	B-ADVP	O
,	,	0000	,	O	O
to	to	T000	TO	B-PP	O
other	other	O360	JJ	B-NP	O
nutritional	nutritional	N363	JJ	I-NP	O
or	or	O600	CC	I-NP	O
metabolic	metabolic	M314	JJ	I-NP	O
factors	factor	F236	NNS	I-NP	O
.	.	0000	.	O	O

CONCLUSION	CONCLUSION	C524	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
extensive	extensive	E235	JJ	I-NP	O
peripheral	peripheral	P616	JJ	I-NP	O
tissue	tissue	T200	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
and	and	A530	CC	O	O
relatively	relatively	R431	RB	B-NP	O
low	low	L000	JJ	I-NP	O
concentration	concentration	C525	NN	I-NP	O
of	of	O100	IN	B-PP	O
colchicine	colchicine	C425	NN	B-NP	O
in	in	I500	IN	B-PP	O
breast	breast	B623	NN	B-NP	O
milk	milk	M420	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
amount	amount	A530	NN	I-NP	O
ingested	ingest	I523	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
infant	infant	I515	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
small	small	S540	JJ	B-ADJP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
based	base	B230	VBN	B-PP	O
on	on	O500	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
experience	experience	E216	NN	I-NP	O
,	,	0000	,	O	O
nursing	nursing	N625	NN	B-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
safe	safe	S100	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
lactating	lactate	L235	VBG	B-VP	O
women	woman	W500	NNS	B-NP	O
with	with	W300	IN	B-PP	O
FMF	FMF	F510	NNP	B-NP	B-Disease
who	who	W000	WP	B-NP	O
continue	continue	C535	VBP	B-VP	O
to	to	T000	TO	I-VP	O
take	take	T200	VB	I-VP	O
colchicine	colchicine	C425	NN	B-NP	O
.	.	0000	.	O	O

Abnormal	Abnormal	A156	JJ	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
produce	produce	P632	VBP	B-VP	O
only	only	O540	RB	B-NP	O
mild	mild	M430	JJ	I-NP	O
myopathy	myopathy	M130	NN	I-NP	B-Disease
in	in	I500	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
.	.	0000	.	O	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
commonly	commonly	C540	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
CTG	CTG	C320	NN	B-NP	O
repeat	repeat	R130	NN	I-NP	O
expansions	expansion	E215	NNS	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
DM	DM	D500	NN	B-NP	O
-	-	0000	HYPH	O	O
protein	protein	P635	NN	B-NP	O
kinase	kinase	K520	NN	I-NP	O
(	(	0000	(	O	O
DMPK	DMPK	D512	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
altered	alter	A436	VBN	B-NP	O
expression	expression	E216	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
DMPK	DMPK	D512	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
ubiquitously	ubiquitously	U123	RB	I-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
muscle	muscle	M240	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
lineages	lineage	L520	NNS	I-NP	O
during	during	D652	IN	B-PP	O
development	development	D141	NN	B-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
examined	examine	E253	VBN	I-VP	O
by	by	B000	IN	B-PP	O
disrupting	disrupt	D261	VBG	B-VP	O
the	the	T000	DT	B-NP	O
endogenous	endogenous	E532	JJ	I-NP	O
Dmpk	Dmpk	D512	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
overexpressing	overexpresse	O162	VBG	B-VP	O
a	a	A000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
human	human	H500	JJ	I-NP	O
DMPK	DMPK	D512	NN	I-NP	O
transgene	transgene	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
.	.	0000	.	O	O

Nullizygous	Nullizygous	N420	JJ	B-ADJP	O
(	(	0000	(	O	O
-	-	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	O	O
)	)	0000	)	O	O
mice	mouse	M200	NNS	B-NP	O
showed	show	S300	VBD	B-VP	O
only	only	O540	RB	B-NP	O
inconsistent	inconsistent	I525	JJ	I-NP	O
and	and	A530	CC	I-NP	O
minor	minor	M560	JJ	I-NP	O
size	size	S200	NN	I-NP	O
changes	change	C520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
head	head	H300	NN	B-NP	O
and	and	A530	CC	I-NP	O
neck	neck	N200	NN	I-NP	O
muscle	muscle	M240	NN	I-NP	O
fibres	fibre	F162	NNS	I-NP	O
at	at	A300	IN	B-PP	O
older	old	O436	JJR	B-NP	O
age	age	A200	NN	I-NP	O
,	,	0000	,	O	O
animals	animal	A542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
highest	high	H230	JJS	I-NP	O
DMPK	DMPK	D512	NN	I-NP	O
transgene	transgene	T652	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
hypertrophic	hypertrophic	H163	JJ	B-NP	B-Disease
cardiomyopathy	cardiomyopathy	C635	NN	I-NP	I-Disease
and	and	A530	CC	O	O
enhanced	enhance	E523	VBD	B-VP	O
neonatal	neonatal	N534	JJ	B-NP	O
mortality	mortality	M634	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
both	both	B300	DT	B-NP	O
models	model	M342	NNS	I-NP	O
lack	lack	L200	VBP	B-VP	O
other	other	O360	JJ	B-NP	O
frequent	frequent	F625	JJ	I-NP	O
DM	DM	D500	NN	I-NP	B-Disease
symptoms	symptom	S513	NNS	I-NP	O
including	include	I524	VBG	B-PP	O
the	the	T000	DT	B-NP	O
fibre	fibre	F160	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
dependent	dependent	D153	JJ	I-NP	O
atrophy	atrophy	A361	NN	I-NP	B-Disease
,	,	0000	,	O	O
myotonia	myotonia	M350	NN	B-NP	B-Disease
,	,	0000	,	O	O
cataract	cataract	C362	NN	B-NP	B-Disease
and	and	A530	CC	O	O
male	male	M400	JJ	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
infertility	infertility	I516	NN	I-NP	I-Disease
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
strengthen	strengthen	S365	VBP	B-VP	O
the	the	T000	DT	B-NP	O
contention	contention	C535	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
simple	simple	S514	JJ	B-NP	O
loss	loss	L200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
or	or	O600	CC	I-NP	O
gain	gain	G500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
of	of	O100	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
DMPK	DMPK	D512	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
the	the	T000	DT	B-NP	O
only	only	O540	JJ	I-NP	O
crucial	crucial	C624	JJ	I-NP	O
requirement	requirement	R265	NN	I-NP	O
for	for	F600	IN	B-PP	O
development	development	D141	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Mice	Mouse	M200	NNS	B-NP	O
lacking	lack	L252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
develop	develop	D141	VBP	B-VP	O
a	a	A000	DT	B-NP	O
late	late	L300	JJ	I-NP	O
onset	onset	O523	NN	I-NP	O
progressive	progressive	P626	JJ	I-NP	O
myopathy	myopathy	M130	NN	I-NP	B-Disease
.	.	0000	.	O	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
resulting	result	R243	VBG	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
expansion	expansion	E215	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
untranslated	untranslated	U536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
(	(	0000	(	O	O
DMPK	DMPK	D512	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
elucidate	elucidate	E423	VB	I-VP	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
DMPK	DMPK	D512	NN	B-NP	O
in	in	I500	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
pathogenesis	pathogenesis	P325	NN	I-NP	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
developed	develop	D141	VBN	I-VP	O
Dmpk	Dmpk	D512	NN	B-NP	B-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
(	(	0000	(	O	O
Dmpk	Dmpk	D512	NN	B-NP	O
-	-	0000	HYPH	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	O	O
)	)	0000	)	O	O
mice	mouse	M200	NNS	B-NP	O
.	.	0000	.	O	O

Dmpk	Dmpk	D512	NN	B-NP	O
-	-	0000	HYPH	O	O
/	/	0000	SYM	O	O
-	-	0000	HYPH	O	O
mice	mouse	M200	NNS	B-NP	O
develop	develop	D141	VBP	B-VP	O
a	a	A000	DT	B-NP	O
late	late	L300	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
,	,	0000	,	O	O
progressive	progressive	P626	JJ	B-NP	B-Disease
skeletal	skeletal	S243	JJ	I-NP	I-Disease
myopathy	myopathy	M130	NN	I-NP	I-Disease
that	that	T300	WDT	B-NP	O
shares	share	S620	VBZ	B-VP	O
some	some	S500	DT	B-NP	O
pathological	pathological	P342	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
with	with	W300	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
.	.	0000	.	O	O

Muscles	Muscle	M242	NNS	B-NP	O
from	from	F650	IN	B-PP	O
mature	mature	M360	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
variation	variation	V635	NN	B-NP	O
in	in	I500	IN	B-PP	O
fibre	fibre	F160	NN	B-NP	O
size	size	S200	NN	I-NP	O
,	,	0000	,	O	O
increased	increase	I526	VBD	B-VP	O
fibre	fibre	F160	NN	B-NP	B-Disease
degeneration	degeneration	D256	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
fibrosis	fibrosis	F162	NN	I-NP	B-Disease
.	.	0000	.	O	O

Adult	Adult	A343	JJ	B-NP	O
Dmpk	Dmpk	D512	NN	I-NP	O
-	-	0000	HYPH	O	O
/	/	0000	SYM	O	O
-	-	0000	HYPH	O	O
mice	mouse	M200	NNS	B-NP	O
show	show	S000	VBP	B-VP	O
ultrastructural	ultrastructural	U436	JJ	B-NP	O
changes	change	C520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
muscle	muscle	M240	NN	B-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
50	50	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
decrease	decrease	D262	NN	I-NP	O
in	in	I500	IN	B-PP	O
force	force	F620	NN	B-NP	O
generation	generation	G563	NN	I-NP	O
compared	compare	C516	VBN	B-VP	O
to	to	T000	TO	B-PP	O
young	young	Y520	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
DMPK	DMPK	D512	NN	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
necessary	necessary	N260	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
maintenance	maintenance	M535	NN	I-NP	O
of	of	O100	IN	B-PP	O
skeletal	skeletal	S243	JJ	B-NP	O
muscle	muscle	M240	NN	I-NP	O
structure	structure	S362	NN	I-NP	O
and	and	A530	CC	I-NP	O
function	function	F523	NN	I-NP	O
and	and	A530	CC	O	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
decrease	decrease	D262	NN	I-NP	O
in	in	I500	IN	B-PP	O
DMPK	DMPK	D512	NN	B-NP	O
levels	level	L142	NNS	I-NP	O
may	may	M000	MD	B-VP	O
contribute	contribute	C536	VB	I-VP	O
to	to	T000	TO	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
pathology	pathology	P342	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
Brca1	Brca1	B620	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
required	require	R263	VBN	I-VP	O
for	for	F600	IN	B-PP	O
embryonic	embryonic	E516	JJ	B-NP	O
cellular	cellular	C460	JJ	I-NP	O
proliferation	proliferation	P641	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gone	go	G500	VBN	B-VP	O
in	in	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
predisposition	predisposition	P632	NN	B-NP	O
to	to	T000	TO	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
that	that	T300	IN	B-SBAR	O
Brca1	Brca1	B620	NN	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	HYPH	O	O
mice	mouse	M200	NNS	B-NP	O
are	be	A600	VBP	B-VP	O
normal	normal	N654	JJ	B-NP	O
and	and	A530	CC	I-NP	O
fertile	fertile	F634	JJ	I-NP	O
and	and	A530	CC	I-NP	O
lack	lack	L200	JJ	I-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
by	by	B000	IN	B-PP	O
age	age	A200	NN	B-NP	O
eleven	eleven	E415	CD	B-NP	O
months	month	M532	NNS	I-NP	O
.	.	0000	.	O	O

Homozygous	Homozygous	H520	JJ	B-NP	O
Brca1	Brca1	B620	NN	I-NP	O
(	(	0000	(	O	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
6	6	0000	CD	I-NP	O
)	)	0000	)	O	O
mutant	mutant	M353	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
die	die	D000	VBP	B-VP	O
before	before	B160	IN	B-SBAR	O
day	day	D000	NN	B-NP	O
7	7	0000	CD	I-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
embryogenesis	embryogenesis	E516	NN	B-NP	O
.	.	0000	.	O	O

Mutant	Mutant	M353	JJ	B-NP	O
embryos	embryo	E516	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
poorly	poorly	P640	RB	I-VP	O
developed	develop	D141	VBN	I-VP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
no	no	N000	DT	B-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
mesoderm	mesoderm	M236	NN	B-NP	O
formation	formation	F653	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
extraembryonic	extraembryonic	E236	JJ	I-NP	O
region	region	R250	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
abnormal	abnormal	A156	JJ	B-ADJP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
aggregation	aggregation	A262	NN	B-NP	O
with	with	W300	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
tetraploid	tetraploid	T361	JJ	I-NP	O
embryos	embryo	E516	NNS	I-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
rescue	rescue	R200	VB	I-VP	O
the	the	T000	DT	B-NP	O
lethality	lethality	L343	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	FW	B-ADVP	O
vivo	vivo	V100	FW	I-ADVP	O
,	,	0000	,	O	O
mutant	mutant	M353	JJ	B-NP	O
embryos	embryo	E516	NNS	I-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
exhibit	exhibit	E213	VB	I-VP	O
increased	increase	I526	VBN	B-NP	O
apoptosis	apoptosis	A132	NN	I-NP	O
but	but	B300	CC	O	O
show	show	S000	VBP	B-VP	O
reduced	reduce	R323	VBN	I-VP	O
cell	cell	C400	NN	B-NP	O
proliferation	proliferation	P641	NN	I-NP	O
accompanied	accompany	A251	VBN	B-VP	O
by	by	B000	IN	B-PP	O
decreased	decrease	D262	VBN	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
cyclin	cyclin	C245	NN	B-NP	O
E	E	E000	NN	I-NP	O
and	and	A530	CC	I-NP	O
mdm	mdm	M350	NN	I-NP	O
-	-	0000	HYPH	O	O
2	2	0000	CD	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
regulator	regulator	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
p53	p53	P000	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
cyclin	cyclin	C245	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
kinase	kinase	K520	NN	I-NP	O
inhibitor	inhibitor	I513	NN	I-NP	O
p21	p21	P000	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
dramatically	dramatically	D653	RB	I-VP	O
increased	increase	I526	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
embryos	embryo	E516	NNS	I-NP	O
.	.	0000	.	O	O

Buttressing	Buttress	B362	VBG	B-VP	O
these	these	T200	DT	B-NP	O
in	in	I500	FW	I-NP	O
vivo	vivo	V100	FW	I-NP	O
observations	observation	O126	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
fact	fact	F230	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
mutant	mutant	M353	JJ	B-NP	O
blastocyst	blastocyst	B423	JJ	I-NP	O
growth	growth	G630	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
grossly	grossly	G624	RB	B-ADJP	O
impaired	impaired	I516	JJ	I-ADJP	O
in	in	I500	FW	B-ADJP	O
vitro	vitro	V360	FW	I-ADJP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
death	death	D300	NN	I-NP	O
of	of	O100	IN	B-PP	O
Brca1	Brca1	B620	NN	B-NP	O
(	(	0000	(	O	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
6	6	0000	CD	I-NP	O
)	)	0000	)	O	O
mutant	mutant	M353	JJ	B-NP	O
embryos	embryo	E516	NNS	I-NP	O
prior	prior	P600	RB	B-ADVP	O
to	to	T000	TO	B-PP	O
gastrulation	gastrulation	G236	NN	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
due	due	D000	JJ	B-ADVP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
failure	failure	F460	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
proliferative	proliferative	P641	JJ	I-NP	O
burst	burst	B623	NN	I-NP	O
required	require	R263	VBN	B-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
germ	germ	G650	NN	I-NP	O
layers	layer	L620	NNS	I-NP	O
.	.	0000	.	O	O

Increased	Increase	I526	VBN	B-NP	O
coronary	coronary	C656	JJ	I-NP	B-Disease
heart	heart	H630	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
American	American	A562	JJ	I-NP	O
men	man	M500	NNS	I-NP	O
with	with	W300	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
cholesteryl	cholesteryl	C423	NN	I-NP	O
ester	ester	E236	NN	I-NP	O
transfer	transfer	T652	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
despite	despite	D213	IN	B-PP	O
increased	increase	I526	VBN	B-NP	O
HDL	HDL	H340	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
.	.	0000	.	O	O

Plasma	Plasma	P425	NN	B-NP	O
high	high	H200	JJ	I-NP	O
density	density	D523	NN	I-NP	O
lipoprotein	lipoprotein	L163	NN	I-NP	O
(	(	0000	(	O	O
HDL	HDL	H340	NN	B-NP	O
)	)	0000	)	O	O
levels	level	L142	NNS	B-NP	O
are	be	A600	VBP	B-VP	O
strongly	strongly	S365	RB	I-VP	O
genetically	genetically	G532	RB	I-VP	O
determined	determine	D365	VBN	I-VP	O
and	and	A530	CC	O	O
show	show	S000	VBP	B-VP	O
a	a	A000	DT	B-NP	O
general	general	G564	JJ	I-NP	O
inverse	inverse	I516	JJ	I-NP	O
relationship	relationship	R435	NN	I-NP	O
with	with	W300	IN	B-PP	O
coronary	coronary	C656	JJ	B-NP	B-Disease
heart	heart	H630	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
CHD	CHD	C300	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
cholesteryl	cholesteryl	C423	NN	I-NP	O
ester	ester	E236	NN	I-NP	O
transfer	transfer	T652	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
CETP	CETP	C310	NN	B-NP	O
)	)	0000	)	O	O
mediates	mediate	M320	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
transfer	transfer	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
cholesteryl	cholesteryl	C423	NN	B-NP	O
esters	ester	E236	NNS	I-NP	O
from	from	F650	IN	B-PP	O
HDL	HDL	H340	NN	B-NP	O
to	to	T000	TO	B-PP	O
other	other	O360	JJ	B-NP	O
lipoproteins	lipoprotein	L163	NNS	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
key	key	K000	JJ	I-NP	O
participant	participant	P632	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
reverse	reverse	R162	JJ	I-NP	O
transport	transport	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
cholesterol	cholesterol	C423	NN	B-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
periphery	periphery	P616	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
liver	liver	L160	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
prevalence	prevalence	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
different	different	D165	JJ	I-NP	O
CETP	CETP	C310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
(	(	0000	(	O	O
D442G	D442G	D200	NN	B-NP	O
,	,	0000	,	O	O
5	5	0000	CD	B-NP	O
.	.	0000	.	O	O
1	1	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
;	;	0000	:	O	O
intron	intron	I536	NN	B-NP	O
14G	14G	G000	NN	I-NP	O
A	A	A000	NN	I-NP	O
,	,	0000	,	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O
5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
3	3	0000	CD	B-NP	O
,	,	0000	,	O	O
469	469	0000	CD	B-NP	O
men	man	M500	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
ancestry	ancestry	A523	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Honolulu	Honolulu	H540	NNP	I-NP	O
Heart	Heart	H630	NNP	I-NP	O
Program	Program	P626	NNP	I-NP	O
and	and	A530	CC	O	O
mutations	mutation	M352	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
decreased	decrease	D262	VBN	B-NP	O
CETP	CETP	C310	NN	I-NP	O
(	(	0000	(	O	O
-	-	0000	SYM	B-NP	O
35	35	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
increased	increase	I526	VBD	B-VP	O
HDL	HDL	H340	NN	B-NP	O
chol	chol	C400	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
(	(	0000	(	O	O
+	+	0000	SYM	B-NP	O
10	10	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
for	for	F600	IN	B-PP	O
D442G	D442G	D200	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
overall	overall	O164	JJ	I-NP	O
prevalence	prevalence	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
definite	definite	D153	JJ	B-NP	O
CHD	CHD	C300	NN	I-NP	B-Disease
was	be	W200	VBD	B-VP	O
21	21	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
in	in	I500	IN	B-PP	O
men	man	M500	NNS	B-NP	O
with	with	W300	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
and	and	A530	CC	O	O
16	16	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
in	in	I500	IN	B-PP	O
men	man	M500	NNS	B-NP	O
without	without	W300	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
relative	relative	R431	JJ	I-NP	O
risk	risk	R200	NN	I-NP	O
(	(	0000	(	O	O
RR	RR	R600	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
CHD	CHD	C300	NN	B-NP	B-Disease
was	be	W200	VBD	B-VP	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

43	43	0000	CD	B-NP	O
in	in	I500	IN	B-PP	O
men	man	M500	NNS	B-NP	O
with	with	W300	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
<	<	0000	SYM	B-ADJP	O
.	.	0000	.	O	O
05	05	0000	CD	B-NP	O
)	)	0000	)	O	O
;	;	0000	:	O	O
after	after	A136	IN	B-PP	O
adjustment	adjustment	A323	NN	B-NP	O
for	for	F600	IN	B-PP	O
CHD	CHD	C300	NN	B-NP	B-Disease
risk	risk	R200	NN	I-NP	O
factors	factor	F236	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
RR	RR	R600	NN	I-NP	O
was	be	W200	VBD	B-VP	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

55	55	0000	CD	B-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
.	.	0000	.	O	O
02	02	0000	CD	B-NP	O
)	)	0000	)	O	O
;	;	0000	:	O	O
after	after	A136	IN	B-PP	O
additional	additional	A354	JJ	B-NP	O
adjustment	adjustment	A323	NN	I-NP	O
for	for	F600	IN	B-PP	O
HDL	HDL	H340	NN	B-NP	O
levels	level	L142	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
RR	RR	R600	NN	I-NP	O
was	be	W200	VBD	B-VP	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

68	68	0000	CD	B-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
.	.	0000	.	B-NP	O
008	008	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Similar	Similar	S546	JJ	B-NP	O
RR	RR	R600	NN	I-NP	O
values	value	V420	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
obtained	obtain	O135	VBN	I-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
D442G	D442G	D200	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
alone	alone	A450	RB	B-ADVP	O
.	.	0000	.	O	O

Increased	Increase	I526	VBN	B-NP	O
CHD	CHD	C300	NN	I-NP	B-Disease
in	in	I500	IN	B-PP	O
men	man	M500	NNS	B-NP	O
with	with	W300	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
was	be	W200	VBD	B-VP	O
primarily	primarily	P656	RB	I-VP	O
observed	observe	O126	VBN	I-VP	O
for	for	F600	IN	B-PP	O
HDL	HDL	H340	NN	B-NP	O
chol	chol	C400	NN	I-NP	O
41	41	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
60	60	0000	CD	I-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
dl	dl	D400	NN	I-NP	O
;	;	0000	:	O	O
for	for	F600	IN	B-PP	O
HDL	HDL	H340	NN	B-NP	O
chol	chol	C400	NN	I-NP	O
>	>	0000	SYM	B-NP	O
60	60	0000	CD	B-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
dl	dl	D400	NN	B-NP	O
men	man	M500	NNS	I-NP	O
with	with	W300	IN	B-PP	O
and	and	A530	CC	I-PP	O
without	without	W300	IN	I-PP	O
mutations	mutation	M352	NNS	B-NP	O
had	have	H300	VBD	B-VP	O
low	low	L000	JJ	B-NP	O
CHD	CHD	C300	NN	I-NP	B-Disease
prevalence	prevalence	P614	NN	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
genetic	genetic	G532	JJ	B-NP	O
CETP	CETP	C310	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
an	an	A500	DT	B-NP	O
independent	independent	I531	JJ	I-NP	O
risk	risk	R200	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
for	for	F600	IN	B-PP	O
CHD	CHD	C300	NN	B-NP	B-Disease
,	,	0000	,	O	O
primarily	primarily	P656	RB	B-ADVP	O
due	due	D000	JJ	B-PP	O
to	to	T000	TO	B-PP	O
increased	increase	I526	VBN	B-NP	O
CHD	CHD	C300	NN	I-NP	B-Disease
prevalence	prevalence	P614	NN	I-NP	O
in	in	I500	IN	B-PP	O
men	man	M500	NNS	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
D442G	D442G	D200	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	O	O
HDL	HDL	H340	NN	B-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
between	between	B350	IN	B-PP	O
41	41	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
60	60	0000	CD	I-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
dl	dl	D400	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
both	both	B300	CC	O	O
HDL	HDL	H340	NN	B-NP	O
concentration	concentration	C525	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
dynamics	dynamic	D520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
cholesterol	cholesterol	C423	NN	B-NP	O
transport	transport	T652	NN	I-NP	O
through	through	T620	IN	B-PP	O
HDL	HDL	H340	NN	B-NP	O
(	(	0000	(	O	O
i	i	I000	NN	B-NP	O
.	.	0000	.	I-NP	O
e	e	E000	NN	I-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
reverse	reverse	R162	JJ	B-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
transport	transport	T652	NN	I-NP	O
)	)	0000	)	O	O
determine	determine	D365	VBP	B-VP	O
the	the	T000	DT	B-NP	O
anti	anti	A530	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
atherogenicity	atherogenicity	A362	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HDL	HDL	H340	NN	I-NP	O
fraction	fraction	F623	NN	I-NP	O
.	.	0000	.	O	O

Mapping	Map	M152	VBG	B-VP	O
the	the	T000	DT	B-NP	O
homolog	homolog	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
Rb1	Rb1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
14	14	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
higher	high	H260	JJR	B-NP	O
primates	primate	P653	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Rb1	Rb1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
implicated	implicate	I514	VBN	I-VP	O
with	with	W300	IN	B-PP	O
retinoblastoma	retinoblastoma	R351	NN	B-NP	B-Disease
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
located	located	L230	JJ	B-ADJP	O
on	on	O500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
Chromosome	Chromosome	C652	NN	I-NP	O
(	(	0000	(	O	O
Chr	Chr	C600	NN	B-NP	O
)	)	0000	)	O	O
13q14	13q14	Q000	CD	B-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
unique	unique	U520	JJ	I-NP	O
sequence	sequence	S252	NN	I-NP	O
human	human	H500	JJ	I-NP	O
Rb1	Rb1	R100	NN	I-NP	O
cosmid	cosmid	C253	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
probe	probe	P610	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	I-VP	O
localize	localize	L242	VB	I-VP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
on	on	O500	IN	B-PP	O
apes	ape	A120	NNS	B-NP	O
Chr	Chr	C600	NN	B-NP	O
14	14	0000	CD	I-NP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
FISH	FISH	F200	NN	I-NP	O
technique	technique	T252	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
conservation	conservation	C526	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Rb1	Rb1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
higher	high	H260	JJR	B-NP	O
primates	primate	P653	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
corresponding	correspond	C621	VBG	I-NP	O
equivalent	equivalent	E214	JJ	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
(	(	0000	(	O	O
14q14	14q14	Q000	CD	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	NN	I-NP	O
may	may	M000	MD	B-VP	O
serve	serve	S610	VB	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
phylogenetic	phylogenetic	P425	JJ	I-NP	O
marker	marker	M626	NN	I-NP	O
to	to	T000	TO	B-VP	O
further	further	F636	RB	I-VP	O
trace	trace	T620	VB	I-VP	O
the	the	T000	DT	B-NP	O
evolutionary	evolutionary	E143	JJ	I-NP	O
pathway	pathway	P300	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
descent	descent	D253	NN	I-NP	O
.	.	0000	.	O	O

Wiskott	Wiskott	W230	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
:	:	0000	:	O	O
no	no	N000	DT	B-NP	O
strict	strict	S362	JJ	I-NP	O
genotype	genotype	G531	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlations	correlation	C643	NNS	I-NP	O
but	but	B300	CC	O	O
clustering	cluster	C423	VBG	B-VP	O
of	of	O100	IN	B-PP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
amino	amino	A500	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
terminal	terminal	T654	JJ	I-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
WASP	WASP	W210	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
WASP	WASP	W210	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
mutated	mutate	M300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
presenting	present	P625	VBG	B-VP	O
with	with	W300	IN	B-PP	O
WAS	WAS	W200	NN	B-NP	B-Disease
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
showing	show	S520	VBG	B-VP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
thrombocytopenia	thrombocytopenia	T651	NN	I-NP	I-Disease
.	.	0000	.	O	O

Mutation	Mutation	M350	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
19	19	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
German	German	G650	JJ	B-NP	O
,	,	0000	,	I-NP	O
Swiss	Swiss	S200	JJ	I-NP	O
and	and	A530	CC	I-NP	O
Turkish	Turkish	T620	JJ	I-NP	O
descent	descent	D253	NN	I-NP	O
by	by	B000	IN	B-PP	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
and	and	A530	CC	I-NP	O
sequencing	sequencing	S252	NN	I-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
and	and	A530	CC	I-NP	O
10	10	0000	CD	I-NP	O
known	know	K500	VBN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
striking	striking	S362	JJ	I-NP	O
clustering	clustering	C423	NN	I-NP	O
of	of	O100	IN	B-PP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
four	four	F600	CD	I-NP	O
exons	exon	E252	NNS	I-NP	O
contrasted	contrast	C536	VBN	B-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
random	random	R535	JJ	I-NP	O
distribution	distribution	D236	NN	I-NP	O
of	of	O100	IN	B-PP	O
nonsense	nonsense	N525	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

More	More	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
85	85	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
known	know	K500	VBN	I-NP	O
missense	missense	M252	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
localized	localize	L242	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
amino	amino	A500	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
terminal	terminal	T654	JJ	I-NP	O
stretch	stretch	S363	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
WASP	WASP	W210	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
;	;	0000	:	O	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
contained	contain	C535	VBD	B-VP	O
a	a	A000	DT	B-NP	O
mutational	mutational	M354	JJ	I-NP	O
hot	hot	H300	JJ	I-NP	O
spot	spot	S130	NN	I-NP	O
at	at	A300	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
86	86	0000	CD	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
genotype	genotype	G531	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlation	correlation	C643	NN	I-NP	O
emerged	emerge	E562	VBD	B-VP	O
after	after	A136	IN	B-PP	O
a	a	A000	DT	B-NP	O
comparison	comparison	C516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
identified	identify	I353	VBN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
resulting	result	R243	VBG	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
picture	picture	P236	NN	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
classical	classical	C424	JJ	I-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
substitution	substitution	S123	NN	I-NP	O
at	at	A300	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
86	86	0000	CD	I-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
extremely	extremely	E236	RB	I-NP	O
variable	variable	V614	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
Swiss	Swiss	S200	JJ	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
extended	extend	E235	VBN	I-NP	O
homology	homology	H542	NN	I-NP	O
search	search	S620	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
distant	distant	D235	JJ	I-NP	O
relationship	relationship	R435	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
stretch	stretch	S363	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
vasodilator	vasodilator	V234	NN	I-NP	O
-	-	0000	HYPH	O	O
stimulated	stimulate	S354	VBN	B-VP	O
phosphoprotein	phosphoprotein	P216	NN	B-NP	O
(	(	0000	(	O	O
VASP	VASP	V210	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
maintenance	maintenance	M535	NN	I-NP	O
of	of	O100	IN	B-PP	O
cyto	cyto	C300	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
architecture	architecture	A623	NN	I-NP	O
by	by	B000	IN	B-PP	O
interacting	interact	I536	VBG	B-VP	O
with	with	W300	IN	B-PP	O
actin	actin	A235	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
like	like	L200	JJ	I-NP	O
filaments	filament	F453	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Influence	Influence	I514	NN	B-NP	O
of	of	O100	IN	B-PP	O
PAX6	PAX6	P200	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
dosage	dosage	D200	NN	I-NP	O
on	on	O500	IN	B-PP	O
development	development	D141	NN	B-NP	O
:	:	0000	:	O	O
overexpression	overexpression	O162	NN	B-NP	O
causes	cause	C200	VBZ	B-VP	O
severe	severe	S160	JJ	B-NP	O
eye	eye	E000	NN	I-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Aniridia	Aniridia	A563	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
man	man	M500	NN	B-NP	O
and	and	A530	CC	O	O
Small	Small	S540	JJ	B-NP	O
eye	eye	E000	NN	I-NP	O
in	in	I500	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
are	be	A600	VBP	B-VP	O
semidominant	semidominant	S535	JJ	B-NP	B-Disease
developmental	developmental	D141	JJ	I-NP	I-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
paired	paired	P630	JJ	I-NP	O
box	box	B200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
PAX6	PAX6	P200	NN	I-NP	O
.	.	0000	.	O	O

Whereas	Whereas	W620	IN	B-SBAR	O
heterozygotes	heterozygote	H362	NNS	B-NP	O
suffer	suffer	S160	VBP	B-VP	O
from	from	F650	IN	B-PP	O
iris	iris	I620	NN	B-NP	B-Disease
hypoplasia	hypoplasia	H142	NN	I-NP	I-Disease
,	,	0000	,	O	O
homozygous	homozygous	H520	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
lack	lack	L200	VBP	B-VP	O
eyes	eye	E200	NNS	B-NP	O
and	and	A530	CC	O	O
nasal	nasal	N240	JJ	B-NP	O
cavities	cavity	C132	NNS	I-NP	O
and	and	A530	CC	O	O
exhibit	exhibit	E213	VBP	B-VP	O
brain	brain	B650	NN	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
gene	gene	G500	NN	B-NP	O
dosage	dosage	D200	NN	I-NP	O
in	in	I500	IN	B-PP	O
more	more	M600	JJR	B-NP	O
detail	detail	D340	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
generated	generate	G563	VBN	I-VP	O
yeast	yeast	Y230	NN	B-NP	O
artificial	artificial	A631	JJ	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
transgenic	transgenic	T652	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
carrying	carry	C652	VBG	B-VP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
PAX6	PAX6	P200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

When	When	W500	WRB	B-ADVP	O
crossed	cross	C623	VBN	B-VP	O
onto	onto	O530	IN	B-PP	O
the	the	T000	DT	B-NP	O
Small	Small	S540	JJ	I-NP	O
eye	eye	E000	NN	I-NP	O
background	background	B265	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
transgene	transgene	T652	NN	I-NP	O
rescues	rescue	R200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

Strikingly	Strikingly	S362	RB	B-ADVP	O
,	,	0000	,	O	O
mice	mouse	M200	NNS	B-NP	O
carrying	carry	C652	VBG	B-VP	O
multiple	multiple	M431	JJ	B-NP	O
copies	copy	C120	NNS	I-NP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
background	background	B265	NN	I-NP	O
show	show	S000	VBP	B-VP	O
specific	specific	S121	JJ	B-NP	O
developmental	developmental	D141	JJ	I-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
eye	eye	E000	NN	I-NP	I-Disease
,	,	0000	,	O	O
but	but	B300	CC	O	O
not	not	N300	RB	O	O
of	of	O100	IN	B-PP	O
other	other	O360	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
expressing	express	E216	VBG	B-VP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
five	five	F100	CD	I-NP	O
different	different	D165	JJ	I-NP	O
eye	eye	E000	NN	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
changes	change	C520	NNS	B-NP	O
in	in	I500	IN	B-PP	O
PAX6	PAX6	P200	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
provide	provide	P613	VBP	B-VP	O
evidence	evidence	E135	NN	B-NP	O
that	that	T300	IN	B-SBAR	O
not	not	N300	RB	B-CONJP	O
only	only	O540	RB	I-CONJP	O
reduced	reduce	R323	VBN	B-VP	O
,	,	0000	,	O	O
but	but	B300	CC	B-CONJP	O
also	also	A420	RB	I-CONJP	O
increased	increase	I526	VBN	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
transcriptional	transcriptional	T652	JJ	B-NP	O
regulators	regulator	R243	NNS	I-NP	O
can	can	C500	MD	B-VP	O
cause	cause	C200	VB	I-VP	O
developmental	developmental	D141	JJ	B-NP	B-Disease
defects	defect	D123	NNS	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Heterodimer	Heterodimer	H363	NN	B-NP	O
formation	formation	F653	NN	I-NP	O
and	and	A530	CC	I-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
galactose	galactose	G423	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
uridylyltransferase	uridylyltransferase	U634	NN	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
fundamental	fundamental	F535	JJ	I-NP	O
questions	question	Q235	NNS	I-NP	O
concerning	concern	C526	VBG	B-VP	O
expression	expression	E216	NN	B-NP	O
and	and	A530	CC	O	O
function	function	F523	NN	B-NP	O
of	of	O100	IN	B-PP	O
dimeric	dimeric	D562	JJ	B-NP	O
enzymes	enzyme	E525	NNS	I-NP	O
involves	involve	I514	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
impact	impact	I512	NN	I-NP	O
of	of	O100	IN	B-PP	O
naturally	naturally	N364	RB	B-VP	O
occurring	occur	O265	VBG	I-VP	O
mutations	mutation	M352	NNS	B-NP	O
on	on	O500	IN	B-PP	O
subunit	subunit	S153	NN	B-NP	O
assembly	assembly	A251	NN	I-NP	O
and	and	A530	CC	O	O
heterodimer	heterodimer	H363	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
question	question	Q235	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
of	of	O100	IN	B-PP	O
particular	particular	P632	JJ	B-NP	O
interest	interest	I536	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
galactose	galactose	G423	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
l	l	L000	NN	I-NP	O
-	-	0000	HYPH	O	O
phosphate	phosphate	P213	NN	B-NP	O
uridylyl	uridylyl	U634	NN	I-NP	O
-	-	0000	HYPH	O	O
transferase	transferase	T652	NN	B-NP	O
(	(	0000	(	O	O
GALT	GALT	G430	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
impairment	impairment	I516	NN	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
metabolic	metabolic	M314	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
galactosemia	galactosemia	G423	NN	I-NP	B-Disease
,	,	0000	,	O	O
because	because	B200	IN	B-SBAR	O
many	many	M500	JJ	B-NP	O
if	if	I100	IN	B-SBAR	O
not	not	N300	RB	O	O
most	most	M230	JJS	B-NP	O
patients	patient	P353	NNS	I-NP	O
studied	study	S300	VBN	B-VP	O
to	to	T000	TO	B-PP	O
date	date	D300	NN	B-NP	O
are	be	A600	VBP	B-VP	O
compound	compound	C515	NN	B-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
rather	rather	R360	RB	B-PP	O
than	than	T500	IN	I-PP	O
true	true	T600	JJ	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
homozygotes	homozygote	H523	NNS	I-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
broad	broad	B630	JJ	I-NP	O
range	range	R520	NN	I-NP	O
of	of	O100	IN	B-PP	O
phenotypic	phenotypic	P531	JJ	B-NP	O
severity	severity	S163	NN	I-NP	O
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
raises	raise	R200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
possibility	possibility	P214	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
allelic	allelic	A420	JJ	B-NP	O
combination	combination	C515	NN	I-NP	O
,	,	0000	,	O	O
not	not	N300	RB	O	O
just	just	J230	RB	B-NP	O
allelic	allelic	A420	JJ	I-NP	O
constitution	constitution	C523	NN	I-NP	O
,	,	0000	,	O	O
may	may	M000	MD	B-VP	O
play	play	P400	VB	I-VP	O
some	some	S500	DT	B-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
determining	determine	D365	VBG	B-VP	O
outcome	outcome	O325	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
work	work	W620	NN	I-NP	O
described	describe	D261	VBN	B-VP	O
herein	herein	H650	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
selected	select	S423	VBN	I-VP	O
two	two	T000	CD	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
naturally	naturally	N364	RB	B-VP	O
occurring	occur	O265	VBG	I-VP	O
null	null	N400	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
GALT	GALT	G430	NN	B-NP	O
,	,	0000	,	I-NP	O
Q188R	Q188R	Q600	NN	I-NP	O
and	and	A530	CC	I-NP	O
R333W	R333W	R000	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
asked	ask	A230	VBD	B-VP	O
the	the	T000	DT	B-NP	O
questions	question	Q235	NNS	I-NP	O
(	(	0000	(	O	O
i	i	I000	NNS	B-NP	O
)	)	0000	)	O	O
what	what	W300	WP	B-NP	O
are	be	A600	VBP	B-VP	O
the	the	T000	DT	B-NP	O
impacts	impact	I512	NNS	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
on	on	O500	IN	B-PP	O
subunit	subunit	S153	NN	B-NP	O
assembly	assembly	A251	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
(	(	0000	(	B-LST	O
ii	ii	I000	LS	I-LST	O
)	)	0000	)	O	O
if	if	I100	IN	B-SBAR	O
heterodimers	heterodimer	H363	NNS	B-NP	O
do	do	D000	VBP	B-VP	O
form	form	F650	VB	I-VP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
they	they	T000	PRP	B-NP	O
active	active	A231	JJ	B-ADJP	O
?	?	0000	.	O	O

To	To	T000	TO	B-VP	O
answer	answer	A526	VB	I-VP	O
these	these	T200	DT	B-NP	O
questions	question	Q235	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
established	establish	E231	VBN	I-VP	O
a	a	A000	DT	B-NP	O
yeast	yeast	Y230	NN	I-NP	O
system	system	S235	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
coexpression	coexpression	C216	NN	I-NP	O
of	of	O100	IN	B-PP	O
epitope	epitope	E131	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
tagged	tag	T230	VBN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
GALT	GALT	G430	NN	I-NP	O
and	and	A530	CC	O	O
investigated	investigate	I512	VBD	B-VP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
extent	extent	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
specific	specific	S121	JJ	B-NP	O
GALT	GALT	G430	NN	I-NP	O
subunit	subunit	S153	NN	I-NP	O
interactions	interaction	I536	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
defined	define	D153	VBN	B-NP	O
heterodimer	heterodimer	H363	NN	I-NP	O
pools	pool	P420	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
both	both	B300	CC	O	O
homodimers	homodimer	H535	NNS	B-NP	O
and	and	A530	CC	I-NP	O
heterodimers	heterodimer	H363	NNS	I-NP	O
do	do	D000	VBP	B-VP	O
form	form	F650	VB	I-VP	O
involving	involve	I514	VBG	I-VP	O
each	each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
subunits	subunit	S153	NNS	I-NP	O
tested	test	T230	VBN	B-VP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
both	both	B300	CC	O	O
heterodimer	heterodimer	H363	NN	B-NP	O
pools	pool	P420	NNS	I-NP	O
retain	retain	R350	VBP	B-VP	O
substantial	substantial	S123	JJ	B-NP	O
enzymatic	enzymatic	E525	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
significant	significant	S251	JJ	B-ADJP	O
not	not	N300	RB	B-CONJP	O
only	only	O540	RB	I-CONJP	O
in	in	I500	IN	B-PP	O
terms	term	T652	NNS	B-NP	O
of	of	O100	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
implications	implication	I514	NNS	I-NP	O
for	for	F600	IN	B-PP	O
furthering	further	F636	VBG	B-VP	O
our	our	O600	PRP$	B-NP	O
understanding	understanding	U536	NN	I-NP	O
of	of	O100	IN	B-PP	O
galactosemia	galactosemia	G423	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
GALT	GALT	G430	NN	I-NP	O
holoenzyme	holoenzyme	H452	NN	I-NP	O
structure	structure	S362	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
function	function	F523	NN	I-NP	O
relationships	relationship	R435	NNS	I-NP	O
but	but	B300	CC	O	O
also	also	A420	RB	B-ADVP	O
because	because	B200	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
system	system	S235	NN	I-NP	O
described	describe	D261	VBN	B-VP	O
may	may	M000	MD	B-VP	O
serve	serve	S610	VB	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
similar	similar	S546	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
other	other	O360	JJ	B-NP	O
complexes	complex	C514	NNS	I-NP	O
composed	compose	C512	VBN	B-VP	O
of	of	O100	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
subunits	subunit	S153	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Cleavage	Cleavage	C412	NN	B-NP	O
of	of	O100	IN	B-PP	O
huntingtin	huntingtin	H535	NN	B-NP	O
by	by	B000	IN	B-PP	O
apopain	apopain	A150	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
proapoptotic	proapoptotic	P613	JJ	I-NP	O
cysteine	cysteine	C235	NN	I-NP	O
protease	protease	P632	NN	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
modulated	modulate	M343	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
polyglutamine	polyglutamine	P424	NN	I-NP	O
tract	tract	T623	NN	I-NP	O
.	.	0000	.	O	O

Apoptosis	Apoptosis	A132	NN	B-NP	O
has	have	H200	VBZ	B-VP	O
recently	recently	R253	RB	I-VP	O
been	be	B500	VBN	I-VP	O
recognized	recognize	R252	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
mode	mode	M300	NN	I-NP	O
of	of	O100	IN	B-PP	O
cell	cell	C400	NN	B-NP	O
death	death	D300	NN	I-NP	O
in	in	I500	IN	B-PP	O
Huntington	Huntington	H535	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
HD	HD	H300	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Apopain	Apopain	A150	NNP	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
counterpart	counterpart	C536	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
nematode	nematode	N530	JJ	I-NP	O
cysteine	cysteine	C235	NN	I-NP	O
protease	protease	P632	NN	I-NP	O
death	death	D300	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
,	,	0000	,	O	O
CED	CED	C300	VBN	B-VP	O
-	-	0000	HYPH	B-NP	O
3	3	0000	CD	I-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
key	key	K000	JJ	I-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
proteolytic	proteolytic	P634	JJ	B-NP	O
events	event	E153	NNS	I-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
apoptosis	apoptosis	A132	NN	B-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
apoptotic	apoptotic	A132	JJ	B-NP	O
extracts	extract	E236	NNS	I-NP	O
and	and	A530	CC	O	O
apopain	apopain	A150	VB	B-VP	O
itself	itself	I324	PRP	B-NP	O
specifically	specifically	S121	RB	B-ADVP	O
cleave	cleave	C410	VBP	B-VP	O
the	the	T000	DT	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
,	,	0000	,	O	O
huntingtin	huntingtin	H535	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
rate	rate	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
cleavage	cleavage	C412	NN	B-NP	O
increases	increase	I526	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
length	length	L523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
huntingtin	huntingtin	H535	NN	I-NP	O
polyglutamine	polyglutamine	P424	NN	I-NP	O
tract	tract	T623	NN	I-NP	O
,	,	0000	,	O	O
providing	provide	P613	VBG	B-VP	O
an	an	A500	DT	B-NP	O
explanation	explanation	E214	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
gain	gain	G500	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
of	of	O100	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
function	function	F523	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
CAG	CAG	C200	NN	B-NP	O
expansion	expansion	E215	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
huntingtin	huntingtin	H535	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
cleaved	cleave	C413	VBN	I-VP	O
by	by	B000	IN	B-PP	O
cysteine	cysteine	C235	NN	B-NP	O
proteases	protease	P632	NNS	I-NP	O
and	and	A530	CC	O	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
HD	HD	H300	NN	B-NP	B-Disease
might	might	M230	MD	B-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
inappropriate	inappropriate	I516	JJ	B-NP	I-Disease
apoptosis	apoptosis	A132	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
'	'	0000	SYM	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
lies	lie	L200	VBZ	B-VP	O
within	within	W350	IN	B-PP	O
a	a	A000	DT	B-NP	O
duplicated	duplicated	D142	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
17q21	17q21	Q000	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
begin	begin	B250	VB	I-VP	O
to	to	T000	TO	I-VP	O
address	address	A362	VB	I-VP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
abnormal	abnormal	A156	JJ	B-NP	O
regulation	regulation	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
/	/	0000	SYM	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
susceptibility	susceptibility	S213	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
critical	critical	C632	JJ	I-NP	O
step	step	S310	NN	I-NP	O
in	in	I500	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	O
breast	breast	B623	NN	I-NP	O
/	/	0000	SYM	B-NP	O
ovarian	ovarian	O165	JJ	I-NP	O
tumorigenesis	tumorigenesis	T562	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
determined	determine	D365	VBN	I-VP	O
the	the	T000	DT	B-NP	O
detailed	detailed	D343	JJ	I-NP	O
structure	structure	S362	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
genomic	genomic	G520	JJ	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
genome	genome	G500	NN	I-NP	O
contains	contain	C535	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
tandem	tandem	T535	JJ	I-NP	O
duplication	duplication	D142	NN	I-NP	O
of	of	O100	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
30	30	0000	CD	I-NP	O
kilobases	kilobas	K412	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
copies	copy	C120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
exons	exon	E252	NNS	I-NP	O
1	1	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
2	2	0000	CD	I-NP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
1	1	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
3	3	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
adjacent	adjacent	A325	JJ	I-NP	O
1A1	1A1	A000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
3B	3B	B000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	B-PP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
reported	report	R163	VBN	I-NP	O
295	295	0000	CD	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
intergenic	intergenic	I536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

Sequence	Sequence	S252	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
duplicated	duplicate	D142	VBN	I-NP	O
exons	exon	E252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
and	and	A530	CC	I-NP	O
1A1	1A1	A000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
3B	3B	B000	NN	I-NP	O
and	and	A530	CC	O	O
flanking	flanking	F452	NN	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
reveals	reveal	R142	VBZ	B-VP	O
maintenance	maintenance	M535	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
exon	exon	E250	NN	I-NP	O
structure	structure	S362	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
degree	degree	D260	NN	I-NP	O
of	of	O100	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
sequence	sequence	S252	NN	I-NP	O
identity	identity	I353	NN	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
are	be	A600	VBP	B-VP	O
non	non	N500	AFX	O	O
-	-	0000	HYPH	O	O
processed	process	P623	VBN	B-NP	O
pseudogenes	pseudogene	P232	NNS	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
duplication	duplication	D142	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
recent	recent	R253	JJ	I-NP	O
event	event	E153	NN	I-NP	O
in	in	I500	IN	B-PP	O
evolutionary	evolutionary	E143	JJ	B-NP	O
terms	term	T652	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
also	also	A420	RB	B-ADVP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
processed	process	P623	VBN	I-NP	O
pseudogene	pseudogene	P232	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
acidic	acidic	A232	JJ	I-NP	O
ribosomal	ribosomal	R125	JJ	I-NP	O
phosphoprotein	phosphoprotein	P216	NN	I-NP	O
P1	P1	P000	NN	I-NP	O
(	(	0000	(	O	O
ARPP1	ARPP1	A610	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
inserted	insert	I526	VBN	I-VP	O
directly	directly	D623	RB	B-ADVP	O
upstream	upstream	U123	RB	B-ADVP	O
of	of	O100	IN	B-PP	O
pseudo	pseudo	P230	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
exon	exon	E250	NN	I-NP	O
1A	1A	A000	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
believe	believe	B410	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
could	could	C430	MD	B-VP	O
not	not	N300	RB	I-VP	O
only	only	O540	RB	I-VP	O
confound	confound	C515	VB	I-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
could	could	C430	MD	B-VP	O
have	have	H100	VB	I-VP	O
implications	implication	I514	NNS	B-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
and	and	A530	CC	I-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
regulation	regulation	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
transcription	transcription	T652	NN	I-NP	O
,	,	0000	,	O	O
translation	translation	T652	NN	B-NP	O
and	and	A530	CC	I-NP	O
function	function	F523	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Deletion	Deletion	D435	NN	B-NP	O
of	of	O100	IN	B-PP	O
small	small	S540	JJ	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
ribonucleoprotein	ribonucleoprotein	R152	NN	I-NP	O
polypeptide	polypeptide	P413	NN	I-NP	O
N	N	N000	NN	I-NP	O
(	(	0000	(	O	O
SNRPN	SNRPN	S561	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
detected	detect	D323	VBN	B-VP	O
by	by	B000	IN	B-PP	O
fluorescence	fluorescence	F462	NN	B-NP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
:	:	0000	:	O	O
two	two	T000	CD	B-NP	O
sibs	sib	S120	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
typical	typical	T124	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
without	without	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
cytogenetic	cytogenetic	C325	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
15q	15q	Q000	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
ribonucleoprotein	ribonucleoprotein	R152	NN	I-NP	O
polypeptide	polypeptide	P413	NN	I-NP	O
N	N	N000	NN	I-NP	O
(	(	0000	(	O	O
SNRPN	SNRPN	S561	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
regarded	regard	R263	VBN	I-VP	O
as	as	A200	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
candidates	candidate	C532	NNS	I-NP	O
for	for	F600	IN	B-PP	O
Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PWS	PWS	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
two	two	T000	CD	B-NP	O
sibs	sib	S120	NNS	I-NP	O
with	with	W300	IN	B-PP	O
typical	typical	T124	JJ	B-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
presenting	present	P625	VBG	B-VP	O
deletion	deletion	D435	NN	B-NP	O
of	of	O100	IN	B-PP	O
SNRPN	SNRPN	S561	NN	B-NP	O
detected	detect	D323	VBN	B-VP	O
by	by	B000	IN	B-PP	O
fluorescence	fluorescence	F462	NN	B-NP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
(	(	0000	(	O	O
FISH	FISH	F200	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Neither	Neither	N360	CC	O	O
a	a	A000	DT	B-NP	O
cytogenetically	cytogenetically	C325	RB	I-NP	O
detectable	detectable	D323	JJ	I-NP	O
15q12	15q12	Q000	CD	I-NP	O
deletion	deletion	D435	NN	I-NP	O
nor	nor	N600	CC	O	O
a	a	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
D15S11	D15S11	D200	NN	I-NP	O
,	,	0000	,	O	O
D15S10	D15S10	D200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
GABRB3	GABRB3	G161	NN	B-NP	O
cosmid	cosmid	C253	NN	I-NP	O
probes	probe	P612	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
either	either	E360	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
implies	imply	I514	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
smaller	small	S546	JJR	I-NP	O
deletion	deletion	D435	NN	I-NP	O
limited	limit	L530	VBN	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
critical	critical	C632	JJ	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

FISH	FISH	F200	NN	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
SNRPN	SNRPN	S561	NN	I-NP	O
probe	probe	P610	NN	I-NP	O
will	will	W400	MD	B-VP	O
permit	permit	P653	VB	I-VP	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
limited	limited	L530	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
not	not	N300	RB	B-ADJP	O
detectable	detectable	D323	JJ	I-ADJP	O
with	with	W300	IN	B-PP	O
other	other	O360	JJ	B-NP	O
probes	probe	P612	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Expression	Expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
von	von	V500	NNP	I-NP	B-Disease
Hippel	Hippel	H140	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lindau	Lindau	L530	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
tumour	tumour	T560	NN	I-NP	I-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
during	during	D652	IN	B-PP	O
human	human	H500	JJ	B-NP	O
embryogenesis	embryogenesis	E516	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
von	von	V500	NNP	I-NP	B-Disease
Hippel	Hippel	H140	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lindau	Lindau	L530	NNP	I-NP	I-Disease
(	(	0000	(	O	I-Disease
VHL	VHL	V400	NNP	O	I-Disease
)	)	0000	)	O	I-Disease
disease	disease	D200	NN	B-NP	I-Disease
product	product	P632	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
thought	think	T230	VBN	I-VP	O
to	to	T000	TO	B-PP	O
down	down	D500	RB	B-VP	O
-	-	0000	HYPH	I-VP	O
regulate	regulate	R243	VB	I-VP	O
transcription	transcription	T652	NN	B-NP	O
by	by	B000	IN	B-PP	O
antagonizing	antagonize	A532	VBG	B-VP	O
elongin	elongin	E452	NN	B-NP	O
-	-	0000	HYPH	O	O
enhanced	enhance	E523	VBN	B-VP	O
transcriptional	transcriptional	T652	JJ	B-NP	O
elongation	elongation	E452	NN	I-NP	O
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
predispose	predispose	P632	VBP	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
retinal	retinal	R354	JJ	B-NP	B-Disease
,	,	0000	,	I-NP	I-Disease
cerebellar	cerebellar	C614	JJ	I-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
spinal	spinal	S154	JJ	I-NP	I-Disease
haemangioblastomas	haemangioblastoma	H521	NNS	I-NP	I-Disease
,	,	0000	,	O	O
renal	renal	R540	JJ	B-NP	B-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
phaeochromocytoma	phaeochromocytoma	P265	NN	I-NP	B-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
somatic	somatic	S532	JJ	B-NP	O
Inactivation	Inactivation	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
frequent	frequent	F625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
renal	renal	R540	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
haemangioblastoma	haemangioblastoma	H521	NN	I-NP	B-Disease
.	.	0000	.	O	O

Regulation	Regulation	R243	NN	B-NP	O
of	of	O100	IN	B-PP	O
transcript	transcript	T652	NN	B-NP	O
elongation	elongation	E452	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
important	important	I516	JJ	I-NP	O
control	control	C536	NN	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
for	for	F600	IN	B-PP	O
gene	gene	G500	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
might	might	M230	MD	B-VP	O
modify	modify	M310	VB	I-VP	O
the	the	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
proto	proto	P630	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
oncogenes	oncogene	O525	NNS	B-NP	O
and	and	A530	CC	O	O
growth	growth	G630	NN	B-NP	O
suppressor	suppressor	S162	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
during	during	D652	IN	B-PP	O
embryogenesis	embryogenesis	E516	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
therefore	therefore	T616	RB	B-ADVP	O
investigated	investigate	I512	VBD	B-VP	O
the	the	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
VHL	VHL	V400	NN	B-NP	B-Disease
mRNA	mRNA	M650	NN	I-NP	O
during	during	D652	IN	B-PP	O
human	human	H500	JJ	B-NP	O
embryogenesis	embryogenesis	E516	NN	I-NP	O
by	by	B000	IN	B-PP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
at	at	A300	IN	B-PP	O
4	4	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
6	6	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
10	10	0000	CD	I-NP	O
weeks	week	W200	NNS	I-NP	O
post	post	P230	JJ	I-NP	O
conception	conception	C521	NN	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
VHL	VHL	V400	NN	B-NP	B-Disease
mRNA	mRNA	M650	NN	I-NP	O
was	be	W200	VBD	B-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
three	three	T600	CD	I-NP	O
germ	germ	G650	NN	I-NP	O
layers	layer	L620	NNS	I-NP	O
,	,	0000	,	O	O
strong	strong	S365	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
was	be	W200	VBD	B-VP	O
noted	note	N300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
central	central	C536	JJ	I-NP	O
nervous	nervous	N612	JJ	I-NP	O
system	system	S235	NN	I-NP	O
,	,	0000	,	O	O
kidneys	kidney	K352	NNS	B-NP	O
,	,	0000	,	O	O
testis	testis	T232	NN	B-NP	O
and	and	A530	CC	I-NP	O
lung	lung	L520	NN	I-NP	O
.	.	0000	.	O	O

Within	Within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
kidney	kidney	K350	NN	I-NP	O
,	,	0000	,	O	O
VHL	VHL	V400	NN	B-NP	B-Disease
mRNA	mRNA	M650	NN	I-NP	O
was	be	W200	VBD	B-VP	O
differentially	differentially	D165	RB	I-VP	O
expressed	express	E216	VBN	I-VP	O
within	within	W350	IN	B-PP	O
renal	renal	R540	JJ	B-NP	O
tubules	tubule	T142	NNS	I-NP	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
may	may	M000	MD	B-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
kidney	kidney	K350	NN	B-NP	O
development	development	D141	NN	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
alternatively	alternatively	A436	RB	I-NP	O
spliced	splice	S142	VBN	I-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
mRNAs	mRNA	M652	NNS	I-NP	O
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
inclusion	inclusion	I524	NN	B-NP	O
(	(	0000	(	O	O
isoform	isoform	I216	NN	B-NP	O
I	I	I000	CD	I-NP	O
)	)	0000	)	O	O
or	or	O600	CC	O	O
exclusion	exclusion	E242	NN	B-NP	O
(	(	0000	(	O	O
isoform	isoform	I216	NN	B-NP	O
II	II	I000	CD	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
2	2	0000	CD	I-NP	O
are	be	A600	VBP	B-VP	O
transcribed	transcribe	T652	VBN	I-VP	O
in	in	I500	IN	B-PP	O
adult	adult	A343	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
if	if	I100	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
isoforms	isoform	I216	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
differentially	differentially	D165	RB	I-VP	O
expressed	express	E216	VBN	I-VP	O
during	during	D652	IN	B-PP	O
embryogenesis	embryogenesis	E516	NN	B-NP	O
,	,	0000	,	O	O
VHL	VHL	V400	NN	B-NP	B-Disease
mRNA	mRNA	M650	NN	I-NP	O
was	be	W200	VBD	B-VP	O
reverse	reverse	R162	NN	B-NP	O
transcribed	transcribe	T652	VBN	B-VP	O
from	from	F650	IN	B-PP	O
13	13	0000	CD	B-NP	O
fetal	fetal	F340	JJ	I-NP	O
tissues	tissue	T200	NNS	I-NP	O
(	(	0000	(	O	O
8	8	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
10	10	0000	CD	I-NP	O
weeks	week	W200	NNS	I-NP	O
gestation	gestation	G235	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
quantitative	quantitative	Q531	JJ	I-NP	O
distribution	distribution	D236	NN	I-NP	O
of	of	O100	IN	B-PP	O
VHL	VHL	V400	NN	B-NP	B-Disease
mRNA	mRNA	M650	NN	I-NP	O
within	within	W350	IN	B-PP	O
fetal	fetal	F340	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
reflected	reflect	R142	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
seen	see	S500	VBN	B-VP	O
by	by	B000	IN	B-PP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
ratio	ratio	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
isoforms	isoform	I216	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
similar	similar	S546	JJ	B-ADJP	O
between	between	B350	IN	B-PP	O
tissues	tissue	T200	NNS	B-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
genes	gene	G520	NNS	I-NP	O
regulated	regulate	R243	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
have	have	H100	VBP	B-VP	O
not	not	N300	RB	I-VP	O
yet	yet	Y300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
,	,	0000	,	O	O
our	our	O600	PRP$	B-NP	O
findings	finding	F535	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
compatible	compatible	C513	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
VHL	VHL	V400	NN	B-NP	B-Disease
-	-	0000	HYPH	O	O
mediated	mediate	M300	VBN	B-VP	O
control	control	C536	NN	B-NP	O
of	of	O100	IN	B-PP	O
transcriptional	transcriptional	T652	JJ	B-NP	O
elongation	elongation	E452	NN	I-NP	O
may	may	M000	MD	B-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
human	human	H500	JJ	I-NP	O
development	development	D141	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
in	in	I500	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
:	:	0000	:	O	O
role	role	R400	NN	B-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
hereditary	hereditary	H636	JJ	I-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
largely	largely	L624	RB	I-VP	O
attributed	attribute	A361	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
inheritance	inheritance	I563	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
or	or	O600	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
yet	yet	Y300	RB	B-ADJP	O
clear	clear	C460	JJ	I-ADJP	O
what	what	W300	WDT	B-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
explained	explain	E214	VBN	I-VP	O
by	by	B000	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
or	or	O600	CC	O	O
by	by	B000	IN	B-PP	O
some	some	S500	DT	B-NP	O
other	other	O360	JJ	I-NP	O
unidentified	unidentified	U535	JJ	I-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	I-NP	O
s	s	S000	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
the	the	T000	DT	B-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
explained	explain	E214	VBN	B-VP	O
by	by	B000	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
or	or	O600	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
sample	sample	S514	NN	I-NP	O
of	of	O100	IN	B-PP	O
North	North	N630	JJ	B-NP	O
American	American	A562	JJ	I-NP	O
hereditary	hereditary	H636	JJ	I-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
assess	assess	A200	VB	B-VP	O
the	the	T000	DT	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
additional	additional	A354	JJ	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
may	may	M000	MD	B-VP	O
confer	confer	C516	VB	I-VP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
risk	risk	R200	NN	I-NP	O
.	.	0000	.	O	O

Twenty	Twenty	T530	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
three	three	T600	CD	I-NP	O
families	family	F542	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
through	through	T620	IN	B-PP	O
two	two	T000	CD	B-NP	O
high	high	H200	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
risk	risk	R200	NN	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
research	research	R262	NN	I-NP	O
programs	program	P626	NNS	I-NP	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
was	be	W200	VBD	B-VP	O
undertaken	undertake	U536	VBN	I-VP	O
to	to	T000	TO	I-VP	O
establish	establish	E231	VB	I-VP	O
linkage	linkage	L520	NN	B-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cases	case	C200	NNS	I-NP	O
and	and	A530	CC	I-NP	O
markers	marker	M626	NNS	I-NP	O
on	on	O500	IN	B-PP	O
chromosomes	chromosome	C652	NNS	B-NP	O
17q	17q	Q000	NN	I-NP	O
(	(	0000	(	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
13q	13q	Q000	NN	B-NP	O
(	(	0000	(	O	O
BRCA2	BRCA2	B620	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Mutation	Mutation	M350	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
undertaken	undertake	U536	VBN	I-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
14	14	0000	CD	B-NP	O
(	(	0000	(	O	O
61	61	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
23	23	0000	CD	I-NP	O
families	family	F542	NNS	I-NP	O
studied	study	S300	VBN	B-VP	O
was	be	W200	VBD	B-VP	O
attributed	attribute	A361	VBN	I-VP	O
to	to	T000	TO	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
combination	combination	C515	NN	I-NP	O
of	of	O100	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
and	and	A530	CC	I-NP	O
mutation	mutation	M350	NN	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
families	family	F542	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
attributed	attribute	A361	VBN	I-VP	O
to	to	T000	TO	B-PP	O
BRCA2	BRCA2	B620	NN	B-NP	O
.	.	0000	.	O	O

Five	Five	F100	CD	B-NP	O
families	family	F542	NNS	I-NP	O
(	(	0000	(	O	O
22	22	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
provided	provide	P613	VBD	B-VP	O
evidence	evidence	E135	NN	B-NP	O
against	against	A252	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
both	both	B300	CC	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
or	or	O600	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
five	five	F100	CD	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
or	or	O600	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
status	status	S320	NN	I-NP	O
of	of	O100	IN	B-PP	O
four	four	F600	CD	B-NP	O
families	family	F542	NNS	I-NP	O
(	(	0000	(	O	O
17	17	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
could	could	C430	MD	B-VP	O
not	not	N300	RB	I-VP	O
be	be	B000	VB	I-VP	O
determined	determine	D365	VBN	I-VP	O
.	.	0000	.	O	O

BRCA1	BRCA1	B620	NN	B-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
probably	probably	P614	RB	B-ADVP	O
explain	explain	E214	VBP	B-VP	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
that	that	T300	WDT	B-NP	O
exists	exist	E232	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
North	North	N630	JJ	I-NP	O
American	American	A562	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
or	or	O600	CC	I-NP	O
more	more	M600	JJR	I-NP	O
additional	additional	A354	JJ	I-NP	O
genes	gene	G520	NNS	I-NP	O
may	may	M000	MD	B-VP	O
yet	yet	Y300	RB	I-VP	O
be	be	B000	VB	I-VP	O
found	find	F530	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
explain	explain	E214	VB	B-VP	O
some	some	S500	DT	B-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
intronic	intronic	I536	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
lariat	lariat	L630	NN	I-NP	O
branchpoint	branchpoint	B652	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
direct	direct	D623	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
human	human	H500	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
(	(	0000	(	O	O
fish	fish	F200	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
eye	eye	E000	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
step	step	S310	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
splicing	splicing	S142	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
from	from	F650	IN	B-PP	O
nuclear	nuclear	N246	JJ	B-NP	O
precursors	precursor	P626	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mRNA	mRNA	M650	NN	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
formation	formation	F653	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
lariat	lariat	L630	NN	I-NP	O
structure	structure	S362	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
intronic	intronic	I536	JJ	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
,	,	0000	,	O	O
known	know	K500	VBN	B-VP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
branchpoint	branchpoint	B652	NN	I-NP	O
region	region	R250	NN	I-NP	O
,	,	0000	,	O	O
plays	play	P420	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
central	central	C536	JJ	I-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
process	process	P620	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
here	here	H600	RB	B-ADVP	O
describe	describe	D261	VBP	B-VP	O
a	a	A000	DT	B-NP	O
point	point	P530	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
such	such	S200	JJ	B-NP	O
a	a	A000	DT	I-NP	O
sequence	sequence	S252	NN	I-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
sisters	sister	S236	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
suffer	suffer	S160	VB	I-VP	O
from	from	F650	IN	B-PP	O
fish	fish	F200	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
eye	eye	E000	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
FED	FED	F300	VBN	B-VP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
coding	cod	C352	VBG	B-VP	O
for	for	F600	IN	B-PP	O
lecithin	lecithin	L235	JJ	B-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
acyltransferase	acyltransferase	A243	NN	I-NP	O
(	(	0000	(	O	O
LCAT	LCAT	L230	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Sequencing	Sequencing	S252	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
LCAT	LCAT	L230	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
three	three	T600	CD	I-NP	O
probands	proband	P615	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
compound	compound	C515	NN	B-NP	O
heterozygosity	heterozygosity	H362	NN	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
4	4	0000	CD	I-NP	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
reported	report	R163	VBN	I-VP	O
to	to	T000	TO	I-VP	O
underlie	underlie	U536	VB	I-VP	O
the	the	T000	DT	B-NP	O
FED	FED	F300	JJ	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
point	point	P530	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
located	locate	L230	VBN	B-VP	O
in	in	I500	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
4	4	0000	CD	I-NP	O
(	(	0000	(	O	O
IVS4	IVS4	I120	CD	B-NP	O
T	T	T000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
22C	22C	C000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
performing	perform	P616	VBG	B-VP	O
in	in	I500	FW	B-NP	O
vitro	vitro	V360	FW	I-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
LCAT	LCAT	L230	NN	B-NP	O
minigenes	minigene	M525	NNS	I-NP	O
and	and	A530	CC	O	O
reverse	reverse	R162	JJ	B-NP	O
transcriptase	transcriptase	T652	NN	I-NP	O
PCR	PCR	P260	NN	I-NP	O
on	on	O500	IN	B-PP	O
mRNA	mRNA	M650	NN	B-NP	O
isolated	isolate	I243	VBN	B-VP	O
from	from	F650	IN	B-PP	O
leukocytes	leukocyte	L232	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
was	be	W200	VBD	B-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
cause	cause	C200	VB	I-VP	O
a	a	A000	DT	B-NP	O
null	null	N400	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
complete	complete	C514	JJ	B-NP	O
intron	intron	I536	NN	I-NP	O
retention	retention	R353	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
conclusion	conclusion	C524	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
point	point	P530	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
lariat	lariat	L630	NN	I-NP	O
branchpoint	branchpoint	B652	NN	I-NP	O
consensus	consensus	C525	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
causes	cause	C200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
null	null	N400	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
FED	FED	F300	NNP	B-NP	B-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
our	our	O600	PRP$	B-NP	O
finding	finding	F535	NN	I-NP	O
illustrates	illustrate	I423	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
importance	importance	I516	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
sequence	sequence	S252	NN	I-NP	O
for	for	F600	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
human	human	H500	JJ	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
processing	processing	P625	NN	I-NP	O
.	.	0000	.	O	O

Finally	Finally	F540	RB	B-ADVP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
report	report	R163	NN	I-NP	O
provides	provide	P613	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
widely	widely	W340	RB	I-NP	O
applicable	applicable	A142	JJ	I-NP	O
strategy	strategy	S363	NN	I-NP	O
which	which	W200	WDT	B-NP	O
ensures	ensure	E526	VBZ	B-VP	O
fast	fast	F230	JJ	B-NP	O
and	and	A530	CC	I-NP	O
effective	effective	E123	JJ	I-NP	O
screening	screening	S265	NN	I-NP	O
for	for	F600	IN	B-PP	O
intronic	intronic	I536	JJ	B-NP	O
defects	defect	D123	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
underlie	underlie	U536	VBP	B-VP	O
differential	differential	D165	JJ	B-NP	O
gene	gene	G500	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
variant	variant	V653	JJ	B-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
in	in	I500	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
identified	identify	I353	VBN	I-VP	O
14	14	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
telangiectasia	telangiectasia	T452	NN	B-NP	I-Disease
(	(	0000	(	O	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
mutation	mutation	M350	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
less	less	L200	RBR	I-NP	O
severe	severe	S160	JJ	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
and	and	A530	CC	I-NP	O
cellular	cellular	C460	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
(	(	0000	(	O	O
approximately	approximately	A162	RB	B-NP	O
10	10	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
-	-	0000	HYPH	O	O
15	15	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
identified	identify	I353	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
United	United	U530	NNP	I-NP	O
Kingdom	Kingdom	K523	NNP	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
10	10	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
all	all	A400	PDT	B-NP	O
the	the	T000	DT	I-NP	O
homozygotes	homozygote	H523	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
a	a	A000	DT	B-NP	O
137	137	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
insertion	insertion	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
point	point	P530	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
sequence	sequence	S252	NN	I-NP	O
resembling	resemble	R251	VBG	B-VP	O
a	a	A000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
donor	donor	D560	NN	I-NP	O
site	site	S300	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
allele	allele	A400	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
each	each	E200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
less	less	L200	RBR	I-NP	O
severe	severe	S160	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
some	some	S500	DT	B-NP	O
degree	degree	D260	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
splicing	splicing	S142	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
occurs	occur	O262	VBZ	B-VP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
alternative	alternative	A436	JJ	I-NP	O
product	product	P632	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
insertion	insertion	I526	NN	I-NP	O
-	-	0000	HYPH	O	O
containing	contain	C535	VBG	B-VP	O
allele	allele	A400	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
137	137	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
PCR	PCR	P260	NN	I-NP	O
product	product	P632	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
the	the	T000	DT	B-NP	O
insertion	insertion	I526	NN	I-NP	O
was	be	W200	VBD	B-VP	O
lowest	low	L230	JJS	B-ADJP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
who	who	W000	WP	B-NP	O
showed	show	S300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
later	later	L360	JJ	I-NP	O
onset	onset	O523	NN	I-NP	O
of	of	O100	IN	B-PP	O
cerebellar	cerebellar	C614	JJ	B-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
further	further	F636	JJ	I-NP	O
four	four	F600	CD	I-NP	O
families	family	F542	NNS	I-NP	O
who	who	W000	WP	B-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
have	have	H100	VB	I-VP	O
this	this	T200	DT	B-NP	O
insertion	insertion	I526	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
detected	detect	D323	VBN	B-VP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
of	of	O100	IN	B-PP	O
four	four	F600	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
are	be	A600	VBP	B-VP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
normally	normally	N654	RB	B-ADJP	O
rare	rare	R600	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
demonstration	demonstration	D523	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
giving	give	G152	VBG	B-VP	O
rise	rise	R200	NN	B-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
slightly	slightly	S423	RB	I-NP	O
milder	mild	M436	JJR	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
T	T	T000	NN	B-NP	I-Disease
raises	raise	R200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
interesting	interesting	I536	JJ	I-NP	O
question	question	Q235	NN	I-NP	O
of	of	O100	IN	B-PP	O
what	what	W300	WP	B-NP	O
range	range	R520	NN	B-NP	O
of	of	O100	IN	B-PP	O
phenotypes	phenotype	P531	NNS	B-NP	O
might	might	M230	MD	B-VP	O
occur	occur	O260	VB	I-VP	O
in	in	I500	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
in	in	I500	IN	B-PP	O
whom	whom	W500	WP	B-NP	O
both	both	B300	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
milder	mild	M436	JJR	B-ADJP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
possibility	possibility	P214	NN	I-NP	O
might	might	M230	MD	B-VP	O
be	be	B000	VB	I-VP	O
that	that	T300	IN	B-SBAR	O
individuals	individual	I531	NNS	B-NP	O
who	who	W000	WP	B-NP	O
are	be	A600	VBP	B-VP	O
compound	compound	C515	JJ	B-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
for	for	F600	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
more	more	M600	RBR	B-ADJP	O
common	common	C500	JJ	I-ADJP	O
than	than	T500	IN	B-SBAR	O
we	we	W000	PRP	B-NP	O
realize	realize	R420	VBP	B-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Mutation	Mutation	M350	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
exclusively	exclusively	E242	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
non	non	N500	AFX	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
papillary	papillary	P146	JJ	I-NP	I-Disease
renal	renal	R540	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
define	define	D150	VB	I-VP	O
the	the	T000	DT	B-NP	O
possible	possible	P214	JJ	I-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
renal	renal	R540	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
,	,	0000	,	O	O
91	91	0000	CD	B-NP	O
different	different	D165	JJ	I-NP	O
parenchymal	parenchymal	P652	JJ	I-NP	B-Disease
tumours	tumour	T562	NNS	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
kidney	kidney	K350	NN	I-NP	I-Disease
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
investigated	investigate	I512	VBN	I-VP	O
for	for	F600	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
by	by	B000	IN	B-PP	O
single	single	S524	JJ	B-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
(	(	0000	(	O	O
SSCP	SSCP	S210	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
heteroduplex	heteroduplex	H363	NN	B-NP	O
(	(	0000	(	O	O
HD	HD	H300	NN	B-NP	O
)	)	0000	)	O	O
techniques	technique	T252	NNS	B-NP	O
.	.	0000	.	O	O

Chromosome	Chromosome	C652	NN	B-NP	O
3p	3p	P000	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
98	98	0000	CD	B-NP	O
per	per	P600	IN	B-PP	O
cent	cent	C530	NN	B-NP	O
of	of	O100	IN	B-PP	O
non	non	N500	AFX	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
papillary	papillary	P146	JJ	I-NP	I-Disease
renal	renal	R540	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
25	25	0000	CD	B-NP	O
per	per	P600	IN	B-PP	O
cent	cent	C530	NN	B-NP	O
of	of	O100	IN	B-PP	O
chromophobe	chromophobe	C651	NN	B-NP	O
renal	renal	R540	JJ	I-NP	B-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
22	22	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
43	43	0000	CD	I-NP	O
non	non	N500	AFX	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
papillary	papillary	P146	JJ	I-NP	I-Disease
renal	renal	R540	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
,	,	0000	,	O	O
abnormally	abnormally	A156	RB	B-VP	O
migrating	migrate	M263	VBG	I-VP	O
DNA	DNA	D500	NN	B-NP	O
bands	band	B532	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
by	by	B000	IN	B-PP	O
SSCP	SSCP	S210	NN	B-NP	O
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
HD	HD	H300	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
mobility	mobility	M143	NN	I-NP	O
shift	shift	S130	NN	I-NP	O
was	be	W200	VBD	B-VP	O
seen	see	S500	VBN	I-VP	O
in	in	I500	IN	B-PP	O
any	any	A500	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
23	23	0000	CD	I-NP	O
chromophobe	chromophobe	C651	NN	I-NP	O
renal	renal	R540	JJ	I-NP	B-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
15	15	0000	CD	B-NP	O
papillary	papillary	P146	JJ	I-NP	B-Disease
renal	renal	R540	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
tumours	tumour	T562	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
ten	ten	T500	CD	B-NP	O
renal	renal	R540	JJ	I-NP	B-Disease
oncocytomas	oncocytoma	O523	NNS	I-NP	I-Disease
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
changes	change	C520	NNS	I-NP	O
other	other	O360	JJ	B-ADJP	O
than	than	T500	IN	B-PP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
3p	3p	P000	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
analysed	analyse	A542	VBN	I-VP	O
for	for	F600	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

None	None	N500	NN	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
tumours	tumour	T562	NNS	I-NP	B-Disease
showed	show	S300	VBD	B-VP	O
abnormal	abnormal	A156	JJ	B-NP	O
migration	migration	M263	NN	I-NP	O
patterns	pattern	P365	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
mutation	mutation	M350	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
exclusively	exclusively	E242	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
non	non	N500	AFX	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
papillary	papillary	P146	JJ	I-NP	I-Disease
renal	renal	R540	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Emery	Emery	E560	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Dreifuss	Dreifuss	D612	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
emerin	emerin	E565	NN	B-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
fragment	fragment	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
emerin	emerin	E565	NN	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
prepared	prepare	P616	VBN	I-VP	O
by	by	B000	IN	B-PP	O
PCR	PCR	P260	NN	B-NP	O
and	and	A530	CC	O	O
expressed	express	E216	VBN	B-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
recombinant	recombinant	R251	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
in	in	I500	IN	B-PP	O
Escherichia	Escherichia	E262	NNP	B-NP	O
coli	coli	C400	NNP	I-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
this	this	T200	DT	B-NP	O
as	as	A200	IN	B-PP	O
immunogen	immunogen	I525	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
prepared	prepare	P616	VBD	B-VP	O
a	a	A000	DT	B-NP	O
panel	panel	P540	NN	I-NP	O
of	of	O100	IN	B-PP	O
12	12	0000	CD	B-NP	O
monoclonal	monoclonal	M524	JJ	I-NP	O
antibodies	antibody	A531	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
recognise	recognise	R252	VBP	B-VP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
four	four	F600	CD	I-NP	O
different	different	D165	JJ	I-NP	O
epitopes	epitope	E131	NNS	I-NP	O
on	on	O500	IN	B-PP	O
emerin	emerin	E565	NN	B-NP	O
in	in	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
ensure	ensure	E526	VB	I-VP	O
that	that	T300	DT	B-NP	O
emerin	emerin	E565	NN	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
distinguished	distinguish	D235	VBN	I-VP	O
from	from	F650	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
specific	specific	S121	JJ	I-NP	O
cross	cross	C620	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
reacting	react	R235	VBG	B-VP	O
proteins	protein	P635	NNS	B-NP	O
.	.	0000	.	O	O

All	All	A400	PDT	B-NP	O
the	the	T000	DT	I-NP	O
mAbs	mAb	M120	NNS	I-NP	O
recognised	recognise	R252	VBD	B-VP	O
a	a	A000	DT	B-NP	O
34	34	0000	CD	I-NP	O
kDa	kDa	K300	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
tested	test	T230	VBN	B-VP	O
,	,	0000	,	O	O
though	though	T200	IN	B-SBAR	O
minor	minor	M560	JJ	B-NP	O
emerin	emerin	E565	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
related	relate	R430	VBN	I-NP	O
bands	band	B532	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
some	some	S500	DT	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
.	.	0000	.	O	O

Immunofluorescence	Immunofluorescence	I514	NN	B-NP	O
microscopy	microscopy	M262	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
emerin	emerin	E565	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
located	located	L230	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
rim	rim	R500	NN	I-NP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
examined	examine	E253	VBN	B-VP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
muscle	muscle	M240	NN	I-NP	O
biopsy	biopsy	B120	NN	I-NP	O
from	from	F650	IN	B-PP	O
an	an	A500	DT	B-NP	O
Emery	Emery	E560	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Dreifuss	Dreifuss	D612	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
EMDM	EMDM	E535	NN	B-NP	B-Disease
)	)	0000	)	O	O
patient	patient	P353	NN	B-NP	O
showed	show	S300	VBD	B-VP	O
complete	complete	C514	JJ	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
emerin	emerin	E565	NN	B-NP	O
by	by	B000	IN	B-PP	O
both	both	B300	CC	O	O
Western	Western	W236	JJ	B-NP	O
blotting	blotting	B435	NN	I-NP	O
and	and	A530	CC	O	O
immunohistochemistry	immunohistochemistry	I523	NN	B-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
a	a	A000	DT	B-NP	O
simple	simple	S514	JJ	I-NP	O
diagnostic	diagnostic	D252	JJ	I-NP	O
antibody	antibody	A531	NN	I-NP	O
test	test	T230	NN	I-NP	O
for	for	F600	IN	B-PP	O
EDMD	EDMD	E353	NN	B-NP	B-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Biochemical	Biochemical	B252	JJ	B-NP	O
fractionation	fractionation	F623	NN	I-NP	O
of	of	O100	IN	B-PP	O
brain	brain	B650	NN	B-NP	O
and	and	A530	CC	I-NP	O
liver	liver	L160	NN	I-NP	O
tissues	tissue	T200	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
emerin	emerin	E565	NN	B-NP	O
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
nuclei	nucleus	N240	NNS	B-NP	O
purified	purify	P613	VBN	B-VP	O
by	by	B000	IN	B-PP	O
centrifugation	centrifugation	C536	NN	B-NP	O
through	through	T620	IN	B-PP	O
65	65	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
sucrose	sucrose	S262	NN	I-NP	O
and	and	A530	CC	O	O
was	be	W200	VBD	B-VP	O
absent	absent	A125	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
soluble	soluble	S414	JJ	B-NP	O
fractions	fraction	F623	NNS	I-NP	O
(	(	0000	(	O	O
post	post	P230	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
100	100	0000	CD	B-NP	O
,	,	0000	,	O	O
000	000	0000	CD	B-NP	O
g	g	G000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

From	From	F650	IN	B-PP	O
these	these	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
,	,	0000	,	O	O
together	together	T236	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
sequence	sequence	S252	NN	B-NP	O
and	and	A530	CC	O	O
structural	structural	S362	JJ	B-NP	O
homologies	homology	H542	NNS	I-NP	O
between	between	B350	IN	B-PP	O
emerin	emerin	E565	NN	B-NP	O
,	,	0000	,	O	O
thymopoietins	thymopoietin	T513	NNS	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
lamina	lamina	L500	NN	I-NP	O
-	-	0000	HYPH	O	O
associated	associate	A230	VBN	B-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
LAP2	LAP2	L100	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
emerin	emerin	E565	NN	B-NP	O
will	will	W400	MD	B-VP	O
prove	prove	P610	VB	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
one	one	O500	CD	B-NP	O
member	member	M516	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
of	of	O100	IN	B-PP	O
inner	inner	I560	JJ	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Mutation	Mutation	M350	NN	B-NP	O
of	of	O100	IN	B-PP	O
MSH3	MSH3	M200	NN	B-NP	O
in	in	I500	IN	B-PP	O
endometrial	endometrial	E535	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
functional	functional	F523	JJ	I-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
heteroduplex	heteroduplex	H363	NN	B-NP	O
repair	repair	R160	NN	I-NP	O
.	.	0000	.	O	O

Many	Many	M500	JJ	B-NP	O
human	human	H500	JJ	I-NP	O
tumours	tumour	T562	NNS	I-NP	B-Disease
have	have	H100	VBP	B-VP	O
length	length	L523	NN	B-NP	O
alterations	alteration	A436	NNS	I-NP	O
in	in	I500	IN	B-PP	O
repetitive	repetitive	R131	JJ	B-NP	O
sequence	sequence	S252	NN	I-NP	O
elements	element	E453	NNS	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
microsatellite	microsatellite	M262	NN	I-NP	B-Disease
instability	instability	I523	NN	I-NP	I-Disease
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
attributed	attribute	A361	VBN	I-VP	O
to	to	T000	TO	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
DNA	DNA	D500	NN	I-NP	O
mismatch	mismatch	M253	NN	I-NP	O
repair	repair	R160	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
nonpolyposis	nonpolyposis	N514	NN	I-NP	I-Disease
colorectal	colorectal	C462	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
(	(	0000	(	O	O
HNPCC	HNPCC	H512	NN	B-NP	B-Disease
)	)	0000	)	O	O
kindreds	kindred	K536	NNS	B-NP	O
,	,	0000	,	O	O
many	many	M500	JJ	B-NP	O
sporadic	sporadic	S163	JJ	I-NP	B-Disease
tumours	tumour	T562	NNS	I-NP	I-Disease
exhibit	exhibit	E213	VBP	B-VP	O
instability	instability	I523	NN	B-NP	O
but	but	B300	CC	O	O
no	no	N000	DT	B-NP	O
detectable	detectable	D323	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
therefore	therefore	T616	RB	B-ADVP	O
of	of	O100	IN	B-PP	O
interest	interest	I536	NN	B-NP	O
to	to	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
other	other	O360	JJ	B-NP	O
genes	gene	G520	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
contribute	contribute	C536	VBP	B-VP	O
to	to	T000	TO	B-PP	O
this	this	T200	DT	B-NP	O
instability	instability	I523	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
yeast	yeast	Y230	NN	B-NP	O
,	,	0000	,	O	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
several	several	S164	JJ	B-NP	O
genes	gene	G520	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
RTH	RTH	R300	NN	B-NP	O
and	and	A530	CC	I-NP	O
MSH3	MSH3	M200	NN	I-NP	O
,	,	0000	,	O	O
cause	cause	C200	VBP	B-VP	O
microsatellite	microsatellite	M262	NN	B-NP	O
instability	instability	I523	NN	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
screened	screen	S265	VBD	B-VP	O
16	16	0000	CD	B-NP	O
endometrial	endometrial	E535	JJ	I-NP	B-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
with	with	W300	IN	B-PP	O
microsatellite	microsatellite	M262	NN	B-NP	O
instability	instability	I523	NN	I-NP	O
for	for	F600	IN	B-PP	O
alterations	alteration	A436	NNS	B-NP	O
in	in	I500	IN	B-PP	O
FEN1	FEN1	F500	NN	B-NP	O
(	(	0000	(	O	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
homolog	homolog	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
RTH	RTH	R300	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
MSH3	MSH3	M200	NN	B-NP	O
(	(	0000	(	O	O
refs	ref	R120	NNS	B-NP	O
12	12	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
14	14	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
we	we	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
no	no	N000	DT	B-NP	O
FEN1	FEN1	F500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
MSH3	MSH3	M200	NN	B-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
endometrial	endometrial	E535	JJ	I-NP	B-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
endometrial	endometrial	E535	JJ	I-NP	B-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
.	.	0000	.	O	O

Extracts	Extract	E236	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
were	be	W600	VBD	B-VP	O
deficient	deficient	D125	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
repair	repair	R160	NN	B-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
substrates	substrate	S123	NNS	I-NP	O
containing	contain	C535	VBG	B-VP	O
mismatches	mismatch	M253	NNS	B-NP	O
or	or	O600	CC	O	O
extra	extra	E236	JJ	B-NP	O
nucleotides	nucleotide	N243	NNS	I-NP	O
.	.	0000	.	O	O

Introducing	Introduce	I536	VBG	B-VP	O
chromosome	chromosome	C652	NN	B-NP	O
5	5	0000	CD	I-NP	O
,	,	0000	,	O	O
encoding	encode	E523	VBG	B-VP	O
the	the	T000	DT	B-NP	O
MSH3	MSH3	M200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
into	into	I530	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
increased	increase	I526	VBD	B-VP	O
the	the	T000	DT	B-NP	O
stability	stability	S314	NN	I-NP	O
of	of	O100	IN	B-PP	O
some	some	S500	DT	B-NP	O
but	but	B300	CC	I-NP	O
not	not	N300	RB	I-NP	O
all	all	A400	DT	B-NP	O
microsatellites	microsatellite	M262	NNS	I-NP	O
.	.	0000	.	O	O

Extracts	Extract	E236	NNS	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
cells	cell	C420	NNS	I-NP	O
repaired	repair	R163	VBD	B-VP	O
certain	certain	C635	JJ	B-NP	O
substrates	substrate	S123	NNS	I-NP	O
containing	contain	C535	VBG	B-VP	O
extra	extra	E236	JJ	B-NP	O
nucleotides	nucleotide	N243	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
were	be	W600	VBD	B-VP	O
deficient	deficient	D125	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
repair	repair	R160	NN	B-NP	O
of	of	O100	IN	B-PP	O
those	those	T200	DT	B-NP	O
containing	contain	C535	VBG	I-NP	O
mismatches	mismatch	M253	NNS	I-NP	O
or	or	O600	CC	O	O
other	other	O360	JJ	B-NP	O
extra	extra	E236	JJ	I-NP	O
nucleotides	nucleotide	N243	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
subsequent	subsequent	S125	JJ	I-NP	O
search	search	S620	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
HHUA	HHUA	H000	NN	B-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
MSH6	MSH6	M200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Together	Together	T236	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
MSH3	MSH3	M200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
product	product	P632	NN	I-NP	O
that	that	T300	WDT	B-NP	O
functions	function	F523	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
repair	repair	R160	NN	B-NP	O
of	of	O100	IN	B-PP	O
some	some	S500	DT	B-NP	O
but	but	B300	CC	I-NP	O
not	not	N300	RB	I-NP	O
all	all	A400	DT	B-NP	O
pre	pre	P600	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
mutational	mutational	M354	JJ	I-NP	O
intermediates	intermediate	I536	NNS	I-NP	O
,	,	0000	,	O	O
its	its	I320	PRP$	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
tumours	tumour	T562	NNS	B-NP	B-Disease
can	can	C500	MD	B-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
instability	instability	I523	NN	I-NP	O
and	and	A530	CC	O	O
,	,	0000	,	O	O
as	as	A200	IN	B-PP	O
in	in	I500	IN	B-PP	O
yeast	yeast	Y230	NN	B-NP	O
,	,	0000	,	O	O
MSH3	MSH3	M200	NN	B-NP	O
and	and	A530	CC	I-NP	O
MSH6	MSH6	M200	NN	I-NP	O
are	be	A600	VBP	B-VP	O
partially	partially	P634	RB	B-ADJP	O
redundant	redundant	R353	JJ	I-ADJP	O
for	for	F600	IN	B-PP	O
mismatch	mismatch	M253	NN	B-NP	O
repair	repair	R160	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Comparative	Comparative	C516	JJ	B-NP	O
genome	genome	G500	NN	I-NP	O
mapping	mapping	M152	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
region	region	R250	NN	I-NP	O
in	in	I500	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
,	,	0000	,	O	O
rat	rat	R300	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Syrian	Syrian	S650	JJ	B-NP	O
hamster	hamster	H523	NN	I-NP	O
.	.	0000	.	O	O

Chromosomal	Chromosomal	C652	JJ	B-NP	O
locations	location	L235	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Atm	Atm	A350	NN	I-NP	O
(	(	0000	(	O	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
telangiectasia	telangiectasia	T452	NN	B-NP	I-Disease
(	(	0000	(	O	O
AT	AT	A300	NN	B-NP	B-Disease
)	)	0000	)	O	O
-	-	0000	HYPH	B-VP	O
mutated	mutate	M300	VBN	I-VP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
Acat1	Acat1	A230	NN	B-NP	O
(	(	0000	(	O	O
mitochondrial	mitochondrial	M325	JJ	B-NP	O
acetoacetyl	acetoacetyl	A232	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
CoA	CoA	C000	NN	I-NP	O
thiolase	thiolase	T420	NN	I-NP	O
)	)	0000	)	O	O
genes	gene	G520	NNS	B-NP	O
in	in	I500	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
,	,	0000	,	O	O
rat	rat	R300	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Syrian	Syrian	S650	JJ	B-NP	O
hamster	hamster	H523	NN	I-NP	O
were	be	W600	VBD	B-VP	O
determined	determine	D365	VBN	I-VP	O
by	by	B000	IN	B-PP	O
direct	direct	D623	JJ	B-NP	O
R	R	R000	NN	I-NP	O
-	-	0000	HYPH	O	O
banding	band	B535	VBG	B-VP	O
FISH	FISH	F200	NN	B-NP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
genes	gene	G520	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
colocalized	colocalize	C424	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
D	D	D000	NN	I-NP	O
band	band	B530	NN	I-NP	O
of	of	O100	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
9	9	0000	CD	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
proximal	proximal	P625	JJ	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
q24	q24	Q000	NN	B-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
rat	rat	R300	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
8	8	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
qa4	qa4	Q000	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
qa5	qa5	Q000	NN	I-NP	O
of	of	O100	IN	B-PP	O
Syrian	Syrian	S650	JJ	B-NP	O
hamster	hamster	H523	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
12	12	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
regions	region	R252	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
and	and	A530	CC	O	O
rat	rat	R300	NN	B-NP	O
were	be	W600	VBD	B-VP	O
homologous	homologous	H542	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
11q	11q	Q000	NN	I-NP	O
.	.	0000	.	O	O

Fine	Fine	F500	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
linkage	linkage	L520	NN	I-NP	O
mapping	mapping	M152	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
AT	AT	A300	NN	I-NP	B-Disease
region	region	R250	NN	I-NP	O
was	be	W200	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
using	use	U252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
interspecific	interspecific	I536	JJ	I-NP	O
backcross	backcross	B262	NN	I-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

Atm	Atm	A350	NN	B-NP	O
,	,	0000	,	O	O
Acat1	Acat1	A230	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Npat	Npat	N130	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
isolated	isolate	I243	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
AT	AT	A300	NN	I-NP	O
region	region	R250	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
12	12	0000	CD	B-NP	O
flanking	flanking	F452	NN	I-NP	O
microsatellite	microsatellite	M262	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
examined	examine	E253	VBN	I-VP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
recombinations	recombination	R251	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
among	among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
Atm	Atm	A350	NN	I-NP	O
,	,	0000	,	O	O
Npat	Npat	N130	NN	B-NP	O
,	,	0000	,	O	O
Acat1	Acat1	A230	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
D9Mit6	D9Mit6	D530	NN	B-NP	O
loci	locus	L200	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
these	these	T200	DT	B-NP	O
loci	locus	L200	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
mapped	map	M130	VBN	I-VP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

0	0	0000	CD	B-NP	O
cM	cM	C500	NN	I-NP	O
distal	distal	D234	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
D9Mit99	D9Mit99	D530	NN	B-NP	O
and	and	A530	CC	O	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
cM	cM	C500	NN	I-NP	O
proximal	proximal	P625	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
D9Mit102	D9Mit102	D530	NN	B-NP	O
.	.	0000	.	O	O

Comparison	Comparison	C516	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
map	map	M100	NN	I-NP	O
of	of	O100	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
9	9	0000	CD	I-NP	O
(	(	0000	(	O	O
MMU9	MMU9	M500	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
11	11	0000	CD	I-NP	O
(	(	0000	(	O	O
HSA11	HSA11	H200	NN	B-NP	O
)	)	0000	)	O	O
indicates	indicate	I532	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
rearrangement	rearrangement	R652	NN	I-NP	O
due	due	D000	JJ	B-PP	O
to	to	T000	TO	B-PP	O
an	an	A500	DT	B-NP	O
inversion	inversion	I516	NN	I-NP	O
between	between	B350	IN	B-PP	O
Ets1	Ets1	E320	NN	B-NP	O
and	and	A530	CC	I-NP	O
Atm	Atm	A350	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
Npat	Npat	N130	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
Acat1	Acat1	A230	NN	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
inversion	inversion	I516	NN	I-NP	O
of	of	O100	IN	B-PP	O
MMU9	MMU9	M500	NN	B-NP	O
originated	originate	O625	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
breakage	breakage	B620	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
boundary	boundary	B536	NN	I-NP	O
between	between	B350	IN	B-PP	O
Gria4	Gria4	G600	NN	B-NP	O
and	and	A530	CC	I-NP	O
Atm	Atm	A350	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
Npat	Npat	N130	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
Acat1	Acat1	A230	NN	I-NP	O
on	on	O500	IN	B-PP	O
HSA11	HSA11	H200	NN	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
type	type	T100	NN	I-NP	O
of	of	O100	IN	B-PP	O
inversion	inversion	I516	NN	B-NP	O
appeared	appear	A163	VBD	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
conserved	conserve	C526	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
three	three	T600	CD	I-NP	O
rodent	rodent	R353	NN	I-NP	O
species	specie	S120	NNS	I-NP	O
,	,	0000	,	O	O
mouse	mouse	M200	NN	B-NP	O
,	,	0000	,	O	O
rat	rat	R300	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Syrian	Syrian	S650	JJ	B-NP	O
hamster	hamster	H523	NN	I-NP	O
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
additional	additional	A354	JJ	B-NP	O
comparative	comparative	C516	JJ	I-NP	O
mapping	mapping	M152	NN	I-NP	O
data	datum	D300	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Rck	Rck	R200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O

An	An	A500	DT	B-NP	O
animal	animal	A540	NN	I-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
Norrie	Norrie	N600	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
ND	ND	N300	NN	B-NP	B-Disease
)	)	0000	)	O	O
:	:	0000	:	O	O
gene	gene	G500	NN	B-NP	O
targeting	targeting	T623	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
ND	ND	N300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
elucidate	elucidate	E423	VB	I-VP	O
the	the	T000	DT	B-NP	O
cellular	cellular	C460	JJ	I-NP	O
and	and	A530	CC	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
processes	process	P620	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Norrie	Norrie	N600	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
ND	ND	N300	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
used	use	U230	VBN	I-VP	O
gene	gene	G500	NN	B-NP	O
targeting	target	T623	VBG	B-VP	O
technology	technology	T254	NN	B-NP	O
to	to	T000	TO	B-VP	O
generate	generate	G563	VB	I-VP	O
ND	ND	N300	NN	B-NP	B-Disease
mutant	mutant	M353	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
murine	murine	M650	JJ	I-NP	O
homologue	homologue	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ND	ND	N300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
cloned	clone	C453	VBN	I-VP	O
and	and	A530	CC	O	O
shown	show	S500	VBN	B-VP	O
to	to	T000	TO	I-VP	O
encode	encode	E523	VB	I-VP	O
a	a	A000	DT	B-NP	O
polypeptide	polypeptide	P413	NN	I-NP	O
that	that	T300	WDT	B-NP	O
shares	share	S620	VBZ	B-VP	O
94	94	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
with	with	W300	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
human	human	H500	JJ	I-NP	O
counterpart	counterpart	C536	NN	I-NP	O
.	.	0000	.	O	O

RNA	RNA	R500	NN	B-NP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
expression	expression	E216	NN	B-NP	O
in	in	I500	IN	B-PP	O
retina	retina	R350	NN	B-NP	O
,	,	0000	,	O	O
brain	brain	B650	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
olfactory	olfactory	O412	JJ	I-NP	O
bulb	bulb	B410	NN	I-NP	O
and	and	A530	CC	I-NP	O
epithelium	epithelium	E134	NN	I-NP	O
of	of	O100	IN	B-PP	O
2	2	0000	CD	B-NP	O
week	week	W200	NN	I-NP	O
old	old	O430	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

Hemizygous	Hemizygous	H520	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
carrying	carry	C652	VBG	B-VP	O
a	a	A000	DT	B-NP	O
replacement	replacement	R142	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
2	2	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ND	ND	N300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
developed	develop	D141	VBD	B-VP	O
retrolental	retrolental	R364	JJ	B-NP	O
structures	structure	S362	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
vitreous	vitreous	V362	JJ	I-NP	O
body	body	B300	NN	I-NP	O
and	and	A530	CC	O	O
showed	show	S300	VBD	B-VP	O
an	an	A500	DT	B-NP	O
overall	overall	O164	JJ	I-NP	O
disorganization	disorganization	D262	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
retinal	retinal	R354	JJ	I-NP	O
ganglion	ganglion	G524	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
layer	layer	L600	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
outer	outer	O360	JJ	I-NP	O
plexiform	plexiform	P421	NN	I-NP	O
layer	layer	L600	NN	I-NP	O
disappears	disappear	D216	VBZ	B-VP	O
occasionally	occasionally	O254	RB	B-ADVP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
juxtaposed	juxtapose	J231	VBN	I-NP	O
inner	inner	I560	JJ	I-NP	O
and	and	A530	CC	I-NP	O
outer	outer	O360	JJ	I-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
layer	layer	L600	NN	I-NP	O
.	.	0000	.	O	O

At	At	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
regions	region	R252	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
outer	outer	O360	JJ	I-NP	O
segments	segment	S253	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
photoreceptor	photoreceptor	P362	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
layer	layer	L600	NN	I-NP	O
are	be	A600	VBP	B-VP	O
no	no	N000	RB	I-VP	O
longer	longer	L526	RB	I-VP	O
present	present	P625	JJ	I-VP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
ocular	ocular	O246	JJ	I-NP	O
findings	finding	F535	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
observations	observation	O126	NNS	B-NP	O
in	in	I500	IN	B-PP	O
ND	ND	N300	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
generated	generate	G563	VBN	I-NP	O
mouse	mouse	M200	NN	I-NP	O
line	line	L500	NN	I-NP	O
provides	provide	P613	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
faithful	faithful	F314	JJ	I-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
study	study	S300	NN	B-NP	O
of	of	O100	IN	B-PP	O
early	early	E640	JJ	B-NP	O
pathogenic	pathogenic	P325	JJ	I-NP	O
events	event	E153	NNS	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
recessive	recessive	R210	JJ	B-NP	I-Disease
neurological	neurological	N642	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
hybrid	hybrid	H163	NN	I-NP	O
PAX3	PAX3	P200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
FKHR	FKHR	F260	NN	I-NP	O
fusion	fusion	F250	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
alveolar	alveolar	A414	JJ	B-NP	B-Disease
rhabdomyosarcoma	rhabdomyosarcoma	R135	NN	I-NP	I-Disease
transforms	transform	T652	VBZ	B-VP	O
fibroblasts	fibroblast	F161	NNS	B-NP	O
in	in	I500	IN	B-PP	O
culture	culture	C436	NN	B-NP	O
.	.	0000	.	O	O

Pediatric	Pediatric	P362	JJ	B-NP	B-Disease
alveolar	alveolar	A414	JJ	I-NP	I-Disease
rhabdomyosarcoma	rhabdomyosarcoma	R135	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
translocation	translocation	T652	NN	I-NP	O
that	that	T300	WDT	B-NP	O
fuses	fuse	F200	VBZ	B-VP	O
parts	part	P632	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAX3	PAX3	P200	NN	I-NP	O
and	and	A530	CC	I-NP	O
FKHR	FKHR	F260	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

PAX3	PAX3	P200	NN	B-NP	O
codes	cod	C320	VBZ	B-VP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
transcriptional	transcriptional	T652	JJ	I-NP	O
regulator	regulator	R243	NN	I-NP	O
that	that	T300	WDT	B-NP	O
controls	control	C536	VBZ	B-VP	O
developmental	developmental	D141	JJ	B-NP	O
programs	program	P626	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
FKHR	FKHR	F260	NN	B-NP	O
codes	code	C320	NNS	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
forkhead	forkhead	F623	NN	I-NP	O
-	-	0000	HYPH	O	O
winged	wing	W523	VBN	B-NP	O
helix	helix	H420	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
also	also	A420	RB	B-ADVP	O
a	a	A000	DT	B-NP	O
likely	likely	L240	JJ	I-NP	O
transcription	transcription	T652	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
PAX3	PAX3	P200	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
FKHR	FKHR	F260	NN	I-NP	O
fusion	fusion	F250	NN	I-NP	O
product	product	P632	NN	I-NP	O
retains	retain	R352	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
domains	domain	D520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAX3	PAX3	P200	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
activator	activator	A231	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
FKHR	FKHR	F260	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
PAX3	PAX3	P200	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
FKHR	FKHR	F260	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
function	function	F523	VB	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
transcriptional	transcriptional	T652	JJ	I-NP	O
activator	activator	A231	NN	I-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
RCAS	RCAS	R200	NN	I-NP	O
retroviral	retroviral	R361	JJ	I-NP	O
vector	vector	V236	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
introduced	introduce	I536	VBN	I-VP	O
the	the	T000	DT	B-NP	O
PAX3	PAX3	P200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
FKHR	FKHR	F260	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
into	into	I530	IN	B-PP	O
chicken	chicken	C250	NN	B-NP	O
embryo	embryo	E516	NN	I-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
.	.	0000	.	O	O

Expression	Expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAX3	PAX3	P200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
FKHR	FKHR	F260	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
cells	cell	C420	NNS	I-NP	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
transformation	transformation	T652	VB	I-VP	O
the	the	T000	DT	B-NP	O
cells	cell	C420	NNS	I-NP	O
become	become	B250	VBP	B-VP	O
enlarged	enlarge	E546	VBN	I-VP	O
,	,	0000	,	O	O
grow	grow	G600	VB	B-VP	O
tightly	tightly	T234	RB	I-VP	O
packed	pack	P230	VBN	I-VP	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
layers	layer	L620	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
acquire	acquire	A260	VB	B-VP	O
the	the	T000	DT	B-NP	O
ability	ability	A143	NN	I-NP	O
for	for	F600	IN	B-PP	O
anchorage	anchorage	A526	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
independent	independent	I531	JJ	I-NP	O
growth	growth	G630	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
cellular	cellular	C460	JJ	I-NP	O
transformation	transformation	T652	NN	I-NP	O
in	in	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
will	will	W400	MD	B-VP	O
facilitate	facilitate	F243	VB	I-VP	O
studies	study	S320	NNS	B-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
of	of	O100	IN	B-PP	O
PAX3	PAX3	P200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
FKHR	FKHR	F260	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
induced	induce	I532	VBN	I-NP	O
oncogenesis	oncogenesis	O525	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Somatic	Somatic	S532	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
cell	cell	C400	NN	I-NP	O
selection	selection	S423	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
determinant	determinant	D365	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
blood	blood	B430	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
cell	cell	C400	NN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
heterozygotes	heterozygote	H362	NNS	B-NP	O
for	for	F600	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
causing	cause	C252	VBG	B-VP	O
severe	severe	S160	JJ	B-NP	O
enzyme	enzyme	E525	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

X	X	X000	SYM	O	O
-	-	0000	HYPH	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
inactivation	inactivation	I523	NN	I-NP	O
in	in	I500	IN	B-PP	O
mammals	mammal	M542	NNS	B-NP	O
is	be	I200	VBZ	B-VP	O
regarded	regard	R263	VBN	I-VP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
essentially	essentially	E253	RB	I-NP	O
random	random	R535	JJ	I-NP	O
process	process	P620	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
resulting	result	R243	VBG	I-NP	O
somatic	somatic	S532	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
cell	cell	C400	NN	I-NP	O
mosaicism	mosaicism	M250	NN	I-NP	O
creates	create	C632	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
opportunity	opportunity	O163	NN	I-NP	O
for	for	F600	IN	B-PP	O
cell	cell	C400	NN	B-NP	O
selection	selection	S423	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
most	most	M230	JJS	B-NP	O
people	people	P140	NNS	I-NP	O
with	with	W300	IN	B-PP	O
red	red	R300	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
blood	blood	B430	NN	I-NP	O
-	-	0000	HYPH	O	O
cell	cell	C400	NN	B-NP	O
glucose	glucose	G420	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
G6PD	G6PD	G130	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
deficient	deficient	D125	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
only	only	O540	RB	I-VP	O
moderately	moderately	M363	RB	I-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
nucleated	nucleated	N243	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
subset	subset	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
hemizygous	hemizygous	H520	JJ	B-NP	O
males	male	M420	NNS	I-NP	O
who	who	W000	WP	B-NP	O
suffer	suffer	S160	VBP	B-VP	O
from	from	F650	IN	B-PP	O
chronic	chronic	C652	JJ	B-NP	B-Disease
nonspherocytic	nonspherocytic	N521	JJ	I-NP	I-Disease
hemolytic	hemolytic	H543	JJ	I-NP	I-Disease
anemia	anemia	A500	NN	I-NP	I-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
underlying	underlie	U536	VBG	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
(	(	0000	(	O	O
designated	designate	D253	VBN	B-VP	O
class	class	C420	NN	B-NP	O
I	I	I000	CD	I-NP	O
)	)	0000	)	O	O
cause	cause	C200	VBP	B-VP	O
more	more	M600	JJR	B-NP	O
-	-	0000	HYPH	I-NP	O
severe	severe	S160	JJ	I-NP	O
G6PD	G6PD	G130	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
this	this	T200	DT	B-NP	O
might	might	M230	MD	B-VP	O
provide	provide	P613	VB	I-VP	O
an	an	A500	DT	B-NP	O
opportunity	opportunity	O163	NN	I-NP	O
for	for	F600	IN	B-PP	O
selection	selection	S423	NN	B-NP	O
in	in	I500	IN	B-PP	O
heterozygous	heterozygous	H362	JJ	B-NP	O
females	female	F542	NNS	I-NP	O
during	during	D652	IN	B-PP	O
development	development	D141	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
test	test	T230	VB	I-VP	O
this	this	T200	DT	B-NP	O
possibility	possibility	P214	NN	I-NP	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
four	four	F600	CD	B-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
for	for	F600	IN	B-PP	O
class	class	C420	NN	B-NP	O
I	I	I000	CD	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
two	two	T000	CD	B-NP	O
with	with	W300	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
Portici	Portici	P632	NN	I-NP	O
(	(	0000	(	O	O
1178G	1178G	G000	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
with	with	W300	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
Bari	Bari	B600	NN	I-NP	O
(	(	0000	(	O	O
1187C	1187C	C000	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
T	T	T000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
in	in	I500	IN	B-PP	O
fractionated	fractionate	F623	VBN	B-NP	O
blood	blood	B430	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
types	type	T120	NNS	I-NP	O
(	(	0000	(	O	O
including	include	I524	VBG	B-PP	O
erythroid	erythroid	E636	JJ	B-NP	O
,	,	0000	,	I-NP	O
myeloid	myeloid	M430	JJ	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
lymphoid	lymphoid	L513	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
lineages	lineage	L520	NNS	I-NP	O
)	)	0000	)	O	O
there	there	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
excess	excess	E200	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
normal	normal	N654	JJ	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
concordance	concordance	C526	NN	I-NP	O
that	that	T300	IN	B-NP	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
degree	degree	D260	NN	I-NP	O
of	of	O100	IN	B-PP	O
imbalance	imbalance	I514	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
blood	blood	B430	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
cell	cell	C400	NN	I-NP	O
lineages	lineage	L520	NNS	I-NP	O
indicates	indicate	I532	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
selective	selective	S423	JJ	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
likely	likely	L240	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
operate	operate	O163	VB	I-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
pluripotent	pluripotent	P461	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
stem	stem	S350	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
appears	appear	A162	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
severe	severe	S160	JJ	B-NP	O
G6PD	G6PD	G130	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
affects	affect	A123	VBZ	B-VP	O
adversely	adversely	A316	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
proliferation	proliferation	P641	NN	I-NP	O
or	or	O600	CC	O	O
the	the	T000	DT	B-NP	O
survival	survival	S614	NN	I-NP	O
of	of	O100	IN	B-PP	O
nucleated	nucleated	N243	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
characteristic	characteristic	C623	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
critical	critical	C632	JJ	B-ADJP	O
during	during	D652	IN	B-PP	O
hematopoiesis	hematopoiesis	H531	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
meiotic	meiotic	M320	JJ	B-NP	O
segregation	segregation	S262	NN	I-NP	O
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
sperm	sperm	S165	NN	I-NP	O
typing	typing	T152	NN	I-NP	O
:	:	0000	:	O	O
meiotic	meiotic	M320	JJ	B-NP	O
drive	drive	D610	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

Meiotic	Meiotic	M320	JJ	B-NP	O
drive	drive	D610	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
locus	locus	L200	NN	B-NP	O
has	have	H200	VBZ	B-VP	O
recently	recently	R253	RB	I-VP	O
been	be	B500	VBN	I-VP	O
suggested	suggest	S230	VBN	I-VP	O
as	as	A200	IN	B-PP	O
being	be	B520	VBG	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
maintaining	maintain	M535	VBG	B-VP	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
population	population	P143	NN	I-NP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
chromosomes	chromosome	C652	NNS	I-NP	O
capable	capable	C140	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
expansion	expansion	E215	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
state	state	S300	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
test	test	T230	VB	I-VP	O
this	this	T200	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
studied	study	S300	VBN	I-VP	O
samples	sample	S514	NNS	B-NP	O
of	of	O100	IN	B-PP	O
single	single	S524	JJ	B-NP	O
sperm	sperm	S165	NN	I-NP	O
from	from	F650	IN	B-PP	O
three	three	T600	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
each	each	E200	DT	B-NP	O
with	with	W300	IN	B-PP	O
one	one	O500	CD	B-NP	O
allele	allele	A400	NN	I-NP	O
larger	large	L626	JJR	B-ADJP	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
allele	allele	A400	NN	I-NP	O
smaller	small	S546	JJR	B-NP	O
than	than	T500	IN	I-NP	O
19	19	0000	CD	I-NP	O
CTG	CTG	C320	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
guard	guard	G630	VB	I-VP	O
against	against	A252	IN	B-PP	O
the	the	T000	DT	B-NP	O
possible	possible	P214	JJ	I-NP	O
problem	problem	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
differential	differential	D165	JJ	B-NP	O
PCR	PCR	P260	NN	I-NP	O
amplification	amplification	A514	NN	I-NP	O
rates	rate	R320	NNS	I-NP	O
based	base	B230	VBN	B-PP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
lengths	length	L523	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
alleles	allele	A420	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
sperm	sperm	S165	NN	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
typed	type	T130	VBN	I-VP	O
at	at	A300	IN	B-PP	O
another	another	A536	DT	B-NP	O
closely	closely	C424	RB	I-NP	O
linked	link	L523	VBN	I-NP	O
marker	marker	M626	NN	I-NP	O
whose	whose	W200	WP$	B-NP	O
allele	allele	A400	NN	I-NP	O
size	size	S200	NN	I-NP	O
was	be	W200	VBD	B-VP	O
unrelated	unrelated	U564	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
size	size	S200	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
statistical	statistical	S323	JJ	B-NP	O
models	model	M342	NNS	I-NP	O
specifically	specifically	S121	RB	B-VP	O
designed	design	D253	VBN	I-VP	O
to	to	T000	TO	B-VP	O
study	study	S300	VB	I-VP	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
sperm	sperm	S165	NN	I-NP	O
segregation	segregation	S262	NN	I-NP	O
data	datum	D300	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
find	find	F530	VBP	B-VP	O
no	no	N000	DT	B-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
meiotic	meiotic	M320	JJ	B-NP	O
segregation	segregation	S262	NN	I-NP	O
distortion	distortion	D236	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
upper	upper	U160	JJ	I-NP	O
limit	limit	L530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
sided	sided	S300	JJ	I-NP	O
95	95	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
confidence	confidence	C513	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
estimate	estimate	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
segregation	segregation	S262	NN	I-NP	O
probability	probability	P614	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
three	three	T600	CD	I-NP	O
donors	donor	D562	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
at	at	A300	IN	B-PP	O
or	or	O600	CC	I-PP	O
below	below	B400	IN	I-PP	O
.	.	0000	.	O	O

515	515	0000	CD	B-NP	O
for	for	F600	IN	B-PP	O
all	all	A400	DT	B-NP	O
models	model	M342	NNS	I-NP	O
considered	consider	C523	VBN	B-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
no	no	N000	DT	B-NP	O
statistically	statistically	S323	RB	I-NP	O
significant	significant	S251	JJ	I-NP	O
difference	difference	D165	NN	I-NP	O
from	from	F650	IN	B-PP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
is	be	I200	VBZ	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
any	any	A500	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
models	model	M342	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
any	any	A500	DT	B-NP	O
greater	great	G636	JJR	I-NP	O
amount	amount	A530	NN	I-NP	O
of	of	O100	IN	B-PP	O
segregation	segregation	S262	NN	B-NP	O
distortion	distortion	D236	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
must	must	M230	MD	B-VP	O
result	result	R243	VB	I-VP	O
from	from	F650	IN	B-PP	O
events	event	E153	NNS	B-NP	O
following	follow	F452	VBG	B-PP	O
sperm	sperm	S165	NN	B-NP	O
ejaculation	ejaculation	E243	NN	I-NP	O
.	.	0000	.	O	O

LPP	LPP	L100	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
preferred	preferred	P616	JJ	I-NP	O
fusion	fusion	F250	NN	I-NP	O
partner	partner	P635	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
of	of	O100	IN	B-PP	O
HMGIC	HMGIC	H520	NN	B-NP	O
in	in	I500	IN	B-PP	O
lipomas	lipoma	L152	NNS	B-NP	B-Disease
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
member	member	M516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
LIM	LIM	L500	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
cytogenetic	cytogenetic	C325	JJ	I-NP	O
subgroup	subgroup	S126	NN	I-NP	O
of	of	O100	IN	B-PP	O
lipomas	lipoma	L152	NNS	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
recurrent	recurrent	R265	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
aberrations	aberration	A163	NNS	I-NP	O
,	,	0000	,	O	O
mainly	mainly	M540	RB	B-NP	O
translocations	translocation	T652	NNS	I-NP	O
,	,	0000	,	O	O
that	that	T300	WDT	B-NP	O
involve	involve	I514	VBP	B-VP	O
chromosome	chromosome	C652	NN	B-NP	O
segment	segment	S253	NN	I-NP	O
12q13	12q13	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
q15	q15	Q000	NN	I-NP	O
.	.	0000	.	O	O

Multiple	Multiple	M431	JJ	B-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
translocation	translocation	T652	NN	I-NP	O
partners	partner	P635	NNS	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
12	12	0000	CD	I-NP	O
but	but	B300	CC	I-NP	O
3q27	3q27	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
q28	q28	Q000	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
preferentially	preferentially	P616	RB	I-VP	O
involved	involve	I514	VBN	I-VP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
previous	previous	P612	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
shown	show	S500	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
mobility	mobility	M143	NN	I-NP	O
group	group	G610	NN	I-NP	O
(	(	0000	(	O	O
HMG	HMG	H520	NN	B-NP	O
)	)	0000	)	O	O
protein	protein	P635	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
HMGIC	HMGIC	H520	NN	I-NP	O
at	at	A300	IN	B-PP	O
12q15	12q15	Q000	CD	B-NP	O
is	be	I200	VBZ	B-VP	O
consistently	consistently	C523	RB	I-VP	O
rearranged	rearrange	R652	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
consequence	consequence	C525	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
translocations	translocation	T652	NNS	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
and	and	A530	CC	I-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
derived	derive	D613	VBN	I-NP	O
translocation	translocation	T652	NN	I-NP	O
partner	partner	P635	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
designated	designate	D253	VBN	I-VP	O
LPP	LPP	L100	NN	B-NP	O
(	(	0000	(	O	O
lipoma	lipoma	L150	NN	B-NP	B-Disease
preferred	prefer	P616	VBN	I-NP	O
partner	partner	P635	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
3	3	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
RACE	RACE	R200	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
HMGIC	HMGIC	H520	NN	B-NP	O
fusion	fusion	F250	NN	I-NP	O
transcripts	transcript	T652	NNS	I-NP	O
in	in	I500	IN	B-PP	O
lipoma	lipoma	L150	NN	B-NP	B-Disease
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
Li	Li	L000	AFX	O	O
-	-	0000	HYPH	O	O
501	501	0000	CD	B-NP	O
/	/	0000	SYM	I-NP	O
SV40	SV40	S100	NN	I-NP	O
,	,	0000	,	O	O
ectopic	ectopic	E231	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
obtained	obtain	O135	VBN	I-VP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
by	by	B000	IN	B-PP	O
CASH	CASH	C200	NN	B-NP	O
(	(	0000	(	O	O
chromosome	chromosome	C652	NN	B-NP	O
assignment	assignment	A253	NN	I-NP	O
using	use	U252	VBG	B-VP	O
somatic	somatic	S532	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
hybrids	hybrid	H163	NNS	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
FISH	FISH	F200	NN	B-NP	O
(	(	0000	(	O	O
fluorescence	fluorescence	F462	NN	B-NP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
)	)	0000	)	O	O
analysis	analysis	A542	NN	B-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
originate	originate	O625	VB	I-VP	O
from	from	F650	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
segment	segment	S253	NN	I-NP	O
3q27	3q27	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
q28	q28	Q000	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
Northern	Northern	N636	JJ	B-NP	O
blot	blot	B430	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
of	of	O100	IN	B-PP	O
over	over	O160	IN	B-NP	O
10	10	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
by	by	B000	IN	B-PP	O
these	these	T200	DT	B-NP	O
ectopic	ectopic	E231	JJ	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
but	but	B300	CC	B-PP	O
not	not	N300	RB	B-PP	O
in	in	I500	IN	I-PP	O
brain	brain	B650	NN	B-NP	O
and	and	A530	CC	O	O
peripheral	peripheral	P616	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
leukocytes	leukocyte	L232	NNS	I-NP	O
.	.	0000	.	O	O

Upon	Upon	U150	IN	B-PP	O
partial	partial	P634	JJ	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
cloning	cloning	C452	NN	I-NP	O
,	,	0000	,	O	O
features	feature	F362	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
organization	organization	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
LPP	LPP	L100	NN	B-NP	O
were	be	W600	VBD	B-VP	O
established	establish	E231	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
span	span	S150	VB	I-VP	O
a	a	A000	DT	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
over	over	O160	IN	B-NP	O
400	400	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
.	.	0000	.	O	O

Nucleotide	Nucleotide	N243	NN	B-NP	O
sequence	sequence	S252	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
composite	composite	C512	JJ	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
of	of	O100	IN	B-PP	O
LPP	LPP	L100	NN	B-NP	O
revealed	reveal	R143	VBD	B-VP	O
an	an	A500	DT	B-NP	O
open	open	O150	JJ	I-NP	O
reading	reading	R352	NN	I-NP	O
frame	frame	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
1836	1836	0000	CD	B-NP	O
nucleotides	nucleotide	N243	NNS	I-NP	O
encoding	encode	E523	VBG	B-VP	O
a	a	A000	DT	B-NP	O
proline	proline	P645	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
rich	rich	R200	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
a	a	A000	DT	B-NP	O
leucine	leucine	L250	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
zipper	zipper	Z160	NN	I-NP	O
motif	motif	M310	NN	I-NP	O
in	in	I500	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
amino	amino	A500	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
terminal	terminal	T654	JJ	I-NP	O
region	region	R250	NN	I-NP	O
and	and	A530	CC	O	O
three	three	T600	CD	B-NP	O
LIM	LIM	L500	NN	I-NP	O
domains	domain	D520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
carboxy	carboxy	C612	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
terminal	terminal	T654	JJ	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
LPP	LPP	L100	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
encoded	encode	E523	VBN	B-NP	O
protein	protein	P635	NN	I-NP	O
should	should	S430	MD	B-VP	O
be	be	B000	VB	I-VP	O
classified	classify	C421	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
member	member	M516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
group	group	G610	NN	I-NP	O
3	3	0000	CD	B-NP	O
proteins	protein	P635	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
LIM	LIM	L500	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
reverse	reverse	R162	JJ	B-NP	O
transcriptase	transcriptase	T652	NN	I-NP	O
combined	combine	C515	VBN	B-VP	O
with	with	W300	IN	B-PP	O
polymerase	polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reactions	reaction	R235	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
lipoma	lipoma	L150	NN	B-NP	B-Disease
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
and	and	A530	CC	O	O
primary	primary	P656	JJ	B-NP	B-Disease
lipomas	lipoma	L152	NNS	I-NP	I-Disease
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
appeared	appear	A163	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
LPP	LPP	L100	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
frequently	frequently	F625	RB	I-VP	O
rearranged	rearrange	R652	VBN	I-VP	O
also	also	A420	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
cases	case	C200	NNS	B-NP	O
without	without	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
cytogenetically	cytogenetically	C325	RB	I-NP	O
detectable	detectable	D323	JJ	I-NP	O
involvement	involvement	I514	NN	I-NP	O
of	of	O100	IN	B-PP	O
3q27	3q27	Q000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
q28	q28	Q000	NN	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
alternative	alternative	A436	JJ	I-NP	O
HMGIC	HMGIC	H520	NN	I-NP	O
/	/	0000	SYM	B-NP	O
LPP	LPP	L100	NN	I-NP	O
hybrid	hybrid	H163	NN	I-NP	O
transcripts	transcript	T652	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
detected	detect	D323	VBN	I-VP	O
;	;	0000	:	O	O
the	the	T000	DT	B-NP	O
difference	difference	D165	NN	I-NP	O
between	between	B350	IN	B-PP	O
them	them	T500	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
mainly	mainly	M540	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
either	either	E360	CC	B-NP	O
two	two	T000	CD	I-NP	O
or	or	O600	CC	I-NP	O
three	three	T600	CD	I-NP	O
LIM	LIM	L500	NN	I-NP	O
domains	domain	D520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
predicted	predict	P632	VBN	I-NP	O
HMGI	HMGI	H520	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
C	C	C000	NN	I-NP	O
/	/	0000	SYM	I-NP	O
LPP	LPP	L100	NN	I-NP	O
fusion	fusion	F250	NN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Absence	Absence	A125	NN	B-NP	O
of	of	O100	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
and	and	A530	CC	O	O
intergenerational	intergenerational	I536	JJ	B-NP	O
stability	stability	S314	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CAG	CAG	C200	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
transgenic	transgenic	T652	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
expressing	express	E216	VBG	B-VP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
Huntington	Huntington	H535	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
transcript	transcript	T652	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
underlying	underlie	U536	VBG	B-VP	O
Huntington	Huntington	H535	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
HD	HD	H300	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
CAG	CAG	C200	NN	B-NP	O
expansion	expansion	E215	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
exon	exon	E250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
CAG	CAG	C200	NN	B-NP	O
expansion	expansion	E215	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
of	of	O100	IN	B-PP	O
HD	HD	H300	NN	B-NP	B-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
produced	produce	P632	VBN	I-VP	O
transgenic	transgenic	T652	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
containing	contain	C535	VBG	B-VP	O
the	the	T000	DT	B-NP	O
full	full	F400	JJ	I-NP	O
length	length	L523	NN	I-NP	O
human	human	H500	JJ	I-NP	O
HD	HD	H300	NN	I-NP	B-Disease
cDNA	cDNA	C350	NN	I-NP	O
with	with	W300	IN	B-PP	O
44	44	0000	CD	B-NP	O
CAG	CAG	C200	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
1	1	0000	CD	B-NP	O
year	year	Y600	NN	I-NP	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
mice	mouse	M200	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
no	no	N000	DT	B-NP	O
behavioral	behavioral	B164	JJ	I-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
morphometric	morphometric	M615	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
at	at	A300	IN	B-PP	O
6	6	0000	CD	B-NP	O
(	(	0000	(	O	O
one	one	O500	CD	B-NP	O
animal	animal	A540	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
9	9	0000	CD	B-NP	O
(	(	0000	(	O	O
two	two	T000	CD	B-NP	O
animals	animal	A542	NNS	I-NP	O
)	)	0000	)	O	O
months	month	M532	NNS	B-NP	O
age	age	A200	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
no	no	N000	DT	B-NP	O
changes	change	C520	NNS	I-NP	O
.	.	0000	.	O	O

Despite	Despite	D213	IN	B-PP	O
high	high	H200	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mRNA	mRNA	M650	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
no	no	N000	DT	B-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
in	in	I500	IN	B-PP	O
any	any	A500	DT	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
transgenic	transgenic	T652	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	FW	B-NP	O
vitro	vitro	V360	FW	I-NP	O
transfection	transfection	T652	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
indicated	indicate	I532	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
inclusion	inclusion	I524	NN	I-NP	O
of	of	O100	IN	B-PP	O
120	120	0000	CD	B-NP	O
bp	bp	B100	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
UTR	UTR	U360	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
construct	construct	C523	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
2349	2349	0000	CD	I-NP	O
prevented	prevent	P615	VBD	B-VP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
cDNA	cDNA	C350	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
of	of	O100	IN	B-PP	O
HD	HD	H300	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
mediated	mediate	M300	VBN	I-VP	O
through	through	T620	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
protein	protein	P635	NN	I-NP	O
interaction	interaction	I536	NN	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
presence	presence	P625	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
RNA	RNA	R500	NN	I-NP	O
transcript	transcript	T652	NN	I-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
CAG	CAG	C200	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
insufficient	insufficient	I521	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
cause	cause	C200	VB	I-VP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

Rather	Rather	R360	RB	B-ADVP	O
,	,	0000	,	O	O
translation	translation	T652	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CAG	CAG	C200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
crucial	crucial	C624	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
of	of	O100	IN	B-PP	O
HD	HD	H300	NN	B-NP	B-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
to	to	T000	TO	B-PP	O
that	that	T300	DT	B-NP	O
seen	see	S500	VBN	B-VP	O
in	in	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
CAG	CAG	C200	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
mice	mouse	M200	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
remarkably	remarkably	R562	RB	B-ADJP	O
stable	stable	S314	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
97	97	0000	CD	B-NP	O
meioses	meiosis	M200	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
genomic	genomic	G520	JJ	B-NP	O
sequences	sequence	S252	NNS	I-NP	O
may	may	M000	MD	B-VP	O
play	play	P400	VB	I-VP	O
a	a	A000	DT	B-NP	O
critical	critical	C632	JJ	I-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
influencing	influence	I514	VBG	B-VP	O
repeat	repeat	R130	NN	B-NP	O
instability	instability	I523	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

FISH	FISH	F200	NN	B-NP	O
studies	study	S320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
aniridia	aniridia	A563	NN	I-NP	I-Disease
and	and	A530	CC	O	O
t	t	T000	NN	B-NP	O
(	(	0000	(	O	O
7	7	0000	CD	B-NP	O
;	;	0000	:	O	O
11	11	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
q31	q31	Q000	NN	B-NP	O
.	.	0000	.	I-NP	O
2	2	0000	CD	I-NP	O
;	;	0000	:	O	O
p13	p13	P000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
2	2	0000	CD	I-NP	O
year	year	Y600	NN	I-NP	O
old	old	O430	JJ	I-NP	O
female	female	F540	NN	I-NP	O
presenting	present	P625	VBG	B-VP	O
with	with	W300	IN	B-PP	O
bilateral	bilateral	B436	JJ	B-NP	B-Disease
sporadic	sporadic	S163	JJ	I-NP	I-Disease
aniridia	aniridia	A563	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
an	an	A500	DT	B-NP	O
apparently	apparently	A165	RB	I-NP	O
balanced	balanced	B452	JJ	I-NP	O
reciprocal	reciprocal	R216	JJ	I-NP	O
translocation	translocation	T652	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
11	11	0000	CD	I-NP	O
breakpoint	breakpoint	B621	NN	I-NP	O
within	within	W350	IN	B-PP	O
band	band	B530	NN	B-NP	O
p13	p13	P000	NN	I-NP	O
.	.	0000	.	O	O

Fluorescence	Fluorescence	F462	NN	B-NP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridisation	hybridisation	H163	NN	I-NP	O
(	(	0000	(	O	O
FISH	FISH	F200	NN	B-NP	O
)	)	0000	)	O	O
studies	study	S320	NNS	B-NP	O
with	with	W300	IN	B-PP	O
distal	distal	D234	JJ	B-NP	O
11p13	11p13	P000	NN	I-NP	O
specific	specific	S121	JJ	I-NP	O
cosmids	cosmid	C253	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
11	11	0000	CD	I-NP	O
breakpoint	breakpoint	B621	NN	I-NP	O
lay	lay	L000	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
(	(	0000	(	O	O
PAX6	PAX6	P200	NN	B-NP	O
)	)	0000	)	O	O
locus	locus	L200	NN	B-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
region	region	R250	NN	I-NP	O
approximately	approximately	A162	RB	B-NP	O
100	100	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
distal	distal	D234	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
PAX6	PAX6	P200	NN	B-NP	O
defined	define	D153	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
cosmid	cosmid	C253	NN	I-NP	O
FO2121	FO2121	F000	NN	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
detectable	detectable	D323	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
within	within	W350	IN	B-PP	O
PAX6	PAX6	P200	NN	B-NP	O
,	,	0000	,	O	O
her	her	H600	PRP$	B-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
may	may	M000	MD	B-VP	O
have	have	H100	VB	I-VP	O
resulted	result	R243	VBN	I-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
disruption	disruption	D261	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
distal	distal	D234	JJ	I-NP	O
chromatin	chromatin	C653	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
either	either	E360	CC	O	O
enhancers	enhancer	E526	NNS	B-NP	O
or	or	O600	CC	O	O
regulators	regulator	R243	NNS	B-NP	O
for	for	F600	IN	B-PP	O
PAX6	PAX6	P200	NN	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
case	case	C200	NN	I-NP	O
may	may	M000	MD	B-VP	O
therefore	therefore	T616	RB	I-VP	O
be	be	B000	VB	I-VP	O
another	another	A536	DT	B-NP	O
example	example	E251	NN	I-NP	O
of	of	O100	IN	B-PP	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
position	position	P235	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
as	as	A200	IN	B-PP	O
recently	recently	R253	RB	B-ADVP	O
described	describe	D261	VBN	B-VP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
familial	familial	F540	JJ	I-NP	B-Disease
aniridia	aniridia	A563	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
cosegregated	cosegregate	C262	VBN	B-VP	O
with	with	W300	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
with	with	W300	IN	B-PP	O
11p13	11p13	P000	NN	B-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Muscle	Muscle	M240	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
different	different	D165	JJ	B-NP	O
variants	variant	V653	NNS	I-NP	O
.	.	0000	.	O	O

Muscle	Muscle	M240	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
investigated	investigate	I512	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Mediterranean	Mediterranean	M365	NNP	B-NP	O
,	,	0000	,	O	O
Seattle	Seattle	S340	NNP	B-NP	O
-	-	0000	HYPH	B-NP	O
like	like	L200	JJ	I-NP	O
and	and	A530	CC	I-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
variants	variant	V653	NNS	I-NP	O
.	.	0000	.	O	O

G6PD	G6PD	G130	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
samples	sample	S514	NNS	B-NP	O
obtained	obtain	O135	VBN	B-VP	O
from	from	F650	IN	B-PP	O
biopsies	biopsy	B120	NNS	B-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
quadriceps	quadricep	Q362	NNS	I-NP	O
muscle	muscle	M240	NN	I-NP	O
of	of	O100	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
males	male	M420	NNS	I-NP	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
female	female	F540	JJ	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
type	type	T100	NN	I-NP	O
of	of	O100	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
variant	variant	V653	NN	I-NP	O
was	be	W200	VBD	B-VP	O
determined	determine	D365	VBN	I-VP	O
by	by	B000	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
,	,	0000	,	O	O
extracted	extract	E236	VBN	B-VP	O
from	from	F650	IN	B-PP	O
blood	blood	B430	NN	B-NP	O
samples	sample	S514	NNS	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
variants	variant	V653	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
in	in	I500	IN	B-PP	O
muscle	muscle	M240	NN	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
statistically	statistically	S323	RB	I-NP	O
significant	significant	S251	JJ	I-NP	O
relationship	relationship	R435	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
between	between	B350	IN	B-PP	O
erythrocytes	erythrocyte	E636	NNS	B-NP	O
and	and	A530	CC	O	O
muscle	muscle	M240	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
male	male	M400	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
(	(	0000	(	O	O
r	r	R000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O
968	968	0000	CD	B-NP	O
;	;	0000	:	O	O
p	p	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
00008	00008	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
equation	equation	E235	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
best	good	B230	JJS	I-NP	O
fit	fit	F300	NN	I-NP	O
line	line	L500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
Y	Y	Y000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

390X	390X	X000	NN	B-NP	O
+	+	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

198	198	0000	CD	B-NP	O
198	198	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
,	,	0000	,	O	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
given	give	G150	VBN	I-NP	O
variant	variant	V653	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
extent	extent	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
in	in	I500	IN	B-PP	O
muscle	muscle	M240	NN	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
determined	determine	D365	VBN	I-VP	O
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
this	this	T200	DT	B-NP	O
equation	equation	E235	NN	I-NP	O
,	,	0000	,	O	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
erythrocytes	erythrocyte	E636	NNS	B-NP	O

Gene	Gene	G500	NN	B-NP	O
therapy	therapy	T610	NN	I-NP	O
for	for	F600	IN	B-PP	O
phenylketonuria	phenylketonuria	P542	NN	B-NP	B-Disease
.	.	0000	.	O	O

Classical	Classical	C424	JJ	B-NP	O
phenylketonuria	phenylketonuria	P542	NN	I-NP	B-Disease
(	(	0000	(	O	O
PKU	PKU	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
hepatic	hepatic	H132	JJ	B-NP	I-Disease
phenylalanine	phenylalanine	P545	NN	I-NP	I-Disease
hydroxylase	hydroxylase	H362	NN	I-NP	I-Disease
(	(	0000	(	O	O
PAH	PAH	P000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Limitations	Limitation	L535	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
current	current	C653	JJ	I-NP	O
dietary	dietary	D360	JJ	I-NP	O
treatment	treatment	T635	NN	I-NP	O
for	for	F600	IN	B-PP	O
PKU	PKU	P200	NN	B-NP	B-Disease
have	have	H100	VBP	B-VP	O
led	lead	L300	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
potential	potential	P353	JJ	B-NP	O
treatments	treatment	T635	NNS	I-NP	O
based	base	B230	VBN	B-VP	O
on	on	O500	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
gene	gene	G500	NN	I-NP	O
transfer	transfer	T652	NN	I-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
different	different	D165	JJ	I-NP	O
vector	vector	V236	NN	I-NP	O
systems	system	S235	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
examined	examine	E253	VBN	I-VP	O
.	.	0000	.	O	O

Vectors	Vector	V236	NNS	B-NP	O
derived	derive	D613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
recombinant	recombinant	R251	JJ	I-NP	O
retrovirus	retrovirus	R361	NN	I-NP	O
or	or	O600	CC	O	O
a	a	A000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
/	/	0000	SYM	B-NP	O
protein	protein	P635	NN	I-NP	O
complex	complex	C514	NN	I-NP	O
can	can	C500	MD	B-VP	O
efficiently	efficiently	E125	RB	I-VP	O
transduce	transduce	T652	VB	I-VP	O
the	the	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
into	into	I530	IN	B-PP	O
PAH	PAH	P000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
hepatocytes	hepatocyte	H132	NNS	I-NP	O
in	in	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
application	application	A142	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
vector	vector	V236	NN	I-NP	O
systems	system	S235	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
presently	presently	P625	RB	I-VP	O
limited	limit	L530	VBN	I-VP	O
by	by	B000	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
low	low	L000	JJ	I-NP	O
transduction	transduction	T652	NN	I-NP	O
efficiency	efficiency	E125	NN	I-NP	O
in	in	I500	FW	B-ADVP	O
vivo	vivo	V100	FW	I-ADVP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
vector	vector	V236	NN	I-NP	O
derived	derive	D613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
recombinant	recombinant	R251	JJ	I-NP	O
adenovirus	adenovirus	A351	NN	I-NP	O
can	can	C500	MD	B-VP	O
restore	restore	R236	VB	I-VP	O
10	10	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
80	80	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
hepatic	hepatic	H132	JJ	I-NP	O
PAH	PAH	P000	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
into	into	I530	IN	B-PP	O
PAH	PAH	P000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
mice	mouse	M200	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
completely	completely	C514	RB	B-VP	O
normalizes	normalize	N654	VBZ	I-VP	O
serum	serum	S650	NN	B-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
treatment	treatment	T635	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
transient	transient	T652	JJ	B-ADJP	O
and	and	A530	CC	O	O
cannot	cannot	C530	MD	B-VP	O
be	be	B000	VB	I-VP	O
effectively	effectively	E123	RB	B-ADVP	O
re	re	R000	AFX	O	O
-	-	0000	HYPH	O	O
administered	administer	A352	VBN	B-VP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
neutralizing	neutralize	N364	VBG	B-VP	O
antibodies	antibody	A531	NNS	B-NP	O
directed	direct	D623	VBN	B-VP	O
against	against	A252	IN	B-PP	O
the	the	T000	DT	B-NP	O
recombinant	recombinant	R251	JJ	I-NP	O
adenoviral	adenoviral	A351	JJ	I-NP	O
vector	vector	V236	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
PKU	PKU	P200	NN	B-NP	B-Disease
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
completely	completely	C514	RB	I-VP	O
corrected	correct	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
gene	gene	G500	NN	I-NP	O
therapy	therapy	T610	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
provide	provide	P613	VBP	B-VP	O
some	some	S500	DT	B-NP	O
direction	direction	D623	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
future	future	F360	JJ	I-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
adenoviral	adenoviral	A351	JJ	B-NP	O
vectors	vector	V236	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Exon	Exon	E250	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
intron	intron	I536	NN	I-NP	O
structure	structure	S362	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
neuronal	neuronal	N654	JJ	I-NP	O
nicotinic	nicotinic	N235	JJ	I-NP	O
acetylcholine	acetylcholine	A234	NN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
alpha	alpha	A410	NN	I-NP	O
4	4	0000	CD	I-NP	O
subunit	subunit	S153	NN	I-NP	O
(	(	0000	(	O	O
CHRNA4	CHRNA4	C650	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
neuronal	neuronal	N654	JJ	I-NP	O
nicotinic	nicotinic	N235	JJ	I-NP	O
acetylcholine	acetylcholine	A234	NN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
alpha	alpha	A410	NN	I-NP	O
4	4	0000	CD	I-NP	O
subunit	subunit	S153	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
CHRNA4	CHRNA4	C650	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
located	locate	L230	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
region	region	R250	NN	I-NP	O
for	for	F600	IN	B-PP	O
three	three	T600	CD	B-NP	O
different	different	D165	JJ	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
benign	benign	B525	JJ	B-NP	B-Disease
familial	familial	F540	JJ	I-NP	I-Disease
neonatal	neonatal	N534	JJ	I-NP	I-Disease
convulsions	convulsion	C514	NNS	I-NP	I-Disease
,	,	0000	,	O	O
autosomal	autosomal	A325	JJ	B-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
nocturnal	nocturnal	N236	JJ	I-NP	I-Disease
frontal	frontal	F653	JJ	I-NP	I-Disease
lobe	lobe	L100	NN	I-NP	I-Disease
epilepsy	epilepsy	E141	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
low	low	L000	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
voltage	voltage	V432	NN	I-NP	O
EEG	EEG	E200	NN	I-NP	O
.	.	0000	.	O	O

Recently	Recently	R253	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
transmembrane	transmembrane	T652	NN	B-NP	O
domain	domain	D500	NN	I-NP	O
2	2	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
CHRNA4	CHRNA4	C650	NN	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
autosomal	autosomal	A325	JJ	B-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
nocturnal	nocturnal	N236	JJ	I-NP	I-Disease
frontal	frontal	F653	JJ	I-NP	I-Disease
lobe	lobe	L100	NN	I-NP	I-Disease
epilepsy	epilepsy	E141	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
extended	extend	E235	VBN	I-NP	O
pedigree	pedigree	P326	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
determined	determine	D365	VBN	I-VP	O
the	the	T000	DT	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
organization	organization	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
CHRNA4	CHRNA4	C650	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
consists	consist	C523	VBZ	B-VP	O
of	of	O100	IN	B-PP	O
six	six	S200	CD	B-NP	O
exons	exon	E252	NNS	I-NP	O
distributed	distribute	D236	VBN	B-VP	O
over	over	O160	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
17	17	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
of	of	O100	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
obtained	obtain	O135	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
regions	region	R252	NNS	I-NP	O
adjacent	adjacent	A325	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
boundaries	boundary	B536	NNS	I-NP	O
enabled	enable	E514	VBD	B-VP	O
us	us	U200	PRP	B-NP	O
to	to	T000	TO	B-VP	O
develop	develop	D141	VB	I-VP	O
a	a	A000	DT	B-NP	O
set	set	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
primer	primer	P656	NN	B-NP	O
pairs	pair	P620	NNS	I-NP	O
for	for	F600	IN	B-PP	O
PCR	PCR	P260	NN	B-NP	O
amplification	amplification	A514	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
sequence	sequence	S252	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
provides	provide	P613	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
comprehensive	comprehensive	C516	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
screening	screening	S265	NN	I-NP	O
of	of	O100	IN	B-PP	O
CHRNA4	CHRNA4	C650	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
above	above	A100	RB	I-NP	O
-	-	0000	HYPH	I-NP	O
mentioned	mention	M535	VBN	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
and	and	A530	CC	O	O
possibly	possibly	P214	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
other	other	O360	JJ	B-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
idiopathic	idiopathic	I313	JJ	B-NP	B-Disease
epilepsies	epilepsy	E141	NNS	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Ashkenazi	Ashkenazi	A252	NN	B-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
population	population	P143	NN	I-NP	O
frequencies	frequency	F625	NNS	I-NP	O
for	for	F600	IN	B-PP	O
common	common	C500	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
.	.	0000	.	O	O

BRCA1	BRCA1	B620	NN	B-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
are	be	A600	VBP	B-VP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
major	major	M260	JJ	I-NP	O
identified	identify	I353	VBN	I-NP	O
causes	cause	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
inherited	inherit	I563	VBN	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
either	either	E360	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
conferring	confer	C516	VBG	B-VP	O
up	up	U100	IN	B-NP	O
to	to	T000	TO	I-NP	O
80	80	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
90	90	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
lifetime	lifetime	L135	NN	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
carrier	carrier	C600	NN	B-NP	O
females	female	F542	NNS	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
account	account	A253	NN	I-NP	O
for	for	F600	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
45	45	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	O	O
90	90	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
inherited	inherit	I563	VBN	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
/	/	0000	SYM	B-NP	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
BRCA2	BRCA2	B620	NN	B-NP	O
account	account	A253	NN	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
comparable	comparable	C516	JJ	I-NP	O
percentage	percentage	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
inherited	inherit	I563	VBN	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

Over	Over	O160	IN	B-PP	O
85	85	0000	CD	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
growing	grow	G652	VBG	I-NP	O
list	list	L230	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA2	BRCA2	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
protein	protein	P635	NN	B-NP	O
truncation	truncation	T652	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
185delAG	185delAG	D420	NN	B-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
reported	report	R163	VBN	I-NP	O
increased	increase	I526	VBN	I-NP	O
carrier	carrier	C600	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
0	0	0000	CD	I-NP	O
.	.	0000	.	O	O

9	9	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
Jewish	Jewish	J200	NNP	I-NP	O
population	population	P143	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
rare	rare	R600	JJ	B-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
Jewish	Jewish	J200	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
6174delT	6174delT	D430	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
BRCA2	BRCA2	B620	NN	B-NP	O
was	be	W200	VBD	B-VP	O
recently	recently	R253	RB	I-VP	O
identified	identify	I353	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
frequent	frequent	F625	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
8	8	0000	CD	B-NP	O
out	out	O300	IN	I-NP	O
of	of	O100	IN	I-NP	O
107	107	0000	CD	I-NP	O
Ashkenazi	Ashkenazi	A252	NN	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
women	woman	W500	NNS	I-NP	O
diagnosed	diagnose	D252	VBN	B-VP	O
with	with	W300	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
by	by	B000	IN	B-PP	O
age	age	A200	NN	B-NP	O
50	50	0000	CD	I-NP	O
(	(	0000	(	O	O
ref	ref	R100	NN	B-NP	O
.	.	0000	.	O	O
8	8	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
male	male	M400	JJ	I-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
conducted	conduct	C532	VBN	I-VP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
scale	scale	S240	NN	I-NP	O
population	population	P143	NN	I-NP	O
study	study	S300	NN	I-NP	O
to	to	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
the	the	T000	DT	B-NP	O
prevalence	prevalence	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
specific	specific	S121	JJ	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
individuals	individual	I531	NNS	I-NP	O
who	who	W000	WP	B-NP	O
were	be	W600	VBD	B-VP	O
unselected	unselecte	U524	VBN	I-VP	O
for	for	F600	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

BRCA1	BRCA1	B620	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
screening	screening	S265	NN	I-NP	O
on	on	O500	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
3	3	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
000	000	0000	CD	I-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
Jewish	Jewish	J200	NNP	I-NP	O
samples	sample	S514	NNS	I-NP	O
determined	determine	D365	VBD	B-VP	O
a	a	A000	DT	B-NP	O
carrier	carrier	C600	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

09	09	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
185delAG	185delAG	D420	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

13	13	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
5382insC	5382insC	I520	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

BRCA2	BRCA2	B620	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
on	on	O500	IN	B-PP	O
3	3	0000	CD	B-NP	O
,	,	0000	,	O	O
085	085	0000	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
population	population	P143	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
carrier	carrier	C600	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

52	52	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
6174delT	6174delT	D430	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
population	population	P143	NN	I-NP	O
-	-	0000	HYPH	O	O
based	base	B230	VBN	B-NP	O
study	study	S300	NN	I-NP	O
confirms	confirm	C516	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
185delAG	185delAG	D420	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
6174delT	6174delT	D430	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
constitute	constitute	C523	VBP	B-VP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
most	most	M230	RBS	I-NP	O
frequent	frequent	F625	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
predisposing	predispose	P632	VBG	B-VP	O
to	to	T000	TO	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
among	among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
Ashkenazim	Ashkenazim	A252	NNP	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
suggests	suggest	S232	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
relatively	relatively	R431	RB	I-NP	O
lower	low	L600	JJR	I-NP	O
penetrance	penetrance	P536	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
6174delT	6174delT	D430	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
BRCA2	BRCA2	B620	NN	B-NP	O

Dual	Dual	D400	JJ	B-NP	O
roles	role	R420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
cellular	cellular	C460	JJ	I-NP	O
response	response	R215	NN	I-NP	O
to	to	T000	TO	B-PP	O
radiation	radiation	R350	NN	B-NP	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
cell	cell	C400	NN	B-NP	O
growth	growth	G630	NN	I-NP	O
control	control	C536	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
mutated	mutate	M300	VBN	B-VP	O
in	in	I500	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
telangiectasia	telangiectasia	T452	NN	B-NP	I-Disease
(	(	0000	(	O	O
AT	AT	A300	NN	B-NP	B-Disease
)	)	0000	)	O	O
patients	patient	P353	NNS	B-NP	O
,	,	0000	,	O	O
denoted	denote	D530	VBN	B-VP	O
ATM	ATM	A350	NNP	B-NP	O
,	,	0000	,	O	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
or	or	O600	CC	I-NP	O
lipid	lipid	L130	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
elucidate	elucidate	E423	VB	I-VP	O
the	the	T000	DT	B-NP	O
functions	function	F523	NNS	I-NP	O
of	of	O100	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
disrupted	disrupt	D261	VBD	B-VP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
through	through	T620	IN	B-PP	O
homologous	homologous	H542	JJ	B-NP	O
recombination	recombination	R251	NN	I-NP	O
in	in	I500	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
.	.	0000	.	O	O

Consistent	Consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
cellular	cellular	C460	JJ	B-NP	O
defects	defect	D123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
AT	AT	A300	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
-	-	0000	HYPH	O	O
/	/	0000	SYM	O	O
-	-	0000	HYPH	O	O
cells	cell	C420	NNS	B-NP	O
are	be	A600	VBP	B-VP	O
hypersensitive	hypersensitive	H162	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
gamma	gamma	G500	SYM	O	O
-	-	0000	HYPH	O	O
irradiation	irradiation	I635	NN	B-NP	O
and	and	A530	CC	O	O
defective	defective	D123	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
cell	cell	C400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
cycle	cycle	C240	NN	I-NP	O
arrest	arrest	A623	NN	I-NP	O
following	follow	F452	VBG	B-PP	O
radiation	radiation	R350	NN	B-NP	O
,	,	0000	,	O	O
correlating	correlate	C643	VBG	B-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
defective	defective	D123	JJ	I-NP	O
up	up	U100	RB	I-NP	O
-	-	0000	HYPH	I-NP	O
regulation	regulation	R243	NN	B-NP	O
of	of	O100	IN	B-PP	O
p53	p53	P000	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
ATM	ATM	A350	NN	B-NP	O
-	-	0000	HYPH	O	O
/	/	0000	SYM	O	O
-	-	0000	HYPH	O	O
mouse	mouse	M200	NN	B-NP	O
thymocytes	thymocyte	T523	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
more	more	M600	RBR	B-ADJP	O
resistant	resistant	R235	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
apoptosis	apoptosis	A132	NN	B-NP	O
induced	induce	I532	VBN	B-VP	O
by	by	B000	IN	B-PP	O
gamma	gamma	G500	SYM	B-NP	O
-	-	0000	HYPH	O	O
irradiation	irradiation	I635	NN	B-NP	O
than	than	T500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
thymocytes	thymocyte	T523	NNS	I-NP	O
.	.	0000	.	O	O

ATM	ATM	A350	NN	B-NP	O
-	-	0000	HYPH	O	O
/	/	0000	SYM	O	O
-	-	0000	HYPH	O	O
fibroblasts	fibroblast	F161	NNS	B-NP	O
are	be	A600	VBP	B-VP	O
inefficient	inefficient	I512	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
G1	G1	G000	NN	B-NP	O
to	to	T000	TO	B-PP	O
S	S	S000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
phase	phase	P200	NN	I-NP	O
progression	progression	P626	NN	I-NP	O
following	follow	F452	VBG	B-PP	O
serum	serum	S650	NN	B-NP	O
stimulation	stimulation	S354	NN	I-NP	O
and	and	A530	CC	O	O
senesce	senesce	S520	NN	B-NP	O
after	after	A136	IN	B-PP	O
only	only	O540	RB	B-NP	O
a	a	A000	DT	I-NP	O
few	few	F000	JJ	I-NP	O
passages	passage	P200	NNS	I-NP	O
in	in	I500	IN	B-PP	O
culture	culture	C436	NN	B-NP	O
.	.	0000	.	O	O

They	They	T000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
an	an	A500	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
constitutive	constitutive	C523	JJ	I-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
p21CP1	p21CP1	P210	NN	B-NP	O
/	/	0000	SYM	B-NP	O
WAF1	WAF1	W100	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
therefore	therefore	T616	RB	B-ADVP	O
critical	critical	C632	JJ	B-ADJP	O
both	both	B300	CC	B-PP	O
for	for	F600	IN	I-PP	O
cellular	cellular	C460	JJ	B-NP	O
responses	response	R215	NNS	I-NP	O
to	to	T000	TO	B-PP	O
ionizing	ionize	I525	VBG	B-VP	O
radiation	radiation	R350	NN	B-NP	O
and	and	A530	CC	B-PP	O
for	for	F600	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
cycle	cycle	C240	NN	I-NP	O
progression	progression	P626	NN	I-NP	O
.	.	0000	.	O	O

ATM	ATM	A350	NN	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
and	and	A530	CC	I-NP	O
thymocytes	thymocyte	T523	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
intermediately	intermediately	I536	RB	B-NP	O
defective	defective	D123	JJ	I-NP	O
responses	response	R215	NNS	I-NP	O
to	to	T000	TO	B-PP	O
irradiation	irradiation	I635	NN	B-NP	O
but	but	B300	CC	O	O
no	no	N000	DT	B-NP	O
growth	growth	G630	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
AT	AT	A300	NN	B-NP	B-Disease
heterozygotes	heterozygote	H362	NNS	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
attributable	attributable	A361	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
poor	poor	P600	JJ	B-NP	O
checkpoint	checkpoint	C215	NN	I-NP	O
function	function	F523	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Targeted	Target	T623	VBN	B-NP	O
disruption	disruption	D261	NN	I-NP	O
of	of	O100	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
growth	growth	G630	NN	B-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
,	,	0000	,	O	O
chromosomal	chromosomal	C652	JJ	B-NP	B-Disease
fragmentation	fragmentation	F625	NN	I-NP	I-Disease
during	during	D652	IN	B-PP	I-Disease
meiosis	meiosis	M200	NN	B-NP	I-Disease
,	,	0000	,	O	O
immune	immune	I500	JJ	B-NP	B-Disease
defects	defect	D123	NNS	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
thymic	thymic	T520	JJ	B-NP	B-Disease
lymphoma	lymphoma	L515	NN	I-NP	I-Disease
.	.	0000	.	O	O

ATM	ATM	A350	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
mutated	mutate	M300	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
human	human	H500	JJ	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
member	member	M516	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
of	of	O100	IN	B-PP	O
kinases	kinase	K520	NNS	B-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
metabolism	metabolism	M314	NN	I-NP	O
and	and	A530	CC	I-NP	O
cell	cell	C400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
cycle	cycle	C240	NN	I-NP	O
checkpoint	checkpoint	C215	NN	I-NP	O
control	control	C536	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
help	help	H410	VB	I-VP	O
clarify	clarify	C461	VB	I-VP	O
the	the	T000	DT	B-NP	O
physiological	physiological	P242	JJ	I-NP	O
roles	role	R420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
disrupted	disrupt	D261	VBD	B-VP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
through	through	T620	IN	B-PP	O
homologous	homologous	H542	JJ	B-NP	O
recombination	recombination	R251	NN	I-NP	O
.	.	0000	.	O	O

Initial	Initial	I534	JJ	B-NP	O
evaluation	evaluation	E143	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
knockout	knockout	K523	NN	I-NP	O
animals	animal	A542	NNS	I-NP	O
indicates	indicate	I532	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
inactivation	inactivation	I523	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
recreates	recreate	R263	VBZ	B-VP	O
much	much	M200	JJ	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
of	of	O100	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
mutant	mutant	M353	NN	I-NP	O
(	(	0000	(	O	O
ATM	ATM	A350	NN	B-NP	O
-	-	0000	HYPH	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	O	O
)	)	0000	)	O	O
mice	mouse	M200	NNS	B-NP	O
are	be	A600	VBP	B-VP	O
viable	viable	V140	JJ	B-ADJP	O
,	,	0000	,	O	O
growth	growth	G630	NN	B-NP	O
-	-	0000	HYPH	O	O
retarded	retard	R363	VBN	B-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
infertile	infertile	I516	JJ	B-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
infertility	infertility	I516	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
/	/	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
mice	mouse	M200	NNS	I-NP	O
results	result	R243	VBZ	B-VP	O
from	from	F650	IN	B-PP	O
meiotic	meiotic	M320	JJ	B-NP	O
failure	failure	F460	NN	I-NP	O
.	.	0000	.	O	O

Meiosis	Meiosis	M200	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
arrested	arrest	A623	VBN	I-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
zygotene	zygotene	Z235	NN	I-NP	O
/	/	0000	SYM	B-NP	O
pachytene	pachytene	P235	NN	I-NP	O
stage	stage	S320	NN	I-NP	O
of	of	O100	IN	B-PP	O
prophase	prophase	P612	NN	B-NP	O
I	I	I000	CD	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
abnormal	abnormal	A156	JJ	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
synapsis	synapsis	S512	NN	I-NP	O
and	and	A530	CC	O	O
subsequent	subsequent	S125	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
fragmentation	fragmentation	F625	NN	I-NP	O
.	.	0000	.	O	O

Immune	Immune	I500	JJ	B-NP	B-Disease
defects	defect	D123	NNS	I-NP	I-Disease
also	also	A420	RB	B-ADVP	O
are	be	A600	VBP	B-VP	O
evident	evident	E135	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
/	/	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
mice	mouse	M200	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
reduced	reduce	R323	VBN	B-NP	O
numbers	number	N516	NNS	I-NP	O
of	of	O100	IN	B-PP	O
B220	B220	B000	NN	B-NP	O
+	+	0000	SYM	B-NP	O
CD43	CD43	C300	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
pre	pre	P600	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
B	B	B000	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
thymocytes	thymocyte	T523	NNS	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
peripheral	peripheral	P616	JJ	B-NP	O
T	T	T000	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
functional	functional	F523	JJ	B-NP	O
impairment	impairment	I516	NN	I-NP	O
of	of	O100	IN	B-PP	O
T	T	T000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
cell	cell	C400	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
dependent	dependent	D153	JJ	I-NP	O
immune	immune	I500	JJ	I-NP	O
responses	response	R215	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
cerebella	cerebella	C614	NN	I-NP	O
of	of	O100	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
-	-	0000	HYPH	O	O
/	/	0000	SYM	O	O
-	-	0000	HYPH	O	O
mice	mouse	M200	NNS	B-NP	O
appear	appear	A160	VBP	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
by	by	B000	IN	B-PP	O
histologic	histologic	H234	JJ	B-NP	O
examination	examination	E253	NN	I-NP	O
at	at	A300	IN	B-PP	O
3	3	0000	CD	B-NP	O
to	to	T000	TO	I-NP	O
4	4	0000	CD	I-NP	O
months	month	M532	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
mice	mouse	M200	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
no	no	N000	DT	B-NP	O
gross	gross	G620	JJ	I-NP	O
behavioral	behavioral	B164	JJ	I-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
rapidly	rapidly	R134	RB	B-ADVP	O
develop	develop	D141	VBP	B-VP	O
thymic	thymic	T520	JJ	B-NP	B-Disease
lymphomas	lymphoma	L515	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
die	die	D000	VB	B-VP	O
before	before	B160	IN	B-PP	O
4	4	0000	CD	B-NP	O
months	month	M532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
age	age	A200	NN	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
plays	play	P420	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
essential	essential	E253	JJ	I-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
diverse	diverse	D162	JJ	I-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
cellular	cellular	C460	JJ	B-NP	O
processes	process	P620	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
meiosis	meiosis	M200	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
growth	growth	G630	NN	I-NP	O
of	of	O100	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
,	,	0000	,	O	O
immune	immune	I500	JJ	B-NP	O
development	development	D141	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
tumor	tumor	T560	NN	B-NP	B-Disease
suppression	suppression	S162	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Cloning	Cloning	C452	NN	B-NP	O
and	and	A530	CC	I-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
very	very	V600	RB	I-NP	O
-	-	0000	HYPH	I-NP	O
long	long	L520	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
acyl	acyl	A240	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
CoA	CoA	C000	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
,	,	0000	,	O	O
chromosomal	chromosomal	C652	JJ	B-NP	O
assignment	assignment	A253	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	I-NP	O
identification	identification	I353	NN	I-NP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
of	of	O100	IN	B-PP	O
nine	nine	N500	CD	B-NP	O
different	different	D165	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
VLCAD	VLCAD	V423	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Very	Very	V600	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
long	long	L520	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
acyl	acyl	A240	NN	I-NP	O
-	-	0000	HYPH	O	O
CoA	CoA	C000	NN	B-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
(	(	0000	(	O	O
VLCAD	VLCAD	V423	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
four	four	F600	CD	B-NP	O
straight	straight	S362	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
acyl	acyl	A240	NN	I-NP	O
-	-	0000	HYPH	O	O
CoA	CoA	C000	NN	B-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
(	(	0000	(	O	O
ACD	ACD	A230	NN	B-NP	O
)	)	0000	)	O	O
enzymes	enzyme	E525	NNS	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
all	all	A400	DT	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
encoded	encode	E523	VBN	I-NP	O
mitochondrial	mitochondrial	M325	JJ	I-NP	O
flavoproteins	flavoprotein	F416	NNS	I-NP	O
catalyzing	catalyze	C342	VBG	B-VP	O
the	the	T000	DT	B-NP	O
initial	initial	I534	JJ	I-NP	O
step	step	S310	NN	I-NP	O
in	in	I500	IN	B-PP	O
fatty	fatty	F300	JJ	B-NP	O
acid	acid	A230	NN	I-NP	O
beta	beta	B300	SYM	B-VP	O
-	-	0000	HYPH	O	O
oxidation	oxidation	O235	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
used	use	U230	VBN	I-VP	O
the	the	T000	DT	B-NP	O
very	very	V600	RB	I-NP	O
fast	fast	F230	JJ	I-NP	O
,	,	0000	,	I-NP	O
Rapid	Rapid	R130	JJ	I-NP	O
Amplification	Amplification	A514	NN	I-NP	O
of	of	O100	IN	B-PP	O
cDNA	cDNA	C350	NN	B-NP	O
Ends	End	E532	NNS	I-NP	O
(	(	0000	(	O	O
RACE	RACE	R200	NN	B-NP	O
)	)	0000	)	O	O
based	based	B230	JJ	B-NP	O
strategy	strategy	S363	NN	I-NP	O
to	to	T000	TO	B-VP	O
obtain	obtain	O135	VB	I-VP	O
the	the	T000	DT	B-NP	O
sequence	sequence	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
cDNAs	cDNA	C352	NNS	B-NP	O
encoding	encode	E523	VBG	B-VP	O
human	human	H500	JJ	B-NP	O
VLCAD	VLCAD	V423	NN	I-NP	O
from	from	F650	IN	B-PP	O
placenta	placenta	P425	NN	B-NP	O
and	and	A530	CC	I-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
.	.	0000	.	O	O

Alignment	Alignment	A425	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
predicted	predict	P632	VBN	I-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
VLCAD	VLCAD	V423	NN	I-NP	O
with	with	W300	IN	B-PP	O
those	those	T200	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
human	human	H500	JJ	I-NP	O
ACD	ACD	A230	NN	I-NP	O
enzymes	enzyme	E525	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
extensive	extensive	E235	JJ	B-NP	O
sequence	sequence	S252	NN	I-NP	O
homology	homology	H542	NN	I-NP	O
.	.	0000	.	O	O

Moreover	Moreover	M616	RB	B-ADVP	O
,	,	0000	,	O	O
human	human	H500	JJ	B-NP	O
VLCAD	VLCAD	V423	NN	I-NP	O
and	and	A530	CC	O	O
human	human	H500	JJ	B-NP	O
acyl	acyl	A240	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
CoA	CoA	C000	NN	I-NP	O
oxidase	oxidase	O232	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
extensive	extensive	E235	JJ	B-NP	O
sequence	sequence	S252	NN	I-NP	O
homology	homology	H542	NN	I-NP	O
corroborating	corroborate	C616	VBG	B-VP	O
the	the	T000	DT	B-NP	O
notion	notion	N350	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
genes	gene	G520	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
evolutionarily	evolutionarily	E143	RB	B-ADJP	O
related	relate	R430	VBN	I-ADJP	O
.	.	0000	.	O	O

Southern	Southern	S365	NN	B-NP	O
blot	blot	B430	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
from	from	F650	IN	B-PP	O
hybrid	hybrid	H163	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
localize	localize	L242	VB	I-VP	O
the	the	T000	DT	B-NP	O
VLCAD	VLCAD	V423	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
to	to	T000	TO	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
17p11	17p11	P000	NN	I-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
p11	p11	P000	NN	I-NP	O
.	.	0000	.	O	O

13105	13105	0000	CD	B-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
Northern	Northern	N636	JJ	B-NP	O
and	and	A530	CC	I-NP	O
Western	Western	W236	JJ	I-NP	O
blot	blot	B430	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
to	to	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
the	the	T000	DT	B-NP	O
tissue	tissue	T200	NN	I-NP	O
specific	specific	S121	JJ	I-NP	O
distribution	distribution	D236	NN	I-NP	O
of	of	O100	IN	B-PP	O
VLCAD	VLCAD	V423	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
and	and	A530	CC	I-NP	O
protein	protein	P635	NN	I-NP	O
in	in	I500	IN	B-PP	O
several	several	S164	JJ	B-NP	O
human	human	H500	JJ	I-NP	O
tissues	tissue	T200	NNS	I-NP	O
we	we	W000	PRP	B-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
VLCAD	VLCAD	V423	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
most	most	M230	RBS	B-ADJP	O
abundant	abundant	A153	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
heart	heart	H630	NN	B-NP	O
and	and	A530	CC	O	O
skeletal	skeletal	S243	JJ	B-NP	O
muscle	muscle	M240	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
agrees	agree	A262	VBZ	B-VP	O
well	well	W400	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
fact	fact	F230	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
cardiac	cardiac	C632	JJ	B-NP	O
and	and	A530	CC	I-NP	O
muscle	muscle	M240	NN	I-NP	O
symptoms	symptom	S513	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
characteristic	characteristic	C623	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
VLCAD	VLCAD	V423	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Northern	Northern	N636	NN	B-NP	O
blot	blot	B430	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
and	and	A530	CC	I-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
cloned	clone	C453	VBN	B-NP	O
PCR	PCR	P260	NN	I-NP	O
amplified	amplify	A514	VBN	I-NP	O
VLCAD	VLCAD	V423	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
from	from	F650	IN	B-PP	O
four	four	F600	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
VLCAD	VLCAD	V423	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
VLCAD	VLCAD	V423	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
was	be	W200	VBD	B-VP	O
undetectable	undetectable	U532	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
patient	patient	P353	NN	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
three	three	T600	CD	I-NP	O
have	have	H100	VBP	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
both	both	B300	DT	B-NP	O
VLCAD	VLCAD	V423	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

Western	Western	W236	NN	B-NP	O
blot	blot	B430	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
patient	patient	P353	NN	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
identified	identify	I353	VBN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
severely	severely	S164	RB	B-NP	O
reduced	reduce	R323	VBN	I-NP	O
amounts	amount	A532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
VLCAD	VLCAD	V423	NN	B-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
bases	base	B200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
combined	combined	C515	JJ	B-NP	B-Disease
subtotal	subtotal	S134	JJ	I-NP	I-Disease
deficiencies	deficiency	D125	NNS	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
C6	C6	C000	NN	B-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
C7	C7	C000	NN	I-NP	I-Disease
:	:	0000	:	O	O
their	their	T600	PRP$	B-NP	O
effects	effect	E123	NNS	I-NP	O
in	in	I500	IN	B-PP	O
combination	combination	C515	NN	B-NP	O
with	with	W300	IN	B-PP	O
other	other	O360	JJ	B-NP	O
C6	C6	C000	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
C7	C7	C000	NN	I-NP	I-Disease
deficiencies	deficiency	D125	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Combined	Combine	C515	VBN	B-NP	B-Disease
subtotal	subtotal	S134	JJ	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
C6	C6	C000	NN	B-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
C7	C7	C000	NN	I-NP	I-Disease
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
both	both	B300	DT	B-NP	O
proteins	protein	P635	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
expressed	express	E216	VBN	I-VP	O
at	at	A300	IN	B-PP	O
very	very	V600	RB	B-NP	O
low	low	L000	JJ	I-NP	O
levels	level	L142	NNS	I-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	O
form	form	F650	NN	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
defect	defect	D123	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
splice	splice	S142	NN	I-NP	O
donor	donor	D560	NN	I-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
15	15	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
C6	C6	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
explains	explain	E214	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
low	low	L000	JJ	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
weight	weight	W230	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
C6	C6	C000	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
probably	probably	P614	RB	B-ADVP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
low	low	L000	JJ	I-NP	O
expressed	express	E216	VBN	I-NP	O
concentration	concentration	C525	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
C7	C7	C000	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
more	more	M600	RBR	B-ADJP	O
enigmatic	enigmatic	E525	JJ	I-ADJP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
weight	weight	W230	NN	I-NP	O
,	,	0000	,	O	O
low	low	L000	JJ	B-NP	O
circulating	circulate	C624	VBG	I-NP	O
concentration	concentration	C525	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
altered	alter	A436	VBN	B-VP	O
isoelectric	isoelectric	I242	JJ	B-NP	O
point	point	P530	NN	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
Arg	Arg	A620	NN	I-NP	O
>	>	0000	SYM	B-NP	O
Ser	Ser	S600	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
11	11	0000	CD	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
only	only	O540	RB	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
alteration	alteration	A436	NN	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
mature	mature	M360	JJ	I-NP	O
C7	C7	C000	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
defects	defect	D123	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
characteristic	characteristic	C623	JJ	I-NP	O
set	set	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
polymorphic	polymorphic	P456	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
C6	C6	C000	NN	I-NP	O
/	/	0000	SYM	B-NP	O
C7	C7	C000	NN	I-NP	O
region	region	R250	NN	I-NP	O
,	,	0000	,	O	O
forming	form	F652	VBG	B-VP	O
a	a	A000	DT	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
combination	combination	C515	NN	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
other	other	O360	JJ	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
containing	contain	C535	VBG	B-VP	O
defective	defective	D123	JJ	B-NP	O
genes	gene	G520	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
lead	lead	L300	VBP	B-VP	O
either	either	E360	CC	B-PP	O
to	to	T000	TO	B-PP	O
C6	C6	C000	NN	B-NP	B-Disease
or	or	O600	CC	I-NP	I-Disease
C7	C7	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
but	but	B300	CC	O	O
with	with	W300	IN	B-PP	O
different	different	D165	JJ	B-NP	O
consequences	consequence	C525	NNS	I-NP	O
.	.	0000	.	O	O

Where	Where	W600	WRB	B-ADVP	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
combined	combine	C515	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
C6	C6	C000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
serum	serum	S650	NN	I-NP	O
C7	C7	C000	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
surprisingly	surprisingly	S616	RB	B-ADJP	O
high	high	H200	JJ	I-ADJP	O
,	,	0000	,	O	O
possibly	possibly	P214	RB	B-ADVP	O
because	because	B200	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
no	no	N000	DT	B-NP	O
C6	C6	C000	NN	I-NP	O
generating	generate	G563	VBG	B-VP	O
C56	C56	C000	NN	B-NP	O
to	to	T000	TO	B-VP	O
consume	consume	C525	VB	I-VP	O
the	the	T000	DT	B-NP	O
C7	C7	C000	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
where	where	W600	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
C7	C7	C000	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
both	both	B300	CC	O	O
defective	defective	D123	JJ	O	O
(	(	0000	(	O	O
but	but	B300	CC	O	O
still	still	S340	RB	B-ADJP	O
partially	partially	P634	RB	I-ADJP	O
functional	functional	F523	JJ	I-ADJP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
profound	profound	P615	JJ	I-NP	O
deficit	deficit	D123	NN	I-NP	O
of	of	O100	IN	B-PP	O
circulating	circulate	C624	VBG	B-VP	O
C7	C7	C000	NN	B-NP	O
because	because	B200	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
ample	ample	A514	JJ	B-NP	O
C6	C6	C000	NN	I-NP	O
to	to	T000	TO	B-VP	O
produce	produce	P632	VB	I-VP	O
C56	C56	C000	NN	B-NP	O
and	and	A530	CC	O	O
consume	consume	C525	VB	B-VP	O
the	the	T000	DT	B-NP	O
already	already	A463	RB	I-NP	O
small	small	S540	JJ	I-NP	O
amount	amount	A530	NN	I-NP	O
of	of	O100	IN	B-PP	O
C7	C7	C000	NN	B-NP	O
.	.	0000	.	O	O

Each	Each	E200	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
also	also	A420	RB	I-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
isolation	isolation	I243	NN	B-NP	O
and	and	A530	CC	O	O
has	have	H200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
expected	expect	E212	VBN	I-NP	O
effect	effect	E123	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
bases	base	B200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
complement	complement	C514	NN	I-NP	B-Disease
C7	C7	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Complement	Complement	C514	NN	B-NP	B-Disease
C7	C7	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
(	(	0000	(	O	O
C7D	C7D	C300	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
frequently	frequently	F625	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
recurrent	recurrent	R265	JJ	B-NP	O
bacterial	bacterial	B236	JJ	I-NP	B-Disease
infections	infection	I512	NNS	I-NP	I-Disease
,	,	0000	,	O	O
especially	especially	E212	RB	B-NP	O
meningitis	meningitis	M523	NN	I-NP	B-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
Neisseria	Neisseria	N260	NNP	B-NP	B-Disease
meningitidis	meningitidis	M523	NNP	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
work	work	W620	NN	I-NP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
bases	base	B200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
C7D	C7D	C300	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
males	male	M420	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
used	use	U230	VBD	B-VP	O
exon	exon	E250	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
PCR	PCR	P260	NN	I-NP	O
/	/	0000	SYM	B-NP	O
single	single	S524	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
screening	screening	S265	NN	I-NP	O
step	step	S310	NN	I-NP	O
for	for	F600	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
.	.	0000	.	O	O

Subsequent	Subsequent	S125	JJ	B-NP	O
direct	direct	D623	JJ	I-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
target	target	T623	NN	I-NP	O
exons	exon	E252	NNS	I-NP	O
identified	identify	I353	VBD	B-VP	O
homozygous	homozygous	H520	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
16	16	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
case	case	C200	NN	B-NP	O
1	1	0000	CD	I-NP	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
15	15	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
case	case	C200	NN	B-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
case	case	C200	NN	B-NP	O
1	1	0000	CD	I-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
T	T	T000	NN	I-NP	O
to	to	T000	TO	B-PP	O
A	A	A000	NN	B-NP	O
transversion	transversion	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
2250	2250	0000	CD	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
third	third	T630	JJ	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
codon	codon	C350	NN	I-NP	O
TGT	TGT	T230	NN	I-NP	O
for	for	F600	IN	B-PP	O
Cys728	Cys728	C200	NN	B-NP	O
,	,	0000	,	O	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
TGA	TGA	T200	NN	I-NP	O
(	(	0000	(	O	O
C728X	C728X	C200	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-SBAR	O
case	case	C200	NN	O	O
2	2	0000	CD	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
2	2	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
(	(	0000	(	O	O
2137delTG	2137delTG	D432	NN	B-NP	O
/	/	0000	SYM	B-NP	O
2138delGT	2138delGT	D423	NN	I-NP	O
/	/	0000	SYM	I-NP	O
2139delTG	2139delTG	D432	NN	I-NP	O
)	)	0000	)	O	O
caused	cause	C230	VBD	B-VP	O
a	a	A000	DT	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
,	,	0000	,	O	O
generating	generate	G563	VBG	B-VP	O
a	a	A000	DT	B-NP	O
premature	premature	P653	JJ	I-NP	O
termination	termination	T653	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
4	4	0000	CD	B-NP	O
to	to	T000	TO	I-NP	O
6	6	0000	CD	I-NP	O
nucleotides	nucleotide	N243	NNS	I-NP	O
downstream	downstream	D523	RB	B-ADVP	O
.	.	0000	.	O	O

Family	Family	F540	RB	B-NP	O
study	study	S300	NN	I-NP	O
in	in	I500	IN	B-PP	O
case	case	C200	NN	B-NP	O
1	1	0000	CD	I-NP	O
confirmed	confirm	C516	VBD	B-VP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
nature	nature	N360	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
defect	defect	D123	NN	I-NP	O
.	.	0000	.	O	O

Moreover	Moreover	M616	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
detected	detect	D323	VBD	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
in	in	I500	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
11	11	0000	CD	I-NP	O
that	that	T300	WDT	B-NP	O
presumably	presumably	P625	RB	B-ADVP	O
is	be	I200	VBZ	B-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
C7D	C7D	C300	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
case	case	C200	NN	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
of	of	O100	IN	B-PP	O
C7D	C7D	C300	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
heterogeneous	heterogeneous	H362	JJ	B-ADJP	O
like	like	L200	IN	B-PP	O
most	most	M230	JJS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
deficiencies	deficiency	D125	NNS	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
components	component	C515	NNS	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

HPRT	HPRT	H163	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
APRT	APRT	A163	NN	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
mice	mouse	M200	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
not	not	N300	RB	O	O
a	a	A000	DT	B-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
lesch	lesch	L200	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
nyhan	nyhan	N500	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Complete	Complete	C514	JJ	B-NP	B-Disease
hypoxanthine	hypoxanthine	H125	NN	I-NP	I-Disease
-	-	0000	HYPH	O	I-Disease
guanine	guanine	G500	NN	B-NP	I-Disease
phosphoribosyl	phosphoribosyl	P216	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
transferase	transferase	T652	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
HPRT	HPRT	H163	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Lesch	Lesch	L200	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
,	,	0000	,	O	O
among	among	A520	IN	B-PP	O
other	other	O360	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
,	,	0000	,	O	O
by	by	B000	IN	B-PP	O
compulsive	compulsive	C514	JJ	B-NP	O
self	self	S410	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
injurious	injurious	I526	JJ	I-NP	O
behavior	behavior	B160	NN	I-NP	O
.	.	0000	.	O	O

HPRT	HPRT	H163	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
mice	mouse	M200	NNS	I-NP	O
generated	generate	G563	VBN	B-VP	O
using	use	U252	VBG	B-VP	O
mouse	mouse	M200	NN	B-NP	O
embryonic	embryonic	E516	JJ	I-NP	O
stem	stem	S350	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
exhibit	exhibit	E213	VBP	B-VP	O
none	none	N500	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
behavioral	behavioral	B164	JJ	I-NP	O
symptoms	symptom	S513	NNS	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Lesch	Lesch	L200	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Administration	Administration	A352	NN	B-NP	O
of	of	O100	IN	B-PP	O
drugs	drug	D620	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
inhibit	inhibit	I513	VBP	B-VP	O
adenine	adenine	A350	NN	B-NP	O
phosphoribosyltransferase	phosphoribosyltransferase	P216	NN	I-NP	O
(	(	0000	(	O	O
APRT	APRT	A163	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
HPRT	HPRT	H163	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
mice	mouse	M200	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
produced	produce	P632	VBN	I-VP	O
the	the	T000	DT	B-NP	O
suggestion	suggestion	S235	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
deficiency	deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
APRT	APRT	A163	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
combination	combination	C515	NN	B-NP	O
with	with	W300	IN	B-PP	O
HPRT	HPRT	H163	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
may	may	M000	MD	B-VP	O
lead	lead	L300	VB	I-VP	O
to	to	T000	TO	B-PP	O
self	self	S410	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
mutilation	mutilation	M343	NN	B-NP	O
behavior	behavior	B160	NN	I-NP	O
[	[	0000	(	O	O
C	C	C000	NN	B-NP	O
.	.	0000	.	O	O
L	L	L000	NN	B-NP	O
.	.	0000	.	O	O
Wu	Wu	W000	NNP	B-NP	O
and	and	A530	CC	I-NP	O
D	D	D000	NNP	I-NP	O
.	.	0000	.	I-NP	O
W	W	W000	NNP	I-NP	O
.	.	0000	.	I-NP	O
Melton	Melton	M435	NNP	I-NP	O
(	(	0000	(	O	O
1993	1993	0000	CD	B-NP	O
)	)	0000	)	O	O
Nature	Nature	N360	NNP	B-NP	O
Genet	Genet	G530	NNP	I-NP	O
.	.	0000	.	I-NP	O
3	3	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
235	235	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
240	240	0000	CD	I-NP	O
]	]	0000	)	O	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
test	test	T230	VB	I-VP	O
this	this	T200	DT	B-NP	O
proposition	proposition	P612	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
bred	breed	B630	VBD	B-VP	O
HPRT	HPRT	H163	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
APRT	APRT	A163	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
doubly	doubly	D140	RB	I-NP	O
-	-	0000	HYPH	I-NP	O
deficient	deficient	D125	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
excrete	excrete	E263	VBP	B-VP	O
adenine	adenine	A350	NN	B-NP	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
highly	highly	H240	RB	I-NP	O
insoluble	insoluble	I524	JJ	I-NP	O
derivative	derivative	D613	NN	I-NP	O
,	,	0000	,	O	O
2	2	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
8	8	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
dihydroxyadenine	dihydroxyadenine	D362	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
also	also	A420	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
human	human	H500	JJ	B-NP	O
APRT	APRT	A163	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
additional	additional	A354	JJ	B-NP	O
abnormalities	abnormality	A156	NNS	I-NP	O
or	or	O600	CC	O	O
any	any	A500	DT	B-NP	O
self	self	S410	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
injurious	injurious	I526	JJ	I-NP	O
behavior	behavior	B160	NN	I-NP	O
were	be	W600	VBD	B-VP	O
not	not	N300	RB	I-VP	O
detected	detect	D323	VBN	I-VP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
APRT	APRT	A163	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
HPRT	HPRT	H163	NN	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
mice	mouse	M200	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
devoid	devoid	D130	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
any	any	A500	DT	B-NP	O
purine	purine	P650	NN	I-NP	O
salvage	salvage	S412	NN	I-NP	O
pathways	pathway	P320	NNS	I-NP	O
,	,	0000	,	O	O
show	show	S000	VBP	B-VP	O
no	no	N000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
and	and	A530	CC	O	O
are	be	A600	VBP	B-VP	O
not	not	N300	RB	O	O
a	a	A000	DT	B-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
behavioral	behavioral	B164	JJ	I-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Lesch	Lesch	L200	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
as	as	A200	IN	B-SBAR	O
previously	previously	P612	RB	B-ADVP	O
suggested	suggest	S230	VBN	B-VP	O

Somatic	Somatic	S532	JJ	B-NP	O
alterations	alteration	A436	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DPC4	DPC4	D120	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
in	in	I500	FW	B-ADVP	O
vivo	vivo	V100	FW	I-ADVP	O
.	.	0000	.	O	O

BACKGROUND	BACKGROUND	B265	NN	B-NP	O
&	&	0000	CC	I-NP	O
AIMS	AIMS	A520	NNS	I-NP	O
The	The	T000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
region	region	R250	NN	I-NP	O
18q21	18q21	Q000	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
frequently	frequently	F625	RB	I-VP	O
deleted	delete	D430	VBN	I-VP	O
in	in	I500	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
such	such	S200	JJ	B-NP	O
frequent	frequent	F625	JJ	I-NP	O
allelic	allelic	A420	JJ	I-NP	O
loss	loss	L200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
hallmark	hallmark	H456	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
DPC4	DPC4	D120	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
located	located	L230	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
18q21	18q21	Q000	NN	B-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
from	from	F650	IN	B-PP	O
examination	examination	E253	NN	B-NP	O
of	of	O100	IN	B-PP	O
pancreatic	pancreatic	P526	JJ	B-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
aim	aim	A500	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
was	be	W200	VBD	B-VP	O
to	to	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
if	if	I100	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
might	might	M230	MD	B-VP	O
also	also	A420	RB	I-VP	O
be	be	B000	VB	I-VP	O
altered	alter	A436	VBN	I-VP	O
in	in	I500	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
.	.	0000	.	O	O

METHODS	METHODS	M320	NNS	B-NP	O
Mutation	Mutation	M350	NN	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DPC4	DPC4	D120	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
were	be	W600	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
on	on	O500	IN	B-PP	O
complementary	complementary	C514	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
samples	sample	S514	NNS	I-NP	O
from	from	F650	IN	B-PP	O
31	31	0000	CD	B-NP	O
primary	primary	P656	JJ	I-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
specimens	specimen	S125	NNS	I-NP	O
using	use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
combination	combination	C515	NN	I-NP	O
of	of	O100	IN	B-PP	O
polymerase	polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
,	,	0000	,	O	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
DNA	DNA	D500	NN	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
Four	Four	F600	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
producing	produce	P632	VBG	B-VP	O
amino	amino	A500	NN	B-NP	O
acid	acid	A230	NN	I-NP	O
substitutions	substitution	S123	NNS	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
somatic	somatic	S532	JJ	I-NP	O
12	12	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DPC4	DPC4	D120	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
31	31	0000	CD	I-NP	O
cancers	cancer	C526	NNS	I-NP	B-Disease
(	(	0000	(	O	O
16	16	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
;	;	0000	:	O	O
5	5	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
31	31	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

CONCLUSIONS	CONCLUSIONS	C524	NNS	B-NP	O
The	The	T000	DT	B-NP	O
DPC4	DPC4	D120	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
may	may	M000	MD	B-VP	O
play	play	P400	VB	I-VP	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
fraction	fraction	F623	NN	I-NP	O
of	of	O100	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
;	;	0000	:	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
allelic	allelic	A420	JJ	B-NP	O
loss	loss	L200	NN	I-NP	O
at	at	A300	IN	B-PP	O
18q21	18q21	Q000	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
very	very	V600	RB	B-VP	O
often	often	O135	RB	I-VP	O
seen	see	S500	VBN	I-VP	O
in	in	I500	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
,	,	0000	,	O	O
only	only	O540	RB	B-NP	O
a	a	A000	DT	I-NP	O
minority	minority	M563	NN	I-NP	O
show	show	S000	NN	I-NP	O
DPC4	DPC4	D120	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
might	might	M230	MD	B-VP	O
be	be	B000	VB	I-VP	O
another	another	A536	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Pleiotropic	Pleiotropic	P436	JJ	B-NP	O
defects	defect	D123	NNS	I-NP	O
in	in	I500	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
telangiectasia	telangiectasia	T452	NN	B-NP	I-Disease
protein	protein	P635	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
deficient	deficient	D125	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
generated	generate	G563	VBN	I-VP	O
a	a	A000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
by	by	B000	IN	B-PP	O
using	use	U252	VBG	B-VP	O
gene	gene	G500	NN	B-NP	O
targeting	targeting	T623	NN	I-NP	O
to	to	T000	TO	B-VP	O
generate	generate	G563	VB	I-VP	O
mice	mouse	M200	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
express	express	E216	VB	I-VP	O
the	the	T000	DT	B-NP	O
Atm	Atm	A350	NNP	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

Atm	Atm	A350	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
deficient	deficient	D125	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
retarded	retard	R363	VBN	I-VP	O
in	in	I500	IN	B-PP	O
growth	growth	G630	NN	B-NP	O
,	,	0000	,	O	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
produce	produce	P632	VB	I-VP	O
mature	mature	M360	JJ	B-NP	O
sperm	sperm	S165	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
exhibit	exhibit	E213	VBP	B-VP	O
severe	severe	S160	JJ	B-NP	O
defects	defect	D123	NNS	I-NP	O
in	in	I500	IN	B-PP	O
T	T	T000	NN	B-NP	O
cell	cell	C400	NN	I-NP	O
maturation	maturation	M363	NN	I-NP	O
while	while	W400	IN	B-SBAR	O
going	go	G520	VBG	B-VP	O
on	on	O500	RP	B-PRT	O
to	to	T000	TO	B-VP	O
develop	develop	D141	VB	I-VP	O
thymomas	thymoma	T520	NNS	B-NP	B-Disease
.	.	0000	.	O	O

Atm	Atm	A350	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
deficient	deficient	D125	JJ	I-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
grow	grow	G600	VBP	B-VP	O
poorly	poorly	P640	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
culture	culture	C436	NN	B-NP	O
and	and	A530	CC	O	O
display	display	D214	VBP	B-VP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
double	double	D140	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
stranded	stranded	S365	JJ	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
breaks	break	B620	NNS	I-NP	O
.	.	0000	.	O	O

Atm	Atm	A350	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
deficient	deficient	D125	JJ	I-NP	O
thymocytes	thymocyte	T523	NNS	I-NP	O
undergo	undergo	U536	VBP	B-VP	O
spontaneous	spontaneous	S153	JJ	B-NP	O
apoptosis	apoptosis	A132	NN	I-NP	O
in	in	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
significantly	significantly	S251	RB	B-NP	O
more	more	M600	JJR	I-NP	O
than	than	T500	IN	B-PP	O
controls	control	C536	NNS	B-NP	O
.	.	0000	.	O	O

Atm	Atm	A350	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
deficient	deficient	D125	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
then	then	T500	RB	B-ADVP	O
exhibit	exhibit	E213	VBP	B-VP	O
many	many	M500	JJ	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
symptoms	symptom	S513	NNS	I-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
cells	cell	C420	NNS	B-NP	O
derived	derive	D613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
them	them	T500	PRP	B-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
Atm	Atm	A350	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
exists	exist	E232	VBZ	B-VP	O
as	as	A200	IN	B-SBAR	O
two	two	T000	CD	B-NP	O
discrete	discrete	D263	JJ	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
species	specie	S120	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
or	or	O600	CC	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	DT	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
can	can	C500	MD	B-VP	O
lead	lead	L300	VB	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
DCC	DCC	D200	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
and	and	A530	CC	I-NP	O
prognosis	prognosis	P625	NN	I-NP	O
in	in	I500	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

BACKGROUND	BACKGROUND	B265	NN	B-NP	O
Allelic	Allelic	A420	JJ	I-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
18q	18q	Q000	NN	I-NP	O
predicts	predict	P632	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
poor	poor	P600	JJ	I-NP	O
outcome	outcome	O325	NN	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
stage	stage	S320	NN	B-NP	B-Disease
II	II	I000	CD	I-NP	I-Disease
colorectal	colorectal	C462	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
inactivated	inactivate	I523	VBN	B-VP	O
by	by	B000	IN	B-PP	O
this	this	T200	DT	B-NP	O
allelic	allelic	A420	JJ	I-NP	O
loss	loss	L200	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
elucidated	elucidate	E423	VBN	I-VP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
DCC	DCC	D200	NN	I-NP	O
(	(	0000	(	O	O
deleted	delete	D430	VBN	B-VP	O
in	in	I500	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
investigated	investigate	I512	VBD	B-VP	O
whether	whether	W360	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DCC	DCC	D200	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
in	in	I500	IN	B-PP	O
tumor	tumor	T560	NN	B-NP	B-Disease
cells	cell	C420	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
prognostic	prognostic	P625	JJ	I-NP	O
marker	marker	M626	NN	I-NP	O
in	in	I500	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
.	.	0000	.	O	O

METHODS	METHODS	M320	NNS	B-NP	O
The	The	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
DCC	DCC	D200	NN	B-NP	O
was	be	W200	VBD	B-VP	O
evaluated	evaluate	E143	VBN	I-VP	O
immunohistochemically	immunohistochemically	I523	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
132	132	0000	CD	B-NP	O
paraffin	paraffin	P615	NN	I-NP	O
-	-	0000	HYPH	O	O
embedded	embed	E513	VBN	B-VP	O
samples	sample	S514	NNS	B-NP	O
from	from	F650	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
curatively	curatively	C631	RB	B-NP	O
resected	resecte	R230	VBN	I-NP	O
stage	stage	S320	NN	I-NP	B-Disease
II	II	I000	CD	I-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
III	III	I000	CD	I-NP	I-Disease
colorectal	colorectal	C462	JJ	I-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Cox	Cox	C200	NNP	I-NP	O
proportional	proportional	P616	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
hazards	hazard	H263	NNS	I-NP	O
model	model	M340	NN	I-NP	O
was	be	W200	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
adjust	adjust	A323	VB	I-VP	O
for	for	F600	IN	B-PP	O
covariates	covariate	C163	NNS	B-NP	O
including	include	I524	VBG	B-PP	O
age	age	A200	NN	B-NP	O
,	,	0000	,	O	O
sex	sex	S200	NN	B-NP	O
,	,	0000	,	O	O
tumor	tumor	T560	NN	B-NP	B-Disease
site	site	S300	NN	I-NP	O
,	,	0000	,	O	O
degree	degree	D260	NN	B-NP	O
of	of	O100	IN	B-PP	O
tumor	tumor	T560	NN	B-NP	B-Disease
differentiation	differentiation	D165	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
use	use	U200	NN	B-NP	O
of	of	O100	IN	B-PP	O
adjuvant	adjuvant	A321	JJ	B-NP	O
therapy	therapy	T610	NN	I-NP	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
The	The	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
DCC	DCC	D200	NN	B-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
strong	strong	S365	JJ	I-NP	O
positive	positive	P231	JJ	I-NP	O
predictive	predictive	P632	JJ	I-NP	O
factor	factor	F236	NN	I-NP	O
for	for	F600	IN	B-PP	O
survival	survival	S614	NN	B-NP	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	O	O
stage	stage	S320	NN	B-NP	B-Disease
II	II	I000	CD	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
stage	stage	S320	NN	B-NP	I-Disease
III	III	I000	CD	I-NP	I-Disease
colorectal	colorectal	C462	JJ	I-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
stage	stage	S320	NN	B-NP	O
II	II	I000	CD	I-NP	O
disease	disease	D200	NN	I-NP	O
whose	whose	W200	WP$	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
expressed	express	E216	VBD	B-VP	O
DCC	DCC	D200	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
five	five	F100	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
survival	survival	S614	NN	I-NP	O
rate	rate	R300	NN	I-NP	O
was	be	W200	VBD	B-VP	O
94	94	0000	CD	B-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
percent	percent	P625	NN	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
DCC	DCC	D200	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
negative	negative	N231	JJ	I-NP	I-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
survival	survival	S614	NN	I-NP	O
rate	rate	R300	NN	I-NP	O
was	be	W200	VBD	B-VP	O
61	61	0000	CD	B-NP	O
.	.	0000	.	O	O

6	6	0000	CD	B-NP	O
percent	percent	P625	NN	I-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
<	<	0000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
stage	stage	S320	NN	B-NP	B-Disease
III	III	I000	CD	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
respective	respective	R212	JJ	I-NP	O
survival	survival	S614	NN	I-NP	O
rates	rate	R320	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
59	59	0000	CD	B-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
percent	percent	P625	NN	I-NP	O
and	and	A530	CC	O	O
33	33	0000	CD	B-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
percent	percent	P625	NN	I-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O
03	03	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

CONCLUSIONS	CONCLUSIONS	C524	NNS	B-NP	O
DCC	DCC	D200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
prognostic	prognostic	P625	JJ	I-NP	O
marker	marker	M626	NN	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
stage	stage	S320	NN	B-NP	B-Disease
II	II	I000	CD	I-NP	I-Disease
or	or	O600	CC	O	I-Disease
stage	stage	S320	NN	B-NP	I-Disease
III	III	I000	CD	I-NP	I-Disease
colorectal	colorectal	C462	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
stage	stage	S320	NN	B-NP	B-Disease
II	II	I000	CD	I-NP	I-Disease
colorectal	colorectal	C462	JJ	I-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
DCC	DCC	D200	NN	B-NP	O
identifies	identify	I353	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
subgroup	subgroup	S126	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
lesions	lesion	L252	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
behave	behave	B100	VBP	B-VP	O
like	like	L200	IN	B-PP	O
stage	stage	S320	NN	B-NP	B-Disease
III	III	I000	CD	B-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
may	may	M000	MD	B-VP	O
thus	thus	T200	RB	I-VP	O
have	have	H100	VB	I-VP	O
therapeutic	therapeutic	T613	JJ	B-NP	O
implications	implication	I514	NNS	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O

Association	Association	A235	NN	B-NP	O
of	of	O100	IN	B-PP	O
anxiety	anxiety	A523	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
related	relate	R430	VBN	I-NP	I-Disease
traits	trait	T632	NNS	I-NP	I-Disease
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
serotonin	serotonin	S635	NN	I-NP	O
transporter	transporter	T652	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
regulatory	regulatory	R243	JJ	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

Transporter	Transporter	T652	NN	B-NP	O
-	-	0000	HYPH	B-PP	O
facilitated	facilitate	F243	VBN	B-NP	O
uptake	uptake	U132	NN	I-NP	O
of	of	O100	IN	B-PP	O
serotonin	serotonin	S635	NN	B-NP	O
(	(	0000	(	O	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
hydroxytryptamine	hydroxytryptamine	H362	NN	I-NP	O
or	or	O600	CC	I-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
HT	HT	H300	NN	I-NP	O
)	)	0000	)	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
implicated	implicate	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
anxiety	anxiety	A523	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
and	and	A530	CC	I-NP	O
animal	animal	A540	NN	I-NP	O
models	model	M342	NNS	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
action	action	A235	NN	B-NP	O
of	of	O100	IN	B-PP	O
widely	widely	W340	RB	B-NP	O
used	use	U230	VBN	I-NP	O
uptake	uptake	U132	NN	I-NP	O
-	-	0000	HYPH	O	O
inhibiting	inhibit	I513	VBG	B-VP	O
antidepressant	antidepressant	A531	NN	B-NP	O
and	and	A530	CC	O	O
antianxiety	antianxiety	A535	JJ	B-NP	O
drugs	drug	D620	NNS	I-NP	O
.	.	0000	.	O	O

Human	Human	H500	JJ	B-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
HT	HT	H300	NN	I-NP	O
transporter	transporter	T652	NN	I-NP	O
(	(	0000	(	O	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
HTT	HTT	H300	NN	I-NP	O
)	)	0000	)	I-NP	O
gene	gene	G500	NN	I-NP	O
transcription	transcription	T652	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
modulated	modulate	M343	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
in	in	I500	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
upstream	upstream	U123	JJ	I-NP	O
regulatory	regulatory	R243	JJ	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
short	short	S630	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
reduces	reduce	R320	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
transcriptional	transcriptional	T652	JJ	I-NP	O
efficiency	efficiency	E125	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
HTT	HTT	H300	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
promoter	promoter	P653	NN	I-NP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
decreased	decrease	D262	VBN	B-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
HTT	HTT	H300	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
and	and	A530	CC	O	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
HT	HT	H300	NN	I-NP	O
uptake	uptake	U132	NN	I-NP	O
in	in	I500	IN	B-PP	O
lymphoblasts	lymphoblast	L514	NNS	B-NP	O
.	.	0000	.	O	O

Association	Association	A235	NN	B-NP	O
studies	study	S320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
independent	independent	I531	JJ	I-NP	O
samples	sample	S514	NNS	I-NP	O
totaling	total	T345	VBG	B-VP	O
505	505	0000	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
HTT	HTT	H300	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
accounts	account	A253	VBZ	B-VP	O
for	for	F600	IN	B-PP	O
3	3	0000	CD	B-NP	O
to	to	T000	TO	I-NP	O
4	4	0000	CD	I-NP	O
percent	percent	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
total	total	T340	JJ	B-NP	O
variation	variation	V635	NN	I-NP	O
and	and	A530	CC	O	O
7	7	0000	CD	B-NP	O
to	to	T000	TO	I-NP	O
9	9	0000	CD	I-NP	O
percent	percent	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
inherited	inherit	I563	VBN	B-NP	O
variance	variance	V652	NN	I-NP	O
in	in	I500	IN	B-PP	O
anxiety	anxiety	A523	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
related	relate	R430	VBN	B-NP	I-Disease
personality	personality	P625	NN	I-NP	I-Disease
traits	trait	T632	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
sibships	sibship	S121	NNS	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Phenotypic	Phenotypic	P531	JJ	B-NP	O
and	and	A530	CC	I-NP	O
genotypic	genotypic	G531	JJ	I-NP	O
overlap	overlap	O164	NN	I-NP	O
between	between	B350	IN	B-PP	O
atelosteogenesis	atelosteogenesis	A342	NN	B-NP	B-Disease
type	type	T100	NN	I-NP	I-Disease
2	2	0000	CD	I-NP	I-Disease
and	and	A530	CC	O	O
diastrophic	diastrophic	D236	JJ	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
diastrophic	diastrophic	D236	JJ	I-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
sulfate	sulfate	S413	NN	I-NP	O
transporter	transporter	T652	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
DTDST	DTDST	D323	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
of	of	O100	IN	B-PP	O
chondrodysplasias	chondrodysplasia	C536	NNS	B-NP	B-Disease
that	that	T300	WDT	B-NP	O
comprises	comprise	C516	VBZ	B-VP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
order	order	O636	NN	B-NP	O
of	of	O100	IN	B-PP	O
increasing	increase	I526	VBG	B-NP	O
severity	severity	S163	NN	I-NP	O
,	,	0000	,	O	O
diastrophic	diastrophic	D236	JJ	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
(	(	0000	(	O	O
DTD	DTD	D300	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
atelosteogenesis	atelosteogenesis	A342	NN	B-NP	B-Disease
type	type	T100	NN	I-NP	I-Disease
2	2	0000	CD	I-NP	I-Disease
(	(	0000	(	O	O
AO2	AO2	A000	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
achondrogenesis	achondrogenesis	A253	NN	B-NP	B-Disease
type	type	T100	NN	I-NP	I-Disease
1B	1B	B000	NN	I-NP	I-Disease
(	(	0000	(	O	O
ACG1B	ACG1B	A210	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
learn	learn	L650	VB	I-VP	O
more	more	M600	JJR	B-NP	O
about	about	A130	IN	B-PP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
DTDST	DTDST	D323	NN	B-NP	B-Disease
chondrodysplasias	chondrodysplasia	C536	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
about	about	A130	IN	B-NP	O
genotype	genotype	G531	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlations	correlation	C643	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
studied	study	S300	VBD	B-VP	O
fibroblast	fibroblast	F161	NN	B-NP	O
cultures	culture	C436	NNS	I-NP	O
of	of	O100	IN	B-PP	O
three	three	T600	CD	B-NP	O
new	new	N000	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
one	one	O500	CD	B-NP	O
with	with	W300	IN	B-PP	O
AO	AO	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
2	2	0000	CD	I-NP	I-Disease
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
with	with	W300	IN	B-PP	O
DTD	DTD	D300	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
intermediate	intermediate	I536	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
(	(	0000	(	O	O
AO2	AO2	A000	NN	B-NP	B-Disease
/	/	0000	SYM	O	O
DTD	DTD	D300	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Reduced	Reduce	R323	VBN	B-NP	O
incorporation	incorporation	I526	NN	I-NP	O
of	of	O100	IN	B-PP	O
inorganic	inorganic	I562	JJ	B-NP	O
sulfate	sulfate	S413	NN	I-NP	O
into	into	I530	IN	B-PP	O
macromolecules	macromolecule	M265	NNS	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
three	three	T600	CD	I-NP	O
.	.	0000	.	O	O

Each	Each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
three	three	T600	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
c862t	c862t	C300	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
predicting	predict	P632	VBG	B-VP	O
a	a	A000	DT	B-NP	O
R279W	R279W	R000	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
third	third	T630	JJ	I-NP	O
extracellular	extracellular	E236	JJ	I-NP	O
loop	loop	L100	NN	I-NP	O
of	of	O100	IN	B-PP	O
DTDST	DTDST	D323	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
(	(	0000	(	O	O
DTD	DTD	D300	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
AO2	AO2	A000	NN	I-NP	B-Disease
/	/	0000	SYM	B-NP	O
DTD	DTD	D300	NN	I-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
no	no	N000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
structural	structural	S362	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
polymerase	polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
amplification	amplification	A514	NN	I-NP	O
and	and	A530	CC	O	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
fibroblast	fibroblast	F161	NN	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
reduced	reduce	R323	VBN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
DTDST	DTDST	D323	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
these	these	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
compound	compound	C515	JJ	B-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
"	"	0000	``	I-NP	O
Finnish	Finnish	F520	JJ	I-NP	O
"	"	0000	''	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
as	as	A200	IN	B-PP	O
yet	yet	Y300	RB	B-ADJP	O
uncharacterized	uncharacterized	U526	JJ	I-ADJP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
level	level	L140	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
causes	cause	C200	VBZ	B-VP	O
reduced	reduce	R323	VBN	I-VP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
DTDST	DTDST	D323	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
third	third	T630	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
(	(	0000	(	O	O
with	with	W300	IN	B-PP	O
AO2	AO2	A000	NN	B-NP	B-Disease
)	)	0000	)	O	O
had	have	H300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
R279W	R279W	R000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
compounded	compound	C515	VBN	B-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
cytosine	cytosine	C325	NN	B-NP	O
418	418	0000	CD	I-NP	O
(	(	0000	(	O	O
delta	delta	D430	SYM	O	O
c418	c418	C000	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
predicting	predict	P632	VBG	B-VP	O
a	a	A000	DT	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
with	with	W300	IN	B-PP	O
premature	premature	P653	JJ	B-NP	O
termination	termination	T653	NN	I-NP	O
.	.	0000	.	O	O

Also	Also	A420	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
delta	delta	D430	NN	I-NP	O
c418	c418	C000	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
was	be	W200	VBD	B-VP	O
underrepresented	underrepresente	U536	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
accordance	accordance	A263	NN	B-NP	O
with	with	W300	IN	B-PP	O
previous	previous	P612	JJ	B-NP	O
observations	observation	O126	NNS	I-NP	O
that	that	T300	IN	B-NP	O
premature	premature	P653	JJ	B-NP	O
stop	stop	S310	NN	I-NP	O
codons	codon	C352	NNS	I-NP	O
reduce	reduce	R320	VBP	B-VP	O
mRNA	mRNA	M650	NN	B-NP	O
levels	level	L142	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DTDST	DTDST	D323	NN	I-NP	O
R279W	R279W	R000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
11	11	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
AO2	AO2	A000	NN	B-NP	B-Disease
or	or	O600	CC	I-NP	O
DTD	DTD	D300	NN	I-NP	B-Disease
emphasizes	emphasize	E512	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
overlap	overlap	O164	NN	I-NP	O
between	between	B350	IN	B-PP	O
these	these	T200	DT	B-NP	O
conditions	condition	C535	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
so	so	S000	RB	B-ADVP	O
far	far	F600	RB	I-ADVP	O
in	in	I500	IN	B-PP	O
8	8	0000	CD	B-NP	O
analyzed	analyze	A542	VBN	I-NP	O
ACG1B	ACG1B	A210	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
allows	allow	A420	VBZ	B-VP	O
some	some	S500	DT	B-NP	O
residual	residual	R234	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
sulfate	sulfate	S413	NN	I-NP	O
transporter	transporter	T652	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
WASP	WASP	W210	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
mutation	mutation	M350	NN	B-NP	O
hotspots	hotspot	H321	NNS	I-NP	O
and	and	A530	CC	O	O
genotype	genotype	G531	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
disparities	disparity	D216	NNS	I-NP	O
in	in	I500	IN	B-PP	O
24	24	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
WAS	WAS	W200	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
immunodeficiency	immunodeficiency	I531	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
recently	recently	R253	RB	I-NP	O
isolated	isolate	I243	VBN	I-NP	O
gene	gene	G500	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
WAS	WAS	W200	NN	B-NP	B-Disease
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
WASP	WASP	W210	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
known	know	K500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
extensive	extensive	E235	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
.	.	0000	.	O	O

Cumulative	Cumulative	C543	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
data	datum	D300	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
revealed	reveal	R143	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
WASP	WASP	W210	NN	B-NP	O
genotypes	genotype	G531	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
also	also	A420	RB	B-ADVP	O
highly	highly	H240	RB	B-ADJP	O
variable	variable	V614	JJ	I-ADJP	O
among	among	A520	IN	B-PP	O
WAS	WAS	W200	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
relationship	relationship	R435	NN	I-NP	O
of	of	O100	IN	B-PP	O
phenotype	phenotype	P531	NN	B-NP	O
with	with	W300	IN	B-PP	O
genotype	genotype	G531	NN	B-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
remains	remain	R520	VBZ	B-VP	O
unclear	unclear	U524	JJ	B-ADJP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
address	address	A362	VB	I-VP	O
this	this	T200	DT	B-NP	O
issue	issue	I200	NN	I-NP	O
we	we	W000	PRP	B-NP	O
characterized	characterize	C623	VBD	B-VP	O
WASP	WASP	W210	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
24	24	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
18	18	0000	CD	B-NP	O
boys	boy	B200	NNS	I-NP	O
with	with	W300	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
classical	classical	C424	JJ	I-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	O
6	6	0000	CD	I-NP	O
boys	boy	B200	NNS	I-NP	O
expressing	express	E216	VBG	B-VP	O
mild	mild	M430	JJ	B-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
then	then	T500	RB	B-VP	O
examined	examine	E253	VBD	I-VP	O
the	the	T000	DT	B-NP	O
degree	degree	D260	NN	I-NP	O
of	of	O100	IN	B-PP	O
correlation	correlation	C643	NN	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
all	all	A400	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
published	publish	P142	VBN	I-NP	O
WASP	WASP	W210	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
with	with	W300	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
severity	severity	S163	NN	I-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
compiled	compile	C514	VBN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
data	datum	D300	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
clustering	clustering	C423	NN	B-NP	O
of	of	O100	IN	B-PP	O
WASP	WASP	W210	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
four	four	F600	CD	I-NP	O
most	most	M230	JJS	I-NP	O
N	N	N000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
terminal	terminal	T654	JJ	I-NP	O
exons	exon	E252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
also	also	A420	RB	B-ADVP	O
identified	identify	I353	VBD	B-VP	O
several	several	S164	JJ	B-NP	O
sites	site	S320	NNS	I-NP	O
within	within	W350	IN	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
as	as	A200	IN	B-PP	O
hotspots	hotspot	H321	NNS	B-NP	O
for	for	F600	IN	B-PP	O
WASP	WASP	W210	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	B-NP	O
severe	severe	S160	JJ	I-NP	O
and	and	A530	CC	I-NP	O
mild	mild	M430	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

Similarly	Similarly	S546	RB	B-ADVP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
cumulative	cumulative	C543	JJ	I-NP	O
data	datum	D300	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
predominance	predominance	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
among	among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
WASP	WASP	W210	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
lesions	lesion	L252	NNS	I-NP	O
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
boys	boy	B200	NNS	B-NP	O
with	with	W300	IN	B-PP	O
isolated	isolate	I243	VBN	B-NP	B-Disease
thrombocytopenia	thrombocytopenia	T651	NN	I-NP	I-Disease
,	,	0000	,	O	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
not	not	N300	RB	I-VP	O
exclusively	exclusively	E242	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
milder	mild	M436	JJR	B-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
phenotypes	phenotype	P531	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
also	also	A420	RB	B-VP	O
comprised	comprise	C516	VBD	I-VP	O
a	a	A000	DT	B-NP	O
substantial	substantial	S123	JJ	I-NP	O
portion	portion	P635	NN	I-NP	O
(	(	0000	(	O	O
38	38	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
WASP	WASP	W210	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
defects	defect	D123	NNS	I-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
the	the	T000	DT	B-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
identical	identical	I353	JJ	B-NP	O
WASP	WASP	W210	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
disparate	disparate	D216	JJ	B-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
,	,	0000	,	O	O
reveal	reveal	R140	VBP	B-VP	O
a	a	A000	DT	B-NP	O
lack	lack	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
phenotype	phenotype	P531	NN	B-NP	O
concordance	concordance	C526	NN	I-NP	O
with	with	W300	IN	B-PP	O
genotype	genotype	G531	NN	B-NP	O
in	in	I500	IN	B-PP	O
WAS	WAS	W200	NN	B-NP	B-Disease
and	and	A530	CC	O	O
thus	thus	T200	RB	B-VP	O
imply	imply	I514	VBP	I-VP	O
that	that	T300	IN	B-SBAR	O
phenotypic	phenotypic	P531	JJ	B-NP	O
outcome	outcome	O325	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
cannot	cannot	C530	MD	B-VP	O
be	be	B000	VB	I-VP	O
reliably	reliably	R414	RB	I-VP	O
predicted	predict	P632	VBN	I-VP	O
solely	solely	S400	RB	B-ADVP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
WASP	WASP	W210	NN	B-NP	O
genotypes	genotype	G531	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
'	'	0000	SYM	I-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	B-Disease
exon	exon	E250	NN	I-NP	O
15	15	0000	CD	I-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
truncated	truncate	T652	VBN	B-NP	O
proteins	protein	P635	NNS	I-NP	O
and	and	A530	CC	O	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
attenuated	attenuate	A353	VBN	B-NP	O
adenomatous	adenomatous	A353	JJ	I-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
.	.	0000	.	O	O

Familial	Familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
(	(	0000	(	O	O
FAP	FAP	F100	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	O
predisposition	predisposition	P632	NN	I-NP	O
to	to	T000	TO	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
numerous	numerous	N562	JJ	B-NP	O
adenomatous	adenomatous	A353	JJ	I-NP	B-Disease
polyps	polyp	P412	NNS	I-NP	I-Disease
predominantly	predominantly	P635	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
colorectal	colorectal	C462	JJ	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
adenomatous	adenomatous	A353	JJ	I-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
(	(	0000	(	O	O
APC	APC	A120	NN	B-NP	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
are	be	A600	VBP	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
most	most	M230	JJS	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
FAP	FAP	F100	NN	B-NP	B-Disease
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	B-Disease
are	be	A600	VBP	B-VP	O
known	know	K500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
relatively	relatively	R431	RB	I-NP	O
mild	mild	M430	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
,	,	0000	,	O	O
called	call	C430	VBN	B-VP	O
attenuated	attenuate	A353	VBD	B-VP	B-Disease
adenomatous	adenomatous	A353	JJ	B-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
(	(	0000	(	O	O
AAPC	AAPC	A120	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
a	a	A000	DT	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
15	15	0000	CD	I-NP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
at	at	A300	IN	B-PP	O
1862	1862	0000	CD	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
Dutch	Dutch	D320	JJ	I-NP	O
kindred	kindred	K536	NN	I-NP	O
with	with	W300	IN	B-PP	O
AAPC	AAPC	A120	NN	B-NP	B-Disease
.	.	0000	.	O	O

Western	Western	W236	NN	B-NP	O
blot	blot	B430	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
lymphoblastoid	lymphoblastoid	L514	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
derived	derive	D613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
from	from	F650	IN	B-PP	O
this	this	T200	DT	B-NP	O
kindred	kindred	K536	NN	I-NP	O
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
reported	report	R163	VBN	I-NP	O
Swiss	Swiss	S200	JJ	I-NP	O
family	family	F540	NN	I-NP	O
carrying	carry	C652	VBG	B-VP	O
a	a	A000	DT	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
1987	1987	0000	CD	I-NP	O
and	and	A530	CC	O	O
displaying	display	D214	VBG	B-VP	O
a	a	A000	DT	B-NP	O
similar	similar	S546	JJ	I-NP	O
attenuated	attenuate	A353	VBN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
,	,	0000	,	O	O
showed	show	S300	VBD	B-VP	O
only	only	O540	RB	B-NP	O
the	the	T000	DT	I-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
study	study	S300	NN	I-NP	O
indicates	indicate	I532	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
chain	chain	C500	NN	B-NP	O
-	-	0000	HYPH	O	O
terminating	terminate	T653	VBG	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
located	locate	L230	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	B-Disease
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
detectable	detectable	D323	JJ	B-NP	O
truncated	truncate	T652	VBN	I-NP	O
polypeptides	polypeptide	P413	NNS	I-NP	O
and	and	A530	CC	O	O
we	we	W000	PRP	B-NP	O
hypothesize	hypothesize	H132	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
likely	likely	L240	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
observed	observe	O126	VBN	I-NP	O
AAPC	AAPC	A120	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Complete	Complete	C514	JJ	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
sequence	sequence	S252	NN	I-NP	O
and	and	A530	CC	O	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
117	117	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
.	.	0000	.	O	O

Over	Over	O160	IN	B-PP	O
100	100	0000	CD	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
associated	associate	A230	VBN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
susceptibility	susceptibility	S213	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
.	.	0000	.	O	O

Loss	Loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
in	in	I500	IN	B-PP	O
>	>	0000	JJR	B-NP	O
90	90	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
tumors	tumor	T562	NNS	B-NP	B-Disease
from	from	F650	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
inherited	inherit	I563	VBN	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
indicates	indicate	I532	VBZ	B-VP	O
tumor	tumor	T560	NN	B-NP	B-Disease
suppressive	suppressive	S162	JJ	I-NP	O
function	function	F523	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
low	low	L000	JJ	I-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
BRCA1	BRCA1	B620	NN	B-NP	O
inactivation	inactivation	I523	NN	I-NP	O
in	in	I500	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
occurs	occur	O262	VBZ	B-VP	O
by	by	B000	IN	B-PP	O
alternative	alternative	A436	JJ	B-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
,	,	0000	,	O	O
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
interstitial	interstitial	I536	JJ	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
or	or	O600	CC	O	O
reduced	reduce	R323	VBN	B-NP	O
transcription	transcription	T652	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
possible	possible	P214	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
genomic	genomic	G520	JJ	I-NP	O
region	region	R250	NN	I-NP	O
that	that	T300	WDT	B-NP	O
may	may	M000	MD	B-VP	O
contribute	contribute	C536	VB	I-VP	O
to	to	T000	TO	B-PP	O
chromosomal	chromosomal	C652	JJ	B-NP	O
instability	instability	I523	NN	I-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
potential	potential	P353	JJ	B-NP	O
transcriptional	transcriptional	T652	JJ	I-NP	O
regulatory	regulatory	R243	JJ	I-NP	O
elements	element	E453	NNS	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
117	117	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
143	143	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
encompassing	encompass	E525	VBG	B-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
was	be	W200	VBD	B-VP	O
obtained	obtain	O135	VBN	I-VP	O
by	by	B000	IN	B-PP	O
random	random	R535	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
four	four	F600	CD	B-NP	O
cosmids	cosmid	C253	NNS	I-NP	O
identified	identify	I353	VBN	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
17	17	0000	CD	I-NP	O
specific	specific	S121	JJ	I-NP	O
library	library	L160	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
24	24	0000	CD	I-NP	O
exons	exon	E252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
span	span	S150	VBP	B-VP	O
an	an	A500	DT	B-NP	O
81	81	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kb	kb	K100	NN	I-NP	O
region	region	R250	NN	I-NP	O
that	that	T300	WDT	B-NP	O
has	have	H200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
unusually	unusually	U524	RB	I-NP	O
high	high	H200	JJ	I-NP	O
density	density	D523	NN	I-NP	O
of	of	O100	IN	B-PP	O
Alu	Alu	A400	NN	B-NP	O
repetitive	repetitive	R131	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
(	(	0000	(	O	O
41	41	0000	CD	B-NP	O
.	.	0000	.	O	O
5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
relatively	relatively	R431	RB	B-NP	O
low	low	L000	JJ	I-NP	O
density	density	D523	NN	I-NP	O
(	(	0000	(	O	O
4	4	0000	CD	B-NP	O
.	.	0000	.	O	O
8	8	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
other	other	O360	JJ	B-NP	O
repetitive	repetitive	R131	JJ	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
.	.	0000	.	O	O

BRCA1	BRCA1	B620	NN	B-NP	O
intron	intron	I536	NN	I-NP	O
lengths	length	L523	NNS	I-NP	O
range	range	R520	NN	I-NP	O
in	in	I500	IN	B-PP	O
size	size	S200	NN	B-NP	O
from	from	F650	IN	B-PP	O
403	403	0000	CD	B-NP	O
bp	bp	B100	NN	I-NP	O
to	to	T000	TO	B-PP	O
9	9	0000	CD	B-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
and	and	A530	CC	O	O
contain	contain	C535	VBP	B-VP	O
the	the	T000	DT	B-NP	O
intragenic	intragenic	I536	JJ	I-NP	O
microsatellite	microsatellite	M262	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
D17S1323	D17S1323	D200	NN	I-NP	O
,	,	0000	,	O	O
D17S1322	D17S1322	D200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
D17S855	D17S855	D200	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
localize	localize	L242	VBP	B-VP	O
to	to	T000	TO	B-PP	O
introns	intron	I536	NNS	B-NP	O
12	12	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
19	19	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
20	20	0000	CD	B-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
to	to	T000	TO	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
contig	contig	C532	NN	I-NP	O
contains	contain	C535	VBZ	B-VP	O
two	two	T000	CD	B-NP	O
complete	complete	C514	JJ	I-NP	O
genes	gene	G520	NNS	I-NP	O
Rho7	Rho7	R000	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
member	member	M516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
rho	rho	R000	JJ	I-NP	O
family	family	F540	NN	I-NP	O
of	of	O100	IN	B-PP	O
GTP	GTP	G310	NN	B-NP	O
binding	binding	B535	NN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
VAT1	VAT1	V300	NN	B-NP	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
abundant	abundant	A153	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
cholinergic	cholinergic	C456	JJ	B-NP	O
synaptic	synaptic	S513	JJ	I-NP	O
vesicles	vesicle	V242	NNS	I-NP	O
.	.	0000	.	O	O

Partial	Partial	P634	JJ	B-NP	O
sequences	sequence	S252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
1A1	1A1	A000	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
3B	3B	B000	NN	B-NP	O
B	B	B000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
box	box	B200	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
pseudogene	pseudogene	P232	NN	I-NP	O
and	and	A530	CC	O	O
IFP	IFP	I100	NN	B-NP	O
35	35	0000	CD	I-NP	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
interferon	interferon	I536	NN	I-NP	O
induced	induce	I532	VBD	B-VP	O
leucine	leucine	L250	NN	B-NP	O
zipper	zipper	Z160	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
reside	reside	R230	NN	B-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
contig	contig	C532	NN	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
L21	L21	L000	NN	I-NP	O
ribosomal	ribosomal	R125	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
pseudogene	pseudogene	P232	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
embedded	embed	E513	VBN	I-VP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
intron	intron	I536	NN	I-NP	O
13	13	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
order	order	O636	NN	I-NP	O
of	of	O100	IN	B-PP	O
genes	gene	G520	NNS	B-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
centromere	centromere	C536	JJ	B-ADJP	O
-	-	0000	HYPH	O	O
1FP	1FP	F100	NN	B-NP	O
35	35	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
VAT1	VAT1	V300	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
Rho7	Rho7	R000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1A1	1A1	A000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
3B	3B	B000	NN	I-NP	O
-	-	0000	HYPH	O	O
telomere	telomere	T456	NN	B-NP	O

Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
RING	RING	R520	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
that	that	T300	WDT	B-NP	O
can	can	C500	MD	B-VP	O
interact	interact	I536	VB	I-VP	O
in	in	I500	FW	B-ADVP	O
vivo	vivo	V100	FW	I-ADVP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
hereditary	hereditary	H636	JJ	I-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
,	,	0000	,	O	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
polypeptide	polypeptide	P413	NN	I-NP	O
that	that	T300	WDT	B-NP	O
contains	contain	C535	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
cysteine	cysteine	C235	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
rich	rich	R200	JJ	I-NP	O
RING	RING	R520	NN	I-NP	O
motif	motif	M310	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
zinc	zinc	Z520	NN	I-NP	O
-	-	0000	HYPH	O	O
binding	bind	B535	VBG	B-NP	O
domain	domain	D500	NN	I-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
regulatory	regulatory	R243	JJ	B-NP	O
proteins	protein	P635	NNS	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
that	that	T300	WDT	B-NP	O
interacts	interact	I536	VBZ	B-VP	O
in	in	I500	FW	B-ADVP	O
vivo	vivo	V100	FW	I-ADVP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
N	N	N000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
associated	associate	A230	VBN	B-NP	O
RING	RING	R520	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
(	(	0000	(	O	O
BARD1	BARD1	B630	NN	B-NP	O
)	)	0000	)	O	O
protein	protein	P635	NN	B-NP	O
contains	contain	C535	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
N	N	N000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
RING	RING	R520	NN	I-NP	O
motif	motif	M310	NN	I-NP	O
,	,	0000	,	O	O
three	three	T600	CD	B-NP	O
tandem	tandem	T535	JJ	I-NP	O
ankyrin	ankyrin	A526	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
sequence	sequence	S252	NN	I-NP	O
with	with	W300	IN	B-PP	O
significant	significant	S251	JJ	B-NP	O
homology	homology	H542	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
phylogenetically	phylogenetically	P425	RB	I-NP	O
conserved	conserve	C526	VBN	I-NP	O
BRCT	BRCT	B623	NN	I-NP	O
domains	domain	D520	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
lie	lie	L000	VBP	B-VP	O
near	near	N600	IN	B-PP	O
the	the	T000	DT	B-NP	O
C	C	C000	NN	I-NP	O
terminus	terminus	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
BARD1	BARD1	B630	NN	I-NP	O
/	/	0000	SYM	B-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
interaction	interaction	I536	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
disrupted	disrupt	D261	VBN	I-VP	O
by	by	B000	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
segregate	segregate	S262	VBP	B-VP	O
with	with	W300	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
susceptibility	susceptibility	S213	NN	I-NP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
BARD1	BARD1	B630	NN	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
mediating	mediate	M352	VBG	B-VP	O
tumour	tumour	T560	NN	B-NP	B-Disease
suppression	suppression	S162	NN	I-NP	O
by	by	B000	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Detection	Detection	D323	NN	B-NP	O
of	of	O100	IN	B-PP	O
heterozygous	heterozygous	H362	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
using	use	U252	VBG	B-VP	O
high	high	H200	JJ	B-NP	O
density	density	D523	NN	I-NP	O
oligonucleotide	oligonucleotide	O425	NN	I-NP	O
arrays	array	A620	NNS	I-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
colour	colour	C460	NN	I-NP	O
fluorescence	fluorescence	F462	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ability	ability	A143	NN	I-NP	O
to	to	T000	TO	B-VP	O
scan	scan	S250	VB	I-VP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
rapidly	rapidly	R134	RB	B-ADVP	O
and	and	A530	CC	I-ADVP	O
accurately	accurately	A263	RB	I-ADVP	O
for	for	F600	IN	B-PP	O
all	all	A400	DT	B-NP	O
possible	possible	P214	JJ	I-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
large	large	L620	JJ	B-NP	O
numbers	number	N516	NNS	I-NP	O
of	of	O100	IN	B-PP	O
patient	patient	P353	NN	B-NP	O
samples	sample	S514	NNS	I-NP	O
will	will	W400	MD	B-VP	O
be	be	B000	VB	I-VP	O
critical	critical	C632	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
future	future	F360	NN	I-NP	O
of	of	O100	IN	B-PP	O
medicine	medicine	M325	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
designed	design	D253	VBN	I-VP	O
high	high	H200	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
density	density	D523	NN	I-NP	O
arrays	array	A620	NNS	I-NP	O
consisting	consist	C523	VBG	B-VP	O
of	of	O100	IN	B-PP	O
over	over	O160	IN	B-PP	O
96	96	0000	CD	B-NP	O
,	,	0000	,	O	O
600	600	0000	CD	B-NP	O
oligonucleotides	oligonucleotide	O425	NNS	I-NP	O
20	20	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
nucleotides	nucleotide	N243	NNS	I-NP	O
(	(	0000	(	O	O
nt	nt	N300	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
length	length	L523	NN	B-NP	O
to	to	T000	TO	B-VP	O
screen	screen	S265	VB	I-VP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
wide	wide	W300	JJ	I-NP	O
range	range	R520	NN	I-NP	O
of	of	O100	IN	B-PP	O
heterozygous	heterozygous	H362	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
.	.	0000	.	O	O

45	45	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
kilobases	kilobas	K412	NNS	I-NP	O
(	(	0000	(	O	O
kb	kb	K100	NN	B-NP	O
)	)	0000	)	O	O
exon	exon	E250	NN	B-NP	O
11	11	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
hereditary	hereditary	H636	JJ	I-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
.	.	0000	.	O	O

Reference	Reference	R165	NN	B-NP	O
and	and	A530	CC	I-NP	O
test	test	T230	NN	I-NP	O
samples	sample	S514	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
co	co	C000	AFX	O	O
-	-	0000	HYPH	O	O
hybridized	hybridize	H163	VBN	B-VP	O
to	to	T000	TO	B-PP	O
these	these	T200	DT	B-NP	O
arrays	array	A620	NNS	I-NP	O
and	and	A530	CC	I-NP	O
differences	difference	D165	NNS	I-NP	O
in	in	I500	IN	B-PP	O
hybridization	hybridization	H163	NN	B-NP	O
patterns	pattern	P365	NNS	I-NP	O
quantitated	quantitate	Q530	VBN	B-VP	O
by	by	B000	IN	B-PP	O
two	two	T000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
colour	colour	C460	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

Fourteen	Fourteen	F635	CD	B-NP	O
of	of	O100	IN	B-PP	O
fifteen	fifteen	F135	CD	B-NP	O
patient	patient	P353	NN	I-NP	O
samples	sample	S514	NNS	I-NP	O
with	with	W300	IN	B-PP	O
known	known	K500	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
accurately	accurately	A263	RB	I-VP	O
diagnosed	diagnose	D252	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
no	no	N000	DT	B-NP	O
false	false	F420	JJ	I-NP	O
positive	positive	P231	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
20	20	0000	CD	B-NP	O
control	control	C536	NN	I-NP	O
samples	sample	S514	NNS	I-NP	O
.	.	0000	.	O	O

Eight	Eight	E230	CD	B-NP	O
single	single	S524	JJ	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	B-ADVP	O
readily	readily	R340	RB	B-ADJP	O
detected	detect	D323	VBN	I-ADJP	O
.	.	0000	.	O	O

DNA	DNA	D500	NN	B-NP	O
chip	chip	C100	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
based	base	B230	VBN	I-NP	O
assays	assay	A200	NNS	I-NP	O
may	may	M000	MD	B-VP	O
provide	provide	P613	VB	I-VP	O
a	a	A000	DT	B-NP	O
valuable	valuable	V414	JJ	I-NP	O
new	new	N000	JJ	I-NP	O
technology	technology	T254	NN	I-NP	O
for	for	F600	IN	B-PP	O
high	high	H200	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
throughput	throughput	T621	NN	I-NP	O
cost	cost	C230	AFX	O	O
-	-	0000	HYPH	B-NP	O
efficient	efficient	E125	JJ	I-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
alterations	alteration	A436	NNS	I-NP	O
.	.	0000	.	O	O

Autosomal	Autosomal	A325	JJ	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
primary	primary	P656	JJ	I-NP	O
hyperparathyroidism	hyperparathyroidism	H161	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
jaw	jaw	J000	NN	I-NP	I-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
renal	renal	R540	JJ	B-NP	B-Disease
hamartomas	hamartoma	H563	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
cystic	cystic	C232	JJ	B-NP	B-Disease
kidney	kidney	K350	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
:	:	0000	:	O	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
1q21	1q21	Q000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
q32	q32	Q000	NN	I-NP	O
and	and	A530	CC	I-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
type	type	T100	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
in	in	I500	IN	B-PP	O
renal	renal	R540	JJ	B-NP	B-Disease
hamartomas	hamartoma	H563	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Hereditary	Hereditary	H636	JJ	B-NP	B-Disease
hyperparathyroidism	hyperparathyroidism	H161	NN	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
jaw	jaw	J000	NN	I-NP	I-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
HPT	HPT	H130	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
JT	JT	J300	NN	I-NP	I-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
OMIM	OMIM	O500	NN	B-NP	O
145001	145001	0000	CD	I-NP	O
)	)	0000	)	O	O
that	that	T300	WDT	B-NP	O
has	have	H200	VBZ	B-VP	O
recently	recently	R253	RB	I-VP	O
been	be	B500	VBN	I-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
chromosomal	chromosomal	C652	JJ	B-NP	O
region	region	R250	NN	I-NP	O
1q21	1q21	Q000	NN	I-NP	O
-	-	0000	HYPH	O	O
q32	q32	Q000	NN	B-NP	O
(	(	0000	(	O	O
HRPT2	HRPT2	H613	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
two	two	T000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
HPT	HPT	H130	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
JT	JT	J300	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
adult	adult	A343	JJ	B-NP	B-Disease
renal	renal	R540	JJ	I-NP	I-Disease
hamartomas	hamartoma	H563	NNS	I-NP	I-Disease
or	or	O600	CC	O	O
cystic	cystic	C232	JJ	B-NP	B-Disease
kidney	kidney	K350	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
prominent	prominent	P653	JJ	B-NP	O
associated	associate	A230	VBN	I-NP	O
features	feature	F362	NNS	I-NP	O
,	,	0000	,	O	O
possibly	possibly	P214	RB	B-ADVP	O
representing	represent	R162	VBG	B-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HPT	HPT	H130	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
JT	JT	J300	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
renal	renal	R540	JJ	B-NP	B-Disease
lesions	lesion	L252	NNS	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
out	out	O300	IN	I-NP	O
of	of	O100	IN	I-NP	O
six	six	S200	CD	I-NP	O
affected	affect	A123	VBN	I-NP	O
individuals	individual	I531	NNS	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
HPT	HPT	H130	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
JT	JT	J300	NN	I-NP	B-Disease
were	be	W600	VBD	B-VP	O
seen	see	S500	VBN	I-VP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
and	and	A530	CC	I-NP	O
two	two	T000	CD	I-NP	O
cases	case	C200	NNS	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
JT	JT	J300	NN	B-NP	B-Disease
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
five	five	F100	CD	I-NP	O
affected	affect	A123	VBN	I-NP	O
individuals	individual	I531	NNS	I-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
affected	affect	A123	VBN	I-NP	O
members	member	M516	NNS	I-NP	O
also	also	A420	RB	B-ADVP	O
exhibited	exhibit	E213	VBD	B-VP	O
polycystic	polycystic	P423	JJ	B-NP	B-Disease
kidney	kidney	K350	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
possibility	possibility	P214	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
latter	latter	L360	JJ	I-NP	O
cosegregating	cosegregating	C262	NN	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
separate	separate	S163	JJ	I-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
dominant	dominant	D530	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
can	can	C500	MD	B-VP	O
not	not	N300	RB	I-VP	O
be	be	B000	VB	I-VP	O
ruled	rule	R430	VBN	I-VP	O
out	out	O300	RP	B-PRT	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
sex	sex	S200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
penetrance	penetrance	P536	NN	I-NP	O
of	of	O100	IN	B-PP	O
primary	primary	P656	JJ	B-NP	B-Disease
HPT	HPT	H130	NN	I-NP	I-Disease
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
predominantly	predominantly	P635	RB	B-NP	O
male	male	M400	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
affected	affect	A123	VBN	I-NP	O
cases	case	C200	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
evident	evident	E135	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Twenty	Twenty	T530	CD	B-NP	O
microsatellite	microsatellite	M262	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
HRPT2	HRPT2	H613	NN	I-NP	O
region	region	R250	NN	I-NP	O
were	be	W600	VBD	B-VP	O
typed	type	T130	VBN	I-VP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
to	to	T000	TO	B-PP	O
markers	marker	M626	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
multiple	multiple	M431	JJ	I-NP	B-Disease
endocrine	endocrine	E532	JJ	I-NP	I-Disease
neoplasia	neoplasia	N142	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
MEN	MEN	M500	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
types	type	T120	NNS	B-NP	I-Disease
1	1	0000	CD	I-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
2	2	0000	CD	I-NP	I-Disease
regions	region	R252	NNS	I-NP	O
at	at	A300	IN	B-PP	O
11q13	11q13	Q000	CD	B-NP	O
and	and	A530	CC	I-NP	O
10q11	10q11	Q000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
kindreds	kindred	K536	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
five	five	F100	CD	B-NP	O
markers	marker	M626	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
1q21	1q21	Q000	NN	I-NP	O
-	-	0000	HYPH	O	O
q32	q32	Q000	NN	B-NP	O
region	region	R250	NN	I-NP	O
(	(	0000	(	O	O
logarithm	logarithm	L263	NN	B-NP	O
-	-	0000	HYPH	O	O
of	of	O100	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
odds	odd	O320	VBZ	B-VP	O
scores	score	S262	NNS	B-NP	O
3	3	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
2	2	0000	CD	I-NP	O
-	-	0000	:	O	O
4	4	0000	CD	B-NP	O
2	2	0000	CD	I-NP	O
-	-	0000	:	O	O
4	4	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
2	2	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
MEN1	MEN1	M500	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	O
MEN2	MEN2	M500	NN	I-NP	B-Disease
regions	region	R252	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
excluded	exclude	E243	VBN	I-VP	O
.	.	0000	.	O	O

Meiotic	Meiotic	M320	JJ	B-NP	O
recombinations	recombination	R251	NNS	I-NP	O
detected	detect	D323	VBN	B-VP	O
in	in	I500	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
individuals	individual	I531	NNS	I-NP	O
placed	place	P423	VBD	B-VP	O
the	the	T000	DT	B-NP	O
locus	locus	L200	NN	I-NP	O
telomeric	telomeric	T456	NN	I-NP	O
of	of	O100	IN	B-PP	O
D1S215	D1S215	D200	NN	B-NP	O
,	,	0000	,	O	O
thus	thus	T200	RB	B-ADVP	O
narrowing	narrow	N652	VBG	B-VP	O
the	the	T000	DT	B-NP	O
HRPT2	HRPT2	H613	NN	I-NP	O
region	region	R250	NN	I-NP	O
from	from	F650	IN	B-PP	O
>	>	0000	SYM	B-NP	O
60	60	0000	CD	I-NP	O
to	to	T000	TO	B-PP	O
approximately	approximately	A162	RB	B-NP	O
34	34	0000	CD	I-NP	O
centimorgans	centimorgan	C535	NNS	I-NP	O
.	.	0000	.	O	O

Loss	Loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
heterozygosity	heterozygosity	H362	NN	B-NP	O
was	be	W200	VBD	B-VP	O
studied	study	S300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
renal	renal	R540	JJ	I-NP	B-Disease
hamartomas	hamartoma	H563	NNS	I-NP	I-Disease
from	from	F650	IN	B-PP	O
two	two	T000	CD	B-NP	O
affected	affect	A123	VBN	I-NP	O
individuals	individual	I531	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
jaw	jaw	J000	JJ	I-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
parathyroid	parathyroid	P636	JJ	I-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
renal	renal	R540	JJ	I-NP	B-Disease
hamartomas	hamartoma	H563	NNS	I-NP	I-Disease
showed	show	S300	VBD	B-VP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
heterozygosity	heterozygosity	H362	NN	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
1q21	1q21	Q000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
q32	q32	Q000	NN	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
losses	loss	L200	NNS	I-NP	O
invariably	invariably	I516	RB	B-ADVP	O
involved	involve	I514	VBD	B-VP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
type	type	T100	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
derived	derive	D613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
unaffected	unaffected	U512	JJ	I-NP	O
parent	parent	P653	NN	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
the	the	T000	DT	B-NP	O
inactivation	inactivation	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O

Independent	Independent	I531	JJ	B-NP	O
origin	origin	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
single	single	S524	JJ	B-NP	O
and	and	A530	CC	I-NP	O
double	double	D140	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
glucose	glucose	G420	NN	I-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
vast	vast	V230	JJ	I-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	CC	B-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
and	and	A530	CC	I-NP	O
sporadic	sporadic	S163	JJ	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
single	single	S524	JJ	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
four	four	F600	CD	I-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
have	have	H100	VBP	B-VP	O
two	two	T000	CD	B-NP	O
point	point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
always	always	A420	RB	B-ADVP	O
376	376	0000	CD	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
G	G	G000	NN	B-NP	O
(	(	0000	(	O	O
126	126	0000	CD	B-NP	O
Asn	Asn	A250	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
Asp	Asp	A210	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
on	on	O500	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
own	own	O500	JJ	I-NP	O
gives	give	G120	NNS	I-NP	O
rise	rise	R200	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
nondeficient	nondeficient	N531	JJ	I-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
,	,	0000	,	O	O
G6PD	G6PD	G130	NN	B-NP	O
A	A	A000	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
study	study	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
who	who	W000	WP	B-NP	O
presented	present	P625	VBD	B-VP	O
with	with	W300	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
favism	favism	F125	NN	I-NP	B-Disease
in	in	I500	IN	B-PP	O
Spain	Spain	S150	NNP	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
that	that	T300	IN	B-NP	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
called	call	C430	VBN	I-VP	O
G6PD	G6PD	G130	NNP	B-NP	O
Malaga	Malaga	M420	NNP	I-NP	O
,	,	0000	,	O	O
whose	whose	W200	WP$	B-NP	O
only	only	O540	RB	I-NP	O
abnormality	abnormality	A156	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
542	542	0000	CD	I-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
T	T	T000	NN	B-NP	O
(	(	0000	(	O	O
181	181	0000	CD	B-NP	O
Asp	Asp	A210	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
Val	Val	V400	NN	I-NP	O
)	)	0000	)	O	O
mutation	mutation	M350	NN	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
as	as	A200	IN	B-SBAR	O
previously	previously	P612	RB	B-ADVP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
association	association	A235	NN	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
A	A	A000	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
double	double	D140	JJ	I-NP	O
mutant	mutant	M353	NN	I-NP	O
,	,	0000	,	O	O
G6PD	G6PD	G130	NN	B-NP	O
Santamaria	Santamaria	S535	NNP	I-NP	O
.	.	0000	.	O	O

G6PD	G6PD	G130	NN	B-NP	O
Malaga	Malaga	M420	NNP	I-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
enzyme	enzyme	E525	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
(	(	0000	(	O	O
class	class	C420	NN	B-NP	O
III	III	I000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
enzymic	enzymic	E525	JJ	I-NP	O
properties	property	P616	NNS	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
Malaga	Malaga	M420	NN	I-NP	O
and	and	A530	CC	O	O
G6PD	G6PD	G130	NN	B-NP	O
Santamaria	Santamaria	S535	NNP	I-NP	O
are	be	A600	VBP	B-VP	O
quite	quite	Q300	RB	B-ADJP	O
similar	similar	S546	JJ	I-ADJP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
case	case	C200	NN	I-NP	O
the	the	T000	DT	B-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
additive	additive	A310	JJ	B-ADJP	O
rather	rather	R360	RB	B-PP	O
than	than	T500	IN	I-PP	O
synergistic	synergistic	S562	JJ	B-ADJP	O
.	.	0000	.	O	O

G6PD	G6PD	G130	NN	B-NP	O
Santamaria	Santamaria	S535	NNP	I-NP	O
might	might	M230	MD	B-VP	O
have	have	H100	VB	I-VP	O
been	be	B500	VBN	I-VP	O
produced	produce	P632	VBN	I-VP	O
by	by	B000	IN	B-PP	O
recombination	recombination	R251	NN	B-NP	O
between	between	B350	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
A	A	A000	NN	I-NP	O
and	and	A530	CC	O	O
G6PD	G6PD	G130	NN	B-NP	O
Malaga	Malaga	M420	NNP	I-NP	O
;	;	0000	:	O	O
however	however	H160	RB	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
the	the	T000	DT	B-NP	O
use	use	U200	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
silent	silent	S453	JJ	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
,	,	0000	,	O	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
542	542	0000	CD	I-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	I-NP	O
>	>	0000	SYM	I-NP	O
T	T	T000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
taken	take	T250	VBN	I-VP	O
place	place	P420	NN	B-NP	O
independently	independently	I531	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
B	B	B000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
to	to	T000	TO	B-VP	O
give	give	G100	VB	I-VP	O
G6PD	G6PD	G130	NN	B-NP	O
Malaga	Malaga	M420	NNP	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
A	A	A000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
to	to	T000	TO	B-VP	O
give	give	G100	VB	I-VP	O
G6PD	G6PD	G130	NN	B-NP	O
Santamaria	Santamaria	S535	NNP	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
help	help	H410	VBP	B-VP	O
to	to	T000	TO	I-VP	O
outline	outline	O345	VB	I-VP	O
the	the	T000	DT	B-NP	O
relationship	relationship	R435	NN	I-NP	O
and	and	A530	CC	I-NP	O
evolution	evolution	E143	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

BRCA1	BRCA1	B620	NN	B-NP	O
R841W	R841W	R000	NN	I-NP	O
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
strong	strong	S365	JJ	I-NP	O
candidate	candidate	C530	NN	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
with	with	W300	IN	B-PP	O
moderate	moderate	M363	JJ	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
cause	cause	C200	VBP	B-VP	O
increased	increase	I526	VBN	B-NP	O
risk	risk	R200	NN	I-NP	O
for	for	F600	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
frequently	frequently	F625	RB	B-ADVP	O
of	of	O100	IN	B-PP	O
early	early	E640	JJ	B-NP	O
onset	onset	O523	NN	I-NP	O
.	.	0000	.	O	O

Many	Many	M500	JJ	B-NP	O
different	different	D165	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
occur	occur	O260	VBP	B-VP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
several	several	S164	JJ	B-NP	O
examples	example	E251	NNS	I-NP	O
of	of	O100	IN	B-PP	O
recurrent	recurrent	R265	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
each	each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
accounts	account	A253	VBZ	B-VP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
heritable	heritable	H631	JJ	B-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
predisposition	predisposition	P632	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
common	common	C500	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
an	an	A500	DT	B-NP	O
etiological	etiological	E342	JJ	I-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
many	many	M500	JJ	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cases	case	C200	NNS	I-NP	O
and	and	A530	CC	O	O
provide	provide	P613	VBP	B-VP	O
the	the	T000	DT	B-NP	O
opportunity	opportunity	O163	NN	I-NP	O
to	to	T000	TO	B-VP	O
examine	examine	E250	VB	I-VP	O
genotype	genotype	G531	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlations	correlation	C643	NNS	I-NP	O
and	and	A530	CC	O	O
genotype	genotype	G531	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
environment	environment	E516	NN	I-NP	O
interactions	interaction	I536	NNS	I-NP	O
in	in	I500	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
identical	identical	I353	JJ	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
lesion	lesion	L250	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
missense	missense	M252	JJ	I-NP	O
change	change	C520	NN	I-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
,	,	0000	,	O	O
2640	2640	0000	CD	B-NP	O
C	C	C000	JJ	I-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
T	T	T000	NN	B-NP	O
(	(	0000	(	O	O
R841W	R841W	R000	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
3	3	0000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
subject	subject	S123	JJ	I-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
305	305	0000	CD	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	O	I-Disease
79	79	0000	CD	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cases	case	C200	NNS	I-NP	O
from	from	F650	IN	B-PP	O
Orange	Orange	O652	NNP	B-NP	O
County	County	C530	NNP	I-NP	O
,	,	0000	,	O	O
CA	CA	C000	NNP	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
are	be	A600	VBP	B-VP	O
consecutive	consecutive	C523	JJ	B-ADJP	O
,	,	0000	,	O	O
population	population	P143	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
based	base	B230	VBN	I-NP	O
cases	case	C200	NNS	I-NP	O
not	not	N300	RB	B-VP	O
selected	select	S423	VBN	I-VP	O
for	for	F600	IN	B-PP	O
age	age	A200	NN	B-NP	O
or	or	O600	CC	I-NP	O
family	family	F540	NN	I-NP	O
history	history	H236	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
three	three	T600	CD	I-NP	O
cases	case	C200	NNS	I-NP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
strong	strong	S365	JJ	I-NP	O
family	family	F540	NN	I-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
,	,	0000	,	O	I-Disease
ovarian	ovarian	O165	JJ	B-ADJP	I-Disease
,	,	0000	,	O	I-Disease
or	or	O600	CC	O	I-Disease
other	other	O360	JJ	B-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
possibly	possibly	P214	RB	B-ADJP	O
related	related	R430	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
and	and	A530	CC	I-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
concordance	concordance	C526	NN	I-NP	O
of	of	O100	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
incidence	incidence	I523	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
R841W	R841W	R000	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
onset	onset	O523	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	O	O
always	always	A420	RB	B-ADVP	O
distinct	distinct	D235	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
typical	typical	T124	JJ	B-NP	O
sporadic	sporadic	S163	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

Testing	Testing	T235	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
sample	sample	S514	NN	I-NP	O
of	of	O100	IN	B-PP	O
413	413	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
individuals	individual	I531	NNS	I-NP	O
to	to	T000	TO	B-VP	O
examine	examine	E250	VB	I-VP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
R841W	R841W	R000	NN	B-NP	O
might	might	M230	MD	B-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
detected	detect	D323	VBD	B-VP	O
one	one	O500	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
instance	instance	I523	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
woman	woman	W500	NN	I-NP	O
with	with	W300	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
diagnosed	diagnose	D252	VBN	B-VP	O
at	at	A300	IN	B-PP	O
age	age	A200	NN	B-NP	O
77	77	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
cancer	cancer	C526	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
parent	parent	P653	NN	I-NP	O
.	.	0000	.	O	O

R841W	R841W	R000	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
likely	likely	L240	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
an	an	A500	DT	B-NP	O
etiologically	etiologically	E342	RB	I-NP	O
significant	significant	S251	JJ	I-NP	O
lesion	lesion	L250	NN	I-NP	O
with	with	W300	IN	B-PP	O
involvement	involvement	I514	NN	B-NP	O
in	in	I500	IN	B-PP	O
close	close	C420	JJ	B-NP	O
to	to	T000	TO	I-NP	O
1	1	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
95	95	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
confidence	confidence	C513	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
of	of	O100	IN	B-PP	O
0	0	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O
7	7	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

Ataxia	Ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
:	:	0000	:	O	O
founder	founder	F536	NN	B-NP	O
effect	effect	E123	NN	I-NP	O
among	among	A520	IN	B-PP	O
north	north	N630	JJ	B-NP	O
African	African	A162	JJ	I-NP	O
Jews	Jew	J200	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
(	(	0000	(	O	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
T	T	T000	NN	B-NP	I-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
cerebellar	cerebellar	C614	JJ	B-NP	B-Disease
degeneration	degeneration	D256	NN	I-NP	I-Disease
,	,	0000	,	O	O
immunodeficiency	immunodeficiency	I531	NN	B-NP	B-Disease
and	and	A530	CC	O	O
cancer	cancer	C526	NN	B-NP	B-Disease
predisposition	predisposition	P632	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
carriers	carrier	C620	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
reported	report	R163	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
moderately	moderately	M363	RB	B-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
prone	prone	P650	NN	B-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
wide	wide	W300	JJ	I-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
most	most	M230	JJS	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
unique	unique	U520	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
single	single	S524	JJ	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
various	various	V620	JJ	B-NP	O
ethnic	ethnic	E352	JJ	I-NP	O
groups	group	G612	NNS	I-NP	O
,	,	0000	,	O	O
precluding	preclude	P624	VBG	B-VP	O
carrier	carrier	C600	NN	B-NP	O
screening	screening	S265	NN	I-NP	O
with	with	W300	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
assays	assay	A200	NNS	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
32	32	0000	CD	B-NP	O
/	/	0000	SYM	O	O
33	33	0000	CD	B-NP	O
defective	defective	D123	JJ	I-NP	O
ATM	ATM	A350	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Jewish	Jewish	J200	JJ	B-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
North	North	N630	JJ	B-NP	O
African	African	A162	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
,	,	0000	,	O	O
coming	come	C520	VBG	B-VP	O
from	from	F650	IN	B-PP	O
various	various	V620	JJ	B-NP	O
regions	region	R252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Morocco	Morocco	M620	NNP	B-NP	O
and	and	A530	CC	I-NP	O
Tunisia	Tunisia	T520	NNP	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
103C	103C	C000	NN	B-NP	O
-	-	0000	HYPH	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
T	T	T000	NNP	B-NP	O
,	,	0000	,	O	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
at	at	A300	IN	B-PP	O
position	position	P235	NN	B-NP	O
35	35	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
keeping	keep	K152	VBG	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
nature	nature	N360	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
various	various	V620	JJ	B-NP	O
antibodies	antibody	A531	NNS	I-NP	O
directed	direct	D623	VBN	B-VP	O
against	against	A252	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
failed	fail	F430	VBD	B-VP	O
to	to	T000	TO	I-VP	O
defect	defect	D123	VB	I-VP	O
this	this	T200	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
in	in	I500	IN	B-PP	O
patient	patient	P353	NN	B-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
rapid	rapid	R130	JJ	I-NP	O
carrier	carrier	C600	NN	I-NP	O
detection	detection	D323	NN	I-NP	O
assay	assay	A200	NN	I-NP	O
detected	detect	D323	VBD	B-VP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
out	out	O300	IN	I-NP	O
of	of	O100	IN	I-NP	O
488	488	0000	CD	I-NP	O
ATM	ATM	A350	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Jewish	Jewish	J200	JJ	B-NP	O
Moroccan	Moroccan	M625	NN	I-NP	O
or	or	O600	CC	O	O
Tunisian	Tunisian	T525	JJ	B-NP	O
origin	origin	O625	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
founder	founder	F536	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
provides	provide	P613	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
unique	unique	U520	JJ	I-NP	O
opportunity	opportunity	O163	NN	I-NP	O
for	for	F600	IN	B-PP	O
population	population	P143	NN	B-NP	O
-	-	0000	HYPH	O	O
based	base	B230	VBN	B-NP	O
screening	screening	S265	NN	I-NP	O
for	for	F600	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
carriers	carrier	C620	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
community	community	C530	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Mutation	Mutation	M350	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
male	male	M400	JJ	I-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
population	population	P143	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
based	base	B230	VBN	I-VP	O
series	series	S620	NN	B-NP	O
of	of	O100	IN	B-PP	O
54	54	0000	CD	B-NP	O
male	male	M400	JJ	I-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cases	case	C200	NNS	I-NP	O
from	from	F650	IN	B-PP	O
Southern	Southern	S365	NNP	B-NP	O
California	California	C416	NNP	I-NP	O
were	be	W600	VBD	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
for	for	F600	IN	B-PP	O
germ	germ	G650	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
/	/	0000	SYM	B-NP	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
genes	gene	G520	NNS	I-NP	O
,	,	0000	,	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
and	and	A530	CC	O	O
BRCA2	BRCA2	B620	NN	B-NP	O
.	.	0000	.	O	O

Nine	Nine	N500	CD	B-NP	O
(	(	0000	(	O	O
17	17	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
/	/	0000	SYM	B-NP	I-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
one	one	O500	CD	I-NP	O
first	first	F623	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
degree	degree	D260	NN	I-NP	O
relative	relative	R431	JJ	B-ADJP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
further	further	F636	JJ	I-NP	O
seven	seven	S150	CD	I-NP	O
(	(	0000	(	O	O
13	13	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
reported	report	R163	VBD	B-VP	O
breast	breast	B623	NN	B-NP	B-Disease
/	/	0000	SYM	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
one	one	O500	CD	I-NP	O
second	second	S253	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
degree	degree	D260	NN	I-NP	O
relative	relative	R431	JJ	B-ADJP	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
no	no	N000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
degree	degree	D260	NN	I-NP	O
relatives	relative	R431	NNS	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
germ	germ	G650	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
line	line	L500	NN	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
male	male	M400	JJ	I-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
(	(	0000	(	O	O
4	4	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
total	total	T340	NN	I-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
carry	carry	C600	VB	I-VP	O
novel	novel	N140	JJ	B-NP	O
truncating	truncate	T652	VBG	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Only	Only	O540	RB	B-NP	O
one	one	O500	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
male	male	M400	JJ	I-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
carrying	carry	C652	VBG	B-VP	O
a	a	A000	DT	B-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
one	one	O500	CD	B-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
degree	degree	D260	NN	I-NP	O
relative	relative	R431	JJ	B-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
eight	eight	E230	CD	I-NP	O
cases	case	C200	NNS	I-NP	O
(	(	0000	(	O	O
89	89	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
male	male	M400	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
/	/	0000	SYM	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
first	first	F623	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
degree	degree	D260	NN	I-NP	O
relatives	relative	R431	NNS	I-NP	O
remain	remain	R500	VBP	B-VP	O
unaccounted	unaccounted	U525	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
either	either	E360	CC	O	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
or	or	O600	CC	O	O
the	the	T000	DT	B-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
basis	basis	B200	NN	I-NP	O
for	for	F600	IN	B-PP	O
Duarte	Duarte	D630	NNP	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
Los	Los	L200	NNP	I-NP	I-Disease
Angeles	Angeles	A524	NNP	I-NP	I-Disease
variant	variant	V653	JJ	I-NP	I-Disease
galactosemia	galactosemia	G423	NN	I-NP	I-Disease
.	.	0000	.	O	O

Human	Human	H500	JJ	B-NP	O
orythrocytes	orythrocyte	O636	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
Duarte	Duarte	D630	JJ	I-NP	B-Disease
enzyme	enzyme	E525	NN	I-NP	I-Disease
variant	variant	V653	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
galactosemia	galactosemia	G423	NN	B-NP	I-Disease
(	(	0000	(	O	O
D	D	D000	NN	B-NP	O
/	/	0000	SYM	B-NP	O
D	D	D000	NN	I-NP	O
)	)	0000	)	O	O
have	have	H100	VBP	B-VP	O
a	a	A000	DT	B-NP	O
characteristic	characteristic	C623	JJ	I-NP	O
isoform	isoform	I216	NN	I-NP	O
on	on	O500	IN	B-PP	O
isoelectric	isoelectric	I242	JJ	B-NP	O
focusing	focusing	F252	NN	I-NP	O
and	and	A530	CC	O	O
50	50	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
reduction	reduction	R323	NN	I-NP	O
in	in	I500	IN	B-PP	O
galactose	galactose	G423	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
uridyltransferase	uridyltransferase	U634	NN	I-NP	O
(	(	0000	(	O	O
GALT	GALT	G430	NN	B-NP	O
)	)	0000	)	O	O
enzyme	enzyme	E525	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Duarte	Duarte	D630	NNP	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
genotype	genotype	G531	NN	I-NP	O
of	of	O100	IN	B-PP	O
N314D	N314D	N300	NN	B-NP	O
/	/	0000	SYM	B-NP	O
N314D	N314D	N300	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
characteristic	characteristic	C623	JJ	I-NP	O
Duarte	Duarte	D630	NNP	I-NP	O
isoform	isoform	I216	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
variant	variant	V653	JJ	I-NP	O
called	call	C430	VBN	B-VP	O
the	the	T000	DT	B-NP	O
"	"	0000	``	I-NP	O
Los	Los	L200	NNP	I-NP	O
Angeles	Angeles	A524	NNP	I-NP	O
(	(	0000	(	O	O
LA	LA	L000	NN	B-NP	O
)	)	0000	)	O	O
phenotype	phenotype	P531	NN	B-NP	O
,	,	0000	,	O	O
"	"	0000	''	O	O
which	which	W200	WDT	B-NP	O
has	have	H200	VBZ	B-VP	O
increased	increase	I526	VBN	I-VP	O
GALT	GALT	G430	NN	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
evaluated	evaluate	E143	VBD	B-VP	O
GALT	GALT	G430	NN	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
and	and	A530	CC	O	O
screened	screen	S265	VBD	B-VP	O
the	the	T000	DT	B-NP	O
GALT	GALT	G430	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
145	145	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
one	one	O500	CD	B-NP	O
or	or	O600	CC	I-NP	O
more	more	M600	JJR	I-NP	O
N314D	N314D	N300	NN	I-NP	O
-	-	0000	HYPH	O	O
containing	contain	C535	VBG	B-VP	O
alleles	allele	A420	NNS	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
seven	seven	S150	CD	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
LA	LA	L000	NN	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
all	all	A400	DT	B-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
1721C	1721C	C000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
T	T	T000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
7	7	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
cis	cis	C200	NN	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
N314D	N314D	N300	NN	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
1721C	1721C	C000	NN	I-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
T	T	T000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
neutral	neutral	N364	JJ	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
for	for	F600	IN	B-PP	O
leucine	leucine	L250	NN	B-NP	O
at	at	A300	IN	B-PP	O
amino	amino	A500	NN	B-NP	O
acid	acid	A230	NN	I-NP	O
218	218	0000	CD	I-NP	O
(	(	0000	(	O	O
L218L	L218L	L400	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
pedigree	pedigree	P326	NN	B-NP	O
analyses	analysis	A542	NNS	I-NP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
1721C	1721C	C000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
T	T	T000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
segregated	segregate	S262	VBD	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
LA	LA	L000	NN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
of	of	O100	IN	B-PP	O
increased	increase	I526	VBN	B-NP	O
GALT	GALT	G430	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
different	different	D165	JJ	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
(	(	0000	(	O	O
LA	LA	L000	NN	B-NP	O
/	/	0000	SYM	O	O
N	N	N000	NN	B-NP	O
,	,	0000	,	O	O
LA	LA	L000	NN	B-NP	O
/	/	0000	SYM	I-NP	O
G	G	G000	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
LA	LA	L000	NN	B-NP	O
/	/	0000	SYM	B-NP	O
D	D	D000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
for	for	F600	IN	B-PP	O
increased	increase	I526	VBN	B-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
LA	LA	L000	NN	I-NP	O
variant	variant	V653	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
compared	compare	C516	VBD	B-VP	O
GALT	GALT	G430	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
,	,	0000	,	O	O
protein	protein	P635	NN	B-NP	O
abundance	abundance	A153	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
enzyme	enzyme	E525	NN	B-NP	O
thermal	thermal	T654	JJ	I-NP	O
stability	stability	S314	NN	I-NP	O
in	in	I500	IN	B-PP	O
lymphoblast	lymphoblast	L514	NN	B-NP	O
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
D	D	D000	NN	B-NP	O
and	and	A530	CC	I-NP	O
LA	LA	L000	NN	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
comparable	comparable	C516	JJ	B-NP	O
genotypes	genotype	G531	NNS	I-NP	O
.	.	0000	.	O	O

GALT	GALT	G430	NN	B-NP	O
protein	protein	P635	NN	I-NP	O
abundance	abundance	A153	NN	I-NP	O
was	be	W200	VBD	B-VP	O
increased	increase	I526	VBN	I-VP	O
in	in	I500	IN	B-PP	O
LA	LA	L000	NN	B-NP	O
compared	compare	C516	VBN	B-VP	O
to	to	T000	TO	B-PP	O
D	D	D000	NN	B-NP	O
alleles	allele	A420	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
mRNA	mRNA	M650	NN	B-NP	O
was	be	W200	VBD	B-VP	O
similar	similar	S546	JJ	B-ADJP	O
among	among	A520	IN	B-PP	O
all	all	A400	DT	B-NP	O
genotypes	genotype	G531	NNS	I-NP	O
.	.	0000	.	O	O

When	When	W500	WRB	B-ADVP	O
LA	LA	L000	NN	B-NP	O
/	/	0000	SYM	B-NP	O
D	D	D000	NN	I-NP	O
and	and	A530	CC	I-NP	O
D	D	D000	NN	I-NP	O
/	/	0000	SYM	B-NP	O
D	D	D000	NN	I-NP	O
GALT	GALT	G430	NN	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
compared	compare	C516	VBN	I-VP	O
to	to	T000	TO	B-PP	O
N	N	N000	NN	B-NP	O
/	/	0000	SYM	B-NP	O
N	N	N000	NN	I-NP	O
GALT	GALT	G430	NN	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
,	,	0000	,	O	O
both	both	B300	DT	B-NP	O
had	have	H300	VBD	B-VP	O
50	50	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
compared	compare	C516	VBN	B-VP	O
to	to	T000	TO	B-PP	O
21	21	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
,	,	0000	,	O	O
reduction	reduction	R323	NN	B-NP	O
in	in	I500	IN	B-PP	O
GALT	GALT	G430	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
type	type	T100	NN	I-NP	O
(	(	0000	(	O	O
N	N	N000	NN	B-NP	O
/	/	0000	SYM	B-NP	O
N	N	N000	NN	I-NP	O
)	)	0000	)	O	O
after	after	A136	IN	B-PP	O
exposure	exposure	E212	NN	B-NP	O
at	at	A300	IN	B-PP	O
identical	identical	I353	JJ	B-NP	O
initial	initial	I534	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
to	to	T000	TO	B-PP	O
50	50	0000	CD	B-NP	O
degrees	degree	D262	NNS	I-NP	O
C	C	C000	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
15	15	0000	CD	B-NP	O
min	min	M500	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
codon	codon	C350	NN	I-NP	O
change	change	C520	NN	I-NP	O
N314D	N314D	N300	NN	I-NP	O
in	in	I500	IN	B-PP	O
cis	cis	C200	NN	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
base	base	B200	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
pair	pair	P600	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
1721C	1721C	C000	NN	I-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
T	T	T000	NN	B-NP	O
produces	produce	P632	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
LA	LA	L000	NN	I-NP	B-Disease
variant	variant	V653	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
galactosemia	galactosemia	G423	NN	B-NP	I-Disease
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
change	change	C520	NN	I-NP	O
increases	increase	I526	VBZ	B-VP	O
GALT	GALT	G430	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
by	by	B000	IN	B-PP	O
increasing	increase	I526	VBG	B-VP	O
GALT	GALT	G430	NN	B-NP	O
protein	protein	P635	NN	I-NP	O
abundance	abundance	A153	NN	I-NP	O
without	without	W300	IN	B-PP	O
increasing	increase	I526	VBG	B-VP	O
transcription	transcription	T652	NN	B-NP	O
or	or	O600	CC	O	O
decreasing	decrease	D262	VBG	B-VP	O
thermal	thermal	T654	JJ	B-NP	O
lability	lability	L143	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
favorable	favorable	F161	JJ	I-NP	O
codon	codon	C350	NN	I-NP	O
bias	bias	B200	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutated	mutate	M300	VBN	I-NP	O
codon	codon	C350	NN	I-NP	O
with	with	W300	IN	B-PP	O
consequently	consequently	C525	RB	B-NP	O
increased	increase	I526	VBN	I-NP	O
translation	translation	T652	NN	I-NP	O
rates	rate	R320	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
postulated	postulate	P234	VBN	I-VP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
TSG101	TSG101	T200	NN	I-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
susceptibility	susceptibility	S213	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
located	located	L230	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
11	11	0000	CD	I-NP	O
band	band	B530	NN	I-NP	O
p15	p15	P000	NN	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
mutated	mutate	M300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Recent	Recent	R253	JJ	B-NP	O
work	work	W620	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
identified	identify	I353	VBN	I-VP	O
a	a	A000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
tsg101	tsg101	T200	NN	B-NP	O
)	)	0000	)	O	O
whose	whose	W200	WP$	B-NP	O
inactivation	inactivation	I523	NN	I-NP	O
in	in	I500	IN	B-PP	O
fibroblasts	fibroblast	F161	NNS	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
cellular	cellular	C460	JJ	B-NP	O
transformation	transformation	T652	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
ability	ability	A143	NN	I-NP	O
to	to	T000	TO	B-VP	O
produce	produce	P632	VB	I-VP	O
metastatic	metastatic	M323	JJ	B-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
nude	nude	N300	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
homolog	homolog	H542	NN	I-NP	O
,	,	0000	,	O	O
TSG101	TSG101	T200	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
we	we	W000	PRP	B-NP	O
isolated	isolate	I243	VBD	B-VP	O
and	and	A530	CC	O	O
mapped	map	M130	VBD	B-VP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
11	11	0000	CD	I-NP	O
,	,	0000	,	O	O
bands	band	B532	NNS	B-NP	O
15	15	0000	CD	B-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
15	15	0000	CD	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
15	15	0000	CD	I-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
region	region	R250	NN	I-NP	O
proposed	propose	P612	VBN	B-VP	O
to	to	T000	TO	I-VP	O
contain	contain	C535	VB	I-VP	O
tumor	tumor	T560	NN	B-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	I-NP	O
s	s	S000	NNS	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
mutated	mutate	M300	VBN	I-VP	O
at	at	A300	IN	B-PP	O
high	high	H200	JJ	B-NP	O
frequency	frequency	F625	NN	I-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
7	7	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
15	15	0000	CD	B-NP	O
uncultured	uncultured	U524	JJ	I-NP	O
primary	primary	P656	JJ	I-NP	O
human	human	H500	JJ	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
,	,	0000	,	O	O
intragenic	intragenic	I536	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
shown	show	S500	VBN	I-VP	O
in	in	I500	IN	B-PP	O
TSG101	TSG101	T200	NN	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
and	and	A530	CC	O	O
transcripts	transcript	T652	NNS	B-NP	O
by	by	B000	IN	B-PP	O
gel	gel	G400	NN	B-NP	O
and	and	A530	CC	O	O
sequence	sequence	S252	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
mutations	mutation	M352	NNS	B-NP	O
affecting	affect	A123	VBG	B-VP	O
two	two	T000	CD	B-NP	O
TSG101	TSG101	T200	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
cancers	cancer	C526	NNS	I-NP	B-Disease
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
TSG101	TSG101	T200	NN	I-NP	O
defects	defect	D123	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
matched	match	M323	VBN	B-NP	O
normal	normal	N654	JJ	I-NP	O
breast	breast	B623	NN	I-NP	O
tissue	tissue	T200	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
strongly	strongly	S365	RB	B-VP	O
implicate	implicate	I514	VBP	I-VP	O
TSG101	TSG101	T200	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease

Moderate	Moderate	M363	JJ	B-NP	O
intergenerational	intergenerational	I536	JJ	I-NP	O
and	and	A530	CC	I-NP	O
somatic	somatic	S532	JJ	I-NP	O
instability	instability	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
55	55	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
transgenic	transgenic	T652	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
expansion	expansion	E215	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
(	(	0000	(	O	O
CTG	CTG	C320	NN	O	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
untranslated	untranslated	U536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
(	(	0000	(	O	O
UTR	UTR	U360	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
DMPK	DMPK	D512	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
(	(	0000	(	O	O
CTG	CTG	C320	NN	O	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
repeat	repeat	R130	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
polymorphic	polymorphic	P456	JJ	B-ADJP	O
and	and	A530	CC	O	O
varies	vary	V620	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
size	size	S200	NN	B-NP	O
between	between	B350	IN	B-PP	O
5	5	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
37	37	0000	CD	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
in	in	I500	IN	B-PP	O
unaffected	unaffected	U512	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
whereas	whereas	W620	IN	B-ADVP	O
in	in	I500	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
patients	patient	P353	NNS	I-NP	O
there	there	T600	RB	B-ADVP	O
are	be	A600	VBP	B-VP	O
between	between	B350	IN	B-PP	O
50	50	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
4	4	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
000	000	0000	CD	I-NP	O
CTGs	CTG	C320	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
size	size	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
(	(	0000	(	O	O
CTG	CTG	C320	NN	O	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
repeat	repeat	R130	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
increases	increase	I526	VBZ	B-VP	O
through	through	T620	IN	B-PP	O
generations	generation	G563	NNS	B-NP	O
,	,	0000	,	O	O
generally	generally	G564	RB	B-ADVP	O
correlates	correlate	C643	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
severity	severity	S163	NN	I-NP	O
and	and	A530	CC	I-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
instability	instability	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
depend	depend	D153	VB	I-VP	O
on	on	O500	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
size	size	S200	NN	I-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
sex	sex	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
transmitting	transmitting	T652	JJ	I-NP	O
parent	parent	P653	NN	I-NP	O
.	.	0000	.	O	O

Moreover	Moreover	M616	RB	B-ADVP	O
,	,	0000	,	O	O
mitotic	mitotic	M320	JJ	B-NP	O
instability	instability	I523	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
different	different	D165	JJ	B-NP	O
human	human	H500	JJ	I-NP	O
DM	DM	D500	NN	I-NP	B-Disease
tissues	tissue	T200	NNS	I-NP	O
shows	show	S200	VBZ	B-VP	O
length	length	L523	NN	B-NP	O
mosaicism	mosaicism	M250	NN	I-NP	O
between	between	B350	IN	B-PP	O
different	different	D165	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
lineages	lineage	L520	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
triplet	triplet	T614	JJ	B-NP	O
instability	instability	I523	NN	I-NP	O
remain	remain	R500	VBP	B-VP	O
elusive	elusive	E421	JJ	B-ADJP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
sequences	sequence	S252	NNS	I-NP	O
in	in	I500	IN	B-PP	O
instability	instability	I523	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
produced	produce	P632	VBD	B-VP	O
transgenic	transgenic	T652	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
containing	contain	C535	VBG	B-VP	O
a	a	A000	DT	B-NP	O
45	45	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kb	kb	K100	NN	I-NP	O
genomic	genomic	G520	JJ	I-NP	O
segment	segment	S253	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
55	55	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
cloned	clone	C453	VBN	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
mildly	mildly	M434	RB	I-NP	O
affected	affect	A123	VBN	I-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
to	to	T000	TO	B-PP	O
other	other	O360	JJ	B-NP	O
mouse	mouse	M200	NN	I-NP	O
models	model	M342	NNS	I-NP	O
containing	contain	C535	VBG	B-VP	O
CAG	CAG	C200	NN	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
within	within	W350	IN	B-PP	O
cDNAs	cDNA	C352	NNS	B-NP	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
mice	mouse	M200	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
both	both	B300	CC	O	O
intergenerational	intergenerational	I536	JJ	B-NP	O
and	and	A530	CC	I-NP	O
somatic	somatic	S532	JJ	I-NP	O
repeat	repeat	R130	NN	I-NP	O
instability	instability	I523	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Missense	Missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Fas	Fas	F200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
autoimmune	autoimmune	A350	JJ	B-NP	B-Disease
lymphoproliferative	lymphoproliferative	L516	JJ	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
and	and	A530	CC	I-NP	O
immunological	immunological	I542	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

Programmed	Program	P626	VBN	B-NP	O
cell	cell	C400	NN	I-NP	O
death	death	D300	NN	I-NP	O
(	(	0000	(	O	O
or	or	O600	CC	O	O
apoptosis	apoptosis	A132	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
physiological	physiological	P242	JJ	I-NP	O
process	process	P620	NN	I-NP	O
essential	essential	E253	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
development	development	D141	NN	I-NP	O
and	and	A530	CC	O	O
homeostatic	homeostatic	H523	JJ	B-NP	O
maintenance	maintenance	M535	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
immune	immune	I500	JJ	I-NP	O
system	system	S235	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Fas	Fas	F200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
Apo	Apo	A100	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
receptor	receptor	R213	NN	I-NP	O
plays	play	P420	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
crucial	crucial	C624	JJ	I-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
regulation	regulation	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
apoptosis	apoptosis	A132	NN	B-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
demonstrated	demonstrate	D523	VBN	B-VP	O
by	by	B000	IN	B-PP	O
lymphoproliferation	lymphoproliferation	L516	NN	B-NP	O
in	in	I500	IN	B-PP	O
MRL	MRL	M640	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
lpr	lpr	L160	NN	I-NP	O
/	/	0000	SYM	B-NP	O
lpr	lpr	L160	NN	I-NP	O
mice	mouse	M200	NNS	I-NP	O
and	and	A530	CC	B-PP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
recently	recently	R253	RB	I-NP	O
described	describe	D261	VBN	I-NP	O
autoimmune	autoimmune	A350	JJ	I-NP	B-Disease
lymphoproliferative	lymphoproliferative	L516	JJ	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
ALPS	ALPS	A412	NN	B-NP	B-Disease
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
,	,	0000	,	O	O
both	both	B300	DT	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Fas	Fas	F200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
ALPS	ALPS	A412	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
three	three	T600	CD	B-NP	O
affected	affect	A123	VBN	I-NP	O
siblings	sibling	S145	NNS	I-NP	O
carry	carry	C600	VBP	B-VP	O
two	two	T000	CD	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
on	on	O500	IN	B-PP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
Fas	Fas	F200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
and	and	A530	CC	O	O
show	show	S000	VBP	B-VP	O
lack	lack	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
Fas	Fas	F200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
induced	induce	I532	VBN	I-NP	O
apoptosis	apoptosis	A132	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
children	child	C436	NNS	I-NP	O
share	share	S600	VBP	B-VP	O
common	common	C500	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
including	include	I524	VBG	B-PP	O
splenomegaly	splenomegaly	S145	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
lymphadenopathy	lymphadenopathy	L513	NN	I-NP	B-Disease
,	,	0000	,	O	O
but	but	B300	CC	O	O
only	only	O540	RB	B-NP	O
one	one	O500	CD	I-NP	O
developed	develop	D141	VBD	B-VP	O
severe	severe	S160	JJ	B-NP	O
autoimmune	autoimmune	A350	JJ	I-NP	B-Disease
manifestations	manifestation	M512	NNS	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
three	three	T600	CD	I-NP	O
siblings	sibling	S145	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
anergic	anergic	A562	JJ	B-NP	O
CD3	CD3	C300	NN	I-NP	O
+	+	0000	SYM	B-NP	O
CD4	CD4	C300	NN	I-NP	O
-	-	0000	SYM	B-NP	O
CD8	CD8	C300	NN	I-NP	O
-	-	0000	SYM	B-NP	O
(	(	0000	(	O	O
double	double	D140	RB	B-ADJP	O
negative	negative	N231	JJ	I-ADJP	O
,	,	0000	,	O	O
[	[	0000	(	O	O
DN	DN	D500	NNP	B-NP	O
]	]	0000	)	O	O
)	)	0000	)	O	O
T	T	T000	NN	B-NP	O
cells	cell	C420	NNS	I-NP	O
;	;	0000	:	O	O
moreover	moreover	M616	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
chronic	chronic	C652	JJ	I-NP	O
lymphocyte	lymphocyte	L512	NN	I-NP	O
activation	activation	A231	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
demonstrated	demonstrate	D523	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
high	high	H200	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
DR	DR	D600	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
on	on	O500	IN	B-PP	O
peripheral	peripheral	P616	JJ	B-NP	O
CD3	CD3	C300	NN	I-NP	O
+	+	0000	SYM	B-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	B-PP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
high	high	H200	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
serum	serum	S650	NN	B-NP	O
activation	activation	A231	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
soluble	soluble	S414	JJ	B-NP	O
interleukin	interleukin	I536	NN	I-NP	O
-	-	0000	HYPH	O	O
2	2	0000	CD	B-NP	O
receptor	receptor	R213	NN	I-NP	O
(	(	0000	(	O	O
slL	slL	S400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
2R	2R	R000	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
soluble	soluble	S414	JJ	B-NP	O
CD30	CD30	C300	NN	I-NP	O
(	(	0000	(	O	O
sCD30	sCD30	S230	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
constitutively	constitutively	C523	RB	I-NP	O
expressed	express	E216	VBN	I-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
up	up	U100	RB	B-ADVP	O
-	-	0000	HYPH	B-NP	O
regulated	regulate	R243	VBN	B-VP	O
following	follow	F452	VBG	B-PP	O
genome	genome	G500	NN	B-NP	O
damage	damage	D520	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
product	product	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
ATM	ATM	A350	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
by	by	B000	IN	B-PP	O
using	use	U252	VBG	B-VP	O
an	an	A500	DT	B-NP	O
antiserum	antiserum	A532	NN	I-NP	O
developed	develop	D141	VBN	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
peptide	peptide	P130	NN	I-NP	O
corresponding	correspond	C621	VBG	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
deduced	deduce	D323	VBN	I-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
,	,	0000	,	I-NP	O
high	high	H200	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
weight	weight	W230	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
predominantly	predominantly	P635	RB	B-VP	O
confined	confine	C515	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
nucleus	nucleus	N242	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
is	be	I200	VBZ	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
and	and	A530	CC	I-NP	O
microsomal	microsomal	M262	JJ	I-NP	O
fractions	fraction	F623	NNS	I-NP	O
from	from	F650	IN	B-PP	O
human	human	H500	JJ	B-NP	O
lymphoblast	lymphoblast	L514	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	O	O
peripheral	peripheral	P616	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
.	.	0000	.	O	O

ATM	ATM	A350	NN	B-NP	O
protein	protein	P635	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
and	and	A530	CC	O	O
localization	localization	L242	NN	B-NP	O
remain	remain	R500	VBP	B-VP	O
constant	constant	C523	JJ	B-ADJP	O
throughout	throughout	T623	IN	B-PP	O
all	all	A400	DT	B-NP	O
stages	stage	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
cycle	cycle	C240	NN	I-NP	O
.	.	0000	.	O	O

Truncated	Truncate	T652	VBN	B-NP	O
ATM	ATM	A350	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
lymphoblasts	lymphoblast	L514	NNS	B-NP	O
from	from	F650	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	B-PP	I-Disease
telangiectasia	telangiectasia	T452	NN	B-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
premature	premature	P653	JJ	B-NP	O
protein	protein	P635	NN	I-NP	O
termination	termination	T653	NN	I-NP	O
.	.	0000	.	O	O

Exposure	Exposure	E212	NN	B-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
human	human	H500	JJ	I-NP	O
cells	cell	C420	NNS	I-NP	O
to	to	T000	TO	B-PP	O
gamma	gamma	G500	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
irradiation	irradiation	I635	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
radiomimetic	radiomimetic	R353	JJ	I-NP	O
drug	drug	D620	NN	I-NP	O
neocarzinostatin	neocarzinostatin	N262	NN	I-NP	O
had	have	H300	VBD	B-VP	O
no	no	N000	DT	B-NP	O
effect	effect	E123	NN	I-NP	O
on	on	O500	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
protein	protein	P635	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
noted	note	N300	VBN	I-NP	O
rise	rise	R200	NN	I-NP	O
in	in	I500	IN	B-PP	O
p53	p53	P000	NN	B-NP	O
levels	level	L142	NNS	I-NP	O
over	over	O160	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
time	time	T500	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
in	in	I500	IN	B-PP	O
ensuring	ensure	E526	VBG	B-VP	O
the	the	T000	DT	B-NP	O
fidelity	fidelity	F343	NN	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
repair	repair	R160	NN	I-NP	O
and	and	A530	CC	O	O
cell	cell	C400	NN	B-NP	O
cycle	cycle	C240	NN	I-NP	O
regulation	regulation	R243	NN	I-NP	O
following	follow	F452	VBG	B-PP	O
genome	genome	G500	NN	B-NP	O
damage	damage	D520	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Type	Type	T100	NN	B-NP	O
III	III	I000	CD	I-NP	O
collagen	collagen	C425	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
crucial	crucial	C624	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
collagen	collagen	C425	NN	B-NP	O
I	I	I000	CD	I-NP	O
fibrillogenesis	fibrillogenesis	F164	NN	I-NP	O
and	and	A530	CC	B-PP	O
for	for	F600	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
cardiovascular	cardiovascular	C631	JJ	I-NP	O
development	development	D141	NN	I-NP	O
.	.	0000	.	O	O

Type	Type	T100	NN	B-NP	O
III	III	I000	CD	I-NP	O
collagen	collagen	C425	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
fibrillar	fibrillar	F164	JJ	I-NP	O
forming	form	F652	VBG	I-NP	O
collagen	collagen	C425	NN	I-NP	O
comprising	comprise	C516	VBG	B-VP	O
three	three	T600	CD	B-NP	O
alpha1	alpha1	A410	NN	I-NP	O
(	(	0000	(	O	O
III	III	I000	CD	B-NP	O
)	)	0000	)	O	O
chains	chain	C520	NNS	B-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
early	early	E640	JJ	B-NP	O
embryos	embryo	E516	NNS	I-NP	O
and	and	A530	CC	B-PP	O
throughout	throughout	T623	IN	B-PP	O
embryogenesis	embryogenesis	E516	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
adult	adult	A343	NN	I-NP	O
,	,	0000	,	O	O
type	type	T100	NN	B-NP	O
III	III	I000	CD	I-NP	O
collagen	collagen	C425	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
component	component	C515	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
extracellular	extracellular	E236	JJ	I-NP	O
matrix	matrix	M362	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
internal	internal	I536	JJ	B-NP	O
organs	organ	O625	NNS	I-NP	O
and	and	A530	CC	I-NP	O
skin	skin	S250	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
COL3A1	COL3A1	C400	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
implicated	implicate	I514	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
type	type	T100	NN	B-NP	B-Disease
IV	IV	I100	CD	I-NP	I-Disease
Ehlers	Ehlers	E462	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Danlos	Danlos	D542	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
aortic	aortic	A632	JJ	B-NP	B-Disease
rupture	rupture	R136	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
early	early	E640	JJ	B-NP	O
adult	adult	A343	JJ	I-NP	O
life	life	L100	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
directly	directly	D623	RB	I-VP	O
study	study	S300	VB	I-VP	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
Col3a1	Col3a1	C400	NN	B-NP	O
in	in	I500	IN	B-PP	O
development	development	D141	NN	B-NP	O
and	and	A530	CC	I-NP	O
disease	disease	D200	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
inactivated	inactivate	I523	VBN	I-VP	O
the	the	T000	DT	B-NP	O
Col3a1	Col3a1	C400	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
embryonic	embryonic	E516	JJ	B-NP	O
stem	stem	S350	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
by	by	B000	IN	B-PP	O
homologous	homologous	H542	JJ	B-NP	O
recombination	recombination	R251	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutated	mutate	M300	VBN	I-NP	O
allele	allele	A400	NN	I-NP	O
was	be	W200	VBD	B-VP	O
transmitted	transmit	T652	VBN	I-VP	O
through	through	T620	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
germ	germ	G650	NN	I-NP	O
line	line	L500	NN	I-NP	O
and	and	A530	CC	O	O
homozygous	homozygous	H520	JJ	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
animals	animal	A542	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
derived	derive	D613	VBN	I-VP	O
from	from	F650	IN	B-PP	O
heterozygous	heterozygous	H362	JJ	B-NP	O
intercrosses	intercross	I536	NNS	I-NP	O
.	.	0000	.	O	O

About	About	A130	IN	B-NP	O
10	10	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
animals	animal	A542	NNS	I-NP	O
survived	survive	S613	VBD	B-VP	O
to	to	T000	TO	B-PP	O
adulthood	adulthood	A343	NN	B-NP	O
but	but	B300	CC	O	O
have	have	H100	VBP	B-VP	O
a	a	A000	DT	B-NP	O
much	much	M200	RB	I-NP	O
shorter	short	S636	JJR	I-NP	O
life	life	L100	NN	I-NP	O
span	span	S150	NN	I-NP	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
death	death	D300	NN	B-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
rupture	rupture	R136	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
blood	blood	B430	NN	I-NP	O
vessels	vessel	V242	NNS	I-NP	O
,	,	0000	,	O	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
type	type	T100	NN	B-NP	B-Disease
IV	IV	I100	CD	I-NP	I-Disease
Ehlers	Ehlers	E462	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Danlos	Danlos	D542	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Ultrastructural	Ultrastructural	U436	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
tissues	tissue	T200	NNS	B-NP	O
from	from	F650	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
type	type	T100	NN	B-NP	O
III	III	I000	CD	I-NP	O
collagen	collagen	C425	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
essential	essential	E253	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
collagen	collagen	C425	NN	I-NP	O
I	I	I000	CD	I-NP	O
fibrillogenesis	fibrillogenesis	F164	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
cardiovascular	cardiovascular	C631	JJ	I-NP	O
system	system	S235	NN	I-NP	O
and	and	A530	CC	O	O
other	other	O360	JJ	B-NP	O
organs	organ	O625	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Nonsense	Nonsense	N525	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
3	3	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
proteolipid	proteolipid	P634	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
PLP	PLP	P410	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
unusual	unusual	U524	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
a	a	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
431	431	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
proteolipid	proteolipid	P634	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
PLP	PLP	P410	NN	B-NP	O
)	)	0000	)	O	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
codon	codon	C350	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
unusual	unusual	U524	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
PMD	PMD	P530	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
creates	create	C632	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
AluI	AluI	A400	NN	I-NP	O
restriction	restriction	R236	NN	I-NP	O
site	site	S300	NN	I-NP	O
,	,	0000	,	O	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
PLP	PLP	P410	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
picture	picture	P236	NN	I-NP	O
resembles	resemble	R251	VBZ	B-VP	O
somewhat	somewhat	S530	RB	B-NP	O
that	that	T300	DT	I-NP	O
of	of	O100	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
spastic	spastic	S123	JJ	B-NP	I-Disease
paraplegia	paraplegia	P614	NN	I-NP	I-Disease
(	(	0000	(	O	O
SPG	SPG	S120	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
differs	differ	D162	VBZ	B-VP	O
from	from	F650	IN	B-PP	O
this	this	T200	DT	B-NP	O
and	and	A530	CC	O	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
classical	classical	C424	JJ	I-NP	O
and	and	A530	CC	I-NP	O
connatal	connatal	C534	JJ	I-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
PMD	PMD	P530	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
that	that	T300	IN	B-NP	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
relatively	relatively	R431	RB	B-ADJP	O
mild	mild	M430	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
form	form	F650	NN	B-NP	O
,	,	0000	,	O	O
onset	onset	O523	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
delayed	delay	D430	VBN	I-VP	O
beyond	beyond	B530	IN	B-PP	O
age	age	A200	NN	B-NP	O
2	2	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
,	,	0000	,	O	O
nystagmus	nystagmus	N232	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
absent	absent	A125	JJ	B-ADJP	O
,	,	0000	,	O	O
tremors	tremor	T656	NNS	B-NP	B-Disease
are	be	A600	VBP	B-VP	O
prominent	prominent	P653	JJ	B-NP	O
,	,	0000	,	I-NP	O
mental	mental	M534	JJ	I-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
severe	severe	S160	JJ	B-ADJP	O
,	,	0000	,	O	O
some	some	S500	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
dementia	dementia	D530	NN	B-NP	B-Disease
or	or	O600	CC	I-NP	O
personality	personality	P625	NN	I-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
progressive	progressive	P626	JJ	B-ADJP	O
rather	rather	R360	RB	B-PP	O
than	than	T500	IN	I-PP	O
static	static	S320	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
some	some	S500	DT	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
several	several	S164	JJ	B-NP	O
females	female	F542	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
signs	sign	S252	NNS	B-NP	O
of	of	O100	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
3B	3B	B000	NN	I-NP	O
,	,	0000	,	O	O
should	should	S430	MD	B-VP	O
block	block	B420	VB	I-VP	O
the	the	T000	DT	B-NP	O
synthesis	synthesis	S532	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
PLP	PLP	P410	NN	I-NP	O
but	but	B300	CC	O	O
spare	spare	S160	JJ	B-NP	O
DM20	DM20	D500	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
isoform	isoform	I216	NN	I-NP	O
whose	whose	W200	WP$	B-NP	O
persistence	persistence	P623	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
mild	mild	M430	JJ	B-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
PLP	PLP	P410	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
associated	associate	A230	VBN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
both	both	B300	CC	B-NP	O
humans	human	H520	NNS	I-NP	O
and	and	A530	CC	I-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Common	Common	C500	JJ	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
and	and	A530	CC	O	O
susceptibility	susceptibility	S213	NN	B-NP	O
to	to	T000	TO	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
general	general	G564	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

Most	Most	M230	RBS	B-NP	O
multiple	multiple	M431	JJ	I-NP	O
case	case	C200	NN	I-NP	O
families	family	F542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
young	young	Y520	JJ	B-NP	O
onset	onset	O523	NN	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	O	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
thought	think	T230	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	B-PP	O
highly	highly	H240	RB	B-NP	O
penetrant	penetrant	P536	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
predisposing	predispose	P632	VBG	I-NP	O
genes	gene	G520	NNS	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
uncommon	uncommon	U525	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
population	population	P143	NN	I-NP	O
and	and	A530	CC	O	O
they	they	T000	PRP	B-NP	O
probably	probably	P614	RB	B-ADVP	O
account	account	A253	VBP	B-VP	O
for	for	F600	IN	B-PP	O
only	only	O540	RB	B-NP	O
a	a	A000	DT	I-NP	O
few	few	F000	JJ	I-NP	O
percent	percent	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
incidence	incidence	I523	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
much	much	M200	RB	I-NP	O
larger	large	L626	JJR	I-NP	O
fraction	fraction	F623	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
might	might	M230	MD	B-VP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
principle	principle	P652	NN	B-NP	O
,	,	0000	,	O	O
be	be	B000	VB	B-VP	O
due	due	D000	JJ	B-PP	O
to	to	T000	TO	B-PP	O
common	common	C500	JJ	B-NP	O
variants	variant	V653	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
confer	confer	C516	VBP	B-VP	O
more	more	M600	RBR	B-NP	O
modest	modest	M323	JJ	I-NP	O
individual	individual	I531	JJ	I-NP	O
risks	risk	R200	NNS	I-NP	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
are	be	A600	VBP	B-VP	O
several	several	S164	JJ	B-NP	O
common	common	C500	JJ	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
which	which	W200	WDT	B-NP	O
generate	generate	G563	VBP	B-VP	O
amino	amino	A500	JJ	B-NP	O
acid	acid	A230	NN	I-NP	O
substitutions	substitution	S123	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
examined	examine	E253	VBN	I-VP	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
four	four	F600	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
Gln356Arg	Gln356Arg	G456	NN	I-NP	O
,	,	0000	,	O	O
Pro871Leu	Pro871Leu	P640	NN	B-NP	O
,	,	0000	,	O	O
Glu1038Gly	Glu1038Gly	G424	NN	B-NP	O
and	and	A530	CC	I-NP	O
Ser1613Gly	Ser1613Gly	S624	NN	I-NP	O
in	in	I500	IN	B-PP	O
large	large	L620	JJ	B-NP	O
series	series	S620	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cases	case	C200	NNS	I-NP	O
and	and	A530	CC	O	O
matched	matched	M323	JJ	B-NP	O
controls	control	C536	NNS	I-NP	O
.	.	0000	.	O	O

Due	Due	D000	JJ	B-PP	O
to	to	T000	TO	B-PP	O
strong	strong	S365	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
four	four	F600	CD	I-NP	O
sites	site	S320	NNS	I-NP	O
generate	generate	G563	VBP	B-VP	O
only	only	O540	RB	B-NP	O
three	three	T600	CD	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
>	>	0000	JJR	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
,	,	0000	,	O	O
defined	define	D153	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
alleles	allele	A420	NNS	I-NP	O
Gln356Pro871Glu1038Ser1613	Gln356Pro871Glu1038Ser1613	G451	NN	I-NP	O
and	and	A530	CC	I-NP	O
Gln356Leu871Gly1038Gly1613	Gln356Leu871Gly1038Gly1613	G454	NN	I-NP	O
,	,	0000	,	O	O
have	have	H100	VBP	B-VP	O
frequencies	frequency	F625	NNS	B-NP	O
of	of	O100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

57	57	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
0	0	0000	CD	I-NP	O
.	.	0000	.	O	O

32	32	0000	CD	B-NP	O
respectively	respectively	R212	RB	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
these	these	T200	DT	B-NP	O
frequencies	frequency	F625	NNS	I-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
differ	differ	D160	VB	I-VP	O
significantly	significantly	S251	RB	B-ADVP	O
between	between	B350	IN	B-PP	O
patient	patient	P353	NN	B-NP	O
and	and	A530	CC	I-NP	O
control	control	C536	NN	I-NP	O
groups	group	G612	NNS	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
make	make	M200	VB	I-VP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
contribution	contribution	C536	NN	I-NP	O
to	to	T000	TO	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
risk	risk	R200	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
our	our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
Arg356	Arg356	A620	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
may	may	M000	MD	B-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
genotype	genotype	G531	NN	I-NP	O
distribution	distribution	D236	NN	I-NP	O
in	in	I500	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
from	from	F650	IN	B-PP	O
that	that	T300	DT	B-NP	O
in	in	I500	IN	B-PP	O
controls	control	C536	NNS	B-NP	O
(	(	0000	(	O	O
Arg356	Arg356	A620	NN	B-NP	O
homozygotes	homozygote	H523	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
more	more	M600	RBR	B-ADJP	O
frequent	frequent	F625	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
control	control	C536	NN	I-NP	O
groups	group	G612	NNS	I-NP	O
,	,	0000	,	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
01	01	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
protective	protective	P632	JJ	B-ADJP	O
against	against	A252	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

If	If	I100	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
finding	finding	F535	NN	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
confirmed	confirm	C516	VBN	I-VP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
may	may	M000	MD	B-VP	O
provide	provide	P613	VB	I-VP	O
an	an	A500	DT	B-NP	O
insight	insight	I523	NN	I-NP	O
into	into	I530	IN	B-PP	O
the	the	T000	DT	B-NP	O
structural	structural	S362	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
important	important	I516	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
function	function	F523	NN	I-NP	O
.	.	0000	.	O	O

Kniest	Kni	K523	JJS	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
:	:	0000	:	O	O
Dr	Dr	D600	NNP	B-NP	O
.	.	0000	.	I-NP	O
W	W	W000	NNP	I-NP	O
.	.	0000	.	O	O

Kniest	Kni	K523	JJS	B-ADVP	O
,	,	0000	,	O	O
his	his	H200	PRP$	B-NP	O
patient	patient	P353	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
.	.	0000	.	O	O

Kniest	Kni	K523	JJS	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
chondrodysplasia	chondrodysplasia	C536	NN	I-NP	B-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
defective	defective	D123	JJ	I-NP	B-Disease
formation	formation	F653	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
type	type	T100	NN	B-NP	I-Disease
II	II	I000	CD	I-NP	I-Disease
collagen	collagen	C425	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
about	about	A130	IN	B-PP	O
Dr	Dr	D600	NNP	B-NP	O
.	.	0000	.	I-NP	O
Kniest	Kniest	K523	NNP	I-NP	O
,	,	0000	,	O	O
who	who	W000	WP	B-NP	O
first	first	F623	RB	B-ADVP	O
described	describe	D261	VBD	B-VP	O
the	the	T000	DT	B-NP	O
condition	condition	C535	NN	I-NP	O
in	in	I500	IN	B-PP	O
1952	1952	0000	CD	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
his	his	H200	PRP$	B-NP	O
patient	patient	P353	NN	I-NP	O
,	,	0000	,	O	O
who	who	W000	WP	B-NP	O
,	,	0000	,	O	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
50	50	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
severely	severely	S164	RB	I-VP	B-Disease
handicapped	handicap	H532	VBN	I-VP	I-Disease
with	with	W300	IN	B-PP	O
short	short	S630	JJ	B-NP	B-Disease
stature	stature	S360	NN	I-NP	I-Disease
,	,	0000	,	O	O
restricted	restricted	R236	JJ	B-NP	B-Disease
joint	joint	J530	JJ	I-NP	I-Disease
mobility	mobility	M143	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
blindness	blindness	B453	NN	B-NP	B-Disease
but	but	B300	CC	O	O
is	be	I200	VBZ	B-VP	O
mentally	mentally	M534	RB	B-ADJP	O
alert	alert	A463	JJ	I-ADJP	O
and	and	A530	CC	O	O
leads	lead	L320	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
active	active	A231	JJ	I-NP	O
life	life	L100	NN	I-NP	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
DNA	DNA	D500	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
base	base	B200	NN	I-NP	O
(	(	0000	(	O	O
G	G	G000	NN	B-NP	O
)	)	0000	)	O	O
deletion	deletion	D435	NN	B-NP	O
involving	involve	I514	VBG	B-VP	O
the	the	T000	DT	B-NP	O
GT	GT	G300	NN	I-NP	O
dinucleotide	dinucleotide	D524	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
start	start	S363	NN	I-NP	O
of	of	O100	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
18	18	0000	CD	I-NP	O
destroying	destroy	D236	VBG	B-VP	O
a	a	A000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
COL2A1	COL2A1	C400	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
accordance	accordance	A263	NN	B-NP	O
with	with	W300	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
findings	finding	F535	NNS	I-NP	O
in	in	I500	IN	B-PP	O
other	other	O360	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Kniest	Kni	K523	JJS	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
confirms	confirm	C516	NNS	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
original	original	O625	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
,	,	0000	,	O	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
small	small	S540	JJ	B-NP	O
inframe	inframe	I516	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
often	often	O135	RB	B-ADVP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
exon	exon	E250	NN	B-NP	O
skipping	skipping	S215	NN	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
COL2A1	COL2A1	C400	NN	B-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Cloning	Cloning	C452	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
homogentisate	homogentisate	H525	NN	I-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
2	2	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
dioxygenase	dioxygenase	D252	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
key	key	K000	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
of	of	O100	IN	B-PP	O
alkaptonuria	alkaptonuria	A421	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
determined	determine	D365	VBD	B-VP	O
48	48	0000	CD	B-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
residues	residue	R232	NNS	I-NP	O
from	from	F650	IN	B-PP	O
five	five	F100	CD	B-NP	O
peptides	peptide	P132	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
homogeneous	homogeneous	H525	JJ	I-NP	O
monomer	monomer	M560	NN	I-NP	O
of	of	O100	IN	B-PP	O
homogentisate	homogentisate	H525	NN	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
2	2	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
dioxygenase	dioxygenase	D252	NN	B-NP	O
(	(	0000	(	O	O
HGO	HGO	H200	NN	B-NP	O
;	;	0000	:	O	O
E	E	E000	NN	B-NP	O
.	.	0000	.	O	O
C	C	C000	NN	B-NP	O
.	.	0000	.	O	O
1	1	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
13	13	0000	CD	I-NP	O
.	.	0000	.	O	O
11	11	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
15	15	0000	CD	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
liver	liver	L160	NN	I-NP	O
.	.	0000	.	O	O

After	After	A136	IN	B-PP	O
digestion	digestion	D235	NN	B-NP	O
with	with	W300	IN	B-PP	O
trypsin	trypsin	T612	NN	B-NP	O
,	,	0000	,	O	O
peptides	peptide	P132	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
separated	separate	S163	VBN	I-VP	O
by	by	B000	IN	B-PP	O
reversed	reverse	R162	VBN	B-NP	O
phase	phase	P200	NN	I-NP	O
chromatography	chromatography	C653	NN	I-NP	O
and	and	A530	CC	O	O
amino	amino	A500	NN	B-NP	O
acid	acid	A230	NN	I-NP	O
sequenced	sequence	S252	VBN	B-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
deduced	deduce	D323	VBN	I-NP	O
codon	codon	C350	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
three	three	T600	CD	B-NP	O
peptides	peptide	P132	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
derive	derive	D610	VB	I-VP	O
degenerated	degenerated	D256	JJ	B-NP	O
oligomeres	oligomere	O425	NNS	I-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
combining	combine	C515	VBG	B-VP	O
these	these	T200	DT	B-NP	O
oligos	oligo	O420	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
were	be	W600	VBD	B-VP	O
able	able	A140	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
amplify	amplify	A514	VB	I-VP	O
fragments	fragment	F625	NNS	B-NP	O
from	from	F650	IN	B-PP	O
100	100	0000	CD	B-NP	O
to	to	T000	TO	I-NP	O
300	300	0000	CD	I-NP	O
bases	base	B200	NNS	I-NP	O
(	(	0000	(	O	O
b	b	B000	NN	B-NP	O
)	)	0000	)	O	O
from	from	F650	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
liver	liver	L160	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
by	by	B000	IN	B-PP	O
polymerase	polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
after	after	A136	IN	B-PP	O
reverse	reverse	R162	JJ	B-NP	O
transcription	transcription	T652	NN	I-NP	O
(	(	0000	(	O	O
RT	RT	R300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
PCR	PCR	P260	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
fragment	fragment	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
200	200	0000	CD	B-NP	O
b	b	B000	NN	I-NP	O
was	be	W200	VBD	B-VP	O
cloned	clone	C453	VBN	I-VP	O
and	and	A530	CC	O	O
used	use	U230	VBN	B-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
probe	probe	P610	NN	I-NP	O
to	to	T000	TO	B-VP	O
screen	screen	S265	VB	I-VP	O
a	a	A000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
liver	liver	L160	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
library	library	L160	NN	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
clone	clone	C450	NN	I-NP	O
from	from	F650	IN	B-PP	O
this	this	T200	DT	B-NP	O
library	library	L160	NN	I-NP	O
contained	contain	C535	VBD	B-VP	O
the	the	T000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
insert	insert	I526	NN	I-NP	O
for	for	F600	IN	B-PP	O
HGO	HGO	H200	NN	B-NP	O
as	as	A200	IN	B-SBAR	O
determined	determine	D365	VBN	B-VP	O
by	by	B000	IN	B-PP	O
sequencing	sequencing	S252	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
encodes	encode	E523	VBZ	B-VP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
50	50	0000	CD	B-NP	O
kDa	kDa	K300	NN	I-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
predicted	predict	P632	VBN	B-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
of	of	O100	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
HGO	HGO	H200	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
overall	overall	O164	JJ	I-NP	O
identity	identity	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
41	41	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
corresponding	correspond	C621	VBG	I-NP	O
gene	gene	G500	NN	I-NP	O
hmgA	hmgA	H520	NN	I-NP	O
from	from	F650	IN	B-PP	O
Aspergillus	Aspergillus	A216	NN	B-NP	O
.	.	0000	.	O	O

Sequence	Sequence	S252	NN	B-NP	O
similarities	similarity	S546	NNS	I-NP	O
to	to	T000	TO	B-PP	O
human	human	H500	JJ	B-NP	O
expressed	express	E216	VBN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
tags	tag	T200	NNS	I-NP	O
(	(	0000	(	O	O
EST	EST	E230	NN	B-NP	O
)	)	0000	)	O	O
clones	clone	C452	NNS	B-NP	O
ranged	range	R523	VBD	B-VP	O
from	from	F650	IN	B-PP	O
70	70	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
to	to	T000	TO	I-NP	O
20	20	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
positions	position	P235	NNS	I-NP	O
of	of	O100	IN	B-PP	O
122	122	0000	CD	B-NP	O
conserved	conserve	C526	VBN	B-VP	O
amino	amino	A500	JJ	B-NP	O
acids	acid	A232	NNS	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
determined	determine	D365	VBN	I-VP	O
by	by	B000	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
sequence	sequence	S252	NN	I-NP	O
alignment	alignment	A425	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
one	one	O500	CD	B-NP	O
first	first	F623	JJ	I-NP	O
intron	intron	I536	NN	I-NP	O
of	of	O100	IN	B-PP	O
928	928	0000	CD	B-NP	O
b	b	B000	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
HGO	HGO	H200	NN	B-NP	O
seems	seem	S520	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
various	various	V620	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
shown	show	S500	VBN	B-VP	O
by	by	B000	IN	B-PP	O
RT	RT	R300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
PCR	PCR	P260	NN	I-NP	O
on	on	O500	IN	B-PP	O
different	different	D165	JJ	B-NP	O
cDNAs	cDNA	C352	NNS	I-NP	O
.	.	0000	.	O	O

FISH	FISH	F200	NN	B-NP	O
experiments	experiment	E216	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
whole	whole	W400	JJ	I-NP	O
murine	murine	M650	JJ	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
as	as	A200	IN	B-PP	O
probe	probe	P610	NN	B-NP	O
clearly	clearly	C464	RB	B-ADVP	O
revealed	reveal	R143	VBD	B-VP	O
signals	signal	S254	NNS	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
band	band	B530	NN	I-NP	O
3q13	3q13	Q000	NN	I-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
q21	q21	Q000	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
corresponds	correspond	C621	VBZ	B-VP	O
well	well	W400	RB	B-ADVP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
previous	previous	P612	JJ	I-NP	O
assignment	assignment	A253	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
locus	locus	L200	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
alkaptonuria	alkaptonuria	A421	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
AKU	AKU	A200	NN	B-NP	O
)	)	0000	)	O	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
region	region	R250	NN	I-NP	O
by	by	B000	IN	B-PP	O
multipoint	multipoint	M431	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
therefore	therefore	T616	RB	B-ADVP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
HGO	HGO	H200	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
encodes	encode	E523	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
alkaptonuria	alkaptonuria	A421	NN	B-NP	B-Disease
.	.	0000	.	O	O

PTEN	PTEN	P350	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
tyrosine	tyrosine	T625	NN	I-NP	O
phosphatase	phosphatase	P213	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
mutated	mutate	M300	VBN	B-VP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
brain	brain	B650	NN	I-NP	B-Disease
,	,	0000	,	O	I-Disease
breast	breast	B623	NN	B-NP	I-Disease
,	,	0000	,	O	I-Disease
and	and	A530	CC	O	I-Disease
prostate	prostate	P623	NN	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Mapping	Mapping	M152	NN	B-NP	O
of	of	O100	IN	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
on	on	O500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
10q23	10q23	Q000	CD	I-NP	O
has	have	H200	VBZ	B-VP	O
led	lead	L300	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
isolation	isolation	I243	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
PTEN	PTEN	P350	NN	B-NP	O
,	,	0000	,	O	O
that	that	T300	WDT	B-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
mutated	mutate	M300	VBN	I-VP	O
at	at	A300	IN	B-PP	O
considerable	considerable	C523	JJ	B-NP	O
frequency	frequency	F625	NN	I-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
cancers	cancer	C526	NNS	I-NP	B-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
preliminary	preliminary	P645	JJ	B-NP	O
screens	screen	S265	NNS	I-NP	O
,	,	0000	,	O	O
mutations	mutation	M352	NNS	B-NP	O
of	of	O100	IN	B-PP	O
PTEN	PTEN	P350	NN	B-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
31	31	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
13	13	0000	CD	B-NP	O
/	/	0000	SYM	O	O
42	42	0000	CD	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
glioblastoma	glioblastoma	G414	NN	B-NP	B-Disease
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
and	and	A530	CC	O	O
xenografts	xenograft	X526	NNS	B-NP	O
,	,	0000	,	O	O
100	100	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
4	4	0000	CD	B-NP	O
/	/	0000	SYM	I-NP	O
4	4	0000	CD	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
prostate	prostate	P623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
,	,	0000	,	O	O
6	6	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
4	4	0000	CD	B-NP	O
/	/	0000	SYM	O	O
65	65	0000	CD	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
and	and	A530	CC	O	O
xenografts	xenograft	X526	NNS	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
17	17	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
3	3	0000	CD	B-NP	O
/	/	0000	SYM	O	O
18	18	0000	CD	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
primary	primary	P656	JJ	B-NP	B-Disease
glioblastomas	glioblastoma	G414	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
predicted	predict	P632	VBN	I-NP	O
PTEN	PTEN	P350	NN	I-NP	O
product	product	P632	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
tyrosine	tyrosine	T625	NN	I-NP	O
phosphatase	phosphatase	P213	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
and	and	A530	CC	O	O
extensive	extensive	E235	JJ	B-NP	O
homology	homology	H542	NN	I-NP	O
to	to	T000	TO	B-PP	O
tensin	tensin	T525	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
that	that	T300	WDT	B-NP	O
interacts	interact	I536	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
actin	actin	A235	NN	B-NP	O
filaments	filament	F453	NNS	I-NP	O
at	at	A300	IN	B-PP	O
focal	focal	F240	JJ	B-NP	O
adhesions	adhesion	A325	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
homologies	homology	H542	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
PTEN	PTEN	P350	NN	B-NP	O
may	may	M000	MD	B-VP	O
suppress	suppress	S162	VB	I-VP	O
tumor	tumor	T560	NN	B-NP	B-Disease
cell	cell	C400	NN	I-NP	O
growth	growth	G630	NN	I-NP	O
by	by	B000	IN	B-PP	O
antagonizing	antagonize	A532	VBG	B-VP	O
protein	protein	P635	NN	B-NP	O
tyrosine	tyrosine	T625	NN	I-NP	O
kinases	kinase	K520	NNS	I-NP	O
and	and	A530	CC	O	O
may	may	M000	MD	B-VP	O
regulate	regulate	R243	VB	I-VP	O
tumor	tumor	T560	NN	B-NP	B-Disease
cell	cell	C400	NN	I-NP	O
invasion	invasion	I512	NN	I-NP	O
and	and	A530	CC	O	O
metastasis	metastasis	M323	NN	B-NP	B-Disease
through	through	T620	IN	B-PP	O
interactions	interaction	I536	NNS	B-NP	O
at	at	A300	IN	B-PP	O
focal	focal	F240	JJ	B-NP	O
adhesions	adhesion	A325	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Heterogeneity	Heterogeneity	H362	NN	B-NP	O
in	in	I500	IN	B-PP	O
Schwartz	Schwartz	S263	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Jampel	Jampel	J514	NNP	I-NP	I-Disease
chondrodystrophic	chondrodystrophic	C536	JJ	I-NP	I-Disease
myotonia	myotonia	M350	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Schwartz	Schwartz	S263	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Jampel	Jampel	J514	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
SJS	SJS	S200	NN	B-NP	B-Disease
;	;	0000	:	O	O
chondrodystrophic	chondrodystrophic	C536	JJ	B-NP	B-Disease
myotonia	myotonia	M350	NN	I-NP	I-Disease
;	;	0000	:	O	O
McK	McK	M200	NN	B-NP	O
255	255	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
800	800	0000	CD	I-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
recessively	recessively	R214	RB	I-NP	B-Disease
inherited	inherit	I563	VBN	I-NP	I-Disease
condition	condition	C535	NN	I-NP	I-Disease
defined	define	D153	VBN	B-VP	O
by	by	B000	IN	B-PP	O
myotonia	myotonia	M350	NN	B-NP	B-Disease
,	,	0000	,	O	O
short	short	S630	JJ	B-NP	B-Disease
stature	stature	S360	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
bone	bone	B500	NN	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
between	between	B350	IN	B-PP	O
SJS	SJS	S200	NN	B-NP	B-Disease
and	and	A530	CC	O	O
chromosomal	chromosomal	C652	JJ	B-NP	O
region	region	R250	NN	I-NP	O
1q36	1q36	Q000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
34	34	0000	CD	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
several	several	S164	JJ	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
yet	yet	Y300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
studied	study	S300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
and	and	A530	CC	I-NP	O
radiological	radiological	R342	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
in	in	I500	IN	B-PP	O
81	81	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
literature	literature	L363	NN	I-NP	O
and	and	A530	CC	O	O
5	5	0000	CD	B-NP	O
own	own	O500	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
trying	try	T652	VBG	B-VP	O
to	to	T000	TO	I-VP	O
identify	identify	I353	VB	I-VP	O
distinct	distinct	D235	JJ	B-NP	O
subgroups	subgroup	S126	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
tested	test	T230	VBD	B-VP	O
genetic	genetic	G532	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
SJS	SJS	S200	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
1	1	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
two	two	T000	CD	B-NP	O
affected	affect	A123	VBN	I-NP	O
sibs	sib	S120	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
have	have	H100	VBP	B-VP	O
mild	mild	M430	JJ	B-NP	O
skeletal	skeletal	S243	JJ	I-NP	O
changes	change	C520	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
secondary	secondary	S253	JJ	B-NP	O
consequences	consequence	C525	NNS	I-NP	O
of	of	O100	IN	B-PP	O
myotonia	myotonia	M350	NN	B-NP	B-Disease
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
another	another	A536	DT	B-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
appear	appear	A160	VBP	B-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
primary	primary	P656	JJ	B-NP	O
bone	bone	B500	NN	I-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
myotonia	myotonia	M350	NN	B-NP	B-Disease
.	.	0000	.	O	O

Within	Within	W350	IN	B-PP	O
this	this	T200	DT	B-NP	O
latter	latter	L360	JJ	I-NP	O
group	group	G610	NN	I-NP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
are	be	A600	VBP	B-VP	O
differences	difference	D165	NNS	B-NP	O
in	in	I500	IN	B-PP	O
age	age	A200	NN	B-NP	O
of	of	O100	IN	B-PP	O
manifestation	manifestation	M512	NN	B-NP	O
,	,	0000	,	O	O
clinical	clinical	C452	JJ	B-NP	O
course	course	C620	NN	I-NP	O
and	and	A530	CC	I-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
bone	bone	B500	NN	B-NP	O
changes	change	C520	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
tentatively	tentatively	T531	RB	B-ADVP	O
isolate	isolate	I243	VBP	B-VP	O
three	three	T600	CD	B-NP	O
different	different	D165	JJ	I-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
SJS	SJS	S200	NN	B-NP	B-Disease
type	type	T100	NN	I-NP	I-Disease
1A	1A	A000	NN	I-NP	I-Disease
,	,	0000	,	O	O
usually	usually	U240	RB	B-VP	O
recognized	recognize	R252	VBN	I-VP	O
in	in	I500	IN	B-PP	O
childhood	childhood	C430	NN	B-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
moderate	moderate	M363	JJ	B-NP	O
bone	bone	B500	NN	I-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
,	,	0000	,	O	O
corresponding	correspond	C621	VBG	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
original	original	O625	JJ	I-NP	O
descriptions	description	D261	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Schwartz	Schwartz	S263	NNP	B-NP	O
,	,	0000	,	I-NP	O
Jampel	Jampel	J514	NNP	I-NP	O
and	and	A530	CC	I-NP	O
Aberfeld	Aberfeld	A161	NNP	I-NP	O
;	;	0000	:	O	O
type	type	T100	NN	B-NP	O
1B	1B	B000	NN	I-NP	O
,	,	0000	,	O	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
type	type	T100	NN	B-NP	O
1A	1A	A000	NN	I-NP	O
but	but	B300	CC	O	O
recognizable	recognizable	R252	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
birth	birth	B630	NN	B-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
more	more	M600	RBR	B-NP	O
pronounced	pronounced	P652	JJ	I-NP	O
bone	bone	B500	NN	I-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
resembling	resemble	R251	VBG	B-VP	O
Kniest	Kni	K523	JJS	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
;	;	0000	:	O	O
and	and	A530	CC	O	O
type	type	T100	NN	B-NP	O
2	2	0000	CD	I-NP	O
,	,	0000	,	O	O
manifest	manif	M512	JJS	B-ADVP	O
at	at	A300	IN	B-PP	O
birth	birth	B630	NN	B-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
increased	increase	I526	VBN	B-NP	O
mortality	mortality	M634	NN	I-NP	O
and	and	A530	CC	I-NP	O
bone	bone	B500	NN	I-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
resembling	resemble	R251	VBG	B-VP	O
Pyle	Pyle	P400	NN	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
two	two	T000	CD	B-NP	O
sibs	sib	S120	NNS	I-NP	O
affected	affect	A123	VBN	B-VP	O
by	by	B000	IN	B-PP	O
SJS	SJS	S200	NN	B-NP	B-Disease
type	type	T100	NN	I-NP	I-Disease
2	2	0000	CD	I-NP	I-Disease
showed	show	S300	VBD	B-VP	O
evidence	evidence	E135	NN	B-NP	O
against	against	A252	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
1p36	1p36	P000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
34	34	0000	CD	I-NP	O
.	.	0000	.	O	O

CONCLUSIONS	CONCLUSIONS	C524	NNS	B-NP	O
SJS	SJS	S200	NN	I-NP	B-Disease
is	be	I200	VBZ	B-VP	O
clinically	clinically	C452	RB	B-ADVP	O
and	and	A530	CC	O	O
radiologically	radiologically	R342	RB	B-ADJP	O
heterogeneous	heterogeneous	H362	JJ	I-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
causes	cause	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
heterogeneity	heterogeneity	H362	NN	B-NP	O
are	be	A600	VBP	B-VP	O
not	not	N300	RB	I-VP	O
known	know	K500	VBN	I-VP	O
yet	yet	Y300	RB	B-ADVP	O
but	but	B300	CC	O	O
are	be	A600	VBP	B-VP	O
likely	likely	L240	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
include	include	I524	VB	I-VP	O
both	both	B300	CC	O	O
different	different	D165	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
SJS	SJS	S200	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
1	1	0000	CD	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
SJS	SJS	S200	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
tentative	tentative	T531	JJ	I-NP	O
clinico	clinico	C452	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
radiological	radiological	R342	JJ	I-NP	O
classification	classification	C421	NN	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
useful	useful	U214	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
genotype	genotype	G531	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlations	correlation	C643	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
overview	overview	O161	NN	I-NP	O
of	of	O100	IN	B-PP	O
WT1	WT1	W300	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
WT1	WT1	W300	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
were	be	W600	VBD	B-VP	O
anticipated	anticipate	A532	VBN	I-VP	O
to	to	T000	TO	B-VP	O
explain	explain	E214	VB	I-VP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
childhood	childhood	C430	NN	I-NP	O
kidney	kidney	K350	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
Wilms	Wilms	W452	NNP	B-NP	B-Disease
tumour	tumour	T560	NN	I-NP	I-Disease
(	(	0000	(	O	O
WT	WT	W300	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Six	Six	S200	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
on	on	O500	IN	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
review	review	R100	VBP	B-VP	O
100	100	0000	CD	B-NP	O
reports	report	R163	NNS	I-NP	O
of	of	O100	IN	B-PP	O
intragenic	intragenic	I536	JJ	B-NP	O
WT1	WT1	W300	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
examine	examine	E250	VB	B-VP	O
the	the	T000	DT	B-NP	O
accompanying	accompany	A251	VBG	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
.	.	0000	.	O	O

While	While	W400	IN	B-SBAR	O
only	only	O540	RB	B-NP	O
5	5	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
Wilms	Wilms	W452	NNP	I-NP	I-Disease
tumours	tumour	T562	NNS	I-NP	I-Disease
have	have	H100	VBP	B-VP	O
intragenic	intragenic	I536	JJ	B-NP	O
WT1	WT1	W300	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
>	>	0000	SYM	B-NP	O
90	90	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Denys	Deny	D520	NNPS	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Drash	Drash	D620	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
renal	renal	R540	JJ	B-NP	B-Disease
nephropathy	nephropathy	N161	NN	I-NP	I-Disease
,	,	0000	,	O	O
gonadal	gonadal	G534	JJ	B-ADJP	B-Disease
anomaly	anomaly	A540	RB	B-ADVP	I-Disease
,	,	0000	,	O	O
predisposition	predisposition	P632	NN	B-NP	B-Disease
to	to	T000	TO	B-PP	I-Disease
WT	WT	W300	NN	B-NP	I-Disease
)	)	0000	)	O	O
carry	carry	C600	VBP	B-VP	O
constitutional	constitutional	C523	JJ	B-NP	O
intragenic	intragenic	I536	JJ	I-NP	O
WT1	WT1	W300	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

WT1	WT1	W300	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
also	also	A420	RB	I-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
in	in	I500	IN	B-PP	O
juvenile	juvenile	J154	JJ	B-NP	B-Disease
granulosa	granulosa	G654	NN	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
tumour	tumour	T560	NN	I-NP	I-Disease
,	,	0000	,	O	O
non	non	N500	AFX	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
asbestos	asbestos	A212	NN	I-NP	I-Disease
related	relate	R430	VBN	I-NP	I-Disease
mesothelioma	mesothelioma	M234	NN	I-NP	I-Disease
,	,	0000	,	O	O
desmoplastic	desmoplastic	D251	JJ	B-NP	B-Disease
small	small	S540	JJ	I-NP	I-Disease
round	round	R530	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
tumour	tumour	T560	NN	I-NP	I-Disease
and	and	A530	CC	O	O
,	,	0000	,	O	O
most	most	M230	RBS	B-ADVP	O
recently	recently	R253	RB	I-ADVP	O
,	,	0000	,	O	O
acute	acute	A230	JJ	B-NP	B-Disease
myeloid	myeloid	M430	JJ	I-NP	I-Disease
leukemia	leukemia	L250	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
autosomal	autosomal	A325	JJ	B-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
myotonia	myotonia	M350	NN	I-NP	I-Disease
congenita	congenita	C525	NN	I-NP	I-Disease
affects	affect	A123	VBZ	B-VP	O
pore	pore	P600	NN	B-NP	O
properties	property	P616	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
muscle	muscle	M240	NN	I-NP	O
chloride	chloride	C463	NN	I-NP	O
channel	channel	C540	NN	I-NP	O
.	.	0000	.	O	O

Autosomal	Autosomal	A325	JJ	B-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
myotonia	myotonia	M350	NN	I-NP	I-Disease
congenita	congenita	C525	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
skeletal	skeletal	S243	JJ	B-NP	I-Disease
muscle	muscle	M240	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
voltage	voltage	V432	NN	I-NP	O
-	-	0000	HYPH	O	O
gated	gate	G300	VBN	B-NP	O
Cl	Cl	C400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
channel	channel	C540	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
CLCN1	CLCN1	C425	NN	B-NP	O
,	,	0000	,	O	O
7q35	7q35	Q000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
predicting	predict	P632	VBG	B-VP	O
the	the	T000	DT	B-NP	O
substitution	substitution	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
Gly	Gly	G400	NN	B-NP	O
230	230	0000	CD	I-NP	O
by	by	B000	IN	B-PP	O
glutamic	glutamic	G435	JJ	B-NP	O
acid	acid	A230	NN	I-NP	O
(	(	0000	(	O	O
G230E	G230E	G000	NN	B-NP	O
)	)	0000	)	O	O
between	between	B350	IN	B-PP	O
segments	segment	S253	NNS	B-NP	O
D3	D3	D000	NN	I-NP	O
and	and	A530	CC	I-NP	O
D4	D4	D000	NN	I-NP	O
dramatically	dramatically	D653	RB	B-ADVP	O
alters	alter	A436	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
pore	pore	P600	NN	I-NP	O
properties	property	P616	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
recombinant	recombinant	R251	JJ	I-NP	O
human	human	H500	JJ	I-NP	O
muscle	muscle	M240	NN	I-NP	O
Cl	Cl	C400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
channel	channel	C540	NN	I-NP	O
(	(	0000	(	O	O
hCIC	hCIC	H200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
expressed	express	E216	VBN	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
mammalian	mammalian	M545	JJ	I-NP	O
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
(	(	0000	(	O	O
tsA201	tsA201	T200	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
G230E	G230E	G000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
causes	cause	C200	VBZ	B-VP	O
substantial	substantial	S123	JJ	B-NP	O
changes	change	C520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
anion	anion	A500	NN	B-NP	O
and	and	A530	CC	I-NP	O
cation	cation	C350	NN	I-NP	O
selectivity	selectivity	S423	NN	I-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
a	a	A000	DT	B-NP	O
fundamental	fundamental	F535	JJ	I-NP	O
change	change	C520	NN	I-NP	O
in	in	I500	IN	B-PP	O
rectification	rectification	R231	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
current	current	C653	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
voltage	voltage	V432	NN	I-NP	O
relationship	relationship	R435	NN	I-NP	O
.	.	0000	.	O	O

Whereas	Whereas	W620	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
channels	channel	C542	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
pronounced	pronounced	P652	JJ	B-NP	O
inward	inward	I563	JJ	I-NP	O
rectification	rectification	R231	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
Cl	Cl	C400	NN	I-NP	O
>	>	0000	SYM	B-NP	O
thiocyanate	thiocyanate	T253	NN	I-NP	O
>	>	0000	SYM	I-NP	O
Br	Br	B600	NN	I-NP	O
>	>	0000	SYM	B-NP	O
NO	NO	N000	NN	I-NP	O
(	(	0000	(	O	O
3	3	0000	CD	B-NP	O
)	)	0000	)	O	O
>	>	0000	SYM	B-NP	O
I	I	I000	NN	I-NP	O
>	>	0000	SYM	B-NP	O
CH	CH	C000	NN	I-NP	O
(	(	0000	(	B-LST	O
3	3	0000	LS	I-LST	O
)	)	0000	)	O	O
SO	SO	S000	NN	B-NP	O
(	(	0000	(	O	O
3	3	0000	CD	B-NP	O
)	)	0000	)	O	O
selectivity	selectivity	S423	NN	B-NP	O
,	,	0000	,	O	O
G230E	G230E	G000	NN	B-NP	O
exhibits	exhibit	E213	VBZ	B-VP	O
outward	outward	O363	JJ	B-NP	O
rectification	rectification	R231	NN	I-NP	O
at	at	A300	IN	B-PP	O
positive	positive	P231	JJ	B-NP	O
potentials	potential	P353	NNS	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
thiocyanate	thiocyanate	T253	NN	I-NP	O
>	>	0000	SYM	O	O
NO	NO	N000	NN	B-NP	O
(	(	0000	(	O	O
3	3	0000	CD	B-NP	O
)	)	0000	)	O	O
>	>	0000	SYM	B-NP	O
I	I	I000	NN	I-NP	O
>	>	0000	SYM	B-NP	O
Br	Br	B600	NN	I-NP	O
>	>	0000	SYM	I-NP	O
Cl	Cl	C400	NN	I-NP	O
>	>	0000	SYM	B-NP	O
CH	CH	C000	NN	I-NP	O
(	(	0000	(	O	O
3	3	0000	CD	B-NP	O
)	)	0000	)	O	O
SO	SO	S000	NN	B-NP	O
(	(	0000	(	O	O
3	3	0000	CD	B-NP	O
)	)	0000	)	O	O
selectivity	selectivity	S423	NN	B-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
cation	cation	C350	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
anion	anion	A500	NN	I-NP	O
permeability	permeability	P651	NN	I-NP	O
ratio	ratio	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
much	much	M200	RB	B-ADJP	O
greater	great	G636	JJR	I-ADJP	O
than	than	T500	IN	B-PP	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
channel	channel	C540	NN	I-NP	O
.	.	0000	.	O	O

Voltage	Voltage	V432	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
dependent	dependent	D153	JJ	I-NP	O
blocks	block	B420	NNS	I-NP	O
by	by	B000	IN	B-PP	O
intracellular	intracellular	I536	JJ	B-NP	O
and	and	A530	CC	I-NP	O
extracellular	extracellular	E236	JJ	I-NP	O
iodide	iodide	I300	NN	I-NP	O
help	help	H410	NN	I-NP	O
to	to	T000	TO	B-VP	O
distinguish	distinguish	D235	VB	I-VP	O
two	two	T000	CD	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
ion	ion	I500	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
hClC	hClC	H242	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
conduction	conduction	C532	NN	I-NP	O
pathway	pathway	P300	NN	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
binding	binding	B535	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
preserved	preserve	P626	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	NN	I-NP	O
but	but	B300	CC	O	O
have	have	H100	VBP	B-VP	O
decreased	decrease	D262	VBN	I-VP	O
affinities	affinity	A153	NNS	B-NP	O
for	for	F600	IN	B-PP	O
iodide	iodide	I300	NN	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
Gly	Gly	G400	NN	B-NP	O
230	230	0000	CD	I-NP	O
is	be	I200	VBZ	B-VP	O
critical	critical	C632	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
ion	ion	I500	NN	I-NP	O
conductance	conductance	C532	NN	I-NP	O
in	in	I500	IN	B-PP	O
hClC	hClC	H242	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
residue	residue	R230	NN	I-NP	O
resides	reside	R232	VBZ	B-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
channel	channel	C540	NN	I-NP	O
pore	pore	P600	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
PAX6	PAX6	P200	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
simple	simple	S514	JJ	B-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
:	:	0000	:	O	O
an	an	A500	DT	B-NP	O
evaluation	evaluation	E143	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
detection	detection	D323	NN	I-NP	O
in	in	I500	IN	B-PP	O
12	12	0000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

Twelve	Twelve	T410	CD	B-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
five	five	F100	CD	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
history	history	H236	NN	I-NP	O
and	and	A530	CC	O	O
seven	seven	S150	CD	B-NP	O
presumed	presume	P625	VBN	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
sporadic	sporadic	S163	JJ	B-ADJP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
exhaustively	exhaustively	E231	RB	I-VP	O
screened	screen	S265	VBN	I-VP	O
in	in	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
test	test	T230	VB	I-VP	O
what	what	W300	WP	B-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
people	people	P140	NNS	B-NP	O
with	with	W300	IN	B-PP	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
,	,	0000	,	O	O
uncomplicated	uncomplicate	U525	VBN	B-VP	O
by	by	B000	IN	B-PP	O
associated	associate	A230	VBN	B-NP	O
anomalies	anomaly	A542	NNS	I-NP	O
,	,	0000	,	O	O
carry	carry	C600	VBP	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
PAX6	PAX6	P200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
90	90	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
mutation	mutation	M350	NN	I-NP	O
detection	detection	D323	NN	I-NP	O
techniques	technique	T252	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
if	if	I100	IN	B-SBAR	O
one	one	O500	CD	B-NP	O
method	method	M300	NN	I-NP	O
was	be	W200	VBD	B-VP	O
superior	superior	S160	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
truncation	truncation	T652	NN	I-NP	O
test	test	T230	NN	I-NP	O
(	(	0000	(	O	O
PTT	PTT	P300	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
on	on	O500	IN	B-PP	O
RT	RT	R300	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
PCR	PCR	P260	NN	I-NP	O
products	product	P632	NNS	I-NP	O
,	,	0000	,	O	O
SSCP	SSCP	S210	NN	B-NP	O
on	on	O500	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
PCR	PCR	P260	NN	I-NP	O
amplifications	amplification	A514	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
chemical	chemical	C524	JJ	B-NP	O
cleavage	cleavage	C412	NN	I-NP	O
of	of	O100	IN	B-PP	O
mismatch	mismatch	M253	NN	B-NP	O
on	on	O500	IN	B-PP	O
both	both	B300	CC	O	O
RT	RT	R300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
PCR	PCR	P260	NN	I-NP	O
and	and	A530	CC	O	O
genomic	genomic	G520	JJ	B-NP	O
amplifications	amplification	A514	NNS	I-NP	O
.	.	0000	.	O	O

For	For	F600	IN	B-PP	O
RT	RT	R300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
PCR	PCR	P260	NN	I-NP	O
products	product	P632	NNS	I-NP	O
,	,	0000	,	O	O
only	only	O540	RB	B-NP	O
the	the	T000	DT	I-NP	O
translated	translate	T652	VBN	I-NP	O
portion	portion	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
screened	screen	S265	VBN	I-VP	O
.	.	0000	.	O	O

On	On	O500	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
products	product	P632	NNS	I-NP	O
exons	exon	E252	NNS	I-NP	O
1	1	0000	CD	B-NP	O
to	to	T000	TO	B-PP	O
13	13	0000	CD	B-NP	O
(	(	0000	(	O	O
including	include	I524	VBG	B-PP	O
740	740	0000	CD	B-NP	O
bp	bp	B100	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
untranslated	untranslated	U536	JJ	I-NP	O
sequence	sequence	S252	NN	I-NP	O
and	and	A530	CC	O	O
all	all	A400	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
/	/	0000	SYM	B-VP	O
exon	exon	E250	NN	B-NP	O
boundaries	boundary	B536	NNS	I-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
screened	screen	S265	VBN	I-VP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
neuroretina	neuroretina	N635	NN	I-NP	O
specific	specific	S121	JJ	I-NP	O
enhancer	enhancer	E526	NN	I-NP	O
in	in	I500	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
4	4	0000	CD	I-NP	O
.	.	0000	.	O	O

Ten	Ten	T500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
possible	possible	P214	JJ	I-NP	O
12	12	0000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
five	five	F100	CD	I-NP	O
familial	familial	F540	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
and	and	A530	CC	O	O
five	five	F100	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
sporadic	sporadic	S163	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
,	,	0000	,	O	O
all	all	A400	DT	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
conformed	conform	C516	VBD	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
functional	functional	F523	JJ	I-NP	O
outcome	outcome	O325	NN	I-NP	O
of	of	O100	IN	B-PP	O
haploinsufficiency	haploinsufficiency	H145	NN	B-NP	O
.	.	0000	.	O	O

Five	Five	F100	CD	B-NP	O
were	be	W600	VBD	B-VP	O
splice	splice	S142	NN	B-NP	O
site	site	S300	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
(	(	0000	(	O	O
one	one	O500	CD	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
donor	donor	D560	NN	I-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
4	4	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
two	two	T000	CD	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
donor	donor	D560	NN	I-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
6	6	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
one	one	O500	CD	I-NP	O
in	in	I500	IN	B-PP	O
each	each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
acceptor	acceptor	A213	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
introns	intron	I536	NNS	B-NP	O
8	8	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
9	9	0000	CD	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
five	five	F100	CD	B-NP	O
were	be	W600	VBD	B-VP	O
nonsense	nonsense	N525	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
8	8	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
9	9	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
10	10	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
11	11	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
12	12	0000	CD	B-NP	O
.	.	0000	.	O	O

SSCP	SSCP	S210	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
individually	individually	I531	RB	B-NP	O
amplified	amplify	A514	VBN	I-NP	O
exons	exon	E252	NNS	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
which	which	W200	WDT	B-NP	O
nine	nine	N500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
10	10	0000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
seen	see	S500	VBN	I-VP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
useful	useful	U214	JJ	I-NP	O
detection	detection	D323	NN	I-NP	O
method	method	M300	NN	I-NP	O
for	for	F600	IN	B-PP	O
PAX6	PAX6	P200	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Insulin	Insulin	I524	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
region	region	R250	NN	I-NP	O
contributes	contribute	C536	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
to	to	T000	TO	B-PP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
may	may	M000	MD	B-VP	O
not	not	N300	RB	O	O
to	to	T000	TO	B-PP	O
low	low	L000	JJ	B-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
,	,	0000	,	O	O
insulin	insulin	I524	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
dependent	dependent	D153	JJ	I-NP	I-Disease
diabetes	diabetes	D132	NN	I-NP	I-Disease
mellitus	mellitus	M432	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
Japanese	Japanese	J152	NNPS	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Caucasian	Caucasian	C250	JJ	I-NP	O
population	population	P143	NN	I-NP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
insulin	insulin	I524	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
INS	INS	I520	NN	B-NP	O
)	)	0000	)	O	O
region	region	R250	NN	B-NP	O
contains	contain	C535	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
insulin	insulin	I524	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
dependent	dependent	D153	JJ	I-NP	I-Disease
diabetes	diabetes	D132	NN	I-NP	I-Disease
mellitus	mellitus	M432	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
(	(	0000	(	O	O
IDDM2	IDDM2	I350	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
population	population	P143	NN	I-NP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
no	no	N000	DT	B-NP	O
report	report	R163	NN	I-NP	O
demonstrating	demonstrate	D523	VBG	B-VP	O
the	the	T000	DT	B-NP	O
contribution	contribution	C536	NN	I-NP	O
of	of	O100	IN	B-PP	O
IDDM2	IDDM2	I350	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
of	of	O100	IN	B-PP	O
IDDM	IDDM	I350	NN	B-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conducted	conduct	C532	VBD	B-VP	O
an	an	A500	DT	B-NP	O
association	association	A235	NN	I-NP	O
study	study	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
IDDM	IDDM	I350	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
subjects	subject	S123	NNS	I-NP	O
with	with	W300	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
in	in	I500	IN	B-PP	O
INS	INS	I520	NN	B-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
association	association	A235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
INS	INS	I520	NN	I-NP	O
region	region	R250	NN	I-NP	O
with	with	W300	IN	B-PP	O
IDDM	IDDM	I350	NN	B-NP	B-Disease
.	.	0000	.	O	O

Alleles	Allele	A420	NNS	B-NP	O
positively	positively	P231	RB	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
IDDM	IDDM	I350	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
INS	INS	I520	NN	B-NP	O
region	region	R250	NN	I-NP	O
were	be	W600	VBD	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
as	as	A200	IN	B-PP	O
those	those	T200	DT	B-NP	O
positively	positively	P231	RB	B-NP	O
-	-	0000	HYPH	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
IDDM	IDDM	I350	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
Caucasian	Caucasian	C250	JJ	B-NP	O
population	population	P143	NN	I-NP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
positively	positively	P231	RB	B-ADVP	O
-	-	0000	HYPH	O	O
associated	associate	A230	VBN	B-NP	O
alleles	allele	A420	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
very	very	V600	RB	B-ADJP	O
common	common	C500	JJ	I-ADJP	O
(	(	0000	(	O	O
allele	allele	A400	NN	B-NP	O
frequencies	frequency	F625	NNS	I-NP	O
>	>	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
9	9	0000	CD	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
general	general	G564	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
IDDM2	IDDM2	I350	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
to	to	T000	TO	B-PP	O
IDDM	IDDM	I350	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
Japanese	Japanese	J152	NNPS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
frequencies	frequency	F625	NNS	I-NP	O
of	of	O100	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
associated	associate	A230	VBN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
general	general	G564	JJ	I-NP	O
population	population	P143	NN	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
IDDM2	IDDM2	I350	NN	B-NP	O
locus	locus	L200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
low	low	L000	JJ	I-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
IDDM	IDDM	I350	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
Japanese	Japanese	J152	NNPS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
complement	complement	C514	NN	I-NP	O
C9	C9	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
:	:	0000	:	O	O
identification	identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
causing	cause	C252	VBG	B-VP	O
deficiency	deficiency	D125	NN	B-NP	O
and	and	A530	CC	I-NP	O
revision	revision	R125	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
structure	structure	S362	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ninth	ninth	N530	JJ	I-NP	O
component	component	C515	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
complement	complement	C514	NN	I-NP	O
(	(	0000	(	O	O
C9	C9	C000	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
last	last	L230	JJ	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
complement	complement	C514	NN	I-NP	O
components	component	C515	NNS	I-NP	O
creating	create	C635	VBG	B-VP	O
the	the	T000	DT	B-NP	O
membrane	membrane	M516	NN	I-NP	O
attack	attack	A320	NN	I-NP	O
complex	complex	C514	NN	I-NP	O
.	.	0000	.	O	O

C9	C9	C000	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
serum	serum	S650	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
encoded	encode	E523	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
located	locate	L230	VBN	B-VP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
5p	5p	P000	NN	I-NP	O
.	.	0000	.	O	O

Deficiency	Deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
terminal	terminal	T654	JJ	B-NP	I-Disease
complement	complement	C514	NN	I-NP	I-Disease
components	component	C515	NNS	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
generally	generally	G564	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
recurrent	recurrent	R265	JJ	B-NP	O
neisseria	neisseria	N260	NN	I-NP	B-Disease
infections	infection	I512	NNS	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
studied	study	S300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
described	describe	D261	VBN	I-NP	O
Swiss	Swiss	S200	JJ	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
inherited	inherit	I563	VBN	B-NP	B-Disease
C9	C9	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
C9	C9	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
developed	develop	D141	VBD	B-VP	O
an	an	A500	DT	B-NP	O
approach	approach	A162	NN	I-NP	O
using	use	U252	VBG	B-VP	O
exon	exon	E250	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
PCR	PCR	P260	NN	I-NP	O
and	and	A530	CC	O	O
direct	direct	D623	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
sequencing	sequencing	S252	NN	I-NP	O
.	.	0000	.	O	O

As	As	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
C9	C9	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
two	two	T000	CD	B-NP	O
different	different	D165	JJ	I-NP	O
point	point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
both	both	B300	DT	B-NP	O
generating	generate	G563	VBG	I-NP	O
TGA	TGA	T200	NN	I-NP	O
stop	stop	S310	NN	I-NP	O
codons	codon	C352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
sequence	sequence	S252	NN	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
C	C	C000	NN	I-NP	O
to	to	T000	TO	B-PP	O
A	A	A000	NN	B-NP	O
exchange	exchange	E252	NN	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
2	2	0000	CD	I-NP	O
at	at	A300	IN	B-PP	O
cDNA	cDNA	C350	NN	B-NP	O
position	position	P235	NN	I-NP	O
166	166	0000	CD	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
C	C	C000	NN	I-NP	O
to	to	T000	TO	B-PP	O
T	T	T000	NN	B-NP	O
exchange	exchange	E252	NN	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
located	locate	L230	VBN	I-VP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
4	4	0000	CD	I-NP	O
(	(	0000	(	O	O
cDNA	cDNA	C350	NN	B-NP	O
position	position	P235	NN	I-NP	O
464	464	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
family	family	F540	NN	B-NP	O
studies	study	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
three	three	T600	CD	B-NP	O
first	first	F623	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
degree	degree	D260	NN	I-NP	O
relatives	relative	R431	NNS	I-NP	O
with	with	W300	IN	B-PP	O
heterozygous	heterozygous	H362	JJ	B-NP	O
C9	C9	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
segregating	segregate	S262	VBG	I-VP	O
independently	independently	I531	RB	B-ADVP	O
.	.	0000	.	O	O

Therefore	Therefore	T616	RB	B-ADVP	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
sufficient	sufficient	S125	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
explain	explain	E214	VB	I-VP	O
the	the	T000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
deficiency	deficiency	D125	NN	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	PDT	O	O
the	the	T000	DT	B-NP	O
probands	proband	P615	NNS	I-NP	O
studied	study	S300	VBN	B-VP	O
.	.	0000	.	O	O

DNA	DNA	D500	NN	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
intron	intron	I536	NN	I-NP	O
junctions	junction	J523	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
revisions	revision	R125	NNS	B-NP	O
regarding	regard	R263	VBG	B-VP	O
the	the	T000	DT	B-NP	O
boundaries	boundary	B536	NNS	I-NP	O
between	between	B350	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
4	4	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
5	5	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
6	6	0000	CD	B-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
between	between	B350	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
10	10	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
11	11	0000	CD	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
additional	additional	A354	JJ	I-NP	O
introns	intron	I536	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
6	6	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
10	10	0000	CD	I-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
DNA	DNA	D500	NN	B-NP	O
marker	marker	M626	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
conducted	conduct	C532	VBN	I-VP	O
using	use	U252	VBG	B-VP	O
known	known	K500	JJ	B-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
C6	C6	C000	NN	I-NP	O
,	,	0000	,	O	O
C7	C7	C000	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
C9	C9	C000	NN	B-NP	O
genes	gene	G520	NNS	I-NP	O
,	,	0000	,	O	O
confirming	confirm	C516	VBG	B-VP	O
the	the	T000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
observed	observe	O126	VBN	I-NP	O
C9	C9	C000	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
with	with	W300	IN	B-PP	O
defined	define	D153	VBN	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
women	woman	W500	NNS	B-NP	O
attending	attend	A353	VBG	B-VP	O
clinics	clinic	C452	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
evaluate	evaluate	E143	VBP	B-VP	O
the	the	T000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

BACKGROUND	BACKGROUND	B265	NN	B-NP	O
To	To	T000	TO	B-VP	O
define	define	D150	VB	I-VP	O
the	the	T000	DT	B-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
among	among	A520	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
seen	see	S500	VBN	B-VP	O
in	in	I500	IN	B-PP	O
clinics	clinic	C452	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
evaluate	evaluate	E143	VBP	B-VP	O
the	the	T000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
analyzed	analyze	A542	VBD	B-VP	O
DNA	DNA	D500	NN	B-NP	O
samples	sample	S514	NNS	I-NP	O
from	from	F650	IN	B-PP	O
women	woman	W500	NNS	B-NP	O
seen	see	S500	VBN	B-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
setting	set	S352	VBG	I-NP	O
and	and	A530	CC	I-NP	O
constructed	construct	C523	VBN	I-NP	O
probability	probability	P614	NN	I-NP	O
tables	table	T142	NNS	I-NP	O
to	to	T000	TO	B-VP	O
provide	provide	P613	VB	I-VP	O
estimates	estimate	E235	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
likelihood	likelihood	L243	NN	I-NP	O
of	of	O100	IN	B-PP	O
finding	find	F535	VBG	B-VP	O
a	a	A000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
individual	individual	I531	JJ	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

METHODS	METHODS	M320	NNS	B-NP	O
Clinical	Clinical	C452	JJ	I-NP	O
information	information	I516	NN	I-NP	O
,	,	0000	,	O	O
family	family	F540	NN	B-NP	O
histories	history	H236	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
blood	blood	B430	NN	B-NP	O
for	for	F600	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
were	be	W600	VBD	B-VP	O
obtained	obtain	O135	VBN	I-VP	O
from	from	F650	IN	B-PP	O
263	263	0000	CD	B-NP	O
women	woman	W500	NNS	I-NP	O
with	with	W300	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Conformation	Conformation	C516	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
sensitive	sensitive	S523	JJ	I-NP	O
gel	gel	G400	NN	I-NP	O
electrophoresis	electrophoresis	E423	NN	I-NP	O
and	and	A530	CC	O	O
DNA	DNA	D500	NN	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
were	be	W600	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
16	16	0000	CD	B-NP	O
percent	percent	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
women	woman	W500	NNS	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Only	Only	O540	RB	B-NP	O
7	7	0000	CD	I-NP	O
percent	percent	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
women	woman	W500	NNS	B-NP	O
from	from	F650	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
but	but	B300	CC	B-CONJP	O
not	not	N300	RB	I-CONJP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
had	have	H300	VBD	B-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
rates	rate	R320	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
higher	high	H260	JJR	B-ADJP	O
among	among	A520	IN	B-PP	O
women	woman	W500	NNS	B-NP	O
from	from	F650	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	CC	O	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Among	Among	A520	IN	B-PP	O
family	family	F540	NN	B-NP	O
members	member	M516	NNS	I-NP	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
average	average	A162	JJ	I-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
less	less	L200	JJR	B-NP	O
than	than	T500	IN	I-NP	O
55	55	0000	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
woman	woman	W500	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
ancestry	ancestry	A523	NN	I-NP	O
were	be	W600	VBD	B-VP	O
all	all	A400	DT	O	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
detecting	detect	D323	VBG	B-VP	O
a	a	A000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
association	association	A235	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
bilateral	bilateral	B436	JJ	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
or	or	O600	CC	O	O
the	the	T000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
position	position	P235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

CONCLUSIONS	CONCLUSIONS	C524	NNS	B-NP	O
Among	Among	A520	IN	B-PP	O
women	woman	W500	NNS	B-NP	O
with	with	W300	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
percentage	percentage	P625	NN	I-NP	O
with	with	W300	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
coding	coding	C352	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
region	region	R250	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
less	less	L200	JJR	B-ADJP	O
than	than	T500	IN	B-PP	O
the	the	T000	DT	B-NP	O
45	45	0000	CD	I-NP	O
percent	percent	P625	NN	I-NP	O
predicted	predict	P632	VBN	B-VP	O
by	by	B000	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
linkage	linkage	L520	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
even	even	E150	RB	B-PP	O
in	in	I500	IN	I-PP	O
a	a	A000	DT	B-NP	O
referral	referral	R164	JJ	I-NP	O
clinic	clinic	C452	NN	I-NP	O
specializing	specialize	S124	VBG	B-VP	O
in	in	I500	IN	B-PP	O
screening	screen	S265	VBG	B-VP	O
women	woman	W500	NNS	B-NP	O
from	from	F650	IN	B-PP	O
high	high	H200	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
risk	risk	R200	NN	I-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
tests	test	T232	NNS	B-NP	O
for	for	F600	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
will	will	W400	MD	B-VP	O
be	be	B000	VB	I-VP	O
negative	negative	N231	JJ	B-ADJP	O
and	and	A530	CC	O	O
therefore	therefore	T616	RB	B-ADJP	O
uninformative	uninformative	U516	JJ	I-ADJP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
arginine	arginine	A625	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
rich	rich	R200	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
ARP	ARP	A610	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
pancreatic	pancreatic	P526	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ARP	ARP	A610	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
conserved	conserve	C526	VBN	I-NP	O
arginine	arginine	A625	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
rich	rich	R200	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
from	from	F650	IN	B-PP	O
chromosomal	chromosomal	C652	JJ	B-NP	O
band	band	B530	NN	I-NP	O
3p21	3p21	P000	NN	I-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

At	At	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
cytogenetic	cytogenetic	C325	JJ	I-NP	O
level	level	L140	NN	I-NP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
frequently	frequently	F625	RB	I-VP	O
deleted	delete	D430	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
different	different	D165	JJ	B-NP	O
solid	solid	S430	JJ	I-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
not	not	N300	RB	O	O
in	in	I500	IN	B-PP	O
pancreatic	pancreatic	P526	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
reported	report	R163	VBN	I-VP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
ATG50	ATG50	A320	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
AGG	AGG	A200	NN	I-NP	O
)	)	0000	)	O	O
or	or	O600	CC	O	O
deletion	deletion	D435	NN	B-NP	O
of	of	O100	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
50	50	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ARP	ARP	A610	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
different	different	D165	JJ	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
types	type	T120	NNS	I-NP	I-Disease
(	(	0000	(	O	O
Shridhar	Shridhar	S636	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	FW	I-NP	O
,	,	0000	,	O	O
1996	1996	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
1996a	1996a	A000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
observed	observe	O126	VBN	I-VP	O
mutations	mutation	M352	NNS	B-NP	O
involving	involve	I514	VBG	B-VP	O
codon	codon	C350	NN	B-NP	O
50	50	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
11	11	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
37	37	0000	CD	B-NP	O
pancreatic	pancreatic	P526	JJ	I-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
50	50	0000	CD	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
roughly	roughly	R240	RB	B-NP	O
the	the	T000	DT	I-NP	O
same	same	S500	JJ	I-NP	O
in	in	I500	IN	B-PP	O
pancreatic	pancreatic	P526	JJ	B-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
as	as	A200	IN	B-PP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
tumors	tumor	T562	NNS	B-NP	B-Disease
previously	previously	P612	RB	B-VP	O
examined	examine	E253	VBN	I-VP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
detected	detect	D323	VBN	I-VP	O
mutations	mutation	M352	NNS	B-NP	O
at	at	A300	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
51	51	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
PCR	PCR	P260	NN	I-NP	O
subclones	subclone	S124	NNS	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
other	other	O360	JJ	I-NP	O
pancreatic	pancreatic	P526	JJ	I-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ARP	ARP	A610	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
are	be	A600	VBP	B-VP	O
thus	thus	T200	RB	I-VP	O
commonly	commonly	C540	RB	I-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
pancreatic	pancreatic	P526	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
many	many	M500	JJ	B-NP	O
other	other	O360	JJ	I-NP	O
cancers	cancer	C526	NNS	I-NP	B-Disease
.	.	0000	.	O	O

Difficulties	Difficulty	D124	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ascertainment	ascertainment	A263	NN	I-NP	O
of	of	O100	IN	B-PP	O
C9	C9	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
:	:	0000	:	O	O
lessons	lesson	L252	NNS	B-NP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
drawn	draw	D650	VBN	I-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
compound	compound	C515	NN	I-NP	O
heterozygote	heterozygote	H362	NN	I-NP	O
C9	C9	C000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
subject	subject	S123	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
long	long	L520	RB	B-ADVP	O
-	-	0000	HYPH	O	O
surviving	survive	S615	VBG	B-VP	O
mismatched	mismatch	M253	VBN	B-NP	O
kidney	kidney	K350	NN	I-NP	O
allografts	allograft	A426	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
investigated	investigate	I512	VBN	I-VP	O
for	for	F600	IN	B-PP	O
complement	complement	C514	NN	B-NP	O
function	function	F523	NN	I-NP	O
using	use	U252	VBG	B-VP	O
haemolytic	haemolytic	H543	JJ	B-NP	O
assays	assay	A200	NNS	I-NP	O
in	in	I500	IN	B-PP	O
agarose	agarose	A262	NN	B-NP	O
gels	gel	G420	NNS	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
patient	patient	P353	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
no	no	N000	DT	B-NP	O
alternative	alternative	A436	JJ	I-NP	O
pathway	pathway	P300	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
but	but	B300	CC	O	O
a	a	A000	DT	B-NP	O
low	low	L000	JJ	I-NP	O
normal	normal	N654	JJ	I-NP	O
classical	classical	C424	JJ	I-NP	O
pathway	pathway	P300	NN	I-NP	O
.	.	0000	.	O	O

Surprisingly	Surprisingly	S616	RB	B-ADVP	O
,	,	0000	,	O	O
investigation	investigation	I512	NN	B-NP	O
revealed	reveal	R143	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
complement	complement	C514	NN	I-NP	O
was	be	W200	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
all	all	A400	DT	B-NP	O
components	component	C515	NNS	I-NP	O
except	except	E213	IN	B-PP	O
C9	C9	C000	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
functionally	functionally	F523	RB	B-ADJP	O
absent	absent	A125	JJ	I-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
was	be	W200	VBD	B-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
markers	marker	M626	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
C6	C6	C000	NN	I-NP	O
,	,	0000	,	I-NP	O
C7	C7	C000	NN	I-NP	O
and	and	A530	CC	I-NP	O
C9	C9	C000	NN	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
5	5	0000	CD	I-NP	O
and	and	A530	CC	O	O
therefore	therefore	T616	RB	B-VP	O
appears	appear	A162	VBZ	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
compound	compound	C515	NN	I-NP	O
heterozygote	heterozygote	H362	NN	I-NP	O
for	for	F600	IN	B-PP	O
two	two	T000	CD	B-NP	O
uncharacterized	uncharacterized	U526	JJ	I-NP	O
C9	C9	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

Serological	Serological	S642	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
by	by	B000	IN	B-PP	O
ELISA	ELISA	E420	NN	B-NP	O
revealed	reveal	R143	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
he	he	H000	PRP	B-NP	O
has	have	H200	VBZ	B-VP	O
trace	trace	T620	NN	B-NP	O
concentrations	concentration	C525	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
functional	functional	F523	JJ	I-NP	O
C9	C9	C000	NN	I-NP	O
molecule	molecule	M424	NN	I-NP	O
.	.	0000	.	O	O

Western	Western	W236	NN	B-NP	O
blot	blot	B430	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	O	O
sufficiently	sufficiently	S125	RB	B-ADJP	O
sensitive	sensitive	S523	JJ	I-ADJP	O
to	to	T000	TO	B-VP	O
permit	permit	P653	VB	I-VP	O
detection	detection	D323	NN	B-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
molecule	molecule	M424	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
hypothesize	hypothesize	H132	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
C9	C9	C000	NN	B-NP	I-Disease
and	and	A530	CC	B-PP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
directing	direct	D623	VBG	B-VP	O
hyposynthesis	hyposynthesis	H125	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
defective	defective	D123	JJ	I-NP	O
C9	C9	C000	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
also	also	A420	RB	B-ADVP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
C9	C9	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
more	more	M600	RBR	B-ADJP	O
common	common	C500	JJ	I-ADJP	O
among	among	A520	IN	B-PP	O
Caucasians	Caucasian	C252	NNPS	B-NP	O
than	than	T500	IN	B-SBAR	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Screening	Screening	S265	NN	B-NP	O
for	for	F600	IN	B-PP	O
ESR	ESR	E260	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
leukocyte	leukocyte	L230	NN	B-NP	O
DNA	DNA	D500	NN	I-NP	O
from	from	F650	IN	B-PP	O
143	143	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
familial	familial	F540	JJ	B-NP	O
clustering	clustering	C423	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
/	/	0000	SYM	B-NP	I-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	O	O
tumour	tumour	T560	NN	B-NP	B-Disease
DNA	DNA	D500	NN	I-NP	O
from	from	F650	IN	B-PP	O
96	96	0000	CD	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
screened	screen	S265	VBN	I-VP	O
for	for	F600	IN	B-PP	O
base	base	B200	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
estrogen	estrogen	E236	NN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
ESR	ESR	E260	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
were	be	W600	VBD	B-VP	O
carrying	carry	C652	VBG	I-VP	O
a	a	A000	DT	B-NP	O
Gly160Cys	Gly160Cys	G420	NN	I-NP	O
germline	germline	G654	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
alteration	alteration	A436	NN	I-NP	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
(	(	0000	(	O	O
four	four	F600	CD	B-NP	O
females	female	F542	NNS	I-NP	O
and	and	A530	CC	O	O
four	four	F600	CD	B-NP	O
males	male	M420	NNS	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
729	729	0000	CD	B-NP	O
controls	control	C536	NNS	I-NP	O
(	(	0000	(	O	O
366	366	0000	CD	B-NP	O
female	female	F540	JJ	I-NP	O
,	,	0000	,	O	O
363	363	0000	CD	B-NP	O
males	male	M420	NNS	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
substitution	substitution	S123	NN	I-NP	O
probably	probably	P614	RB	B-ADVP	O
represents	represent	R162	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
229	229	0000	CD	I-NP	O
female	female	F540	JJ	I-NP	O
controls	control	C536	NNS	I-NP	O
in	in	I500	IN	B-PP	O
whom	whom	W500	WP	B-NP	O
family	family	F540	NN	B-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
was	be	W200	VBD	B-VP	O
known	know	K500	VBN	I-VP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
who	who	W000	WP	B-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
sister	sister	S236	NN	I-NP	O
with	with	W300	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
carrying	carry	C652	VBG	I-VP	O
the	the	T000	DT	B-NP	O
variant	variant	V653	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

Hence	Hence	H520	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
possible	possible	P214	JJ	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
significance	significance	S251	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
glycine	glycine	G425	NN	I-NP	O
into	into	I530	IN	B-PP	O
cysteine	cysteine	C235	NN	B-NP	O
cannot	cannot	C530	MD	B-VP	O
be	be	B000	VB	I-VP	O
completely	completely	C514	RB	I-VP	O
ruled	rule	R430	VBN	I-VP	O
out	out	O300	RP	B-PRT	O
and	and	A530	CC	O	O
should	should	S430	MD	B-VP	O
be	be	B000	VB	I-VP	O
further	further	F636	RBR	B-ADJP	O
investigated	investigate	I512	VBN	I-ADJP	O
.	.	0000	.	O	O

Somatic	Somatic	S532	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
not	not	N300	RB	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
any	any	A500	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
tumours	tumour	T562	NNS	I-NP	B-Disease
studied	study	S300	VBN	B-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
data	datum	D300	NNS	I-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
provide	provide	P613	VB	I-VP	O
support	support	S163	NN	B-NP	O
for	for	F600	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
ESR	ESR	E260	NN	I-NP	O
base	base	B200	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
important	important	I516	JJ	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
for	for	F600	IN	B-PP	O
hormonal	hormonal	H654	JJ	B-NP	O
therapy	therapy	T610	NN	I-NP	O
resistance	resistance	R235	NN	I-NP	O
in	in	I500	IN	B-PP	O
estrogen	estrogen	E236	NN	B-NP	B-Disease
receptor	receptor	R213	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
positive	positive	P231	JJ	I-NP	I-Disease
breast	breast	B623	NN	I-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
bases	base	B200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
C7	C7	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
:	:	0000	:	O	O
three	three	T600	CD	B-NP	O
different	different	D165	JJ	I-NP	O
defects	defect	D123	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
C7	C7	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
investigated	investigate	I512	VBN	I-VP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
Irish	Irish	I620	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
Israeli	Israeli	I264	JJ	B-NP	O
families	family	F542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Moroccan	Moroccan	M625	NNP	B-NP	O
Sephardic	Sephardic	S163	NNP	I-NP	O
Jewish	Jewish	J200	NNP	I-NP	O
origin	origin	O625	NN	I-NP	O
.	.	0000	.	O	O

Exon	Exon	E250	NN	B-NP	O
PCR	PCR	P260	NN	I-NP	O
and	and	A530	CC	I-NP	O
sequencing	sequencing	S252	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
point	point	P530	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
splice	splice	S142	NN	I-NP	O
acceptor	acceptor	A213	NN	I-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
1	1	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
Irish	Irish	I620	JJ	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
Irish	Irish	I620	JJ	I-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
exons	exon	E252	NNS	B-NP	O
7	7	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
8	8	0000	CD	I-NP	O
failed	fail	F430	VBD	B-VP	O
to	to	T000	TO	I-VP	O
amplify	amplify	A514	VB	I-VP	O
and	and	A530	CC	O	O
they	they	T000	PRP	B-NP	O
were	be	W600	VBD	B-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
deleted	delete	D430	VBN	I-VP	O
.	.	0000	.	O	O

Marker	Marker	M626	NN	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
C6	C6	C000	NN	I-NP	O
and	and	A530	CC	I-NP	O
C7	C7	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
region	region	R250	NN	I-NP	O
and	and	A530	CC	O	O
Southern	Southern	S365	JJ	B-NP	O
blots	blot	B432	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
Irish	Irish	I620	JJ	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
also	also	A420	RB	B-ADVP	O
segregate	segregate	S262	VBP	B-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
easily	easily	E240	RB	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
heterozygotes	heterozygote	H362	NNS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Israeli	Israeli	I264	JJ	I-NP	O
C7	C7	C000	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
deficient	deficient	D125	JJ	B-NP	I-Disease
cases	case	C200	NNS	I-NP	O
all	all	A400	DT	B-ADVP	O
share	share	S600	VBP	B-VP	O
a	a	A000	DT	B-NP	O
C7	C7	C000	NN	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
and	and	A530	CC	O	O
are	be	A600	VBP	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
mis	mis	M200	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
sense	sense	S520	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
9	9	0000	CD	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
individual	individual	I531	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
markers	marker	M626	NNS	B-NP	O
at	at	A300	IN	B-PP	O
adjacent	adjacent	A325	JJ	B-NP	O
C6	C6	C000	NN	I-NP	O
loci	locus	L200	NNS	I-NP	O
,	,	0000	,	O	O
showing	show	S520	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
an	an	A500	DT	B-NP	O
intergenic	intergenic	I536	JJ	I-NP	O
recombination	recombination	R251	NN	I-NP	O
and	and	A530	CC	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
of	of	O100	IN	B-PP	O
appreciable	appreciable	A162	JJ	B-NP	O
antiquity	antiquity	A532	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
of	of	O100	IN	B-PP	O
classical	classical	C424	JJ	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
Duarte	Duarte	D630	JJ	I-NP	I-Disease
galactosemia	galactosemia	G423	NN	I-NP	I-Disease
:	:	0000	:	O	O
mutation	mutation	M350	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
by	by	B000	IN	B-PP	O
denaturing	denature	D536	VBG	B-VP	O
gradient	gradient	G635	NN	B-NP	O
gel	gel	G400	NN	I-NP	O
electrophoresis	electrophoresis	E423	NN	I-NP	O
.	.	0000	.	O	O

Classical	Classical	C424	JJ	B-NP	B-Disease
galactosemia	galactosemia	G423	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
one	one	O500	CD	B-NP	O
common	common	C500	JJ	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
Q188R	Q188R	Q600	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
by	by	B000	IN	B-PP	O
several	several	S164	JJ	B-NP	O
rare	rare	R600	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
galactose	galactose	G423	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
uridyltransferase	uridyltransferase	U634	NN	I-NP	O
(	(	0000	(	O	O
GALT	GALT	G430	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
of	of	O100	IN	B-PP	O
GALT	GALT	G430	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
Duarte	Duarte	D630	NNP	I-NP	O
variant	variant	V653	NN	I-NP	O
,	,	0000	,	O	O
occurs	occur	O262	VBZ	B-VP	O
as	as	A200	IN	B-PP	O
two	two	T000	CD	B-NP	O
types	type	T120	NNS	I-NP	O
,	,	0000	,	O	O
Duarte	Duarte	D630	NNP	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
(	(	0000	(	O	O
D	D	D000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
Duarte	Duarte	D630	NN	B-NP	O
-	-	0000	HYPH	O	O
2	2	0000	CD	B-NP	O
(	(	0000	(	O	O
D	D	D000	NN	B-NP	O
-	-	0000	HYPH	O	O
2	2	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
both	both	B300	DT	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
carry	carry	C600	VBP	B-VP	O
the	the	T000	DT	B-NP	O
sequence	sequence	S252	NN	I-NP	O
change	change	C520	NN	I-NP	O
N314D	N314D	N300	NN	I-NP	O
.	.	0000	.	O	O

D	D	D000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
increases	increase	I526	NNS	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
D	D	D000	NN	B-NP	O
-	-	0000	HYPH	O	O
2	2	0000	CD	B-NP	O
decreases	decrease	D262	VBZ	B-VP	O
GALT	GALT	G430	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
study	study	S300	VB	I-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
genetics	genetic	G532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
classical	classical	C424	JJ	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
Duarte	Duarte	D630	JJ	I-NP	I-Disease
galactosemia	galactosemia	G423	NN	I-NP	I-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
analyzed	analyze	A542	VBD	B-VP	O
the	the	T000	DT	B-NP	O
GALT	GALT	G430	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
30	30	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
classical	classical	C424	JJ	B-NP	B-Disease
galactosemia	galactosemia	G423	NN	I-NP	I-Disease
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
10	10	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
D	D	D000	NN	I-NP	O
-	-	0000	HYPH	O	O
2	2	0000	CD	B-NP	O
variant	variant	V653	NN	I-NP	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
3	3	0000	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
carrying	carry	C652	VBG	B-VP	O
the	the	T000	DT	B-NP	O
D	D	D000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
allele	allele	A400	NN	I-NP	O
by	by	B000	IN	B-PP	O
denaturing	denature	D536	VBG	B-VP	O
gradient	gradient	G635	NN	B-NP	O
gel	gel	G400	NN	I-NP	O
electrophoresis	electrophoresis	E423	NN	I-NP	O
(	(	0000	(	O	O
DGGE	DGGE	D200	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

DGGE	DGGE	D200	NN	B-NP	O
detected	detect	D323	VBD	B-VP	O
59	59	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
60	60	0000	CD	I-NP	O
classical	classical	C424	JJ	I-NP	O
galactosemia	galactosemia	G423	NN	I-NP	B-Disease
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

Q188R	Q188R	Q600	NN	B-NP	O
accounted	account	A253	VBD	B-VP	O
for	for	F600	IN	B-PP	O
60	60	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
,	,	0000	,	O	O
K285N	K285N	K500	NN	B-NP	O
accounted	account	A253	VBD	B-VP	O
for	for	F600	IN	B-PP	O
28	28	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

Eight	Eight	E230	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
candidate	candidate	C530	NN	I-NP	O
galactosemia	galactosemia	G423	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
.	.	0000	.	O	O

On	On	O500	IN	B-PP	O
all	all	A400	DT	B-NP	O
D	D	D000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
2	2	0000	CD	I-NP	O
alleles	allele	A420	NNS	I-NP	O
N314D	N314D	N300	NN	I-NP	O
occurred	occur	O263	VBD	B-VP	O
in	in	I500	IN	B-PP	O
cis	cis	C200	NN	B-NP	O
with	with	W300	IN	B-PP	O
two	two	T000	CD	B-NP	O
intronic	intronic	I536	JJ	I-NP	O
sequence	sequence	S252	NN	I-NP	O
changes	change	C520	NNS	I-NP	O
,	,	0000	,	O	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
D	D	D000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
alleles	allele	A420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
cis	cis	C200	NN	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
neutral	neutral	N364	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
7	7	0000	CD	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
causing	cause	C252	VBG	B-VP	O
galactosemia	galactosemia	G423	NN	B-NP	B-Disease
are	be	A600	VBP	B-VP	O
highly	highly	H240	RB	B-ADJP	O
heterogeneous	heterogeneous	H362	JJ	I-ADJP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
K285N	K285N	K500	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
common	common	C500	JJ	I-NP	O
galactosemia	galactosemia	G423	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Isolation	Isolation	I243	NN	B-NP	O
of	of	O100	IN	B-PP	O
full	full	F400	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
length	length	L523	NN	I-NP	O
ATM	ATM	A350	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
and	and	A530	CC	I-NP	O
correction	correction	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
cellular	cellular	C460	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
mutated	mutate	M300	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
(	(	0000	(	O	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
ATM	ATM	A350	NN	B-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
recently	recently	R253	RB	I-VP	O
identified	identify	I353	VBN	I-VP	O
by	by	B000	IN	B-PP	O
positional	positional	P235	JJ	B-NP	O
cloning	cloning	C452	NN	I-NP	O
.	.	0000	.	O	O

ATM	ATM	A350	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
member	member	M516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
phosphatidylinositol	phosphatidylinositol	P213	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kinase	kinase	K520	NN	I-NP	O
superfamily	superfamily	S161	NN	I-NP	O
,	,	0000	,	O	O
some	some	S500	DT	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
protein	protein	P635	NN	B-NP	O
kinases	kinase	K520	NNS	I-NP	O
and	and	A530	CC	O	O
appear	appear	A160	VBP	B-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
important	important	I516	JJ	B-NP	O
roles	role	R420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
cell	cell	C400	NN	B-NP	O
cycle	cycle	C240	NN	I-NP	O
control	control	C536	NN	I-NP	O
and	and	A530	CC	O	O
radiation	radiation	R350	NN	B-NP	O
signal	signal	S254	NN	I-NP	O
transduction	transduction	T652	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
herein	herein	H650	RB	B-ADVP	O
,	,	0000	,	O	O
to	to	T000	TO	B-PP	O
our	our	O600	PRP$	B-NP	O
knowledge	knowledge	K543	NN	I-NP	O
,	,	0000	,	O	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
time	time	T500	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
cloning	cloning	C452	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
full	full	F400	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
length	length	L523	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
for	for	F600	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
and	and	A530	CC	I-NP	O
correction	correction	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
aspects	aspect	A212	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
radio	radio	R300	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
sensitive	sensitive	S523	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
of	of	O100	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
cells	cell	C420	NNS	I-NP	O
by	by	B000	IN	B-PP	O
transfection	transfection	T652	NN	B-NP	O
with	with	W300	IN	B-PP	O
this	this	T200	DT	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
.	.	0000	.	O	O

Overexpression	Overexpression	O162	NN	B-NP	O
of	of	O100	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
in	in	I500	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
cells	cell	C420	NNS	I-NP	O
enhanced	enhance	E523	VBD	B-VP	O
the	the	T000	DT	B-NP	O
survival	survival	S614	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
cells	cell	C420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
response	response	R215	NN	I-PP	O
to	to	T000	TO	I-PP	O
radiation	radiation	R350	NN	B-NP	O
exposure	exposure	E212	NN	I-NP	O
,	,	0000	,	O	O
decreased	decrease	D262	VBD	B-VP	O
radiation	radiation	R350	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
induced	induce	I532	VBN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
aberrations	aberration	A163	NNS	I-NP	O
,	,	0000	,	O	O
reduced	reduce	R323	VBD	B-VP	O
radio	radio	R300	AFX	B-NP	O
-	-	0000	HYPH	B-NP	O
resistant	resistant	R235	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
synthesis	synthesis	S532	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
partially	partially	P634	RB	B-VP	O
corrected	correct	C623	VBN	I-VP	O
defective	defective	D123	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
cycle	cycle	C240	NN	I-NP	O
checkpoints	checkpoint	C215	NNS	I-NP	O
and	and	A530	CC	O	O
induction	induction	I532	NN	B-NP	O
of	of	O100	IN	B-PP	O
stress	stress	S362	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
activated	activate	A231	VBN	I-NP	O
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
correction	correction	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
defects	defect	D123	NNS	I-NP	O
in	in	I500	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
cells	cell	C420	NNS	I-NP	O
provides	provide	P613	VBZ	B-VP	O
further	far	F636	JJR	B-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
multiplicity	multiplicity	M431	NN	I-NP	O
of	of	O100	IN	B-PP	O
effector	effector	E123	NN	B-NP	O
functions	function	F523	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
and	and	A530	CC	O	O
suggests	suggest	S232	VBZ	B-VP	O
possible	possible	P214	JJ	B-NP	O
approaches	approach	A162	NNS	I-NP	O
to	to	T000	TO	B-PP	O
gene	gene	G500	NN	B-NP	O
therapy	therapy	T610	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Fusion	Fusion	F250	NN	B-NP	O
genes	gene	G520	NNS	I-NP	O
resulting	result	R243	VBG	B-VP	O
from	from	F650	IN	B-PP	O
alternative	alternative	A436	JJ	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
translocations	translocation	T652	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
overexpressed	overexpresse	O162	VBN	I-VP	O
by	by	B000	IN	B-PP	O
gene	gene	G500	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
in	in	I500	IN	B-PP	O
alveolar	alveolar	A414	JJ	B-NP	B-Disease
rhabdomyosarcoma	rhabdomyosarcoma	R135	NN	I-NP	I-Disease
.	.	0000	.	O	O

Chromosomal	Chromosomal	C652	JJ	B-NP	O
translocations	translocation	T652	NNS	I-NP	O
identified	identify	I353	VBN	B-VP	O
in	in	I500	IN	B-PP	O
hematopoietic	hematopoietic	H531	JJ	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
solid	solid	S430	JJ	I-NP	I-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
deregulated	deregulate	D624	VBN	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
protooncogenes	protooncogene	P635	NNS	B-NP	O
or	or	O600	CC	O	O
creation	creation	C635	NN	B-NP	O
of	of	O100	IN	B-PP	O
chimeric	chimeric	C562	JJ	B-NP	O
proteins	protein	P635	NNS	I-NP	O
with	with	W300	IN	B-PP	O
tumorigenic	tumorigenic	T562	JJ	B-NP	O
potential	potential	P353	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
pediatric	pediatric	P362	JJ	I-NP	O
solid	solid	S430	JJ	I-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
alveolar	alveolar	A414	JJ	I-NP	B-Disease
rhabdomyosarcoma	rhabdomyosarcoma	R135	NN	I-NP	I-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
consistent	consistent	C523	JJ	I-NP	O
t	t	T000	NN	I-NP	O
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
;	;	0000	:	O	O
13	13	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
q35	q35	Q000	NN	B-NP	O
;	;	0000	:	O	O
q14	q14	Q000	NN	B-NP	O
)	)	0000	)	O	O
or	or	O600	CC	O	O
variant	variant	V653	JJ	B-NP	O
t	t	T000	NN	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
;	;	0000	:	O	O
13	13	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
p36	p36	P000	NN	B-NP	O
;	;	0000	:	O	O
q14	q14	Q000	NN	B-NP	O
)	)	0000	)	O	O
translocation	translocation	T652	NN	B-NP	O
generates	generate	G563	VBZ	B-VP	O
PAX3	PAX3	P200	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
FKHR	FKHR	F260	NN	I-NP	O
or	or	O600	CC	I-NP	O
PAX7	PAX7	P200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
FKHR	FKHR	F260	NN	I-NP	O
fusion	fusion	F250	NN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
report	report	R163	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
in	in	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
to	to	T000	TO	B-PP	O
functional	functional	F523	JJ	B-NP	O
alterations	alteration	A436	NNS	I-NP	O
these	these	T200	DT	B-NP	O
translocations	translocation	T652	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
fusion	fusion	F250	NN	B-NP	O
product	product	P632	NN	I-NP	O
overexpression	overexpression	O162	NN	I-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
PAX3	PAX3	P200	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
FKHR	FKHR	F260	NN	I-NP	O
and	and	A530	CC	I-NP	O
PAX7	PAX7	P200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
FKHR	FKHR	F260	NN	I-NP	O
overexpression	overexpression	O162	NN	I-NP	O
occurs	occur	O262	VBZ	B-VP	O
by	by	B000	IN	B-PP	O
distinct	distinct	D235	JJ	B-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
.	.	0000	.	O	O

Transcription	Transcription	T652	NN	B-NP	O
of	of	O100	IN	B-PP	O
PAX3	PAX3	P200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
FKHR	FKHR	F260	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
increased	increase	I526	VBN	I-VP	O
relative	relative	R431	JJ	B-ADVP	O
to	to	T000	TO	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
PAX3	PAX3	P200	NN	I-NP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
copy	copy	C100	NN	I-NP	O
number	number	N516	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
independent	independent	I531	JJ	I-NP	O
process	process	P620	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
PAX7	PAX7	P200	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
FKHR	FKHR	F260	NN	I-NP	O
overexpression	overexpression	O162	NN	I-NP	O
results	result	R243	VBZ	B-VP	O
from	from	F650	IN	B-PP	O
fusion	fusion	F250	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
amplification	amplification	A514	NN	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
gene	gene	G500	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
selected	select	S423	VBN	I-VP	O
to	to	T000	TO	I-VP	O
overexpress	overexpress	O162	VB	I-VP	O
PAX3	PAX3	P200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
FKHR	FKHR	F260	NN	I-NP	O
and	and	A530	CC	I-NP	O
PAX7	PAX7	P200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
FKHR	FKHR	F260	NN	I-NP	O
in	in	I500	IN	B-PP	O
alveolar	alveolar	A414	JJ	B-NP	B-Disease
rhabdomyosarcoma	rhabdomyosarcoma	R135	NN	I-NP	I-Disease
,	,	0000	,	O	O
presumably	presumably	P625	RB	B-ADJP	O
due	due	D000	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
differences	difference	D165	NNS	B-NP	O
in	in	I500	IN	B-PP	O
regulation	regulation	R243	NN	B-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
loci	locus	L200	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
postulate	postulate	P234	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
overexpression	overexpression	O162	NN	I-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
ensure	ensure	E526	VBP	B-VP	O
a	a	A000	DT	B-NP	O
critical	critical	C632	JJ	I-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
gene	gene	G500	NN	B-NP	O
product	product	P632	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
oncogenic	oncogenic	O525	JJ	I-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
fusions	fusion	F252	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

atm	atm	A350	NN	B-NP	O
and	and	A530	CC	I-NP	O
p53	p53	P000	NN	I-NP	O
cooperate	cooperate	C163	VBP	B-VP	O
in	in	I500	IN	B-PP	O
apoptosis	apoptosis	A132	NN	B-NP	O
and	and	A530	CC	I-NP	O
suppression	suppression	S162	NN	I-NP	O
of	of	O100	IN	B-PP	O
tumorigenesis	tumorigenesis	T562	NN	B-NP	O
,	,	0000	,	B-PP	O
but	but	B300	CC	I-PP	O
not	not	N300	RB	B-PP	O
in	in	I500	IN	I-PP	O
resistance	resistance	R235	NN	B-NP	O
to	to	T000	TO	B-PP	O
acute	acute	A230	JJ	B-NP	B-Disease
radiation	radiation	R350	NN	I-NP	I-Disease
toxicity	toxicity	T230	NN	I-NP	I-Disease
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
atm	atm	A350	NN	B-NP	O
and	and	A530	CC	I-NP	O
p53	p53	P000	NN	I-NP	O
cause	cause	C200	VBP	B-VP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
associated	associate	A230	VBN	I-NP	I-Disease
diseases	disease	D200	NNS	I-NP	I-Disease
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
and	and	A530	CC	O	O
Li	Li	L000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Fraumeni	Fraumeni	F650	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
genes	gene	G520	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
believed	believe	B413	VBN	I-VP	O
to	to	T000	TO	I-VP	O
interact	interact	I536	VB	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
pathways	pathway	P320	NNS	B-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
regulation	regulation	R243	NN	B-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
damage	damage	D520	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
induced	induce	I532	VBN	B-NP	O
cell	cell	C400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
cycle	cycle	C240	NN	I-NP	O
checkpoints	checkpoint	C215	NNS	I-NP	O
,	,	0000	,	O	O
apoptosis	apoptosis	A132	NN	B-NP	O
and	and	A530	CC	I-NP	O
radiation	radiation	R350	NN	I-NP	O
sensitivity	sensitivity	S523	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
cellular	cellular	C460	JJ	B-NP	O
proliferation	proliferation	P641	NN	I-NP	O
.	.	0000	.	O	O

Atm	Atm	A350	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
null	null	N400	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
those	those	T200	DT	B-NP	O
null	null	N400	NN	I-NP	O
for	for	F600	IN	B-PP	O
p53	p53	P000	NN	B-NP	O
,	,	0000	,	O	O
develop	develop	D141	VBP	B-VP	O
mainly	mainly	M540	RB	B-ADVP	O
T	T	T000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
lymphomas	lymphoma	L515	NNS	I-NP	I-Disease
,	,	0000	,	O	O
supporting	support	S163	VBG	B-VP	O
the	the	T000	DT	B-NP	O
view	view	V000	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
genes	gene	G520	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
similar	similar	S546	JJ	B-NP	O
roles	role	R420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
thymocyte	thymocyte	T523	NN	B-NP	O
development	development	D141	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
study	study	S300	VB	I-VP	O
the	the	T000	DT	B-NP	O
interactions	interaction	I536	NNS	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
genes	gene	G520	NNS	I-NP	O
on	on	O500	IN	B-PP	O
an	an	A500	DT	B-NP	O
organismal	organismal	O625	JJ	I-NP	O
level	level	L140	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
bred	breed	B630	VBD	B-VP	O
mice	mouse	M200	NNS	B-NP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
null	null	N400	JJ	B-NP	O
alleles	allele	A420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	CC	O	O
atm	atm	A350	NN	B-NP	O
and	and	A530	CC	O	O
p53	p53	P000	NN	B-NP	O
to	to	T000	TO	B-VP	O
produce	produce	P632	VB	I-VP	O
all	all	A400	DT	B-NP	O
genotypic	genotypic	G531	JJ	I-NP	O
combinations	combination	C515	NNS	I-NP	O
.	.	0000	.	O	O

Mice	Mouse	M200	NNS	B-NP	O
doubly	doubly	D140	RB	B-ADJP	O
null	null	N400	JJ	I-ADJP	O
for	for	F600	IN	B-PP	O
atm	atm	A350	NN	B-NP	O
and	and	A530	CC	I-NP	O
p53	p53	P000	NN	I-NP	O
exhibited	exhibit	E213	VBD	B-VP	O
a	a	A000	DT	B-NP	O
dramatic	dramatic	D653	JJ	I-NP	O
acceleration	acceleration	A246	NN	I-NP	O
of	of	O100	IN	B-PP	O
tumour	tumour	T560	NN	B-NP	B-Disease
formation	formation	F653	NN	I-NP	O
relative	relative	R431	JJ	B-ADVP	O
to	to	T000	TO	B-PP	O
singly	singly	S524	RB	B-NP	O
null	null	N400	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
both	both	B300	DT	B-NP	O
genes	gene	G520	NNS	I-NP	O
collaborate	collaborate	C416	VBP	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
manner	manner	M560	NN	I-NP	O
to	to	T000	TO	B-VP	O
prevent	prevent	P615	VB	I-VP	O
tumorigenesis	tumorigenesis	T562	NN	B-NP	O
.	.	0000	.	O	O

With	With	W300	IN	B-PP	O
respect	respect	R212	NN	B-NP	O
to	to	T000	TO	B-PP	O
their	their	T600	PRP$	B-NP	O
roles	role	R420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
apoptosis	apoptosis	A132	NN	B-NP	O
,	,	0000	,	O	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
atm	atm	A350	NN	B-NP	O
rendered	rendered	R536	JJ	I-NP	O
thymocytes	thymocyte	T523	NNS	I-NP	O
only	only	O540	RB	B-ADJP	O
partly	partly	P634	RB	I-ADJP	O
resistant	resistant	R235	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
irradiation	irradiation	I635	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
induced	induce	I532	VBN	I-NP	O
apoptosis	apoptosis	A132	NN	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
additional	additional	A354	JJ	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
p53	p53	P000	NN	B-NP	O
engendered	engender	E525	VBD	B-VP	O
complete	complete	C514	JJ	B-NP	O
resistance	resistance	R235	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
implies	imply	I514	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
irradiation	irradiation	I635	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
induced	induce	I532	VBN	I-NP	O
atm	atm	A350	NN	I-NP	O
and	and	A530	CC	I-NP	O
p53	p53	P000	NN	I-NP	O
apoptotic	apoptotic	A132	JJ	I-NP	O
pathways	pathway	P320	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
not	not	N300	RB	O	O
completely	completely	C514	RB	B-ADJP	O
congruent	congruent	C526	JJ	I-ADJP	O
.	.	0000	.	O	O

Finally	Finally	F540	RB	B-ADVP	O
-	-	0000	HYPH	B-ADJP	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
to	to	T000	TO	B-PP	O
prior	prior	P600	JJ	B-NP	O
predictions	prediction	P632	NNS	I-NP	O
-	-	0000	HYPH	B-NP	O
atm	atm	A350	NN	I-NP	O
and	and	A530	CC	I-NP	O
p53	p53	P000	NN	I-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
appear	appear	A160	VB	I-VP	O
to	to	T000	TO	I-VP	O
interact	interact	I536	VB	I-VP	O
in	in	I500	IN	B-PP	O
acute	acute	A230	JJ	B-NP	B-Disease
radiation	radiation	R350	NN	I-NP	I-Disease
toxicity	toxicity	T230	NN	I-NP	I-Disease
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
a	a	A000	DT	B-NP	O
separate	separate	S163	JJ	I-NP	O
atm	atm	A350	NN	I-NP	O
effector	effector	E123	NN	I-NP	O
pathway	pathway	P300	NN	I-NP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
damage	damage	D520	NN	I-NP	O
response	response	R215	NN	I-NP	O
and	and	A530	CC	O	O
having	have	H152	VBG	B-VP	O
implications	implication	I514	NNS	B-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
prognosis	prognosis	P625	NN	I-NP	O
and	and	A530	CC	I-NP	O
treatment	treatment	T635	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
tumours	tumour	T562	NNS	I-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Trinucleotide	Trinucleotide	T652	NN	B-NP	O
repeat	repeat	R130	NN	I-NP	O
expansion	expansion	E215	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
reduces	reduce	R320	VBZ	B-VP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
DMAHP	DMAHP	D510	NN	B-NP	O
.	.	0000	.	O	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
,	,	0000	,	O	O
or	or	O600	CC	O	O
dystrophia	dystrophia	D236	NN	B-NP	B-Disease
myotonica	myotonica	M352	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
multisystem	multisystem	M432	NN	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
expansion	expansion	E215	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
untranslated	untranslated	U536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMPK	DMPK	D512	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
19q13	19q13	Q000	CD	I-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
(	(	0000	(	O	O
refs	ref	R120	NNS	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
3	3	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
five	five	F100	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
ago	ago	A200	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
pathogenic	pathogenic	P325	JJ	I-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
underlying	underlie	U536	VBG	B-VP	O
this	this	T200	DT	B-NP	O
most	most	M230	RBS	I-NP	O
prevalent	prevalent	P614	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	O
adult	adult	A343	JJ	I-NP	O
neuromuscular	neuromuscular	N652	JJ	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
remain	remain	R500	VBP	B-VP	O
elusive	elusive	E421	JJ	B-ADJP	O
.	.	0000	.	O	O

Previous	Previous	P612	JJ	B-NP	O
work	work	W620	NN	I-NP	O
from	from	F650	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
laboratory	laboratory	L163	NN	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
DNase	DNase	D520	NN	I-NP	O
l	l	L000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
hypersensitive	hypersensitive	H162	JJ	I-NP	O
site	site	S300	NN	I-NP	O
located	located	L230	JJ	I-NP	O
adjacent	adjacent	A325	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
eliminated	eliminate	E453	VBN	I-VP	O
by	by	B000	IN	B-PP	O
repeat	repeat	R130	NN	B-NP	O
expansion	expansion	E215	NN	I-NP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
large	large	L620	JJ	B-NP	O
CTG	CTG	C320	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
repeat	repeat	R130	NN	I-NP	O
arrays	array	A620	NNS	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
local	local	L240	JJ	I-NP	O
chromatin	chromatin	C653	NN	I-NP	O
environment	environment	E516	NN	I-NP	O
that	that	T300	WDT	B-NP	O
represses	repress	R162	VBZ	B-VP	O
gene	gene	G500	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
hypersensitive	hypersensitive	H162	JJ	I-NP	O
site	site	S300	NN	I-NP	O
contains	contain	C535	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
enhancer	enhancer	E526	NN	I-NP	O
element	element	E453	NN	I-NP	O
that	that	T300	WDT	B-NP	O
regulates	regulate	R243	VBZ	B-VP	O
transcription	transcription	T652	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
adjacent	adjacent	A325	JJ	I-NP	O
DMAHP	DMAHP	D510	NN	I-NP	O
homeobox	homeobox	H512	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
DMAHP	DMAHP	D510	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
cells	cell	C420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
hypersensitive	hypersensitive	H162	JJ	I-NP	O
site	site	S300	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
two	two	T000	CD	I-NP	O
-	-	0000	HYPH	B-ADVP	O
to	to	T000	TO	B-PP	O
fourfold	fourfold	F614	JJ	B-NP	O
reduction	reduction	R323	NN	I-NP	O
in	in	I500	IN	B-PP	O
steady	steady	S300	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
state	state	S300	NN	I-NP	O
DMAHP	DMAHP	D510	NN	I-NP	O
transcript	transcript	T652	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
relative	relative	R431	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
controls	control	C536	NNS	I-NP	O
.	.	0000	.	O	O

Allele	Allele	A400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
specific	specific	S121	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
DMAHP	DMAHP	D510	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
steady	steady	S300	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
state	state	S300	NN	I-NP	O
transcript	transcript	T652	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
allele	allele	A400	NN	I-NP	O
were	be	W600	VBD	B-VP	O
greatly	greatly	G634	RB	I-VP	O
reduced	reduce	R323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
comparison	comparison	C516	NN	B-NP	O
to	to	T000	TO	B-PP	O
those	those	T200	DT	B-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

Together	Together	T236	RB	B-ADVP	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
CTG	CTG	C320	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
repeat	repeat	R130	NN	I-NP	O
expansions	expansion	E215	NNS	I-NP	O
can	can	C500	MD	B-VP	O
suppress	suppress	S162	VB	I-VP	O
local	local	L240	JJ	B-NP	O
gene	gene	G500	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
and	and	A530	CC	O	O
implicate	implicate	I514	VBP	B-VP	O
DMAHP	DMAHP	D510	NN	B-NP	O
in	in	I500	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
pathogenesis	pathogenesis	P325	NN	I-NP	O
.	.	0000	.	O	O

Constitutively	Constitutively	C523	RB	B-NP	O
methylated	methylate	M343	VBN	I-NP	O
CpG	CpG	C120	NN	I-NP	O
dinucleotides	dinucleotide	D524	NNS	I-NP	O
as	as	A200	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
hot	hot	H300	JJ	I-NP	O
spots	spot	S132	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
retinoblastoma	retinoblastoma	R351	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
RB1	RB1	R100	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
wide	wide	W300	JJ	I-NP	O
spectrum	spectrum	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
,	,	0000	,	O	O
ranging	range	R525	VBG	B-VP	O
from	from	F650	IN	B-PP	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
to	to	T000	TO	B-PP	O
large	large	L620	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
,	,	0000	,	O	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
retinoblastoma	retinoblastoma	R351	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
RB1	RB1	R100	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
throughout	throughout	T623	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
;	;	0000	:	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
alterations	alteration	A436	NNS	I-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
appear	appear	A160	VB	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
homogeneously	homogeneously	H525	RB	I-VP	O
distributed	distribute	D236	VBN	I-VP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
particular	particular	P632	JJ	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
-	-	0000	HYPH	O	O
causing	cause	C252	VBG	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
premature	premature	P653	JJ	I-NP	O
termination	termination	T653	NN	I-NP	O
of	of	O100	IN	B-PP	O
protein	protein	P635	NN	B-NP	O
synthesis	synthesis	S532	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
occur	occur	O260	VBP	B-VP	O
as	as	A200	IN	B-PP	O
C	C	C000	NN	B-NP	O
-	-	0000	HYPH	O	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
T	T	T000	NN	I-NP	O
transitions	transition	T652	NNS	I-NP	O
at	at	A300	IN	B-PP	O
CpG	CpG	C120	NN	B-NP	O
dinucleotides	dinucleotide	D524	NNS	I-NP	O
(	(	0000	(	O	O
CpGs	CpG	C120	NNS	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Such	Such	S200	JJ	B-NP	O
recurrent	recurrent	R265	JJ	I-NP	O
CpG	CpG	C120	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
those	those	T200	DT	B-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
RB1	RB1	R100	NN	B-NP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
likely	likely	L240	JJ	B-ADJP	O
the	the	T000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
deamination	deamination	D535	NN	I-NP	O
of	of	O100	IN	B-PP	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
methylcytosine	methylcytosine	M342	NN	I-NP	O
within	within	W350	IN	B-PP	O
these	these	T200	DT	B-NP	O
CpGs	CpG	C120	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
used	use	U230	VBD	B-VP	O
the	the	T000	DT	B-NP	O
sodiumbisulfite	sodiumbisulfite	S351	JJ	I-NP	O
conversion	conversion	C516	NN	I-NP	O
method	method	M300	NN	I-NP	O
to	to	T000	TO	B-VP	O
detect	detect	D323	VB	I-VP	O
cytosine	cytosine	C325	NN	B-NP	O
methylation	methylation	M343	NN	I-NP	O
in	in	I500	IN	B-PP	O
representative	representative	R162	JJ	B-NP	O
exons	exon	E252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
RB1	RB1	R100	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
analyzed	analyze	A542	VBD	B-VP	O
DNA	DNA	D500	NN	B-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
tissues	tissue	T200	NNS	B-NP	O
and	and	A530	CC	O	O
specifically	specifically	S121	RB	B-NP	O
targeted	target	T623	VBN	I-NP	O
CGA	CGA	C200	NN	I-NP	O
codons	codon	C352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
RB1	RB1	R100	NN	B-NP	O
,	,	0000	,	O	O
where	where	W600	WRB	B-ADVP	O
recurrent	recurrent	R265	JJ	B-NP	O
premature	premature	P653	JJ	I-NP	O
termination	termination	T653	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
DNA	DNA	D500	NN	B-NP	O
methylation	methylation	M343	NN	I-NP	O
within	within	W350	IN	B-PP	O
RB1	RB1	R100	NN	B-NP	O
exons	exon	E252	NNS	I-NP	O
8	8	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
14	14	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
25	25	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
27	27	0000	CD	B-NP	O
appeared	appear	A163	VBD	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
restricted	restrict	R236	VBN	I-VP	O
to	to	T000	TO	B-PP	O
CpGs	CpG	C120	NNS	B-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
six	six	S200	CD	B-NP	O
CGA	CGA	C200	NN	I-NP	O
codons	codon	C352	NNS	I-NP	O
.	.	0000	.	O	O

Other	Other	O360	JJ	B-NP	O
codons	codon	C352	NNS	I-NP	O
containing	contain	C535	VBG	B-VP	O
methylated	methylate	M343	VBN	B-NP	O
cytosines	cytosine	C325	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
mutated	mutate	M300	VBN	I-VP	O
.	.	0000	.	O	O

Therefore	Therefore	T616	RB	B-ADVP	O
,	,	0000	,	O	O
disease	disease	D200	NN	B-NP	O
-	-	0000	HYPH	O	O
causing	cause	C252	VBG	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
at	at	A300	IN	B-PP	O
CpGs	CpG	C120	NNS	B-NP	O
in	in	I500	IN	B-PP	O
RB1	RB1	R100	NN	B-NP	O
appear	appear	A160	VBP	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
determined	determine	D365	VBN	I-VP	O
by	by	B000	IN	B-PP	O
several	several	S164	JJ	B-NP	O
factors	factor	F236	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
the	the	T000	DT	B-NP	O
constitutive	constitutive	C523	JJ	I-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
methylation	methylation	M343	NN	I-NP	O
at	at	A300	IN	B-PP	O
cytosines	cytosine	C325	NNS	B-NP	O
within	within	W350	IN	B-PP	O
CpGs	CpG	C120	NNS	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
codon	codon	C350	NN	I-NP	O
within	within	W350	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
methylated	methylate	M343	VBN	I-NP	O
cytosine	cytosine	C325	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
located	located	L230	JJ	B-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
particular	particular	P632	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
within	within	W350	IN	B-PP	O
which	which	W200	WDT	B-NP	O
that	that	T300	DT	B-NP	O
codon	codon	C350	NN	I-NP	O
resides	reside	R232	VBZ	B-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
von	von	V500	NNP	I-NP	B-Disease
Hippel	Hippel	H140	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lindau	Lindau	L530	NNP	I-NP	I-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
interacts	interact	I536	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
Sp1	Sp1	S100	NN	B-NP	O
to	to	T000	TO	B-VP	O
repress	repress	R162	VB	I-VP	O
vascular	vascular	V246	JJ	B-NP	O
endothelial	endothelial	E534	JJ	I-NP	O
growth	growth	G630	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
promoter	promoter	P653	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
von	von	V500	NNP	I-NP	B-Disease
Hippel	Hippel	H140	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lindau	Lindau	L530	NNP	I-NP	I-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
VHL	VHL	V400	NN	B-NP	O
)	)	0000	)	O	O
has	have	H200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
critical	critical	C632	JJ	I-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
of	of	O100	IN	B-PP	O
clear	clear	C460	JJ	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
renal	renal	R540	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
(	(	0000	(	O	O
RCC	RCC	R200	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
VHL	VHL	V400	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
both	both	B300	DT	B-NP	O
von	von	V500	NNP	B-NP	B-Disease
Hippel	Hippel	H140	NNP	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
Lindau	Lindau	L530	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
-	-	0000	HYPH	B-VP	I-Disease
associated	associate	A230	VBN	B-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
sporadic	sporadic	S163	JJ	I-NP	I-Disease
RCCs	RCC	R200	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Recent	Recent	R253	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
vascular	vascular	V246	JJ	B-NP	O
endothelial	endothelial	E534	JJ	I-NP	O
growth	growth	G630	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
(	(	0000	(	O	O
VEGF	VEGF	V210	NN	B-NP	O
)	)	0000	)	O	O
mRNA	mRNA	M650	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
upregulated	upregulate	U162	VBN	I-VP	O
in	in	I500	IN	B-PP	O
RCC	RCC	R200	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
and	and	A530	CC	O	I-Disease
von	von	V500	NNP	B-NP	I-Disease
Hippel	Hippel	H140	NNP	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
Lindau	Lindau	L530	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
associated	associate	A230	VBN	I-NP	I-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
therefore	therefore	T616	RB	I-VP	O
assessed	assess	A230	VBN	I-VP	O
the	the	T000	DT	B-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
on	on	O500	IN	B-PP	O
VEGF	VEGF	V210	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
.	.	0000	.	O	O

VEGF	VEGF	V210	NN	B-NP	O
promoter	promoter	P653	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
luciferase	luciferase	L216	NN	I-NP	O
constructs	construct	C523	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
transiently	transiently	T652	RB	I-VP	O
cotransfected	cotransfecte	C365	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
VHL	VHL	V400	NN	I-NP	O
(	(	0000	(	O	O
wt	wt	W300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
VHL	VHL	V400	NN	I-NP	O
)	)	0000	)	O	O
vector	vector	V236	NN	B-NP	O
in	in	I500	IN	B-PP	O
several	several	S164	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
293	293	0000	CD	B-NP	O
embryonic	embryonic	E516	JJ	I-NP	O
kidney	kidney	K350	NN	I-NP	O
and	and	A530	CC	I-NP	O
RCC	RCC	R200	NN	I-NP	B-Disease
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
.	.	0000	.	O	O

wt	wt	W300	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
VHL	VHL	V400	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
inhibited	inhibit	I513	VBD	B-VP	O
VEGF	VEGF	V210	NN	B-NP	O
promoter	promoter	P653	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
dose	dose	D200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
manner	manner	M560	NN	I-NP	O
up	up	U100	IN	B-NP	O
to	to	T000	TO	I-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
to	to	T000	TO	B-PP	O
10	10	0000	CD	B-NP	O
-	-	0000	HYPH	O	O
fold	fold	F430	RB	B-ADVP	O
.	.	0000	.	O	O

Deletion	Deletion	D435	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
defined	define	D153	VBD	B-VP	O
a	a	A000	DT	B-NP	O
144	144	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
VEGF	VEGF	V210	NN	I-NP	O
promoter	promoter	P653	NN	I-NP	O
necessary	necessary	N260	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
VHL	VHL	V400	NN	B-NP	O
repression	repression	R162	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
responsive	responsive	R215	JJ	I-NP	O
element	element	E453	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
GC	GC	G200	NN	B-NP	O
rich	rich	R200	JJ	B-ADJP	O
and	and	A530	CC	O	O
specifically	specifically	S121	RB	B-VP	O
binds	bind	B532	VBZ	I-VP	O
the	the	T000	DT	B-NP	O
transcription	transcription	T652	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
Sp1	Sp1	S100	NN	I-NP	O
in	in	I500	IN	B-PP	O
crude	crude	C630	JJ	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
extracts	extract	E236	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
Drosophila	Drosophila	D621	NN	B-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
cotransfected	cotransfecte	C365	VBN	B-NP	O
VHL	VHL	V400	NN	I-NP	O
represses	repress	R162	VBZ	B-VP	O
Sp1	Sp1	S100	NN	B-NP	O
-	-	0000	HYPH	O	O
mediated	mediate	M300	VBN	B-NP	O
activation	activation	A231	NN	I-NP	O
but	but	B300	CC	B-CONJP	O
not	not	N300	RB	I-CONJP	O
basal	basal	B240	JJ	B-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
VEGF	VEGF	V210	NN	I-NP	O
promoter	promoter	P653	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
next	next	N230	RB	B-ADVP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
in	in	I500	IN	B-PP	O
coimmunoprecipitates	coimmunoprecipitate	C516	NNS	B-NP	O
that	that	T300	IN	B-SBAR	O
VHL	VHL	V400	NN	B-NP	O
and	and	A530	CC	I-NP	O
Sp1	Sp1	S100	NN	I-NP	O
were	be	W600	VBD	B-VP	O
part	part	P630	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
complex	complex	C514	NN	I-NP	O
and	and	A530	CC	O	O
,	,	0000	,	O	O
by	by	B000	IN	B-PP	O
using	use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
glutathione	glutathione	G435	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
S	S	S000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
transferase	transferase	T652	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
VHL	VHL	V400	NN	I-NP	O
fusion	fusion	F250	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
and	and	A530	CC	O	O
purified	purify	P613	VBN	B-NP	O
Sp1	Sp1	S100	NN	I-NP	O
,	,	0000	,	O	O
that	that	T300	IN	B-SBAR	O
VHL	VHL	V400	NN	B-NP	O
and	and	A530	CC	I-NP	O
Sp1	Sp1	S100	NN	I-NP	O
directly	directly	D623	RB	B-ADVP	O
interact	interact	I536	VBP	B-VP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
endogenous	endogenous	E532	JJ	B-NP	O
VEGF	VEGF	V210	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
suppressed	suppress	S162	VBN	I-VP	O
in	in	I500	IN	B-PP	O
permanent	permanent	P653	JJ	B-NP	O
RCC	RCC	R200	NN	I-NP	B-Disease
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
expressing	express	E216	VBG	B-VP	O
wt	wt	W300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
VHL	VHL	V400	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
nuclear	nuclear	N246	JJ	B-NP	O
run	run	R500	NN	I-NP	O
-	-	0000	HYPH	B-ADVP	O
on	on	O500	IN	B-PP	O
studies	study	S320	NNS	B-NP	O
indicated	indicate	I532	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
VHL	VHL	V400	NN	B-NP	O
regulation	regulation	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
VEGF	VEGF	V210	NN	B-NP	O
occurs	occur	O262	VBZ	B-VP	O
at	at	A300	IN	B-ADVP	O
least	least	L230	JJS	I-ADVP	O
partly	partly	P634	RB	B-ADVP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
transcriptional	transcriptional	T652	JJ	I-NP	O
level	level	L140	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
observations	observation	O126	NNS	I-NP	O
support	support	S163	VBP	B-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
for	for	F600	IN	B-PP	O
VHL	VHL	V400	NN	B-NP	O
-	-	0000	HYPH	O	O
mediated	mediate	M300	VBN	B-VP	O
transcriptional	transcriptional	T652	JJ	B-NP	O
repression	repression	R162	NN	I-NP	O
via	via	V000	IN	B-PP	O
a	a	A000	DT	B-NP	O
direct	direct	D623	JJ	I-NP	O
inhibitory	inhibitory	I513	JJ	I-NP	O
action	action	A235	NN	I-NP	O
on	on	O500	IN	B-PP	O
Sp1	Sp1	S100	NN	B-NP	O
and	and	A530	CC	O	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
Sp1	Sp1	S100	NN	B-NP	O
inhibition	inhibition	I513	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
important	important	I516	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
of	of	O100	IN	B-PP	O
von	von	V500	NNP	B-NP	B-Disease
Hippel	Hippel	H140	NNP	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
Lindau	Lindau	L530	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
RCC	RCC	R200	NN	I-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Adult	Adult	A343	JJ	B-NP	B-Disease
onset	onset	O523	NN	I-NP	I-Disease
globoid	globoid	G413	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
leukodystrophy	leukodystrophy	L232	NN	I-NP	I-Disease
(	(	0000	(	O	O
Krabbe	Krabbe	K610	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
)	)	0000	)	O	O
:	:	0000	:	O	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
galactosylceramidase	galactosylceramidase	G423	NN	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
from	from	F650	IN	B-PP	O
four	four	F600	CD	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
examined	examine	E253	VBD	B-VP	O
galactosylceramidase	galactosylceramidase	G423	NN	B-NP	O
(	(	0000	(	O	O
GALC	GALC	G420	NN	B-NP	O
)	)	0000	)	O	O
cDNA	cDNA	C350	NN	B-NP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
adult	adult	A343	JJ	B-NP	B-Disease
onset	onset	O523	NN	I-NP	I-Disease
globoid	globoid	G413	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
leukodystrophy	leukodystrophy	L232	NN	I-NP	I-Disease
(	(	0000	(	O	O
Krabbe	Krabbe	K610	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
;	;	0000	:	O	O
AO	AO	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
GLD	GLD	G430	NN	I-NP	I-Disease
)	)	0000	)	O	O
by	by	B000	IN	B-PP	O
polymerase	polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
/	/	0000	SYM	B-NP	O
single	single	S524	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
(	(	0000	(	O	O
PCR	PCR	P260	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
SSCP	SSCP	S210	NN	I-NP	O
)	)	0000	)	O	O
analysis	analysis	A542	NN	B-NP	O
,	,	0000	,	O	O
subsequent	subsequent	S125	JJ	B-NP	O
sequence	sequence	S252	NN	I-NP	O
determination	determination	D365	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
restriction	restriction	R236	NN	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
digestion	digestion	D235	NN	I-NP	O
of	of	O100	IN	B-PP	O
PCR	PCR	P260	NN	B-NP	O
products	product	P632	NNS	I-NP	O
,	,	0000	,	O	O
initial	initial	I534	JJ	B-NP	O
symptoms	symptom	S513	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
the	the	T000	DT	B-NP	O
onset	onset	O523	NN	I-NP	O
of	of	O100	IN	B-PP	O
slowly	slowly	S400	RB	B-NP	O
progressive	progressive	P626	JJ	I-NP	O
spastic	spastic	S123	JJ	I-NP	B-Disease
paraplegia	paraplegia	P614	NN	I-NP	I-Disease
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
middle	middle	M340	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
decade	decade	D230	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
all	all	A400	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
diminished	diminish	D523	VBN	I-VP	B-Disease
GALC	GALC	G420	NN	B-NP	I-Disease
activity	activity	A231	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
leukocytes	leukocyte	L232	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
three	three	T600	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
(	(	0000	(	O	O
I66M	I66M	I500	NN	B-NP	O
,	,	0000	,	O	O
G270D	G270D	G300	NN	B-NP	O
,	,	0000	,	O	O
L618S	L618S	L200	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
exon	exon	E250	NN	I-NP	O
-	-	0000	HYPH	O	O
6	6	0000	CD	B-NP	O
skipping	skipping	S215	NN	I-NP	O
(	(	0000	(	O	O
535	535	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
573del	573del	D400	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
only	only	O540	RB	B-NP	O
the	the	T000	DT	I-NP	O
I66M	I66M	I500	NN	I-NP	O
mutant	mutant	M353	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
only	only	O540	RB	I-NP	O
the	the	T000	DT	I-NP	O
G27OD	G27OD	G300	NN	I-NP	O
mutant	mutant	M353	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
fourth	fourth	F630	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
carried	carry	C630	VBD	B-VP	O
a	a	A000	DT	B-NP	O
compound	compound	C515	NN	I-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
535	535	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
573del	573del	D400	NN	I-NP	O
and	and	A530	CC	I-NP	O
L618S	L618S	L200	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
enzymatic	enzymatic	E525	JJ	I-NP	O
activities	activity	A231	NNS	I-NP	O
produced	produce	P632	VBN	B-VP	O
by	by	B000	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
constructed	construct	C523	VBD	B-VP	O
mutated	mutate	M300	VBN	I-VP	O
GALC	GALC	G420	NN	B-NP	O
cDNAs	cDNA	C352	NNS	I-NP	O
and	and	A530	CC	O	O
expressed	express	E216	VBD	B-VP	O
them	them	T500	PRP	B-NP	O
in	in	I500	IN	B-PP	O
COS	COS	C200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
viz	viz	V200	NN	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
G270D	G270D	G300	NN	B-NP	O
,	,	0000	,	O	O
L618S	L618S	L200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
exon	exon	E250	NN	B-NP	O
-	-	0000	HYPH	O	O
6	6	0000	CD	B-NP	O
skipping	skipping	S215	NN	I-NP	O
(	(	0000	(	O	O
535	535	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
573del	573del	D400	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
produced	produce	P632	VBD	B-VP	O
diminished	diminish	D523	VBN	I-VP	B-Disease
GALC	GALC	G420	NN	B-NP	I-Disease
activity	activity	A231	NN	I-NP	I-Disease
as	as	A200	IN	B-SBAR	O
expected	expect	E212	VBN	B-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
I66M	I66M	I500	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
GALC	GALC	G420	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
(	(	0000	(	O	O
I289	I289	I000	NN	B-NP	O
)	)	0000	)	O	O
had	have	H300	VBD	B-VP	O
normal	normal	N654	JJ	B-NP	O
activity	activity	A231	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
when	when	W500	WRB	B-ADVP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
V289	V289	V000	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
were	be	W600	VBD	B-VP	O
introduced	introduce	I536	VBN	I-VP	O
into	into	I530	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
had	have	H300	VBD	B-VP	O
decreased	decrease	D262	VBN	I-VP	O
activity	activity	A231	NN	B-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
combination	combination	C515	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
unique	unique	U520	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
causes	cause	C200	VBZ	B-VP	O
conformational	conformational	C516	JJ	B-NP	O
change	change	C520	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
GALC	GALC	G420	NN	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
low	low	L000	JJ	B-NP	O
enzymatic	enzymatic	E525	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

AO	AO	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
GLD	GLD	G430	NN	I-NP	I-Disease
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
those	those	T200	DT	B-NP	O
found	find	F530	VBN	B-VP	O
here	here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
located	located	L230	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
N	N	N000	NN	I-NP	O
-	-	0000	HYPH	O	O
terminus	terminus	T652	NN	B-NP	O
(	(	0000	(	O	O
I66M	I66M	I500	NN	B-NP	O
,	,	0000	,	O	O
G270D	G270D	G300	NN	B-NP	O
,	,	0000	,	O	O
535	535	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
573del	573del	D400	NN	I-NP	O
)	)	0000	)	O	O
or	or	O600	CC	O	O
C	C	C000	NN	B-NP	O
-	-	0000	HYPH	O	O
terminus	terminus	T652	NN	B-NP	O
(	(	0000	(	O	O
L618S	L618S	L200	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
GALC	GALC	G420	NN	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
the	the	T000	DT	B-NP	O
reported	report	R163	VBN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
infantile	infantile	I515	JJ	I-NP	O
form	form	F650	NN	I-NP	O
(	(	0000	(	O	O
IF	IF	I100	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
GLD	GLD	G430	NN	I-NP	I-Disease
)	)	0000	)	O	O
are	be	A600	VBP	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
central	central	C536	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
difference	difference	D165	NN	I-NP	O
in	in	I500	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
sites	site	S320	NNS	I-NP	O
may	may	M000	MD	B-VP	O
affect	affect	A123	VB	I-VP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
GLD	GLD	G430	NN	B-NP	B-Disease
.	.	0000	.	O	O

